

FORM PTO-1390 (REV. 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 50.US3.PCT
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (If known, see 37 CFR 1.5)
			09/807506
INTERNATIONAL APPLICATION NO. PCT/IB99/01730	INTERNATIONAL FILING DATE October 12, 1999	PRIORITY DATE CLAIMED October 13, 1998	
TITLE OF INVENTION GENES, PROTEINS AND BIALLELIC MARKERS RELATED TO CENTRAL NERVOUS SYSTEM DISEASE			
APPLICANT(S) FOR DO/EO/US Marta BLUMENFELD, Lydie BOUGUELERET, Ilya CHUMAKOV, Daniel COHEN, Laurent ESSIUX			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<ol style="list-style-type: none">1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))<ol style="list-style-type: none">a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).<ol style="list-style-type: none">a. <input type="checkbox"/> is attached hereto.b. <input checked="" type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))<ol style="list-style-type: none">a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).b. <input type="checkbox"/> have been communicated by the International Bureau.c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.d. <input checked="" type="checkbox"/> have not been made and will not be made.8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).			
Items 11 to 20 below concern document(s) or information included:			
<ol style="list-style-type: none">11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.15. <input type="checkbox"/> A substitute specification.16. <input type="checkbox"/> A change of power of attorney and/or address letter.17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).20. <input type="checkbox"/> Other items or information:			

U.S. APPLICATION NO. (known, see 37 CFR 1.53) 09/807506		INTERNATIONAL APPLICATION NO. PCT/IB99/01730		ATTORNEY'S DOCKET NUMBER	
---	--	---	--	--------------------------	--

21. <input type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. \$1000.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS PTO USE ONLY	
				\$	860.00
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	130.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
Total claims	24 - 20 =	4	x \$18.00	\$	64.00
Independent claims	8 - 3 =	5	x \$80.00	\$	400.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				\$	270.00
TOTAL OF ABOVE CALCULATIONS =				\$	1,724.00
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$	0.00
SUBTOTAL =				\$	1,724.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	0.00
TOTAL NATIONAL FEE =				\$	1,724.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$	0.00
TOTAL FEES ENCLOSED =				\$	1,724.00
				Amount to be refunded:	\$
				charged:	\$

a. ☒ A check in the amount of \$ 1,724.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. 50-1181 in the amount of \$ _____ to cover the above fees.
 A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any
 overpayment to Deposit Account No. 50-1181. A duplicate copy of this sheet is enclosed.


d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card
 information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR
 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

GENSET CORP.
 10665 Sorrento Valley Road
 San Diego, CA 92121-1609

Telephone: 858/597-2600
 Facsimile: 858/597-2601


 SIGNATURE
 John Lucas, Ph.D., J.D.
 NAME
43,373
 REGISTRATION NUMBER

Express Mail Label #EL821903793US

09807506 020601

Our Ref. No. 50.US3.PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:)
)
Inventor(s) : **Marta BLUMENFELD, et al.**)
) Art Unit : Unknown
Serial No. :)
) Examiner : Unassigned
Filed : **April 12, 2001**)
)
Priority Claimed on PCT Application:)
)
Serial No. : **PCT/IB99/01730**)
)
International Filing Date : **October 12, 1999**)
)
Title : **GENES, PROTEINS AND BIALLELIC**)
MARKERS RELATED TO CENTRAL)
NERVOUS SYSTEM DISEASE)

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Prior to the issuance of a first Office Action in the above-identified application, please
amendment the application as follows:

In the Claims:

Please cancel claims 6-7, 9-10, 12, 16-18, 20-22, 26-27, 29-34, 38, 40-46, 49-50, 52-56
as filed in the PCT parent application upon which priority for this application is claimed.

Please amend claims 11, 13, 19, 23, 37, 48, 51 and 57 as follows.

11. (Amended) [An isolated, purified, or recombinant polynucleotide] The polynucleotide of claim 3 consisting essentially of a contiguous span of 8 to 50 nucleotides of anyone of SEQ ID Nos 1 to 3 and 32 to 69 or the complement thereof, wherein the 3' end of said contiguous span is located at the 3' end of said polynucleotide, and wherein the 3' end of said polynucleotide is located within 20 nucleotides upstream of a *G713* or *13q31-q33*-related biallelic marker in said sequence.

13. (Amended) A polynucleotide according to claim [12] 11, wherein said polynucleotide consists essentially of a sequence selected from the following sequences: D1 to D49, and E1 to E49.

19. (Amended) A polynucleotide according to any one of claims 1, 2[, 3, 11, 14, 15 or 16] or 3 attached to a solid support.

23. (Amended) A recombinant vector comprising a polynucleotide according to [any one of claims] claim 1.

37. (Amended) A method of estimating the frequency of a haplotype for a set of biallelic markers in a population, comprising:

- a) genotyping at least one *G713*- or *13q31-q33*-related biallelic marker according to claim [29] 28 for each individual in said population;
- b) genotyping a second biallelic marker by determining the identity of the nucleotides at said second biallelic marker for both copies of said second biallelic marker present in the genome of each individual in said population; and

- c) applying a haplotype determination method to the identities of the nucleotides determined in steps a) and b) to obtain an estimate of said frequency.

48. (Amended) A method according to [any one of claims 28, 35, 36, 37, 39 or] claim 47 wherein said *13q31-q33*-related biallelic marker is selected from the group consisting of A12 to A49 and the complements thereof.

51. (Amended) A computer readable medium having stored thereon a sequence selected from the group consisting of a nucleic acid code comprising one of the following:

- a) [a contiguous span of at least 12 nucleotides of SEQ ID Nos 1, 2 or 3, or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions:
1 to 3236, 3547 to 3585 and 4649 to 5222 of SEQ ID No 1, or a variant thereof or a sequence complementary thereto;
1 to 16155 and 16331 to 21278 of SEQ ID No 2 or a variant thereof or a sequence complementary thereto; and
1 to 5531, 6844 to 7237, 7798 to 8184, 8667 to 9074, and 9356 to 21636 of SEQ ID No 3, or a variant thereof or a sequence complementary thereto;] the polynucleotide of claim 1;
- b) a contiguous span of at least 12 nucleotides of SEQ ID No 31 or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions: 1 to 480 and 717 to 983 of SEQ ID No 31;
- c) a contiguous span of at least 12 nucleotides of SEQ ID No 4 or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions: 1 to 519 and 2563 to 5566 of SEQ ID No 4;
- d) a contiguous span of at least 12 nucleotides of SEQ ID No 6 or the complements thereof;
- e) a contiguous span of at least 12 nucleotides of at least one of SEQ ID Nos 32 to 69, or the complements thereof; and

- f) a nucleotide sequence complementary to any one of the preceding nucleotide sequences.

57. (Amended) A method for comparing a first sequence to a reference sequence, comprising the steps of:

reading said first sequence and said reference sequence through use of a computer program which compares sequences; and

determining differences between said first sequence and said reference sequence with said computer program,

wherein said first sequence is selected from the group consisting of a nucleic acid code comprising one of the following:

- a) [a contiguous span of at least 12 nucleotides of SEQ ID Nos 1, 2 or 3, or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions:
1 to 3236, 3547 to 3585 and 4649 to 5222 of SEQ ID No 1, or a variant thereof or a sequence complementary thereto;
1 to 16155 and 16331 to 21278 of SEQ ID No 2 or a variant thereof or a sequence complementary thereto; and
1 to 5531, 6844 to 7237, 7798 to 8184, 8667 to 9074, and 9356 to 21636 of SEQ ID No 3, or a variant thereof or a sequence complementary thereto;] the polynucleotide of claim 1;
- b) a contiguous span of at least 12 nucleotides of SEQ ID No 31 or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions: 1 to 480 and 717 to 983 of SEQ ID No 31;
- c) a contiguous span of at least 12 nucleotides of SEQ ID No 4 or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions: 1 to 519 and 2563 to 5566 of SEQ ID No 4;
- d) a contiguous span of at least 12 nucleotides of SEQ ID No 6 or the complements thereof;

- e) a contiguous span of at least 12 nucleotides of at least one of SEQ ID Nos 32 to 69, or the complements thereof;
 - f) a nucleotide sequence complementary to any one of the preceding nucleotide sequences; and
- a polypeptide code comprising a contiguous span of at least 6 amino acids of SEQ ID Nos 5 or 7.

REMARKS


Claims 1-5, 8, 11, 13-15, 19, 23-25, 28, 35-37, 39, 47-48, 51 and 57 remain in this application. Claims 6-7, 9-10, 12, 16-18, 20-22, 26-27 29-34, 38, 40-46, 49-50, 52-56 have been canceled. Claims 11, 13, 19, 23, 48, 51 and 57 have been amended.

Attached hereto is a marked-up version of the changes made to the claims by the current Preliminary Amendment. The attached page is captioned "**Version with markings to show changes made.**" Also attached is a page showing all the claims as currently pending, which is entitled "**Pending Claims.**"

The Commissioner is hereby authorized to credit any overpayment or charge any additional fees in connection with the filing of this Preliminary Amendment to our Deposit Account No. 50-1181.

Respectfully submitted,
GENSET CORPORATION

Date: 13 Apr 01, 2001

By: 
John Lucas, Ph.D., J.D.
Registration No. 43,373

10665 Sorrento Valley Road
San Diego, CA 92121-1609

Telephone: (858) 597-2600

Facsimile: (858) 597-2601

e-mail: john.lucas@genxy.com


Certificate of Mailing under 37 CFR 1.10

Express Mail Label No.: EL821903793US

Date of Deposit: _____

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10, on the Date of Deposit shown above, postage prepaid and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Signature


AARON J. SCALIA

Typed or Printed Name of Person Signing Certificate

VERSION WITH MARKINGS TO SHOW CHANGES MADE

11. (Amended) [An isolated, purified, or recombinant polynucleotide] The polynucleotide of claim 3 consisting essentially of a contiguous span of 8 to 50 nucleotides of anyone of SEQ ID Nos 1 to 3 and 32 to 69 or the complement thereof, wherein the 3' end of said contiguous span is located at the 3' end of said polynucleotide, and wherein the 3' end of said polynucleotide is located within 20 nucleotides upstream of a *G713 or 13q31-q33*-related biallelic marker in said sequence.

13. (Amended) A polynucleotide according to claim [12] 11, wherein said polynucleotide consists essentially of a sequence selected from the following sequences: D1 to D49, and E1 to E49.

19. (Amended) A polynucleotide according to any one of claims 1, 2[, 3, 11, 14, 15 or 16] or 3 attached to a solid support.

23. (Amended) A recombinant vector comprising a polynucleotide according to [any one of claims] claim 1.

37. (Amended) A method of estimating the frequency of a haplotype for a set of biallelic markers in a population, comprising:

- a) genotyping at least one *G713- or 13q31-q33*-related biallelic marker according to claim [29] 28 for each individual in said population;
- b) genotyping a second biallelic marker by determining the identity of the nucleotides at said second biallelic marker for both copies of said second biallelic marker present in the genome of each individual in said population; and
- c) applying a haplotype determination method to the identities of the nucleotides determined in steps a) and b) to obtain an estimate of said frequency.

48. (Amended) A method according to [any one of claims 28, 35, 36, 37, 39 or] claim 47 wherein said *13q31-q33*-related biallelic marker is selected from the group consisting of A12 to A49 and the complements thereof.

51. (Amended) A computer readable medium having stored thereon a sequence selected from the group consisting of a nucleic acid code comprising one of the following:

- a) [a contiguous span of at least 12 nucleotides of SEQ ID Nos 1, 2 or 3, or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions:
1 to 3236, 3547 to 3585 and 4649 to 5222 of SEQ ID No 1, or a variant thereof or a sequence complementary thereto;
1 to 16155 and 16331 to 21278 of SEQ ID No 2 or a variant thereof or a sequence complementary thereto; and
1 to 5531, 6844 to 7237, 7798 to 8184, 8667 to 9074, and 9356 to 21636 of SEQ ID No 3, or a variant thereof or a sequence complementary thereto;] the polynucleotide of claim 1;
- b) a contiguous span of at least 12 nucleotides of SEQ ID No 31 or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions: 1 to 480 and 717 to 983 of SEQ ID No 31;
- c) a contiguous span of at least 12 nucleotides of SEQ ID No 4 or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions: 1 to 519 and 2563 to 5566 of SEQ ID No 4;
- d) a contiguous span of at least 12 nucleotides of SEQ ID No 6 or the complements thereof;
- e) a contiguous span of at least 12 nucleotides of at least one of SEQ ID Nos 32 to 69, or the complements thereof; and
- f) a nucleotide sequence complementary to any one of the preceding nucleotide sequences.

57. (Amended) A method for comparing a first sequence to a reference sequence, comprising the steps of:

reading said first sequence and said reference sequence through use of a computer program which compares sequences; and

determining differences between said first sequence and said reference sequence with said computer program,

wherein said first sequence is selected from the group consisting of a nucleic acid code comprising one of the following:

- a) [a contiguous span of at least 12 nucleotides of SEQ ID Nos 1, 2 or 3, or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions:
1 to 3236, 3547 to 3585 and 4649 to 5222 of SEQ ID No 1, or a variant thereof or a sequence complementary thereto;
1 to 16155 and 16331 to 21278 of SEQ ID No 2 or a variant thereof or a sequence complementary thereto; and
1 to 5531, 6844 to 7237, 7798 to 8184, 8667 to 9074, and 9356 to 21636 of SEQ ID No 3, or a variant thereof or a sequence complementary thereto;] the polynucleotide of claim 1;
- b) a contiguous span of at least 12 nucleotides of SEQ ID No 31 or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions: 1 to 480 and 717 to 983 of SEQ ID No 31;
- c) a contiguous span of at least 12 nucleotides of SEQ ID No 4 or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions: 1 to 519 and 2563 to 5566 of SEQ ID No 4;
- f) a contiguous span of at least 12 nucleotides of SEQ ID No 6 or the complements thereof;
- g) a contiguous span of at least 12 nucleotides of at least one of SEQ ID Nos 32 to 69, or the complements thereof;
- f) a nucleotide sequence complementary to any one of the preceding nucleotide sequences; and

a polypeptide code comprising a contiguous span of at least 6 amino acids of SEQ ID Nos 5 or 7.

Our Ref. No. 50.US3.PCT

09807506-080304

Claims as Pending after Preliminary Amendment

1. An isolated, purified, or recombinant polynucleotide comprising a contiguous span of at least 12 nucleotides of SEQ ID Nos 1 to 4, 6 and 31, or the complements thereof, wherein said contiguous span comprises:

- at least one of the following nucleotide positions of SEQ ID No 1: 1 to 3585 and 4644 to 5222; and/or
- at least one of the following nucleotide positions of SEQ ID No 2: 1 to 16155 and 16331 to 21278; and/or
- at least one of the following nucleotide positions of SEQ ID No 3: 1 to 5531 and 6355 to 21636; and/or
- at least one of the following nucleotide positions of SEQ ID No 4: 1 to 519 and 2563 to 5566; and/or
- at least one of the following nucleotide positions of SEQ ID No 6: 1 to 1791.

2. An isolated, purified, or recombinant polynucleotide comprising a contiguous span of at least 12 nucleotides of SEQ ID No 31, or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions of SEQ ID No 31: 1 to 480 and 717 to 983.

3. An isolated, purified, or recombinant polynucleotide consisting essentially of a contiguous span of 8 to 50 nucleotides of anyone of SEQ ID Nos 1 to 3 and 32 to 69 or the complement thereof, wherein said span includes a *G713 or 13q31-q33*-related biallelic marker in said sequence.

4. A polynucleotide according to claim 3, wherein said *G713 or 13q31-q33*-related biallelic marker is selected from the group consisting of A1 to A49, and the complements thereof.

5. A polynucleotide according to claim 3, wherein said *13q31-q33*-related biallelic marker is selected from the group consisting of A16 to A20 and the complements thereof.

8. A polynucleotide according to claim 6, wherein said polynucleotide consists essentially of a sequence selected from the following sequences: P1 to P49, and the complementary sequences thereto.

11. The polynucleotide of claim 3 consisting essentially of a contiguous span of 8 to 50 nucleotides of anyone of SEQ ID Nos 1 to 3 and 32 to 69 or the complement thereof, wherein the 3' end of said contiguous span is located at the 3' end of said polynucleotide, and wherein the 3' end of said polynucleotide is located within 20 nucleotides upstream of a *G713 or 13q31-q33*-related biallelic marker in said sequence.

13. A polynucleotide according to claim 11, wherein said polynucleotide consists essentially of a sequence selected from the following sequences: D1 to D49, and E1 to E49.

14. An isolated, purified, or recombinant polynucleotide consisting essentially of a sequence selected from the following sequences: B1 to B49 and C1 to C49.

15. An isolated, purified, or recombinant polynucleotide which encodes a polypeptide comprising a contiguous span of at least 6 amino acids of SEQ ID Nos 5 or 7.

19. A polynucleotide according to any one of claims 1, 2 or 3 attached to a solid support.

23. A recombinant vector comprising a polynucleotide according to claim 1.

24. A host cell comprising a recombinant vector according to claim 23.

25. A non-human host animal or mammal comprising a recombinant vector according to claim 23.

28. A method of genotyping comprising determining the identity of a nucleotide at a *G713- or 13q31-q33*-related biallelic marker or the complement thereof in a biological sample.

35. A method of estimating the frequency of an allele of a *G713- or 13q31-q33*-related biallelic marker in a population comprising:

- a) genotyping individuals from said population for said biallelic marker according to the method of claim 28; and
- b) determining the proportional representation of said biallelic marker in said population.

36. A method of detecting an association between a genotype and a trait, comprising the steps of:

- a) determining the frequency of at least one *G713- or 13q31-q33*-related biallelic marker in trait positive population according to the method of claim 35;
- b) determining the frequency of at least one *G713- or 13q31-q33*-related biallelic marker in a control population according to the method of claim 35; and
- c) determining whether a statistically significant association exists between said genotype and said trait.

37. A method of estimating the frequency of a haplotype for a set of biallelic markers in a population, comprising:

- a) genotyping at least one *G713- or 13q31-q33*-related biallelic marker according to claim 28 for each individual in said population;
- b) genotyping a second biallelic marker by determining the identity of the nucleotides at said second biallelic marker for both copies of said second biallelic marker present in the genome of each individual in said population; and
- c) applying a haplotype determination method to the identities of the nucleotides determined in steps a) and b) to obtain an estimate of said frequency.

39. A method of detecting an association between a haplotype and a trait, comprising the steps of:

- a) estimating the frequency of at least one haplotype in a trait positive population according to the method of claim 37;
- b) estimating the frequency of said haplotype in a control population according to the method of claim 37; and
- c) determining whether a statistically significant association exists between said haplotype and said trait.

47. A method of determining whether an individual is at risk of developing schizophrenia, comprising:

- a) genotyping at least one *13q31-q33*-related biallelic marker according to the method of claim 30; and
- b) correlating the result of step a) with a risk of developing schizophrenia.

48. A method according to claim 47 wherein said *13q31-q33*-related biallelic marker is selected from the group consisting of A12 to A49 and the complements thereof.

51. A computer readable medium having stored thereon a sequence selected from the group consisting of a nucleic acid code comprising one of the following:

- a) the polynucleotide of claim 1;
- b) a contiguous span of at least 12 nucleotides of SEQ ID No 31 or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions: 1 to 480 and 717 to 983 of SEQ ID No 31;
- c) a contiguous span of at least 12 nucleotides of SEQ ID No 4 or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions: 1 to 519 and 2563 to 5566 of SEQ ID No 4;
- d) a contiguous span of at least 12 nucleotides of SEQ ID No 6 or the complements thereof;
- e) a contiguous span of at least 12 nucleotides of at least one of SEQ ID Nos 32 to 69, or the complements thereof; and

- f) a nucleotide sequence complementary to any one of the preceding nucleotide sequences.

57. A method for comparing a first sequence to a reference sequence, comprising the steps of:

reading said first sequence and said reference sequence through use of a computer program which compares sequences; and

determining differences between said first sequence and said reference sequence with said computer program,

wherein said first sequence is selected from the group consisting of a nucleic acid code comprising one of the following:

- a) the polynucleotide of claim 1;
- b) a contiguous span of at least 12 nucleotides of SEQ ID No 31 or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions: 1 to 480 and 717 to 983 of SEQ ID No 31;
- c) a contiguous span of at least 12 nucleotides of SEQ ID No 4 or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions: 1 to 519 and 2563 to 5566 of SEQ ID No 4;
- h) a contiguous span of at least 12 nucleotides of SEQ ID No 6 or the complements thereof;
- i) a contiguous span of at least 12 nucleotides of at least one of SEQ ID Nos 32 to 69, or the complements thereof;
- f) a nucleotide sequence complementary to any one of the preceding nucleotide sequences; and

a polypeptide code comprising a contiguous span of at least 6 amino acids of SEQ ID Nos 5 or 7.

PTO/PGT Rec'd 13 APR 2001

GENES, PROTEINS AND BIALLELIC MARKERS RELATED TO CENTRAL NERVOUS SYSTEM DISEASE

5

FIELD OF THE INVENTION

10

The present invention deals with a novel gene, the G713 gene, located on the 13q33 locus of chromosome 13, and expressed in human brain, the coding sequence of which comprises repeated CAG triplet nucleotide repeats, as well as with single nucleotide polymorphisms, also termed biallelic markers, that are harbored by the G713 gene. The G713 gene represents a candidate gene for central nervous system disorders, including schizophrenia and bipolar disorder.

15

The invention also concerns biallelic markers located on the human chromosome 13q31-q33 locus and the association established between these markers and predisposition to schizophrenia. The invention provides means to determine the predisposition of individuals to schizophrenia as well as means for the diagnosis of such diseases and for the prognosis/detection of an eventual treatment response to agents acting on schizophrenia.

20

Throughout this application, various references are referred to within parentheses. The disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains.

BACKGROUND OF THE INVENTION

25

30

35

Recently, there has been an increasing interest in a new class of genetic diseases caused by abnormal expansions of tracts of trinucleotide repeats. Specifically, an increasing number of human neurodegenerative diseases are recognized to be caused by expansion of a CAG repeat within the protein-coding region of the disease gene. The expanded repeat encodes an expanded tract of glutamines within the protein. Whereas a normal repeat length has no pathological consequence, expansion of the glutamine tract beyond a critical threshold leads to neuronal loss and a degenerative phenotype. To date, eight glutamine-repeat diseases have been identified, including Huntington's disease (HD), spinobulbar muscular atrophy (SBMA), dentatorubral-pallidolusyan atrophy (DRPLA), and five spinocerebellar ataxias (SCAs 1, 2, 6, 7, and SCA3/MJD). These diseases all affect the

nervous system and share a number of common features that are detailed hereafter. First, although normal chromosomes are polymorphic with respect to repeat length, they show very low mutation rates. However, mutant chromosomes with long repeats are highly mutable and tend to increase their repeat number in successive generations. Second, as a general rule, increasing disease severity and/or decreasing age of onset of symptoms correlate with increasing size of triplet expansions. These molecular features can explain the phenomenon of anticipation, which is understood today as the tendency for the disease to manifest at an earlier age in successive generations. In particular, recent reports have suggested that anticipation may be a feature of both schizophrenia and bipolar affective disorder (Ross et al., 1993; Basset et al., 1994; McInnis et al., 1993).

These diseases likely share a common pathophysiology at the protein level : the expanded polyglutamine tract confers a dominant, toxic property upon these otherwise unrelated proteins. The longer the repeat, the earlier the onset and the more severe the disease. For Huntington's disease (HD) in particular, several authors have shown the existence of a correlation between the number of CAG repeats present upstream the huntingtin (Huntington Disease's protein) coding sequence and both the severity and the age of onset of this pathology. For example, Brinkman et al. (1997) have used a large cohort of patients and their study has shown that CAG repeats length is the major determinant of age at onset in HD. By assessing the CAG size alone, these authors were able to predict the likelihood that an individual would be affected by a particular age, for the vast majority of persons tested. This study showed that the lower limit of CAG repeat size in individuals who manifest with HD is 36. These authors showed that there is a trend to increasing penetrance with increasing repeat length in the 36-41 repeat range.

Increasing evidence indicates that expanded polyglutamine itself drives the degenerative process. Isolated, expanded glutamine tracts cause neurodegeneration in transgenic mice and cell death in transfected cells, and an expanded glutamine repeat inserted into a non-disease protein causes neurodegeneration in transgenic mice. Recent evidence indicates that neuronal nuclear inclusions (NI) formed by the disease protein are a unifying pathological feature of these diseases. Although it is unknown whether NI cause the disease or simply reflect the disease process, the fact that they are preferentially found in susceptible neurons indicates that they are intimately linked to disease progression. Analysis of NI in transgenic animals and in HD brain reveals occasional fibrils within the NI consistent with amyloid-like deposition.

An important, unexplained feature of glutamine-repeat diseases is the differing neuronal selectivity among the various diseases. Each disease is characterized by distinct, yet overlapping, patterns of neurodegeneration. Selective patterns of neurodegeneration occur despite the fact that the disease proteins tend to be widely expressed in the brain and elsewhere in the body. Several factors may contribute to cell specificity, including the particular protein context within which the glutamine resides, specific interactions with other proteins whose expression is spatially or temporally restricted, and posttranslational modifications. It has been shown that huntingtin and DRPLA (dentatorubral-pallidoluysian atrophy) proteins were able to interact selectively with the enzyme GADPH. Moreover, a huntingtin-associated protein (HAP-1), whose expression is enriched in brain, has also been shown to bind to huntingtin, this binding being enhanced by an expanded polyglutamine repeat, the length of which is known to correlate with the age of disease onset.

The conformational structure of the triplet nucleotide repeats may also be involved in the development of the associated pathology. Computer modeling of the secondary structure of the *huntingtin* mRNA predicts the formation of a stable stem-loop sequence encoded by the CAG repeat, which becomes more stable as the trinucleotide repeat is lengthened. Structures predicted by such modeling are useful in suggesting mRNA sequences that may be involved in regulating the expression of the mRNAs. Mc Laughlin et al. (1996) have identified cytoplasmic RNA-binding proteins that interact with trinucleotide CAG repeats in a tissue-specific and CAG length-dependent manner, using RNA probes designed on the basis of the Huntington disease gene sequence. Three speculative models have been hypothesized by these authors, which are the followings : (1) RNA-binding protein interaction with CAG repeats of *huntingtin* mRNA may alter the amount of huntingtin protein produced; (2) the protein-RNA interaction may affect the subcellular distribution of the *huntingtin* mRNA; or (3) the RNA-protein interaction may facilitate the altered expression of other proteins.

On another hand, a defective gene involved in brain disorder is not necessarily associated with the presence of trinucleotide repeats in its coding sequence. This is the case, for example, for a gene involved in the X-linked hypohydrotic ectodermal dysplasia (HED) that has been recently isolated and which does not contains any repeat in its coding sequence, and which has been named *TED* (Genebank Accession number AF087142). Hypohydrotic ectodermal dysplasia (HED) affected males show

mental defects, such as moderately severe mental retardation, which may be associated with hypotrichosis, abnormal teeth, and absent sweat glands.

There is a strong need in the art to identify new genes and new proteins that are likely to be involved in the development of diseases affecting the central nervous system, both for diagnostic and therapeutic purposes. Some typical candidate genes are those harboring CAG nucleotide repeats in their coding sequences.

Among the central nervous system diseases, schizophrenia is one of the most severe and debilitating. It usually starts in late adolescence or early adult life and often becomes chronic and disabling. Men and women are at equal risk of developing this illness; however, most males become ill between 16 and 25 years old; females develop symptoms between 25 and 30.

People with schizophrenia often experience both "positive" symptoms (delusions, hallucinations, disorganized thinking, agitation) and "negative" symptoms (lack of drive or initiative, social withdrawal, apathy, emotional unresponsiveness).

Schizophrenia affects 1 % of the world population. There is an estimated 45 million people with schizophrenia in the world, more than 33 million of them in the developing countries.

This disease places a heavy burden on the patient's family and relatives, both in terms of the direct and indirect costs involved and the social stigma associated with the illness, sometimes over generations. Such stigma often leads to isolation and neglect.

Moreover, schizophrenia accounts for a fourth of all mental health costs and takes up one in three psychiatric hospital beds. Most schizophrenia patients are never able to work. The cost of schizophrenia to society is enormous. In the United States, for example, the direct cost of treatment of schizophrenia has been estimated to be close to 0.5% of the gross national product.

Standardized mortality ratios (SMRs) for schizophrenic patients are estimated to be two to four times higher than the general population, and their life expectancy overall is 20 % shorter than for general population. The most common cause of death (in 10 % of patients), is suicide – the risk is 20 times higher than for the general population. Deaths from heart disease and from diseases of the respiratory and digestive system are also increased among schizophrenic patients.

There is no cure for schizophrenia. The objective of treatment is to reduce the severity of the symptoms, if possible to the point of remission. Antipsychotic medications are the most common and most valuable treatment for schizophrenia.

They can be described through four drugs.

The initial drug, chlorpromazine (Thorazine), has revolutionized the treatment of schizophrenic patients by reducing positive (psychotic) symptoms and preventing their recurrence. Patients have been able to leave mental hospitals and live in community programs or their own homes. But these drugs are far from ideal. Some 20% to 30% of patients do not respond to them at all, and others eventually relapse. The drugs are known as neuroleptics because they produce serious neurological side effects, including rigidity and tremors in the arms and legs, muscle spasms, abnormal body movements, and akathisia (restless pacing and fidgeting). These side effects are so troublesome that many patients simply refuse to take the drugs. Besides, neuroleptics do not improve the so-called negative symptoms of schizophrenia and the side effects may even exacerbate these symptoms. Thus, despite the clear beneficial effects of the drugs, even some patients who have a good short-term response will ultimately deteriorate in overall functioning.

These deficiencies of the standard neuroleptics have stimulated a search for new treatments which leads to a new class of drugs named atypical neuroleptics. The first atypical neuroleptic, Clozapine, is effective for about one third of patients who do not respond to standard drugs. It seems to reduce negative as well as positive symptoms, or at least exacerbates negative symptoms less than standard drugs do. Moreover, it has beneficial effects on overall functioning and may reduce the chance of suicide in schizophrenic patients. It does not produce the troubling neurological symptoms of the standard neuroleptics and raise blood levels of the hormone prolactin, excess of which may cause menstrual irregularities and infertility in women, impotence or breast enlargement in men. Many patients who cannot tolerate standard neuroleptics are able to take clozapine. However, clozapine has serious limitations. It was originally withdrawn from the market because it can cause agranulocytosis, a potentially lethal failure of the capacity to produce white blood cells. Agranulocytosis remains a threat that requires careful monitoring and periodic blood tests. Clozapine can also cause seizures and other disturbing side effects -- drowsiness, lowered blood pressure, drooling, bed-wetting, and weight gain. Thus it is usually taken only by patients who do not respond to other drugs.

Researchers have developed new antipsychotic drugs that have the virtues of clozapine without its defects. One of these drugs is risperidone (Risperdal). Early studies suggest that it is as effective as standard neuroleptic drugs for positive symptoms and may be somewhat more effective for negative symptoms. It produces more neurological side effects than clozapine but fewer than standard neuroleptics.

However, it raises prolactin levels. Risperidone is now prescribed for a broad range of psychotic patients, and many clinicians seem to use it before clozapine for patients who do not respond to standard drugs, because they regard it as safer. Another one is Olanzapine (Zyprexa) which is at least as effective as standard drugs for positive symptoms and more effective for negative symptoms. It has few neurological side effects at ordinary clinical doses, and it does not significantly raise prolactin levels. Although it does not produce most of clozapine's most troubling side effects, including agranulocytosis, some patients taking olanzapine may become sedated or dizzy, develop dry mouth, or gain weight. In rare cases liver function tests become transiently abnormal.

Outcome studies in schizophrenia are usually based on hospital treatment samples and may not be representative of the population of schizophrenia patients. At the extremes of outcome, 20 % of patients seem to recover completely after one episode of psychosis, whereas 14-19% of patients develop a chronic unremitting psychosis and never fully recover. In general, clinical outcome at five years seems to follow the rule of thirds : with about 35 % of patients in the poor outcome category; 36 % in the good outcome category, and the remainder with intermediate outcome. Prognosis in schizophrenia does not seem to worsen after five years.

Whatever the reasons, there is increasing evidence that leaving untreated for long periods early in course of the illness may negatively affect the outcome. However, their use is often delayed for patients experiencing a first episode of the illness. The patients may not realize that they are ill, or they may be afraid to seek help; family members sometimes hope the problem will simply disappear or cannot persuade the patient to seek treatment; clinicians may hesitate to prescribe antipsychotic medications when the diagnosis is uncertain because of potential side effects. Indeed, at the first manifestation of the disease, schizophrenia is difficult to distinguish from bipolar manic-depressive disorders, severe depression, drug-related disorders, and stress-related disorders. Since the optimum treatments differ among these diseases, the long term prognosis of the disorder also differs the beginning of the treatment.

All the known molecules used for the treatment of schizophrenia have side effects and act against the symptoms of schizophrenia. There is a strong need for new molecules devoid of side effects and directed against targets which are involved in causal events of schizophrenia. Therefore, tools allowing to find these targets are necessary and useful.

Schizophrenia is now considered to be a brain disease and emphasis is placed on biological determinants. Neuroimaging and neuropathological studies showed evidence of brain abnormalities in schizophrenic patients. The timing of these pathological changes is unclear but is likely to be a defect in early brain development. Profound changes have also occurred in hypotheses concerning neurotransmitter abnormalities in schizophrenia. The dopamine hypothesis has been extensively revised and is no longer considered as a primary causative model.

The aggregation of schizophrenia in families, the evidence from twin and adoption studies, and the lack of variation in incidence world wide, indicate that schizophrenia is primarily a genetic condition, although environmental risk factors are also involved at some level as necessary, sufficient, or interactive causes.

For example, schizophrenia occurs in 1 % of the general population. But, if there is one grandparent with schizophrenia, the risk of getting the illness increases to about 3 % ; one parent with Schizophrenia, to about 10 %. When both parents have schizophrenia, the risk percentage rises to approximately 40 %.

However, the persistence of schizophrenia in the population despite low fertility and high mortality, suggests that genetic transmission occurs principally through persons who do not have the illness.

Consequently, there is a strong need to identify genes involved in schizophrenia. The knowledge of these genes will permit to understand the schizophrenia etiology and could lead to drugs and medications which are directed against the cause of the disease and not only against their symptoms.

There is also a strong need for means for detecting a susceptibility to schizophrenia for preventing or following up the development of the disease. Diagnosis tools could be also useful. Indeed, early identification of subjects at risk of developing schizophrenia would enable early and/or prophylactic treatment to be given.

Moreover, a valuable assessment of the eventual efficacy of a medicament as well as the patient's eventual tolerance to it may permit to enhance the benefit/risk ratio of schizophrenia treatment.

SUMMARY OF THE INVENTION

The present invention pertains to a nucleic acid molecule comprising the genomic sequence of a human gene harboring triplet nucleotide repeats, which is mainly expressed in brain, and which has been named G713 by the inventors. The G713 genomic sequence comprises regulatory sequences located both upstream (5'-

end) and downstream (3'-end) of the transcribed portion of said gene, these regulatory sequences being also part of the invention.

The invention also deals with the complete cDNA sequence encoding the G713 protein, as well as with the corresponding translation product. Another object of the invention concerns the murine cDNA corresponding to the murine orthologue of the human G713 gene.

The invention is also directed to biallelic markers that are located within the G713 genomic sequence, these biallelic markers representing useful tools in order to identify a statistically significant association between specific alleles of G713 and one or several disorders, preferably brain disorders, and most preferably psychiatric disorders like schizophrenia and bipolar disorder.

Oligonucleotide probes or primers hybridizing specifically with a G713 genomic or cDNA sequence are also part of the present invention.

A further object of the invention consists of recombinant vectors comprising any of the nucleic acid sequences above described, and in particular of recombinant vectors comprising a G713 regulatory sequence or a sequence encoding a G713 protein, as well as of cell hosts comprising said nucleic acid sequences or recombinant vectors.

The invention is also directed to methods for the screening of substances or molecules modulating the expression of G713.

The present invention also comprises subject matter stemming from the identification of genetic associations between alleles of biallelic markers located on the human chromosome 13q31-q33 locus and a disease, as confirmed and characterized in a panel of human subjects. Based on the determination of this association, the invention provides a genetic association between alleles of biallelic markers located on the human chromosome 13q31-q33 locus and schizophrenia. The invention also provides appropriate tools for establishing further genetic associations between alleles of biallelic markers on the 13q31-13q33 locus and either side effects or benefits resulting from the administration of agents acting on schizophrenia or schizophrenia symptoms, like chlorpromazine, clozapine, risperidone, olanzapine, sertindole, quetiapine and ziprasidone. The invention also provides appropriate tools for establishing further genetic associations between alleles of biallelic markers on the 13q31-13q33 locus and a trait.

Methods and products are provided for the molecular detection of a genetic susceptibility in humans to schizophrenia. They can be used for diagnosis, staging,

prognosis and monitoring of this disease, which processes can be further included within treatment approaches. The invention also provides for the efficient design and evaluation of suitable therapeutic solutions including individualized strategies for optimizing drug usage, and screening of potential new medicament candidates.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1: Calculated physical properties of the human G713 protein.

Figure 2: Prediction of the two-dimensional structure of the G713 protein, according to the method of Chou-Fasman.

Figure 3: Prediction of the two-dimensional structure of the human G713 protein, according to the method of Garnier-Osguthorpe-Robson.

Figure 4: Calculated physical properties of the mouse G713 protein.

Figure 5: Prediction of the two-dimensional structure of the mouse G713 protein, according to the method of Chou-Fasman.

Figure 6: Prediction of the two-dimensional structure of the mouse G713 protein according to the method of Garnier-Osguthorpe-Robson.

Figure 7: Block diagram of an exemplary computer system.

Figure 8: Flow diagram illustrating one embodiment of a process 200 for comparing a new nucleotide or protein sequence with a database of sequences in order to determine the homology levels between the new sequence and the sequences in the database.

Figure 9: Flow diagram illustrating one embodiment of a process 250 in a computer for determining whether two sequences are homologous.

Figure 10: Flow diagram illustrating one embodiment of an identifier process 300 for detecting the presence of a feature in a sequence.

Figure 11: Distribution of the different possible two markers-haplotypes ordered by decreasing ranges of p-values (increasing statistical significance).

Figure 12: Distribution of the different possible three markers- haplotypes ordered by decreasing ranges of p-values (increasing statistical significance).

DETAILED DESCRIPTION OF THE INVENTION

The present invention concerns polynucleotides and polypeptides related to the G713 human and mouse genes, which are potentially involved in brain disorders, particularly neuronal disorders like, for example schizophrenia or bipolar disorder.

The identification of genes involved in a particular trait such as a specific central nervous system disorder, like schizophrenia, can be carried out through two main

strategies currently used for genetic mapping: linkage analysis and association studies. Linkage analysis requires the study of families with multiple affected individuals and is now useful in the detection of mono- or oligogenic inherited traits. Conversely, association studies examine the frequency of marker alleles in unrelated trait (T+) individuals compared with trait negative (T-) controls, and are generally employed in the detection of polygenic inheritance.

Candidate region on the chromosome 13 (linkage analysis)

The studies of genetic link or of "linkage" are based on the principle according to which two neighboring sequences on a chromosome do not present (or very rarely present) recombinations by crossing-over during meiosis. To do this, chromosomal markers, like microsatellite markers, have been localized with precision on the genome. Genetic link analysis calculates the probabilities of recombinations on the target gene with the chromosomal markers used, according to the genealogical tree, the transmission of the disease, and the transmission of the markers. Thus, if a particular allele of a given marker is transmitted with the disease more often than chance would have it (recombination level between 0 and 0.5), it is possible to deduce that the target gene in question is found in the neighborhood of the marker.

Using this technique, it has been possible to localize several genes of genetic predisposition to familial cancers. In order to be able to be included in a genetic link studies, the families affected by a hereditary form of the disease must satisfy the "informativeness" criteria : several affected subjects (and whose constitutional DNA is available) per generation, and at best having a large number of siblings.

By linkage analysis, a candidate region for schizophrenia has been identified on chromosome 13. Starting from the results of this linkage analysis, the inventors have identified a novel candidate gene for the predisposition to central nervous system disorders, like neuronal disorders such as schizophrenia or bipolar disorder, as it will be further described in details in the present specification. This gene has been named G713 by the inventors.

The G713 gene of the invention is located on chromosome 13, and more precisely on the 13q33 locus of this chromosome. Results of previous linkage studies have shown that chromosome 13 is likely to harbor a schizophrenia susceptibility locus on 13q32 (Blouin et al., 1998; Lin et al., 1997).

The G713 mRNA and the G713 protein share a significant homology with respectively the transcription and the translation products of a gene named *TED* which

is involved in hypohydrotic ectodermal dysplasia, a disease associated with mental retardation. More precisely, the strongest homology found between the two mRNAs is of about 66% nucleotide identity in a stretch of 398 consecutive nucleotides of each of the *G713* and the *TED* mRNAs, without any gap. The strongest protein homology
5 between the *G713* and the *TED* proteins is of 85% amino acid identity in a stretch of 39 consecutive amino acids of each protein, without any gap.

Consequently, one aim of the present invention is to provide for polynucleotides derived from the *G713* gene, particularly those useful to design suitable means for detecting the presence of this gene in a test sample or alternatively the *G713* mRNA
10 molecules that are present in a test sample. Other polynucleotides of the invention are useful to design suitable means to express a desired polynucleotide of interest. The invention also relates to a *G713* polypeptide.

Linkage analyses such as those noted above which led to the observation of a candidate region for schizophrenia on the chromosome 13q32 locus (Blouin et al.,
15 1998) have generally been applied to map simple genetic traits that show clear Mendelian inheritance patterns and which have a high penetrance, but this method suffers from a variety of drawbacks. First, linkage analysis is limited by its reliance on the choice of a genetic model suitable for each studied trait. Furthermore, the resolution attainable using linkage analysis is limited, and complementary studies are
20 required to refine the analysis of the typical 20 Mb regions initially identified through this method. In addition, linkage analysis have proven difficult when applied to complex genetic traits, such as those due to the combined action of multiple genes and/or environmental factors. In such cases, too large an effort and cost are needed to recruit the adequate number of affected families required for applying linkage analysis to
25 these situations. Finally, linkage analysis cannot be applied to the study of traits for which no large informative families are available.

In addition to providing the *G713* polynucleotides and polypeptides discussed above, the present inventors have also discovered alternative means in order to conduct association studies rather than linkage analysis between markers located on
30 the chromosome 13q31-q33 locus and a trait, preferably schizophrenia. More particularly, the inventors have identified biallelic markers and sets of biallelic markers located on the human chromosome 13q31-q33, which biallelic markers or set of biallelic markers have one allele or haplotypes associated with schizophrenia, as it will be further described in details in the present specification. The identification of these
35 biallelic markers in association with schizophrenia has allowed them to narrow the

chromosomal region suspected to contain a genetic determinant involved in predisposition to schizophrenia from about 20 Mb to about 2 Mb. The determination of a narrow chromosomal region harboring a genetic determinant involved in predisposition to schizophrenia was the necessary step towards the identification of the causal or co-factor gene located therein. The borders of this region are defined by two AFM genetic markers : AFM248f1-D13S174 and AFM102xd12-D13S1311, the nucleotide sequences of these markers being both publicly available in the Genbank database.

The association found between the biallelic markers described herein and predisposition to schizophrenia represent a strong presumption on the presence of at least one schizophrenia predisposition gene in this particular genomic region.

These identified polymorphisms are used in the design of assays for the reliable detection of genetic susceptibility to schizophrenia. They can also be used in the design of drug screening protocols to provide an accurate and efficient evaluation of the therapeutic and side-effect potential of new or already existing.

DEFINITIONS

Before describing the invention in greater detail, the following definitions are set forth to illustrate and define the meaning and scope of the terms used to describe the invention herein.

Otherwise indicated, *G713* is used throughout the present description to designate a nucleic acid derived from the human *G713* genomic or mRNA molecules.

The term "heterologous protein", when used herein, is intended to designate any protein or polypeptide other than the *G713* protein. More particularly, the heterologous protein is a compound which can be used as a marker in further experiments with a *G713* regulatory region.

The term "isolated" requires that the material be removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or DNA or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotide could be part of a vector and/or such polynucleotide or polypeptide could be part of a composition, and still be isolated in that the vector or composition is not part of its natural environment.

The term "purified" does not require absolute purity; rather, it is intended as a relative definition. Purification of starting material or natural material to at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated. As an example, purification from 0.1 % concentration to 10 % concentration is two orders of magnitude.

Throughout the present specification, the expression "nucleotide sequence" may be employed to designate indifferently a polynucleotide or a nucleic acid. More precisely, the expression "nucleotide sequence" encompasses the nucleic material itself and is thus not restricted to the sequence information (i.e. the succession of letters chosen among the four base letters) that biochemically characterizes a specific DNA or RNA molecule.

The term "polynucleotide" is understood to mean deoxyribonucleic acid or ribonucleic acid fragments or, more generally, polynucleotides or oligonucleotides where the bases, inter-nucleotide phosphate linkages, or alternatively the ribose rings of the bases, can be chemically modified in a known manner. This may be especially oligonucleotides with α or β anomers, oligonucleotides with inter-nucleotide linkage of the phosphorothioate or methyl phosphonate type, or alternatively oligothionucleotide.

As used herein, the term "non-human animal" refers to any non-human vertebrate, birds and more usually mammals, preferably primates, farm animals such as swine, goats, sheep, donkeys, and horses, rabbits or rodents, more preferably rats or mice. As used herein, the term "animal" is used to refer to any vertebrate, preferable a mammal. Both the terms "animal" and "mammal" expressly embrace human subjects unless preceded with the term "non-human".

As used herein, the term "antibody" refers to a polypeptide or group of polypeptides which are comprised of at least one binding domain, where an antibody binding domain is formed from the folding of variable domains of an antibody molecule to form three-dimensional binding spaces with an internal surface shape and charge distribution complementary to the features of an antigenic determinant of an antigen, which allows an immunological reaction with the antigen. Antibodies include recombinant proteins comprising the binding domains, as wells as fragments, including Fab, Fab', F(ab)₂, and F(ab')₂ fragments.

As used herein, an "antigenic determinant" is the portion of an antigen molecule, in this case a G713 polypeptide, that determines the specificity of the antigen-antibody reaction. An "epitope" refers to an antigenic determinant of a polypeptide. An epitope can comprise as few as 3 amino acids in a spatial

conformation which is unique to the epitope. Generally an epitope comprises at least 6 such amino acids, and more usually at least 8-10 such amino acids. Methods for determining the amino acids which make up an epitope include x-ray crystallography, 2-dimensional nuclear magnetic resonance, and epitope mapping e.g. the Pepscan method described by Geysen et al. 1984; PCT Publication No. WO 84/03564; and PCT Publication No. WO 84/03506.

The term "polymorphism" as used herein refers to the occurrence of two or more alternative genomic sequences or alleles between or among different genomes or individuals. "Polymorphic" refers to the condition in which two or more variants of a specific genomic sequence can be found in a population. A "polymorphic site" is the locus at which the variation occurs. A single nucleotide polymorphism is the replacement of one nucleotide by another nucleotide at the polymorphic site. Deletion of a single nucleotide or insertion of a single nucleotide also gives rise to single nucleotide polymorphisms. In the context of the present invention, "single nucleotide polymorphism" preferably refers to a single nucleotide substitution. Typically, between different individuals, the polymorphic site may be occupied by two different nucleotides.

The term "biallelic polymorphism" and "biallelic marker" are used interchangeably herein to refer to a single nucleotide polymorphism having two alleles at a fairly high frequency in the population. A "biallelic marker allele" refers to the nucleotide variants present at a biallelic marker site. Typically, the frequency of the less common allele of the biallelic markers of the present invention has been validated to be greater than 1%, preferably the frequency is greater than 10%, more preferably the frequency is at least 20% (i.e. heterozygosity rate of at least 0.32), even more preferably the frequency is at least 30% (i.e. heterozygosity rate of at least 0.42). A biallelic marker wherein the frequency of the less common allele is 30% or more is termed a "high quality biallelic marker".

The location of nucleotides in a polynucleotide with respect to the center of the polynucleotide are described herein in the following manner. When a polynucleotide has an odd number of nucleotides, the nucleotide at an equal distance from the 3' and 5' ends of the polynucleotide is considered to be "at the center" of the polynucleotide, and any nucleotide immediately adjacent to the nucleotide at the center, or the nucleotide at the center itself is considered to be "within 1 nucleotide of the center." With an odd number of nucleotides in a polynucleotide any of the five nucleotides positions in the middle of the polynucleotide would be considered to be within 2 nucleotides of the center, and so on. When a polynucleotide has an even number of

nucleotides, there would be a bond and not a nucleotide at the center of the polynucleotide. Thus, either of the two central nucleotides would be considered to be "within 1 nucleotide of the center" and any of the four nucleotides in the middle of the polynucleotide would be considered to be "within 2 nucleotides of the center", and so on. For polymorphisms which involve the substitution, insertion or deletion of 1 or more nucleotides, the polymorphism, allele or biallelic marker is "at the center" of a polynucleotide if the difference between the distance from the substituted, inserted, or deleted polynucleotides of the polymorphism and the 3' end of the polynucleotide, and the distance from the substituted, inserted, or deleted polynucleotides of the polymorphism and the 5' end of the polynucleotide is zero or one nucleotide. If this difference is 0 to 3, then the polymorphism is considered to be "within 1 nucleotide of the center." If the difference is 0 to 5, the polymorphism is considered to be "within 2 nucleotides of the center." If the difference is 0 to 7, the polymorphism is considered to be "within 3 nucleotides of the center," and so on.

As used herein the term "G713-related biallelic marker" relates to a set of biallelic markers in linkage disequilibrium with the G713 gene or a G713 nucleotide sequence. The term G713-related biallelic marker encompasses the biallelic markers A1 to A11 disclosed in Table 2 and any biallelic markers in linkage disequilibrium therewith. The preferred G713-related biallelic marker alleles of the present invention include each one the alleles described in Table 2 individually or in groups consisting of all the possible combinations of the alleles listed.

As used herein the term "13q31-q33-related biallelic marker" relates to a set of biallelic markers residing in the human chromosome 13q31-q33 region. The term 13q31-q33-related biallelic marker encompasses all of the biallelic markers A12 to A49 disclosed in Table 7 as well as biallelic markers in linkage disequilibrium therewith. The preferred chromosome 13q31-q33-related biallelic marker alleles of the present invention include each one the alleles described in Table 7 individually or in groups consisting of all the possible combinations of the alleles listed.

The term "primer" denotes a specific oligonucleotide sequence which is complementary to a target nucleotide sequence and used to hybridize to the target nucleotide sequence. A primer serves as an initiation point for nucleotide polymerization catalyzed by either DNA polymerase, RNA polymerase or reverse transcriptase.

The term "probe" denotes a defined nucleic acid segment (or nucleotide analog segment, e.g., polynucleotide as defined hereinbelow) which can be used to identify a

specific polynucleotide sequence present in samples, said nucleic acid segment comprising a nucleotide sequence complementary of the specific polynucleotide sequence to be identified.

The terms "trait" and "phenotype" are used interchangeably herein and refer to any visible, detectable or otherwise measurable property of an organism such as symptoms of, or susceptibility to a disease for example. Typically the terms "trait" or "phenotype" are used herein to refer to symptoms of, or susceptibility to a disease, a beneficial response to or side effects related to a treatment. Preferably, said trait can be, without to be limited to, cancers, developmental diseases, and neurological diseases.

The term "allele" is used herein to refer to variants of a nucleotide sequence. A biallelic polymorphism has two forms. Diploid organisms may be homozygous or heterozygous for an allelic form.

The term "heterozygosity rate" is used herein to refer to the incidence of individuals in a population, which are heterozygous at a particular allele. In a biallelic system the heterozygosity rate is on average equal to $2P_a(1-P_a)$, where P_a is the frequency of the least common allele. In order to be useful in genetic studies a genetic marker should have an adequate level of heterozygosity to allow a reasonable probability that a randomly selected person will be heterozygous.

The term "genotype" as used herein refers the identity of the alleles present in an individual or a sample. In the context of the present invention a genotype preferably refers to the description of the biallelic marker alleles present in an individual or a sample. The term "genotyping" a sample or an individual for a biallelic marker consists of determining the specific allele or the specific nucleotide(s) carried by an individual at a biallelic marker.

The term "mutation" as used herein refers to a difference in DNA sequence between or among different genomes or individuals which has a frequency below 1%.

The term "haplotype" refers to a combination of alleles present in an individual or a sample on a single chromosome. In the context of the present invention a haplotype preferably refers to a combination of biallelic marker alleles found in a given individual and which may be associated with a phenotype.

The term "upstream" is used herein to refer to a location which, is toward the 5' end of the polynucleotide from a specific reference point.

The terms "base paired" and "Watson & Crick base paired" are used interchangeably herein to refer to nucleotides which can be hydrogen bonded to one

another be virtue of their sequence identities in a manner like that found in double-helical DNA with thymine or uracil residues linked to adenine residues by two hydrogen bonds and cytosine and guanine residues linked by three hydrogen bonds (See Stryer, L., *Biochemistry*, 4th edition, 1995).

5 The terms "complementary" or "complement thereof" are used herein to refer to the sequences of polynucleotides which is capable of forming Watson & Crick base pairing with another specified polynucleotide throughout the entirety of the complementary region. This term is applied to pairs of polynucleotides based solely upon their sequences and not any particular set of conditions under which the two
10 polynucleotides would actually bind.

 As used herein, the term "operably linked" refers to a linkage of polynucleotide elements in a functional relationship. For instance, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the coding sequence.

15 **Variants and fragments**

1- Polynucleotides

 The invention also relates to variants and fragments of the polynucleotides described herein, particularly of a G713 or a 13q31-q33 polynucleotide, and particularly of a G713 or a 13q31-q33 polynucleotide containing one or more biallelic markers
20 according to the invention.

 Variants of polynucleotides, as the term is used herein, are polynucleotides that differ from a reference polynucleotide. A variant of a polynucleotide may be a naturally occurring variant such as a naturally occurring allelic variant, or it may be a variant that is not known to occur naturally. Such non-naturally occurring variants of the
25 polynucleotide may be made by mutagenesis techniques, including those applied to polynucleotides, cells or organisms. Generally, differences are limited so that the nucleotide sequences of the reference and the variant are closely similar overall and, in many regions, identical.

 Changes in the nucleotide of a variant may be silent, which means that they do
30 not alter the amino acids encoded by the polynucleotide.

 However, nucleotide changes may also result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence. The substitutions, deletions or additions may involve one or more nucleotides. The variants may be altered in coding or non-coding regions or both.

Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or additions.

In the context of the present invention, particularly preferred embodiments of a *G713* polynucleotide are those in which the polynucleotides encode polypeptides which retain substantially the same biological function or activity as the mature *G713* protein.

A *G713* polynucleotide fragment is a polynucleotide having a sequence that entirely is the same as part but not all of a given nucleotide sequence, preferably the nucleotide sequence of a *G713* gene, and variants thereof. The fragment can be a portion of an exon or of an intron of a *G713* gene. It can also be a portion of the regulatory sequences of the *G713* gene, preferably of the promoter. Preferably, such fragments comprise at least one of the biallelic markers A1 to A11 or a biallelic marker in linkage disequilibrium with one or more of the biallelic markers A1 to A11.

Variants of *G713* and 13q31-q33 polynucleotides according to the invention include, without being limited to, nucleotide sequences at least 95% identical to a nucleic acid selected from the group consisting of SEQ ID Nos 1-4, 6 and 31-69 or to any polynucleotide fragment of at least 8 consecutive nucleotides from a nucleic acid selected from the group consisting of SEQ ID Nos 1-4, 6 and 31-69 and preferably at least 99% identical, more particularly at least 99.5% identical, and most preferably at least 99.8% identical to a nucleic acid selected from the group consisting of SEQ ID Nos 1-4, 6 and 31-69 or to any polynucleotide fragment of at least 8 consecutive nucleotides of these nucleic acids.

Such fragments may be "free-standing", i.e. not part of or fused to other polynucleotides, or they may be comprised within a single larger polynucleotide of which they form a part or region. However, several fragments may be comprised within a single larger polynucleotide.

As representative examples of polynucleotide fragments of the invention, there may be mentioned those which have from about 4, 6, 8, 15, 20, 25, 40, 10 to 30, 30 to 55, 50 to 100, 75 to 100 or 100 to 200 nucleotides in length. Preferred are those fragments having about 47 nucleotides in length and containing at least one of the *G713* or 13q31-q33 biallelic markers which are described herein. It will of course be understood that the polynucleotides of SEQ ID 1-4, 6 and 31-69 can be shorter or longer, although it is preferred that they at least contain the biallelic marker of the primer which can be located at one end of the fragment.

2- Polypeptides

The invention also relates to variants, fragments, analogs and derivatives of the polypeptides described herein, including mutated human and mouse G713 proteins.

The variant may be 1) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue and such substituted amino acid residue may or may not be one encoded by the genetic code, or 2) one in which one or more of the amino acid residues includes a substituent group, or 3) one in which the mutated G713 is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or 4) one in which the additional amino acids are fused to the mutated G713, such as a leader or secretory sequence or a sequence which is employed for purification of the mutated G713 or a preprotein sequence. Such variants are deemed to be within the scope of those skilled in the art.

A polypeptide fragment is a polypeptide having a sequence that entirely is the same as part but not all of a given polypeptide sequence, preferably a polypeptide encoded by a G713 gene and variants thereof.

Such fragments may be "free-standing", i.e. not part of or fused to other polypeptides, or they may be comprised within a single larger polypeptide of which they form a part or region. However, several fragments may be comprised within a single larger polypeptide.

As representative examples of polypeptide fragments of the invention, there may be mentioned those which have from about 5, 6, 7, 8, 9 or 10 to 15, 10 to 20, 15 to 40, or 30 to 55 amino acids long. Preferred are those fragments containing at least one amino acid mutation in the G713 protein.

More particularly, a variant G713 polypeptide comprises amino acid changes ranging from 1, 2, 3, 4, 5, 10 to 20 substitutions, additions or deletions of one amino acid, preferably from 1 to 10, more preferably from 1 to 5 and most preferably from 1 to 3 substitutions, additions or deletions of one amino acid. The preferred amino acid changes are those which have little or no influence on the biological activity or the capacity of the variant G713 polypeptide to be recognized by antibodies raised against a native G713 protein.

By homologous peptide according to the present invention is meant a polypeptide containing one or several amino acid additions, deletions and/or substitutions in the amino acid sequence of a G713 polypeptide. In the case of an

aminoacid substitution, one or several -consecutive or non-consecutive- amino acids are replaced by "equivalent" amino acids.

The expression "equivalent" amino acid is used herein to designate any amino acid that may be substituted for one of the amino acids having similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydropathic nature of the polypeptide to be substantially unchanged. Generally, the following groups of amino acids represent equivalent changes: (1) Ala, Pro, Gly, Glu, Asp, Gln, Asn, Ser, Thr; (2) Cys, Ser, Tyr, Thr; (3) Val, Ile, Leu, Met, Ala, Phe; (4) Lys, Arg, His; (5) Phe, Tyr, Trp, His.

By an equivalent aminoacid according to the present invention is also meant the replacement of a residue in the L-form by a residue in the D form or the replacement of a Glutamic acid (E) residue by a Pyro-glutamic acid compound. The synthesis of peptides containing at least one residue in the D-form is, for example, described by Koch (1977).

A specific, but not restrictive, embodiment of a modified peptide molecule of interest according to the present invention, which consists in a peptide molecule which is resistant to proteolysis, is a peptide in which the -CONH- peptide bond is modified and replaced by a (CH₂NH) reduced bond, a (NHCO) retro inverso bond, a (CH₂-O) methylene-oxy bond, a (CH₂-S) thiomethylene bond, a (CH₂CH₂) carba bond, a (CO-CH₂) cetomethylene bond, a (CHOH-CH₂) hydroxyethylene bond), a (N-N) bound, a E-alcene bond or also a -CH=CH- bond.

The polypeptide according to the invention could have post-translational modifications. For example, it can present the following modifications: acylation, disulfide bond formation, prenylation, carboxymethylation and phosphorylation.

Complementary polynucleotides

For the purpose of the present invention, a first polynucleotide is deemed to be complementary to a second polynucleotide when each base in the first polynucleotide is paired with its complementary base. Complementary bases are, generally, A and T (or A and U), or C and G.

Identity between nucleic acids or polypeptides

The terms "percentage of sequence identity" and "percentage homology" are used interchangeably herein to refer to comparisons among polynucleotides and polypeptides, and are determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions (i.e., gaps)

as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity. Homology is evaluated using any of the variety of sequence comparison algorithms and programs known in the art. Such algorithms and programs include, but are by no means limited to, TBLASTN, BLASTP, FASTA, TFASTA, and CLUSTALW (Pearson and Lipman, 1988; Altschul et al., 1990; Thompson et al., 1994; Higgins et al., 1996; Altschul et al., 1993). In a particularly preferred embodiment, protein and nucleic acid sequence homologies are evaluated using the Basic Local Alignment Search Tool ("BLAST") which is well known in the art (see, e.g., Karlin and Altschul, 1990; Altschul et al., 1990, 1993, 1997). In particular, five specific BLAST programs are used to perform the following task:

- (1) BLASTP and BLAST3 compare an amino acid query sequence against a protein sequence database;
- (2) BLASTN compares a nucleotide query sequence against a nucleotide sequence database;
- (3) BLASTX compares the six-frame conceptual translation products of a query nucleotide sequence (both strands) against a protein sequence database;
- (4) TBLASTN compares a query protein sequence against a nucleotide sequence database translated in all six reading frames (both strands); and
- (5) TBLASTX compares the six-frame translations of a nucleotide query sequence against the six-frame translations of a nucleotide sequence database.

The BLAST programs identify homologous sequences by identifying similar segments, which are referred to herein as "high-scoring segment pairs," between a query amino or nucleic acid sequence and a test sequence which is preferably obtained from a protein or nucleic acid sequence database. High-scoring segment pairs are preferably identified (i.e., aligned) by means of a scoring matrix, many of which are known in the art. Preferably, the scoring matrix used is the BLOSUM62 matrix (Gonnet et al., 1992; Henikoff and Henikoff, 1993). Less preferably, the PAM or PAM250 matrices may also be used (see, e.g., Schwartz and Dayhoff, eds., 1978). The BLAST programs evaluate the statistical significance of all high-scoring segment pairs identified, and preferably selects those segments which satisfy a user-specified

threshold of significance, such as a user-specified percent homology. Preferably, the statistical significance of a high-scoring segment pair is evaluated using the statistical significance formula of Karlin (see, e.g., Karlin and Altschul, 1990).

Stringent Hybridization Conditions

By way of example and not limitation, procedures using conditions of high stringency are as follows: Prehybridization of filters containing DNA is carried out for 8 h to overnight at 65°C in buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 µg/ml denatured salmon sperm DNA. Filters are hybridized for 48 h at 65°C, the preferred hybridization temperature, in prehybridization mixture containing 100 µg/ml denatured salmon sperm DNA and 5-20 X 10⁶ cpm of ³²P-labeled probe. Alternatively, the hybridization step can be performed at 65°C in the presence of SSC buffer, 1 x SSC corresponding to 0.15M NaCl and 0.05 M Na citrate. Subsequently, filter washes can be done at 37°C for 1 h in a solution containing 2 x SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA, followed by a wash in 0.1 X SSC at 50°C for 45 min. Alternatively, filter washes can be performed in a solution containing 2 x SSC and 0.1% SDS, or 0.5 x SSC and 0.1% SDS, or 0.1 x SSC and 0.1% SDS at 68°C for 15 minute intervals. Following the wash steps, the hybridized probes are detectable by autoradiography. Other conditions of high stringency which may be used are well known in the art and as cited in Sambrook et al., 1989; and Ausubel et al., 1989, are incorporated herein in their entirety. These hybridization conditions are suitable for a nucleic acid molecule of about 20 nucleotides in length. There is no need to say that the hybridization conditions described above are to be adapted according to the length of the desired nucleic acid, following techniques well known to the one skilled in the art. The suitable hybridization conditions may for example be adapted according to the teachings disclosed in the book of Hames and Higgins (1985) or in Sambrook et al.(1989).

BRIEF DESCRIPTION OF THE SEQUENCES PROVIDED IN THE SEQUENCE LISTING

SEQ ID	DESCRIPTION
1	5'-regulatory region + Exon 1 + 5'-end of Intron 1 of <i>hG713</i>
2	3'-end of Intron 1 + Exon 2 of human <i>G713</i> + 5'-end of Intron 2 of <i>hG713</i>
3	3'-end of Intron 2 + Exon 3 + 3'-regulatory region of <i>hG713</i>
4	cDNA of <i>hG713</i>

5	Protein encoded by the cDNA of SEQ ID No 4
6	cDNA of the mouse <i>G713</i>
7	Protein encoded by the cDNA of SEQ ID No 6
8-25	Primers used for isolating the <i>G713</i> cDNA
26-30	Primers used for isolating the <i>mG713</i> cDNA
31	Candidate genomic nucleotide sequence located in the region of the biallelic markers associated with schizophrenia and containing a sequence specifically expressed in individuals affected by schizophrenia.
32-69	Amplification fragments containing the nucleotide sequence of the amplicons which comprise the biallelic markers A12 to A49 located on the human chromosome 13q31-q33 locus.
70	SEQ ID No PU contains a primer containing the additional PU 5' sequence described further in Examples 1(c) and 2(b)
71	SEQ ID No RP contains a primer containing the additional RP 5' sequence described further in Examples 1(c) and 2(b)

In accordance with the regulations relating to Sequence Listings, the following codes have been used in the Sequence Listing to indicate the locations of biallelic markers within the sequences and to identify each of the alleles present at the polymorphic base. The code "r" in the sequences indicates that one allele of the polymorphic base is a guanine, while the other allele is an adenine. The code "y" in the sequences indicates that one allele of the polymorphic base is a thymine, while the other allele is a cytosine. The code "m" in the sequences indicates that one allele of the polymorphic base is an adenine, while the other allele is an cytosine. The code "k" in the sequences indicates that one allele of the polymorphic base is a guanine, while the other allele is a thymine. The code "s" in the sequences indicates that one allele of the polymorphic base is a guanine, while the other allele is a cytosine. The code "w" in the sequences indicates that one allele of the polymorphic base is an adenine, while the other allele is an thymine. The nucleotide code of the original allele at each biallelic marker position has been designated "allele 1" in Tables 2 and 7, and the alternative allele has been designated "allele 2" in Tables 2 and 7.

In some instances, the polymorphic bases of the biallelic markers alter the identity of an amino acids in the encoded polypeptide. This is indicated in the accompanying Sequence Listing by use of the feature VARIANT, placement of an Xaa at the position of the polymorphic amino acid, and definition of Xaa as the two alternative amino acids. For example if one allele of a biallelic marker is the codon CAC, which encodes histidine, while the other allele of the biallelic marker is CAA, which encodes glutamine, the Sequence Listing for the encoded polypeptide will

contain an Xaa at the location of the polymorphic amino acid. In this instance, Xaa would be defined as being histidine or glutamine.

In other instances, Xaa may indicate an amino acid whose identity is unknown. In this instance, the feature UNSURE is used, placement of an Xaa at the position of the unknown amino acid and definition of Xaa as being any of the 20 amino acids or being unknown.

STRATEGY USED FOR IDENTIFYING BOTH mRNA AND GENOMIC SEQUENCES OF THE G713 GENE

a) Isolation of partial G713 cDNA molecules

Isolation of a first partial cDNA (1.3 kb)

Starting from the results of linkage analysis indicating that a valuable central nervous system disorder candidate gene might be located on the chromosome 13q33 locus, an analysis of integrated data of the CEPH-Genethon human genome map (http://www.genethon.fr/genethon_en.html) with Genemap of the human genome (<http://www.ncbi.nlm.nih.gov/SCIENCE96/>) allowed the identification of several clusters of cDNA expressed at least in human brain and assigned to chromosome13. None of the selected transcripts coded for known human genes. One of the selected transcripts has been chosen for further study. A portion of this cDNA fragment is present in an anonymous EST cDNA clone –clone 46473- belonging to the Soares cDNA library of infant brain. Two end sequences of this clone are referenced in the Genbank database, respectively under the accession numbers H09867 (5'-end sequence of clone 46473) and H09780 (3'-end sequence of clone 46473). These end sequences were used to design the two following primers :

- Forward primer g713LF1, designed from the sequence of Genbank Accession number H089867 : 5'- CGCTTGCTTCTGTCTGTGTAACC-3' (SEQ ID No 8), and
- Reverse primer g713LR1, designed from the sequence of Genbank Accession number H09780 : 5'- GTATTTGCGCAGACCATTTTAAGATT-3' (SEQ ID No 9).

5'-extension of the first partial cDNA

A Long Range PCR amplification of the cDNA from the human fetal brain Marathon™ ready library (Clontech, Palo Alto, CA, USA, Cat. Ref n° 7402-1) was performed with the pair of primers g713LF1 and g713LR1. A cDNA fragment of a length of 1.3 kb was amplified, said amplified fragment being subsequently cloned in the proprietary pGenDel vector (US Patent Application N° US 09/058,746 filed on April

10, 1998). The insert has been sequenced by several cycles of primer walking. Sequencing confirmed the presence of structures identical to the sequences of Genbank accession numbers H09867 and H09780, respectively at the 5'-end and at the 3'-end of this 1.3 kb cDNA fragment. Analysis of the entire sequence of the 1.3 kb cDNA fragment showed the absence of any potential coding Open Reading Frame.

In order to isolate the complete 5' portion of the cDNA containing the above 1.3 kb fragment, a RACE (Rapid Amplification of cDNA Ends) has been performed on the cDNA from the human fetal brain Marathon™ ready library using the following primers :

- Primer 713.LF1.5.1 : 5'- ACTGTCTGATTCCACCTATTATGGAG-3' (SEQ ID No 10),
- and
- Primer g713.LF1.5.1n : 5'- TGATTCCACCTATTATGGAGAGCAC-3' (SEQ ID No 11).

Amplification led to the production of a heterogeneous product that has been sequenced with the following nested primer :

Primer g713RACE5R1 : 5'- GGGTAGAAGGGAGACTTAGG- 3' (SEQ ID No 12).

Sequencing gave a 68 bp sequence of very poor quality that contains AT rich repeats.

Another sequencing primer was designed from the 68 bp sequence, which is the following:

Primer g713RACE5R-49 : 5'- GGGCATAGCAATCATTC-3' (SEQ ID No 13).

This primer has been successfully used to determine the partial sequence of the amplified product resulting from the 5'-RACE reaction. This partial sequence has been compared with the nucleotide sequences referenced in Genbank and has been found to be highly homologous to a partial transcript named CTG-A4 (Genbank Accession Number L10374) containing CTG repeats.

Isolation of a 3.2 kb G713 cDNA molecule

cDNA from the human fetal brain Marathon™ ready library was amplified with the following pair of primers :

- Primer derived from the 5'-end of the CTG-A4 sequence (g713CTGLF132) :
5'- GGCTGTGCGTTCCCAAATA-3' (SEQ ID No 14) ; and
- Primer derived from the 3' end of the previously sequenced 1.3 kb cDNA fragment (g713LR1) : 5'- GTATTTGCGCAGACCATTTTAAGATT-3' (SEQ ID No 9).

The amplification reaction yielded to a 3.2 kb cDNA fragment that has been sequenced by primer walking and sub-cloning. Physical linkage between the CTG-A4 fragment and the 1.3 kb fragment was confirmed and a new AT rich repeat between them was identified and sequenced.

3'-extension of the first partial cDNA.

In order to amplify cDNA extending towards the 3'-end of the first partial cDNA, the following primers derived from the 3'-end of the 3.2 kb cDNA described above have been designed :

- Primer (g713RACE3N) : 5'- AAAAATGTTTCGTTCCAGTCTGTTAAGA-3' (SEQ ID No 15); and

- Primer (g713RACE3Nn) : 5'- ATTGCTAGAATTGTTTAGCAGTACATGCA-3' (SEQ ID No 16).

The amplification reaction of the cDNA from the human fetal brain Marathon™ ready library yielded to a 2.5 kb cDNA fragment. A partial sequence of this 2.5 kb cDNA fragment presented a high homology with two ESTs referenced in Genbank under the Accession numbers AA424106 and AA424056. ESTs AA424106 and AA424056 are respectively the 5'-end sequence and the 3'-end sequence of the cDNA clone n° 759953 from the Soares total fetus Nb2HF8 9w human cDNA library. It was found that this publicly available clone terminates in a poly-A tract and contains a polyadenylation signal.

Isolation of a longer G713 cDNA (first attempt to isolate the full length G713 cDNA)

A first strand cDNA synthesis specific primer has been designed from the 3'-end sequence of the cDNA clone n° 759953, this primer (SG1polyA) sequence being the following :

5'- TTTTTTTTTTTTGACAGAG-3' (SEQ ID No 17). A cDNA has been synthesized with the SG1polyA primer, using as template a human fetal brain mRNA library (Clontech, Palo Alto, CA, USA, Cat. Ref. 64019-1). The resulting cDNA produced has then been used as a substrate for a Long Range PCR amplification with the following pair of primers :

- Primer g713CTGLF132 described above, derived from the 5'-end of the G713 transcript : 5'- GGCTGTGCGTTCCCAAATA-3' (SEQ ID No 14); and

- Primer SG1LR100 derived from the Genbank nucleic acid sequence referenced under the accession number AA424056 : 5'- TTTGCCATTTAGCTTAGCAGTACCA-3' (SEQ ID No 18).

The Long Range PCR amplification reaction yielded to a cDNA fragment of 4.5 kb in length that has been sequenced by primer walking with specially designed specific primers.

b) Isolation of the G713 genomic sequences

A BAC library covering the whole human genome has been screened with the two following STSs:

- STS-g713, derived from the 3'-end of the above described 4.5 kb transcript, which is amplified by the following pairs of primers :

Primer 1 :5'- AATATTCTTAACAGACTGGAAC-3' (SEQ ID No 19);

Primer 2 : 5'-CTTTATAGCTATGAAATTTCCC-3' (146 55) (SEQ ID No 20) ; and

- STS g34301, derived from the 5'half of the above described 4.5 kb transcript and containing CAG repeats, this STS being amplified by the following pair of primers :

Primer 1 :5'- CTGATCACTTGTGGTTCTGCGCCG-3' (SEQ ID No 21) ;

Primer 2 : AGGACTCCCCCATGCTCGCCAG-3' (183 67) (SEQ ID No 22).

Three positive BACs were selected after performing the screening with these two above STSs.

STS-g713 positive BAC n° B0106A08 was subcloned in the vector pGen Del (described in the US Patent Application N° US 09/058,746 filed on April 10, 1998) and has been sequenced. The G713 Exons and the 5'- and 3'- adjacent intronic sequences from BAC n° B0106A08 were sequenced directly with the help of the cDNA sequencing primers. BAC n° B0106A08 has been found to contain a portion of the first intron and the two last exons of the G713 gene.

STS-g34301 positive BACs n° B1090E12 and n° B0852B05 have been partially sequenced with the help of the g713 cDNA primers. Both BACs contain the first exon and a portion of the first intron of the G713 gene but do not contain any of the two last exons. The end sequences of the inserts from the BACs n° B0106A08, B1090E12 and B0852B05 were determined and were used to generate STSs for further screening of the BAC library in order to clone the entire intron 1.

c) Isolating the full length cDNA of G713

Sequences immediately upstream of the above described G713 transcript have been determined by several rounds of primer walking using BAC DNA of either BAC n° B1090E12 or n° B0852B05. Complex repeats were found in these regions, which explain the previous failure of the inventors to sequence the 5'-end of the G713 cDNA by RACE PCR, as described hereinbefore.

A serial of Long Range PCR primers was generated from this region and was used in combination with the following primers :

- Primer SG1LR1102, derived from Exon 2 of *G713* :

5'- AAAATACTGGGAACAGAGCCAGG-3' (SEQ ID No : 23); and

- Primer specific of SG1polyA : 5'- TTTTTTTTTTTTGTACAGAG-3' (SEQ ID No : 17), in order to amplify a cDNA fragment containing Exon 1 and Exon 2 of the *G713* cDNA.

5 This reconstruction experiments indicate that mRNA from the *G713* gene starts at least few hundred bases upstream of the previously determined cDNA sequence. The last primer giving detectable amplification from *G713* specific cDNA is Primer SG1LF790 (5'- GCACTTAGAGCGCGGGGT-3' – SEQ ID No 24).

10 The nearly full length clone of *G713* has been produced by amplification from the first strand SG1polyA (5'- TTTTTTTTTTTTGTACAGAG-3' – SEQ ID No 17) specific DNA with the following couple of primers :

- Primer SG1LF834 : 5'- GCCGGAGGCAGCCCA-3' (SEQ ID No 25); and

- Primer SG1LR100 : 5'- TTTGCCATTAGCTTAGCAGTACCA-3' (SEQ ID No 18).

15 This molecule has been cloned and sequenced in order to confirm the deduced full transcript structure, which is described in the nucleic acid sequence of SEQ ID No 4.

G713 genomic polynucleotide, cDNA and associated regulatory regions

G713 genomic sequences

20 The invention concerns a purified, isolated or recombinant nucleic acid encoding the *G713* polypeptide. The present invention concerns the genomic sequence of *G713*, and in a particular aspect deals with a purified or isolated nucleic acid encoding a *G713* polypeptide, wherein said nucleic acid comprises a polynucleotide comprising the whole exons of the *G713* gene. In a specific
25 embodiment, such a purified or isolated nucleic acid may comprise, consist essentially of, or consist of, from 5'-end to 3'-end, the polynucleotide of SEQ ID No 1, the polynucleotide of SEQ ID No 2, the polynucleotide of SEQ ID No 3.

30 The invention also encompasses a purified, isolated, or recombinant polynucleotide comprising a nucleotide sequence having at least 70, 75, 80, 85, 90, or 95% nucleotide identity with a nucleotide sequence of SEQ ID Nos. 1,2 or 3 or a complementary sequence thereto or a fragment thereof. The nucleotide differences as regards to the nucleotide sequence of SEQ ID Nos. 1,2 or 3 may be generally randomly distributed throughout the entire nucleic acid. Nevertheless, preferred nucleic acids are those wherein the nucleotide differences as regards to the nucleotide

sequence of SEQ ID Nos. 1, 2 or 3 are predominantly located outside the coding sequences contained in the exons.

Another object of the invention consists of a purified, isolated, or recombinant nucleic acid that hybridizes with the nucleotide sequence of SEQ ID Nos. 1, 2 or 3 or a complementary sequence thereto or a variant thereof, under the stringent hybridization conditions as defined below.

Particularly preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID Nos. 1, 2 or 3 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID Nos 1, 2 and 3:

1 to 1000, 1001 to 2000, 2001 to 3000, 3001 to 4000 and 4001 to 5222 of SEQ ID No. 1;

1 to 1000, 1001 to 2000, 2001 to 3000, 3001 to 4000 and 4001 to 5000, 5001 to 6000, 6001 to 7000, 7001 to 8000, 8001 to 9000, 9001 to 10000, 10001 to 11000, 11001 to 12000, 12001 to 13000, 13001 to 14000, 14001 to 15000, 15001 to 16000, 16001 to 17000, 17001 to 18000, 18001 to 19000, 19001 to 20000 and 20001 to 21278 of SEQ ID No 2; and

1 to 1000, 1001 to 2000, 2001 to 3000, 3001 to 4000 and 4001 to 5000, 5001 to 6000, 6001 to 7000, 7001 to 8000, 8001 to 9000, 9001 to 10000, 10001 to 11000, 11001 to 12000, 12001 to 13000, 13001 to 14000, 14001 to 15000, 15001 to 16000, 16001 to 17000, 17001 to 18000, 18001 to 19000, 19001 to 20000, 20001 to 21000 and 21001 to 21636 of SEQ ID No 3.

Particularly preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID Nos 1, 2 or 3 or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions of:

SEQ ID No 1: 1 to 3236, 3547 to 3585 and 4649 to 5222, or a variant thereof or a sequence complementary thereto;

SEQ ID No 2: 1 to 16155 and 16331 to 21278 or a variant thereof or a sequence complementary thereto; and

SEQ ID No 3: 1 to 5531, 6844 to 7237, 7798 to 8184, 8667 to 9074, and 9356 to 21636, or a variant thereof or a sequence complementary thereto.

Further preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID Nos. 1, 2 or 3 or the complements thereof, wherein said contiguous span comprises a biallelic marker selected from the group consisting of the biallelic markers A1 to A11. It should be noted that nucleic acid fragments of any size and sequence may also be comprised by the polynucleotides described in this section.

Further preferred embodiments of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 1 or the complements thereof, wherein said contiguous span comprises the nucleotides AGAG at positions 3606 to 3609 of SEQ ID No 1.

As noted, the *G713* genomic nucleic acid comprises 3 exons. Exon 1 starts at the nucleotide in position 3076 and ends at the nucleotide in position 4643 of the nucleotide sequence of SEQ ID No 1; exon 2 starts at the nucleotide in position 16157 and ends at the nucleotide in position 16329 of the nucleotide sequence of SEQ ID No 2; exon 3 starts at the nucleotide in position 5537 and ends at the nucleotide in position 9359 of the nucleotide sequence of SEQ ID No 3. Thus, the invention embodies purified, isolated, or recombinant polynucleotides comprising a nucleotide sequence selected from the group consisting of the 3 exons of the *G713* gene, or a sequence complementary thereto. The invention also deals with purified, isolated, or recombinant nucleic acids comprising a combination of at least two exons of the *G713* gene, wherein the polynucleotides are arranged within the nucleic acid, from the 5'-end to the 3'-end of said nucleic acid, in the same order as in SEQ ID Nos 1, 2 and 3.

The *G713* genomic nucleic acid also comprises intronic polynucleotides that are located respectively at the 3'-end of Exon 1, both at the 5'-end and at the 3'-end of exon 2, and at the 5'-end of Exon 3, these intronic polynucleotides being respectively contained in the nucleic acids of SEQ ID Nos 1 to 3. The nucleic acids defining the *G713* intronic polynucleotides, as well as their fragments and variants, may be used as oligonucleotide primers or probes in order to detect the presence of a copy of the *G713* gene in a test sample, or alternatively in order to amplify a target nucleotide sequence within the *G713* intronic sequences.

These nucleic acids of the invention, as well as their fragments and variants, may be used as oligonucleotide primers or probes in order to detect the presence of a

copy of the *G713* gene in a test sample, or alternatively in order to amplify a target nucleotide sequence within the *G713* intronic sequences.

While this section is entitled "Genomic Sequences," it should be noted that nucleic acid fragments of any size and sequence may also be comprised by the polynucleotides described in this section, flanking the genomic sequences of *G713* on either side or between two or more such genomic sequences.

Human G713 cDNA

The inventors have discovered that the expression of the human *G713* gene leads to the production of at least one mRNA molecule, the cDNA sequence of which is set forth in SEQ ID No 4.

A portion of a cDNA whose sequence is closely related to the *G713* cDNA has been previously isolated by Li et al. (1993) and termed CTG-A4; the corresponding nucleotide sequence is referenced in the Genbank database as the accession number L10374. The sequence disclosed under the Genbank Accession Number L10374 has 99% nucleic acid homology with a portion of 2047 consecutive nucleotides of the *G713* cDNA.

More precisely, Li et al. have screened a human brain cDNA library with a (CTG)₁₀ probe in order to clone the cDNA inserts that hybridize thereto. 40 positive clones were selected, one of which was named CTG-A4. The CTG-A4 insert was assigned to human chromosome 13. Among the 8 novel partial cDNAs isolated by Li et al., several have repeat lengths that are highly polymorphic, making them valuable as PCR typeable linkage markers. This is not the case for the CTG-A4 polynucleotide, that showed only a slight heterozygosity (20%) with only 2 alleles detected.

An object of the invention is thus a purified, isolated, or recombinant nucleic acid comprising the nucleotide sequence of SEQ ID No 4, complementary sequences thereto, as well as allelic variants, and fragments thereof. Moreover, preferred polynucleotides of the invention include purified, isolated, or recombinant *G713* cDNAs consisting of, consisting essentially of, or comprising the sequence of SEQ ID No 4. Particularly preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 4 or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions of SEQ ID No 4: 1 to 519 and 2563 to 5566. Additional preferred embodiments of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20,

25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 4 or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions of SEQ ID No 4: 1 to 166, 473 to 519, 3020 to 3445, 3990 to 4394 and 4874 to 5281.

5 The Open Reading Frame encoding the *G713* protein spans from the nucleotide in position 659 and the nucleotide in position 2032 of the nucleotide sequence of SEQ ID No 4. A purified or isolated nucleic acid comprising the *G713* ORF is an object of the present invention.

10 The cDNA of SEQ ID No 4 includes a 5'-UTR region. This 5'-UTR region starts from the nucleotide at position 1 and ends at the nucleotide in position 658 of SEQ ID No 4. The cDNA of SEQ ID No 4 includes a 3'-UTR region starting from the nucleotide at position 2033 and ending at the nucleotide at position 5566 of SEQ ID No 4. Consequently, the invention concerns a purified, isolated, and recombinant nucleic acid comprising a nucleotide sequence of the 5'UTR of the *G713* cDNA, a sequence
15 complementary thereto, or an allelic variant thereof. The invention also concerns a purified, isolated, and recombinant nucleic acid comprising a nucleotide sequence of the 3'UTR of the *G713* cDNA, a sequence complementary thereto, or an allelic variant thereof.

20 The cDNA of SEQ ID No 4 harbors several polyadenylation signals, located at the following nucleotide positions of SEQ ID No 4: 2531 to 2536, 2538 to 2543, 2873 to 2878, 3307 to 3312, 3843 to 3848, 3859 to 3864, to 4524 to 4529 and 5536 to 5541.

Another object of the invention consists of a purified or isolated nucleic acid comprising the nucleotide sequence of SEQ ID No 4 or fragments thereof. Preferred *G713* cDNA fragments are those located outside the Open Reading Frame, such as
25 the 5'-UTR and the 3'-UTR nucleic acid sequences. The most preferred fragments of the nucleotide sequence of SEQ ID No 4 are comprised in the fragment located between the nucleotide in position 1 and the nucleotide in position 519 of the nucleotide sequence of SEQ ID No 4 and in the fragment located between the nucleotide in position 2563 and the nucleotide in position 5566 of the nucleotide
30 sequence of SEQ ID No 4.

The invention also pertains to a purified or isolated nucleic acid having at least having at least 85, 90, 95, 97, 98 or 99% of nucleotide identity with the nucleotide sequence of SEQ ID No 4, preferably 99.5% and most preferably 99.8% nucleotide identity with the nucleotide sequence of SEQ ID No 4, or a sequence complementary
35 thereto or a biologically active fragment thereof.

The nucleotide differences as regards to the nucleotide sequence of SEQ ID No 4 are generally randomly distributed throughout the entire nucleic acid. Nevertheless, preferred nucleic acids are those wherein the nucleotide differences as regards to the nucleotide sequence of SEQ ID No 4 are predominantly located outside the coding sequences, and more precisely in the 5'-UTR and the 3'-UTR sequences contained in the nucleotide sequence of SEQ ID No 4.

While this section is entitled "G713 cDNA", it should be noted that nucleic acid fragments of any size and sequence may also be comprised by the polynucleotides described in this section, flanking the genomic sequences of G713 on either side or between two or more such genomic sequences.

Murine orthologue of G713

The inventors have also found that the murine genome harbored a gene that is orthologue to G713, which will also be termed murine G713 or mG713. More precisely, the inventors have isolated a murine mRNA containing an Open Reading Frame that share a strong nucleic acid homology with G713 and which encodes for a protein having about 88% amino acid identity with the G713 protein.

Thus, an object of the present invention concerns a purified or isolated nucleic acid comprising the nucleotide sequence of SEQ ID No 6, complementary sequences thereto, as well as allelic variants or fragments or variants thereof. Moreover, preferred polynucleotides of the invention include purified, isolated, or recombinant G713 cDNAs consisting of, consisting essentially of, or comprising the sequence of SEQ ID No 6. Particularly preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 6 or the complements thereof

The Open Reading Frame encoding the mG713 protein spans from the nucleotide in position 51 and the nucleotide in position 1450 of the nucleotide sequence of SEQ ID No 6. A purified or isolated nucleic acid comprising the mG713 ORF is an object of the present invention.

The cDNA of SEQ ID No 6 includes a 5'-UTR region. This 5'-UTR region starts from the nucleotide at position 1 and ends at the nucleotide in position 50 of SEQ ID No 6. The cDNA of SEQ ID No 6 includes a 3'-UTR region starting from the nucleotide at position 1451 and ending at the nucleotide at position 1791 of SEQ ID No 6. Consequently, the invention concerns a purified, isolated, and recombinant nucleic acid comprising a nucleotide sequence of the 5'UTR of the mG713 cDNA, a sequence

complementary thereto, or an allelic variant thereof. The invention also concerns a purified, isolated, and recombinant nucleic acid comprising a nucleotide sequence of the 3'UTR of the *mG713* cDNA, a sequence complementary thereto, or an allelic variant thereof.

5 Another object of the invention consists of a purified or isolated nucleic acid comprising the nucleotide sequence of SEQ ID No 6 or fragments thereof.

The invention also pertains to a purified or isolated nucleic acid having at least 85, 90, 95, 97, 98 or 99% of nucleotide identity with the nucleotide sequence of SEQ ID No 6, preferably 99.5% and most preferably 99.8% nucleotide identity with the
10 nucleotide sequence of SEQ ID No 6.

The nucleotide differences as regards to the nucleotide sequence of SEQ ID No 6 are generally randomly distributed throughout the entire nucleic acid. Nevertheless, preferred nucleic acids are those wherein the nucleotide differences as regards to the nucleotide sequence of SEQ ID No 6 are predominantly located outside the coding
15 sequences, and more precisely in the 5'-UTR and the 3'-UTR sequences contained in the nucleotide sequence of SEQ ID No 6.

Regulatory sequences

As already mentioned hereinbefore, the genomic sequence of the *G713* gene contains regulatory sequences both in the non-coding 5'-flanking region and in the non-
20 coding 3'-flanking region that border the *G713* coding region containing the three exons of this gene.

The longest 5'-regulatory sequence of the *G713* gene is localized between the nucleotide in position 1076 and the nucleotide in position 3075 of the nucleotide sequence of SEQ ID No 1.

25 The longest 3'-regulatory sequence of the *G713* gene is localized between the nucleotide in position 16330 and the nucleotide in position 18329 of the nucleotide sequence of SEQ ID No 3.

Polynucleotides derived from the *G713* regulatory regions described above are useful in order to detect the presence of at least a copy of a nucleotide sequence
30 containing SEQ ID Nos 1 or 3 in a test sample.

Thus, a further object of the present invention consists of a purified or isolated nucleic acid that hybridizes under stringent hybridization conditions with a polynucleotide comprising the nucleotide positions 1076 to 3075 of SEQ ID No 1, or the nucleotide positions 16330 to 18329 of SEQ ID No 3, or a sequence
35 complementary thereto.

The promoter activity of the regulatory regions contained in the *G713* nucleotide sequence of SEQ ID No 1 can be assessed as described below.

In order to identify the relevant biologically active polynucleotide fragments or variants of SEQ ID Nos 1 or 3, the one skill in the art will refer to the book of Sambrook et al. (Sambrook, J. Fritsch, E. F., and T. Maniatis. 1989. Molecular cloning: a laboratory manual. 2ed. Cold Spring Harbor Laboratory, Cold spring Harbor, New York) which describes the use of a recombinant vector carrying a marker gene (i.e. beta galactosidase, chloramphenicol acetyl transferase, etc.) the expression of which will be detected when placed under the control of a biologically active polynucleotide fragments or variants of SEQ ID Nos 1 or 3. Genomic sequences located upstream of the first exon of the *G713* gene are cloned into a suitable promoter reporter vector, such as the pSEAP-Basic, pSEAP-Enhancer, p β gal-Basic, p β gal-Enhancer, or pEGFP-1 Promoter Reporter vectors available from Clontech, or pGL2-basic or pGL3-basic promoterless luciferase reporter gene vector from Promega. Briefly, each of these promoter reporter vectors include multiple cloning sites positioned upstream of a reporter gene encoding a readily assayable protein such as secreted alkaline phosphatase, luciferase, beta galactosidase, or green fluorescent protein. The sequences upstream the *G713* coding region are inserted into the cloning sites upstream of the reporter gene in both orientations and introduced into an appropriate host cell. The level of reporter protein is assayed and compared to the level obtained from a vector which lacks an insert in the cloning site. The presence of an elevated expression level in the vector containing the insert with respect to the control vector indicates the presence of a promoter in the insert. If necessary, the upstream sequences can be cloned into vectors which contain an enhancer for increasing transcription levels from weak promoter sequences. A significant level of expression above that observed with the vector lacking an insert indicates that a promoter sequence is present in the inserted upstream sequence.

Promoter sequences within the upstream genomic DNA may be further defined by constructing nested 5' and/or 3' deletions in the upstream DNA using conventional techniques such as Exonuclease III or appropriate restriction endonuclease digestion. The resulting deletion fragments can be inserted into the promoter reporter vector to determine whether the deletion has reduced or obliterated promoter activity, such as described, for example, by Coles et al. (1998). In this way, the boundaries of the promoters may be defined. If desired, potential individual regulatory sites within the promoter may be identified using site directed mutagenesis or linker scanning to

obliterate potential transcription factor binding sites within the promoter individually or in combination. The effects of these mutations on transcription levels may be determined by inserting the mutations into cloning sites in promoter reporter vectors. This type of assay is well-known to those skilled in the art and is described in WO 97/17359, US 5 374 544, EP 582 796, US 5 698 389, US 5 643 746, US 5 502 176, and US 5 266 488, incorporated herein by reference.

The strength and the specificity of the promoter of the *G713* gene can be assessed through the expression levels of a detectable polynucleotide operably linked to the *G713* promoter in different types of cells and tissues. The detectable polynucleotide may be either a polynucleotide that specifically hybridizes with a predefined oligonucleotide probe, or a polynucleotide encoding a detectable protein, including a *G713* polypeptide or a fragment or a variant thereof. This type of assay is well-known to those skilled in the art and is described in US 5 502 176, and US 5 266 488, incorporated herein by reference. In one embodiment, the efficacy of the promoter of the *G713* gene is assessed in normal and cancer cells.

Polynucleotides carrying the regulatory elements located both at the 5' end and at the 3' end of the *G713* coding region may be advantageously used to control the transcriptional and translational activity of an heterologous polynucleotide of interest.

Thus, the present invention also concerns a purified or isolated nucleic acid comprising a polynucleotide which is selected from the group consisting of the nucleotide sequences SEQ ID Nos 1 and 3, or a sequence complementary thereto or a biologically active fragment or variant thereof.

Preferred fragments of the nucleic acid of SEQ ID No 1 have a length of about 400 nucleotides, more particularly about 300 nucleotides, more preferably 200 nucleotides and most preferably about 100 nucleotides.

Preferred fragments of the nucleic acid of SEQ ID No 3 have a length of about 600 nucleotides, more particularly about 300 nucleotides, more preferably 200 nucleotides and most preferably about 100 nucleotides.

By a biologically active polynucleotide derivative of regulatory polynucleotides of SEQ ID Nos 1 or 3 is intended a polynucleotide comprising or alternatively consisting in a fragment of said polynucleotide which is functional as a regulatory region for expressing a recombinant polypeptide or a recombinant polynucleotide in a recombinant cell host. It could act either as an enhancer or as a repressor.

For the purpose of the invention, a nucleic acid or polynucleotide is "functional" as a regulatory region for expressing a recombinant polypeptide or a recombinant

polynucleotide if said regulatory polynucleotide contains nucleotide sequences which contain transcriptional and translational regulatory information, and such sequences are "operably linked" to nucleotide sequences which encode the desired polypeptide or the desired polynucleotide. An operable linkage is a linkage in which the regulatory nucleic acid and the DNA sequence sought to be expressed are linked in such a way as to permit gene expression.

More precisely, two DNA molecules (such as a polynucleotide containing a promoter region and a polynucleotide encoding a desired polypeptide or polynucleotide) are said to be "operably linked" if the nature of the linkage between the two polynucleotides does not (1) result in the introduction of a frame-shift mutation or (2) interfere with the ability of the polynucleotide containing the promoter to direct the transcription of the coding polynucleotide. The promoter polynucleotide would be operably linked to a polynucleotide encoding a desired polypeptide or a desired polynucleotide if the promoter is capable of effecting transcription of the polynucleotide of interest.

The regulatory polynucleotides of the invention may be prepared from any of the nucleotide sequence of SEQ ID Nos 1 or 3 by cleavage using suitable restriction enzymes, as described for example in the book of Sambrook et al. (1989). Table 5 details the restriction map of the G713 5'-regulatory nucleic acid of SEQ ID No 1. The left column indicates the name of the restriction enzyme preceded by the number of recognition sites for this enzyme present in the nucleotide sequence of SEQ ID No 1, excepted when a "0" is indicated in the column "Position" which indicates the absence of any recognition site for the enzyme in the nucleotide sequence of SEQ ID No 1. The second column discloses the sequence recognized by each enzyme and a " " denotes the site of enzymatic cleavage. Third column depicts the nucleotide position of the nucleotide sequence of SEQ ID No 1 wherein the cleavage occurs. The fourth and fifth columns present the lengths of the nucleic acid fragments generated after enzymatic cleavage.

The regulatory polynucleotides may also be prepared by digestion of any of SEQ ID Nos 1 or 3 by an exonuclease enzyme, such as for example Bal31 (Wabiko et al., 1986).

These regulatory polynucleotides can also be prepared by nucleic acid chemical synthesis, as described elsewhere in the specification, where oligonucleotide probes or primers synthesis is disclosed.

The regulatory polynucleotides according to the invention may be advantageously part of a recombinant expression vector that may be used to express a coding sequence in a desired host cell or host organism. The recombinant expression vectors according to the invention are described elsewhere in the specification.

5 A preferred 5'-regulatory polynucleotide of the invention includes the 5'-untranslated region (5'-UTR) located between the nucleotide at position 1076 and the nucleotide at position 3075 of SEQ ID No 1, or a biologically active fragment or variant thereof.

10 A preferred 3'-regulatory polynucleotide of the invention includes a 3'-non coding region consisting in the nucleotide sequence starting from the nucleotide in position 16330 and ending at the nucleotide in position 18329 of the nucleic acid of SEQ ID No 3.

A further object of the invention consists of a purified or isolated nucleic acid comprising :

- 15 a) a nucleic acid comprising a regulatory polynucleotide of nucleotide positions 1076 to 3075 of SEQ ID No 1 or a biologically active fragment or variant thereof;
- b) a polynucleotide encoding a desired polypeptide or nucleic acid operably linked to the regulatory polynucleotide of nucleotide positions 1076 to 3075 of SEQ ID No 1 or its biologically active fragment or variant thereof;
- 20 c) optionally, a nucleic acid comprising a regulatory polynucleotide of nucleotide positions 16330 to 18329 of SEQ ID No 3 or a biologically active fragment or variant thereof.

In a specific embodiment of the nucleic acid defined above, said nucleic acid includes the 5'-untranslated region (5'-UTR) located between the nucleotide at position 1076 and the nucleotide at position 3075 of SEQ ID No 1, or a biologically active fragment or variant thereof.

In a second specific embodiment of the nucleic acid defined above, said nucleic acid includes the 3'-untranslated region (3'-UTR) consisting in the nucleotide sequence starting from the nucleotide in position 16330 and ending at the nucleotide in position 18329 of the nucleic acid of SEQ ID No 3.

30 The regulatory polynucleotide of nucleotide positions 1076 to 3075 of SEQ ID No 1, or its biologically active fragments or variants, is advantageously operably linked at the 5'-end of the polynucleotide encoding the desired polypeptide or polynucleotide.

The regulatory polynucleotide of nucleotide positions 16330 to 18329 of SEQ ID No 3, or its biologically active fragments and variants, is advantageously placed at the 3'-end of the polynucleotide encoding the desired polypeptide or polynucleotide.

The desired polypeptide encoded by the above described nucleic acid may be of various nature or origin, encompassing proteins of prokaryotic or eukaryotic origin. Among the polypeptides expressed under the control of a *G713* regulatory region, there may be cited bacterial, fungal or viral antigens. Also encompassed are eukaryotic proteins such as intracellular proteins, like "house keeping" proteins, membrane-bound proteins, like receptors, and secreted proteins like the numerous endogenous mediators such as cytokines. Indeed, the desired polypeptide may be either the human or the mouse *G713* protein, especially one of the proteins of the amino acid sequences of SEQ ID No 5 or SEQ ID No 7, or a fragment or variant thereof.

The desired nucleic acids encoded by the above described polynucleotide, usually a RNA molecule, may be complementary to a desired coding polynucleotide, for example to the human or mouse *G713* coding sequence, and thus useful as an antisense polynucleotide.

Such a polynucleotide may be included in a recombinant expression vector in order to express the desired polypeptide or the desired nucleic acid in host cell or in a host organism. Suitable recombinant vectors that contain a polynucleotide such as described hereinbefore are disclosed elsewhere in the specification.

Coding regions

The *G713* open reading frame is contained in the corresponding mRNA of SEQ ID No 4 and is a further object of the present invention.

More precisely, the effective human *G713* coding sequence (CDS) is comprised between the nucleotide at position 659 (first nucleotide of the ATG codon) and the nucleotide at position 2032 (end nucleotide of the TAA codon) of SEQ ID No 4. A purified or isolated polynucleotide comprising the *G713* coding region defined above is another object of the invention.

Further, the effective mouse *G713* coding sequence (CDS) is comprised between the nucleotide at position 51 (first nucleotide of the ATG codon) and the nucleotide at position 1453 (end nucleotide of the TGA codon) of SEQ ID No 6. A purified or isolated polynucleotide comprising the mouse *G713* coding region defined above is another object of the invention.

The above disclosed polynucleotide that contains the coding sequence of the G713 gene of the invention may be expressed in a desired host cell or a desired host organism, when this polynucleotide is placed under the control of suitable expression signals. The expression signals may be either the expression signals contained in the regulatory regions in the G713 gene of the invention or in contrast be exogenous regulatory nucleic sequences. Such a polynucleotide, when placed under the suitable expression signals, may also be inserted in a vector for its expression.

Genomic DNA of human chromosome 13q31-q33 gene expressed in schizophrenia cases

The present invention also concerns the genomic sequence of a schizophrenia candidate gene located on the 13q31-q33 locus and specifically expressed in humans affected by schizophrenia. The present invention encompasses said schizophrenia candidate gene, or genomic sequences consisting of, consisting essentially of, or comprising the sequence of SEQ ID No 31, a sequence complementary thereto, as well as fragments and variants thereof. These polynucleotides may be purified, isolated, or recombinant.

The invention also encompasses a purified, isolated, or recombinant polynucleotide comprising a nucleotide sequence having at least 70, 75, 80, 85, 90, or 95% nucleotide identity with a nucleotide sequence of SEQ ID No 31 or a complementary sequence thereto or a fragment thereof. The nucleotide differences as regards to the nucleotide sequence of SEQ ID No 31 may be generally randomly distributed throughout the entire nucleic acid. Nevertheless, preferred nucleic acids are those wherein the nucleotide differences as regards to the nucleotide sequence of SEQ ID No 31 are predominantly located outside the coding sequences contained in the exons. These nucleic acids, as well as their fragments and variants, may be used as oligonucleotide primers or probes in order to detect the presence of a copy of this schizophrenia candidate gene in a test sample, or alternatively in order to amplify a target nucleotide sequence within said sequences.

Another object of the invention consists of a purified, isolated, or recombinant nucleic acid that hybridizes with the nucleotide sequence of SEQ ID No 31 or a complementary sequence thereto or a variant thereof, under the stringent hybridization conditions as defined above.

Particularly preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20,

25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200 or 500 nucleotides of SEQ ID No 31, or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions of SEQ ID No 31: 1 to 480 and 717 to 983. It should be noted that nucleic acid fragments of any size and sequence may also be comprised by the polynucleotides described in this section.

Probes and primers

Polynucleotides derived from the *G713* gene are useful in order to detect the presence of at least a copy of a nucleotide sequence of SEQ ID Nos 1 to 3, or a fragment, complement, or variant thereof in a test sample.

Particularly preferred probes and primers of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 1 to 3 or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions of SEQ ID No 1 to 3:

1 to 3585 and 4644 to 5222 of SEQ ID No 1, or a variant thereof or a sequence complementary thereto;

1 to 16155 and 16331 to 21278 of SEQ ID No 2, or a variant thereof or a sequence complementary thereto; and

1 to 5531 and 6355 to 21636 of SEQ ID No 3, or a variant thereof or a sequence complementary thereto.

Other preferred probes and primers of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 1 and 3 or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions of SEQ ID No 1 and 3:

1 to 3236, 3547 to 3585 and 4649 to 5222 of SEQ ID No 1, or a variant thereof or a sequence complementary thereto;

1 to 5531, 6844 to 7237, 7798 to 8184, 8667 to 9074, and 9356 to 21636 of SEQ ID No 3, or a variant thereof or a sequence complementary thereto.

Other probes and primers of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID Nos. 1, 2 or 3 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID Nos 1, 2 and 3:

1 to 1000, 1001 to 2000, 2001 to 3000, 3001 to 4000 and 4001 to 5222 of SEQ ID No. 1;

1 to 1000, 1001 to 2000, 2001 to 3000, 3001 to 4000 and 4001 to 5000, 5001 to 6000, 6001 to 7000, 7001 to 8000, 8001 to 9000, 9001 to 10000, 10001 to 11000,
5 11001 to 12000, 12001 to 13000, 13001 to 14000, 14001 to 15000, 15001 to 16000, 16001 to 17000, 17001 to 18000, 18001 to 19000, 19001 to 20000 and 20001 to 21278 of SEQ ID No 2; and

1 to 1000, 1001 to 2000, 2001 to 3000, 3001 to 4000 and 4001 to 5000, 5001 to 6000, 6001 to 7000, 7001 to 8000, 8001 to 9000, 9001 to 10000, 10001 to 11000,
10 11001 to 12000, 12001 to 13000, 13001 to 14000, 14001 to 15000, 15001 to 16000, 16001 to 17000, 17001 to 18000, 18001 to 19000, 19001 to 20000, 20001 to 21000 and 21001 to 21636 of SEQ ID No 3.

Further preferred probes and primers of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18,
15 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID Nos 1 to 3 or the complements thereof, wherein said contiguous span comprises allele 1 of a biallelic marker selected from the group consisting of A1 to A11; optionally said contiguous span comprises allele 2 of a biallelic marker selected from the group consisting of A1 to A11.

20 The invention also concerns a polymorphic marker comprising an insertion in the G713 gene. Embodiments of the invention thus include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 1 or the complements thereof, wherein said contiguous span comprises the
25 nucleotides AGAG at positions 3606 to 3609 of SEQ ID No 1.

Another object of the invention is a purified, isolated, or recombinant nucleic acid comprising the nucleotide sequence of SEQ ID No 4 or 6 complementary sequences thereto, as well as allelic variants, and fragments thereof. Moreover, preferred probes and primers of the invention include purified, isolated, or recombinant
30 G713 cDNAs consisting of, consisting essentially of, or comprising the sequence of SEQ ID Nos 4 or 6. Particularly preferred probes and primers of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 4, or the complements thereof, wherein said contiguous
35 span comprises at least one of the following nucleotide positions of SEQ ID Nos 4: 1 to

519 and 2563 to 5566. Additional preferred probes and primers of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID Nos 4, or the complements thereof, wherein said
5 contiguous span comprises 1 to 166, 473 to 519, 3020 to 3445, 3990 to 4394 and 4874 to 5281.

Thus, the invention also relates to nucleic acid probes characterized in that they hybridize specifically, under the stringent hybridization conditions defined above, with a nucleic acid selected from the group consisting of the nucleotide sequences 1 to 3236,
10 3547 to 3585 and 4649 to 5222 of SEQ ID No 1; 1 to 16155 and 16331 to 21278 of SEQ ID No 2; and 1 to 5531, 6844 to 7237, 7798 to 8184, 8667 to 9074, and 9356 to 21636 of SEQ ID No 3, or a variant thereof or a sequence complementary thereto.

In embodiments described in further detail herein in the section titled G713 and 13q31-q33-related biallelic markers, the invention encompasses isolated, purified, and
15 recombinant polynucleotides consisting of, or consisting essentially of a contiguous span of 8 to 50 nucleotides of any one of SEQ ID Nos 1 to 4 or 6, and the complement thereof, wherein said span includes a G713-related biallelic marker in said sequence; optionally, wherein said G713-related biallelic marker is selected from the group consisting of A1 to A11, and the complements thereof, or optionally the biallelic
20 markers in linkage disequilibrium therewith; optionally, wherein said contiguous span is 18 to 35 nucleotides in length and said biallelic marker is within 4 nucleotides of the center of said polynucleotide; optionally, wherein said polynucleotide consists of said contiguous span and said contiguous span is 25 nucleotides in length and said biallelic marker is at the center of said polynucleotide; optionally, wherein the 3' end of said
25 contiguous span is present at the 3' end of said polynucleotide; and optionally, wherein the 3' end of said contiguous span is located at the 3' end of said polynucleotide and said biallelic marker is present at the 3' end of said polynucleotide.

The formation of stable hybrids depends on the melting temperature (T_m) of the DNA. The T_m depends on the length of the primer or probe, the ionic strength of the
30 solution and the G+C content. The higher the G+C content of the primer or probe, the higher is the melting temperature because G:C pairs are held by three H bonds whereas A:T pairs have only two. The GC content in the probes of the invention usually ranges between 10 and 75 %, preferably between 35 and 60 %, and more preferably between 40 and 55 %.

A probe or a primer according to the invention may be between 8 and 2000 nucleotides in length, or is specified to be at least 12, 15, 18, 20, 25, 35, 40, 50, 60, 70, 80, 100, 250, 500, 1000 nucleotides in length. More particularly, the length of these probes can range from 8, 10, 15, 20, or 30 to 100 nucleotides, preferably from 10 to 50, more preferably from 15 to 30 nucleotides. Shorter probes tend to lack specificity for a target nucleic acid sequence and generally require cooler temperatures to form sufficiently stable hybrid complexes with the template. Longer probes are expensive to produce and can sometimes self-hybridize to form hairpin structures. The appropriate length for primers and probes under a particular set of assay conditions may be empirically determined by one of skill in the art.

The primers and probes can be prepared by any suitable method, including, for example, cloning and restriction of appropriate sequences and direct chemical synthesis by a method such as the phosphodiester method of Narang et al.(1979), the phosphodiester method of Brown et al.(1979), the diethylphosphoramidite method of Beaucage et al.(1981) and the solid support method described in EP 0 707 592. Detection probes are generally nucleic acid sequences or uncharged nucleic acid analogs such as, for example peptide nucleic acids which are disclosed in International Patent Application WO 92/20702, morpholino analogs which are described in U.S. Patents Numbered 5,185,444; 5,034,506 and 5,142,047. The probe may have to be rendered "non-extendable" in that additional dNTPs cannot be added to the probe. In and of themselves analogs usually are non-extendable and nucleic acid probes can be rendered non-extendable by modifying the 3' end of the probe such that the hydroxyl group is no longer capable of participating in elongation. For example, the 3' end of the probe can be functionalized with the capture or detection label to thereby consume or otherwise block the hydroxyl group. Alternatively, the 3' hydroxyl group simply can be cleaved, replaced or modified, U.S. Patent Application Serial No. 07/049,061 filed April 19, 1993 describes modifications, which can be used to render a probe non-extendable.

Any of the polynucleotides of the present invention can be labeled, if desired, by incorporating any label known in the art to be detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include radioactive substances (including, ^{32}P , ^{35}S , ^3H , ^{125}I), fluorescent dyes (including, 5-bromodesoxyuridin, fluorescein, acetylaminofluorene, digoxigenin) or biotin. Preferably, polynucleotides are labeled at their 3' and 5' ends. Examples of non-radioactive labeling of nucleic acid fragments are described in the French patent

No. FR-7810975 or by Urdea et al (1988) or Sanchez-Pescador et al (1988). In addition, the probes according to the present invention may have structural characteristics such that they allow the signal amplification, such structural characteristics being, for example, branched DNA probes as those described by Urdea et al. in 1991 or in the European patent No. EP 0 225 807 (Chiron).

A label can also be used to capture the primer, so as to facilitate the immobilization of either the primer or a primer extension product, such as amplified DNA, on a solid support. A capture label is attached to the primers or probes and can be a specific binding member which forms a binding pair with the solid's phase reagent's specific binding member (e.g. biotin and streptavidin). Therefore depending upon the type of label carried by a polynucleotide or a probe, it may be employed to capture or to detect the target DNA. Further, it will be understood that the polynucleotides, primers or probes provided herein, may, themselves, serve as the capture label. For example, in the case where a solid phase reagent's binding member is a nucleic acid sequence, it may be selected such that it binds a complementary portion of a primer or probe to thereby immobilize the primer or probe to the solid phase. In cases where a polynucleotide probe itself serves as the binding member, those skilled in the art will recognize that the probe will contain a sequence or "tail" that is not complementary to the target. In the case where a polynucleotide primer itself serves as the capture label, at least a portion of the primer will be free to hybridize with a nucleic acid on a solid phase. DNA Labeling techniques are well known to the skilled technician.

The probes of the present invention are useful for a number of purposes. They can be notably used in Southern hybridization to genomic DNA. The probes can also be used to detect PCR amplification products. They may also be used to detect mismatches in the *G713* gene or mRNA using other techniques.

Any of the polynucleotides, primers and probes of the present invention can be conveniently immobilized on a solid support. Solid supports are known to those skilled in the art and include the walls of wells of a reaction tray, test tubes, polystyrene beads, magnetic beads, nitrocellulose strips, membranes, microparticles such as latex particles, sheep (or other animal) red blood cells, duracytes and others. The solid support is not critical and can be selected by one skilled in the art. Thus, latex particles, microparticles, magnetic or non-magnetic beads, membranes, plastic tubes, walls of microtiter wells, glass or silicon chips, sheep (or other suitable animal's) red blood cells and duracytes are all suitable examples. Suitable methods for immobilizing

nucleic acids on solid phases include ionic, hydrophobic, covalent interactions and the like. A solid support, as used herein, refers to any material which is insoluble, or can be made insoluble by a subsequent reaction. The solid support can be chosen for its intrinsic ability to attract and immobilize the capture reagent. Alternatively, the solid

5 phase can retain an additional receptor which has the ability to attract and immobilize the capture reagent. The additional receptor can include a charged substance that is oppositely charged with respect to the capture reagent itself or to a charged substance conjugated to the capture reagent. As yet another alternative, the receptor molecule can be any specific binding member which is immobilized upon (attached to) the solid

10 support and which has the ability to immobilize the capture reagent through a specific binding reaction. The receptor molecule enables the indirect binding of the capture reagent to a solid support material before the performance of the assay or during the performance of the assay. The solid phase thus can be a plastic, derivatized plastic, magnetic or non-magnetic metal, glass or silicon surface of a test tube, microtiter well,

15 sheet, bead, microparticle, chip, sheep (or other suitable animal's) red blood cells, duracytes® and other configurations known to those of ordinary skill in the art. The polynucleotides of the invention can be attached to or immobilized on a solid support individually or in groups of at least 2, 5, 8, 10, 12, 15, 20, or 25 distinct polynucleotides of the invention to a single solid support. In addition, polynucleotides other than those

20 of the invention may be attached to the same solid support as one or more polynucleotides of the invention.

Consequently, the invention also comprises a method for detecting the presence of a nucleic acid comprising a nucleotide sequence selected from a group consisting of SEQ ID Nos 1 to 4 or 6, a fragment or a variant thereof and a

25 complementary sequence thereto in a sample, said method comprising the following steps of:

- a) bringing into contact a nucleic acid probe or a plurality of nucleic acid probes which can hybridize with a nucleotide sequence included in a nucleic acid selected from the group consisting of the nucleotide sequences of SEQ ID Nos 1 to 4 or 6, a fragment or
- 30 a variant thereof and a complementary sequence thereto and the sample to be assayed; and
- b) detecting the hybrid complex formed between the probe and a nucleic acid in the sample.

The invention further concerns a kit for detecting the presence of a nucleic acid

35 comprising a nucleotide sequence selected from a group consisting of SEQ ID Nos 1 to

4 or 6, a fragment or a variant thereof and a complementary sequence thereto in a sample, said kit comprising:

- a) a nucleic acid probe or a plurality of nucleic acid probes which can hybridize with a nucleotide sequence included in a nucleic acid selected from the group consisting of the nucleotide sequences of SEQ ID Nos 1 to 4 or 6, a fragment or a variant thereof and a complementary sequence thereto; and
- b) optionally, the reagents necessary for performing the hybridization reaction.

In a first preferred embodiment of this detection method and kit, said nucleic acid probe or the plurality of nucleic acid probes are labeled with a detectable molecule. In a second preferred embodiment of said method and kit, said nucleic acid probe or the plurality of nucleic acid probes has been immobilized on a substrate. In a third preferred embodiment, the nucleic acid probe or the plurality of nucleic acid probes comprise either a sequence which is selected from the group consisting of the nucleotide sequences of P1 to P11 and the complementary sequence thereto, B1 to B11, C1 to C11, D1 to D11, E1 to E11 or a biallelic marker selected from the group consisting of A1 to A11 and the complements thereto.

Oligonucleotide Arrays

A substrate comprising a plurality of oligonucleotide primers or probes of the invention may be used either for detecting or amplifying targeted sequences in the *G713* gene and may also be used for detecting mutations in the coding or in the non-coding sequences of the *G713* gene.

Any polynucleotide provided herein may be attached in overlapping areas or at random locations on the solid support. Alternatively the polynucleotides of the invention may be attached in an ordered array wherein each polynucleotide is attached to a distinct region of the solid support which does not overlap with the attachment site of any other polynucleotide. Preferably, such an ordered array of polynucleotides is designed to be "addressable" where the distinct locations are recorded and can be accessed as part of an assay procedure. Addressable polynucleotide arrays typically comprise a plurality of different oligonucleotide probes that are coupled to a surface of a substrate in different known locations. The knowledge of the precise location of each polynucleotides location makes these "addressable" arrays particularly useful in hybridization assays. Any addressable array technology known in the art can be employed with the polynucleotides of the invention. One particular embodiment of these polynucleotide arrays is known as the Genechips™, and has been generally described in US Patent 5,143,854; PCT publications WO 90/15070 and 92/10092.

These arrays may generally be produced using mechanical synthesis methods or light directed synthesis methods which incorporate a combination of photolithographic methods and solid phase oligonucleotide synthesis (Fodor et al., 1991). The immobilization of arrays of oligonucleotides on solid supports has been rendered possible by the development of a technology generally identified as "Very Large Scale Immobilized Polymer Synthesis" (VLSIPS™) in which, typically, probes are immobilized in a high density array on a solid surface of a chip. Examples of VLSIPS™ technologies are provided in US Patents 5,143,854; and 5,412,087 and in PCT Publications WO 90/15070, WO 92/10092 and WO 95/11995, which describe methods for forming oligonucleotide arrays through techniques such as light-directed synthesis techniques. In designing strategies aimed at providing arrays of nucleotides immobilized on solid supports, further presentation strategies were developed to order and display the oligonucleotide arrays on the chips in an attempt to maximize hybridization patterns and sequence information. Examples of such presentation strategies are disclosed in PCT Publications WO 94/12305, WO 94/11530, WO 97/29212 and WO 97/31256, the disclosures of which are incorporated herein by reference in their entireties.

In another embodiment of the oligonucleotide arrays of the invention, an oligonucleotide probe matrix may advantageously be used to detect mutations occurring in the *G713* gene and preferably in its regulatory region. For this particular purpose, probes are specifically designed to have a nucleotide sequence allowing their hybridization to the genes that carry known mutations (either by deletion, insertion or substitution of one or several nucleotides). By known mutations, it is meant, mutations on the *G713* gene that have been identified according, for example to the technique used by Huang et al.(1996) or Samson et al.(1996).

Another technique that is used to detect mutations in the *G713* gene is the use of a high-density DNA array. Each oligonucleotide probe constituting a unit element of the high density DNA array is designed to match a specific subsequence of the *G713* genomic DNA or cDNA. Thus, an array consisting of oligonucleotides complementary to subsequences of the target gene sequence is used to determine the identity of the target sequence with the wild gene sequence, measure its amount, and detect differences between the target sequence and the reference wild gene sequence of the *G713* gene. In one such design, termed 4L tiled array, is implemented a set of four probes (A, C, G, T), preferably 15-nucleotide oligomers. In each set of four probes, the perfect complement will hybridize more strongly than mismatched probes.

Consequently, a nucleic acid target of length L is scanned for mutations with a tiled array containing 4L probes, the whole probe set containing all the possible mutations in the known wild reference sequence. The hybridization signals of the 15-mer probe set tiled array are perturbed by a single base change in the target sequence. As a consequence, there is a characteristic loss of signal or a "footprint" for the probes flanking a mutation position. This technique was described by Chee et al. in 1996. Consequently, the invention concerns an array of nucleic acid molecules comprising at least one polynucleotide described above as probes and primers. Preferably, the invention concerns an array of nucleic acid comprising at least two polynucleotides described above as probes and primers.

A further object of the invention consists of an array of nucleic acid sequences comprising either at least one of the sequences selected from the group consisting of P1 to P49, B1 to B49, C1 to C49, D1 to D49, E1 to E49, the sequences complementary thereto, a fragment thereof of at least 8, 10, 12, 15, 18, 20, 25, 30, or 40 consecutive nucleotides thereof, and at least one sequence comprising a biallelic marker selected from the group consisting of A1 to A49 and the complements thereto.

The invention also pertains to an array of nucleic acid sequences comprising either at least two of the sequences selected from the group consisting of P1 to P49, B1 to B49, C1 to C49, D1 to D49, E1 to E49, the sequences complementary thereto, a fragment thereof of at least 8 consecutive nucleotides thereof, and at least two sequences comprising a biallelic marker selected from the group consisting of A1 to A49 and the complements thereof.

G713- AND 13Q31-Q33-RELATED BIALLELIC MARKERS

The inventors have discovered nucleotide polymorphisms located within the genomic DNA containing the *G713* gene, and among them "Single Nucleotide Polymorphisms" or SNPs that are also termed biallelic markers. The inventors have also discovered biallelic markers throughout the human chromosome 13q31-q33 locus.

The invention thus concerns *G713*-related biallelic markers. As used herein the term "*G713*-related biallelic marker" relates to a set of biallelic markers in linkage disequilibrium with the *G713* gene. The term *G713*-related biallelic marker includes the biallelic markers designated A1 to A11 herein as well as an insertion of the nucleotides AGAG in the *G713* gene, described above.

A portion of the *G713* biallelic markers of the present invention are disclosed in Table 2. Their location on the *G713* gene is indicated in Table 2 and also as a single

base polymorphism in the features of in the related SEQ ID Nos 1 to 3. The pairs of primers allowing the amplification of a nucleic acid containing the polymorphic base of one G713 biallelic marker are listed in Table 1 of Example 1(c).

The invention also concerns 13q31-q33-related biallelic markers. As used
5 herein the term "13q31-q33-related biallelic marker" relates to a set of biallelic markers in linkage disequilibrium with the chromosome 13q31-q33 locus. The term 13q31-q33-related biallelic marker includes the biallelic markers designated A12 to A49.

A portion of the 13q31-q33-related biallelic markers of the present invention are disclosed in Table 7. Their location as a single base polymorphism in the features of in
10 the related SEQ ID Nos 32 to 65. The pairs of primers allowing the amplification of a nucleic acid containing the polymorphic base of each 13q31-q33-related biallelic marker are listed in Table 6 of Example 2(b).

The invention also relates to a purified and/or isolated nucleotide sequence comprising a polymorphic base of a G713- or 13q31-q33-related biallelic marker,
15 preferably of a biallelic marker selected from the group consisting of A1 to A49, and the complements thereof. The sequence has between 8 and 1000 nucleotides in length, and preferably comprises a span of at least 8, 10, 12, 15, 18, 20, 25, 35, 40, 50, 60, 70, 80, 100, 250, 500 or 1000 contiguous nucleotides of a nucleotide sequence selected from the group consisting of SEQ ID Nos 1 to 3 and 32 to 69, or a variant thereof or a
20 complementary sequence thereto. These nucleotide sequences comprise the polymorphic base of either allele 1 or allele 2 of the considered biallelic marker. Optionally, said biallelic marker may be within 6, 5, 4, 3, 2, or 1 nucleotides of the center of said polynucleotide or at the center of said polynucleotide. Optionally, the 3' end of said contiguous span may be present at the 3' end of said polynucleotide.
25 Optionally, biallelic marker may be present at the 3' end of said polynucleotide. Optionally, said contiguous span is 18 to 35 nucleotides in length and said biallelic marker is within 4 nucleotides of the center of said polynucleotide; optionally, said polynucleotide consists of said contiguous span and said contiguous span is 25 nucleotides in length and said biallelic marker is at the center of said polynucleotide;
30 optionally, the 3' end of said contiguous span is present at the 3' end of said polynucleotide; and optionally, the 3' end of said contiguous span is located at the 3' end of said polynucleotide and said biallelic marker is present at the 3' end of said polynucleotide. Optionally, said polynucleotide may further comprise a label. Optionally, said polynucleotide can be attached to solid support. In a further

embodiment, the polynucleotides defined above can be used alone or in any combination.

The invention also relates to a purified and/or isolated nucleotide sequence comprising between 8 and 1000 nucleotides in length, and preferably at least 8, 10, 12, 15, 18, 20, 25, 35, 40, 50, 60, 70, 80, 100, 250, 500 or 1000 contiguous nucleotides of a nucleotide sequence selected from the group consisting of SEQ ID Nos 1 to 4, 6 and 32 to 69, or a variant thereof or a complementary sequence thereto. Optionally, the 3' end of said polynucleotide may be located within or at least 2, 4, 6, 8, 10, 12, 15, 18, 20, 25, 50, 100, 250, 500, or 1000 nucleotides upstream of a G713- or 13q31-q33-related biallelic marker in said sequence. Optionally, said G713- or 13q31-q33-related biallelic marker is selected from the group consisting of A1 to A49; Optionally, the 3' end of said polynucleotide may be located within or at least 2, 4, 6, 8, 10, 12, 15, 18, 20, 25, 50, 100, 250, 500, or 1000 nucleotides upstream of a G713- or 13q31-q33-related biallelic marker in said sequence. Optionally, the 3' end of said polynucleotide may be located 1 nucleotide upstream of a G713- or 13q31-q33-related biallelic marker in said sequence. Optionally, said polynucleotide may further comprise a label. Optionally, said polynucleotide can be attached to solid support. In a further embodiment, the polynucleotides defined above can be used alone or in any combination.

In a preferred embodiment, the sequences comprising a polymorphic base of one of the biallelic markers listed in Tables 2 and 7 are selected from the group consisting of the nucleotide sequences that have a contiguous span of, that consist of, that are comprised in, or that comprises a polynucleotide selected from the group consisting of the nucleic acids of the sequences set forth as the amplicons listed in Tables 1 and 6 or a variant thereof or a complementary sequence thereto.

The invention further concerns a nucleic acid encoding the G713 protein, wherein said nucleic acid comprises a polymorphic base of a biallelic marker selected from the group consisting of A1 to A11 and the complements thereof.

The invention also encompasses the use of any polynucleotide for, or any polynucleotide for use in, determining the identity of one or more nucleotides at a G713- or 13q31-q33-related biallelic marker. In addition, the polynucleotides of the invention for use in determining the identity of one or more nucleotides at a G713- or 13q31-q33-related biallelic marker encompass polynucleotides with any further limitation described in this disclosure, or those following, specified alone or in any combination. Optionally, said G713-related biallelic marker is selected from the group

consisting of A1 to A11, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, said 13q31-q33-related biallelic marker is selected from the group consisting of A12 to A49, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, said 13q31-q33-related biallelic marker is selected from the group consisting of A16 to A20 and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, said 13q31-q33-related biallelic marker is selected from the group consisting of A14, A15, A17, A18, A27, A28, A34, A35, A38 and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; Optionally, said polynucleotide may comprise a sequence disclosed in the present specification; Optionally, said polynucleotide may consist of, or consist essentially of any polynucleotide described in the present specification; Optionally, said determining may be performed in a hybridization assay, sequencing assay, microsequencing assay, or an enzyme-based mismatch detection assay; Optionally, said polynucleotide may be attached to a solid support, array, or addressable array; Optionally, said polynucleotide may be labeled. A preferred polynucleotide may be used in a hybridization assay for determining the identity of the nucleotide at a G713- or 13q31-q33-related biallelic marker. Another preferred polynucleotide may be used in a sequencing or microsequencing assay for determining the identity of the nucleotide at a G713- or 13q31-q33-related biallelic marker. A third preferred polynucleotide may be used in an enzyme-based mismatch detection assay for determining the identity of the nucleotide at a G713- or 13q31-q33-related biallelic marker. A fourth preferred polynucleotide may be used in amplifying a segment of polynucleotides comprising a G713- or 13q31-q33-related biallelic marker. Optionally, any of the polynucleotides described above may be attached to a solid support, array, or addressable array; optionally, said polynucleotide may be labeled.

Additionally, the invention encompasses the use of any polynucleotide for, or any polynucleotide for use in, amplifying a segment of nucleotides comprising a G713- or 13q31-q33-related biallelic marker. In addition, the polynucleotides of the invention for use in amplifying a segment of nucleotides comprising a G713- or 13q31-q33-related biallelic marker encompass polynucleotides with any further limitation described in this disclosure, or those following, specified alone or in any combination: optionally, said G713-related biallelic marker is selected from the group consisting of A1 to A11, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, said 13q31-q33-related biallelic marker is selected

from the group consisting of A12 to A49, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, said 13q31-q33-related biallelic marker is selected from the group consisting of A16 to A20 and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, said 13q31-q33-related biallelic marker is selected from the group consisting of A14, A15, A17, A18, A27, A28, A34, A35, A38 and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, said polynucleotide may comprise a sequence disclosed in the present specification; optionally, said polynucleotide may consist of, or consist essentially of any polynucleotide described in the present specification; optionally, said amplifying may be performed by a PCR or LCR. Optionally, said polynucleotide may be attached to a solid support, array, or addressable array. Optionally, said polynucleotide may be labeled.

The primers for amplification or sequencing reaction of a polynucleotide comprising a biallelic marker of the invention may be designed from the disclosed sequences for any method known in the art. A preferred set of primers are fashioned such that the 3' end of the contiguous span of identity with a sequence selected from the group consisting of SEQ ID Nos 1 to 4, 6 and 32 to 69 or a sequence complementary thereto or a variant thereof is present at the 3' end of the primer. Such a configuration allows the 3' end of the primer to hybridize to a selected nucleic acid sequence and dramatically increases the efficiency of the primer for amplification or sequencing reactions. Allele specific primers may be designed such that a polymorphic base of a biallelic marker is at the 3' end of the contiguous span and the contiguous span is present at the 3' end of the primer. Such allele specific primers tend to selectively prime an amplification or sequencing reaction so long as they are used with a nucleic acid sample that contains one of the two alleles present at a biallelic marker. The 3' end of the primer of the invention may be located within or at least 2, 4, 6, 8, 10, 12, 15, 18, 20, 25, 50, 100, 250, 500, or 1000 nucleotides upstream of a G713- or 13q31-q33-related biallelic marker in said sequence or at any other location which is appropriate for their intended use in sequencing, amplification or the location of novel sequences or markers. Thus, another set of preferred amplification primers comprise an isolated polynucleotide consisting essentially of a contiguous span of 8 to 50 nucleotides in a sequence selected from the group consisting of SEQ ID Nos 1 to 4, 6 and 32 to 69 or a sequence complementary thereto or a variant thereof, wherein the 3' end of said contiguous span is located at the 3' end of said

polynucleotide, and wherein the 3' end of said polynucleotide is located upstream of a G713- or 13q31-q33-related biallelic marker in said sequence. Preferably, those amplification primers comprise a sequence selected from the group consisting of the sequences B1 to B49 and C1 to C49. Primers with their 3' ends located 1 nucleotide upstream of a biallelic marker of G713 or 13q31-q33 have a special utility as microsequencing assays. Preferred microsequencing primers are described in Tables 4 and 8. Optionally, said G713-related biallelic marker is selected from the group consisting of A1 to A11, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, said 13q31-q33-related biallelic marker is selected from the group consisting of A12 to A49, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, said 13q31-q33-related biallelic marker is selected from the group consisting of A16 to A20 and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, said 13q31-q33-related biallelic marker is selected from the group consisting of A14, A15, A17, A18, A27, A28, A34, A35, A38 and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, microsequencing primers are selected from the group consisting of the nucleotide sequences D1 to D49 and E1 to E49.

The probes of the present invention may be designed from the disclosed sequences for any method known in the art, particularly methods which allow for testing if a marker disclosed herein is present. A preferred set of probes may be designed for use in the hybridization assays of the invention in any manner known in the art such that they selectively bind to one allele of a biallelic marker, but not the other under any particular set of assay conditions. Preferred hybridization probes comprise the polymorphic base of either allele 1 or allele 2 of the considered biallelic marker. Optionally, said biallelic marker may be within 6, 5, 4, 3, 2, or 1 nucleotides of the center of the hybridization probe or at the center of said probe. In a preferred embodiment, the probes are selected in the group consisting of the sequences P1 to P49 and the complementary sequence thereto.

It should be noted that the polynucleotides of the present invention are not limited to having the exact flanking sequences surrounding the polymorphic bases which are enumerated in Sequence Listing. Rather, it will be appreciated that the flanking sequences surrounding the biallelic markers may be lengthened or shortened to any extent compatible with their intended use and the present invention specifically contemplates such sequences. The flanking regions outside of the contiguous span need

not be homologous to native flanking sequences which actually occur in human subjects. The addition of any nucleotide sequence which is compatible with the nucleotides intended use is specifically contemplated.

Primers and probes may be labeled or immobilized on a solid support as described in "Oligonucleotide probes and primers".

The polynucleotides of the invention which are attached to a solid support encompass polynucleotides with any further limitation described in this disclosure, or those following, specified alone or in any combination: Optionally, said polynucleotides may be specified as attached individually or in groups of at least 2, 5, 8, 10, 12, 15, 20, or 25 distinct polynucleotides of the invention to a single solid support. Optionally, polynucleotides other than those of the invention may attached to the same solid support as polynucleotides of the invention. Optionally, when multiple polynucleotides are attached to a solid support they may be attached at random locations, or in an ordered array. Optionally, said ordered array may be addressable.

The present invention also encompasses diagnostic kits comprising one or more polynucleotides of the invention with a portion or all of the necessary reagents and instructions for genotyping a test subject by determining the identity of a nucleotide at a G713- or 13q31-q33-related biallelic marker. The polynucleotides of a kit may optionally be attached to a solid support, or be part of an array or addressable array of polynucleotides. The kit may provide for the determination of the identity of the nucleotide at a marker position by any method known in the art including, but not limited to, a sequencing assay method, a microsequencing assay method, a hybridization assay method, or an enzyme-based mismatch detection assay method.

Methods For *De Novo* Identification Of Biallelic Markers

Any of a variety of methods can be used to screen a genomic fragment for single nucleotide polymorphisms such as differential hybridization with oligonucleotide probes, detection of changes in the mobility measured by gel electrophoresis or direct sequencing of the amplified nucleic acid. A preferred method for identifying biallelic markers involves comparative sequencing of genomic DNA fragments from an appropriate number of unrelated individuals.

In a first embodiment, DNA samples from unrelated individuals are pooled together, following which the genomic DNA of interest is amplified and sequenced. The nucleotide sequences thus obtained are then analyzed to identify significant polymorphisms. One of the major advantages of this method resides in the fact that

the pooling of the DNA samples substantially reduces the number of DNA amplification reactions and sequencing reactions, which must be carried out. Moreover, this method is sufficiently sensitive so that a biallelic marker obtained thereby usually demonstrates a sufficient frequency of its less common allele to be useful in conducting association studies.

In a second embodiment, the DNA samples are not pooled and are therefore amplified and sequenced individually. This method is usually preferred when biallelic markers need to be identified in order to perform association studies within candidate genes. Preferably, highly relevant gene regions such as promoter regions or exon regions may be screened for biallelic markers. A biallelic marker obtained using this method may show a lower degree of informativeness for conducting association studies, e.g. if the frequency of its less frequent allele may be less than about 10%. Such a biallelic marker will, however, be sufficiently informative to conduct association studies and it will further be appreciated that including less informative biallelic markers in the genetic analysis studies of the present invention, may allow in some cases the direct identification of causal mutations, which may, depending on their penetrance, be rare mutations.

The following is a description of the various parameters of a preferred method used by the inventors for the identification of the biallelic markers of the present invention.

Genomic DNA Samples

The genomic DNA samples from which the biallelic markers of the present invention are generated are preferably obtained from unrelated individuals corresponding to a heterogeneous population of known ethnic background. The number of individuals from whom DNA samples are obtained can vary substantially, preferably from about 10 to about 1000, preferably from about 50 to about 200 individuals. It is usually preferred to collect DNA samples from at least about 100 individuals in order to have sufficient polymorphic diversity in a given population to identify as many markers as possible and to generate statistically significant results. As for the source of the genomic DNA to be subjected to analysis, any test sample can be foreseen without any particular limitation. These test samples include biological samples, which can be tested by the methods of the present invention described herein, and include human and animal body fluids such as whole blood, serum, plasma, cerebrospinal fluid, urine, lymph fluids, and various external secretions of the respiratory, intestinal and genitourinary tracts, tears, saliva, milk, white blood cells,

myelomas and the like; biological fluids such as cell culture supernatants; fixed tissue specimens including tumor and non-tumor tissue and lymph node tissues; bone marrow aspirates and fixed cell specimens. The preferred source of genomic DNA used in the present invention is from peripheral venous blood of each donor.

Techniques to prepare genomic DNA from biological samples are well known to the skilled technician. Details of a preferred embodiment are provided in Example 1(a). The person skilled in the art can choose to amplify pooled or unpooled DNA samples.

DNA Amplification

The identification of biallelic markers in a sample of genomic DNA may be facilitated through the use of DNA amplification methods. DNA samples can be pooled or unpooled for the amplification step. DNA amplification techniques are well known to those skilled in the art.

Amplification techniques that can be used in the context of the present invention include, but are not limited to, the ligase chain reaction (LCR) described in EP-A- 320 308, WO 9320227 and EP-A-439 182, the polymerase chain reaction (PCR, RT-PCR) and techniques such as the nucleic acid sequence based amplification (NASBA) described in Guatelli J.C., et al.(1990) and in Compton J.(1991), Q-beta amplification as described in European Patent Application No 4544610, strand displacement amplification as described in Walker et al.(1996) and EP A 684 315 and, target mediated amplification as described in PCT Publication WO 9322461.

LCR and Gap LCR are exponential amplification techniques, both depend on DNA ligase to join adjacent primers annealed to a DNA molecule. In Ligase Chain Reaction (LCR), probe pairs are used which include two primary (first and second) and two secondary (third and fourth) probes, all of which are employed in molar excess to target. The first probe hybridizes to a first segment of the target strand and the second probe hybridizes to a second segment of the target strand, the first and second segments being contiguous so that the primary probes abut one another in 5' phosphate-3'hydroxyl relationship, and so that a ligase can covalently fuse or ligate the two probes into a fused product. In addition, a third (secondary) probe can hybridize to a portion of the first probe and a fourth (secondary) probe can hybridize to a portion of the second probe in a similar abutting fashion. Of course, if the target is initially double stranded, the secondary probes also will hybridize to the target complement in the first instance. Once the ligated strand of primary probes is separated from the target strand, it will hybridize with the third and fourth probes, which can be ligated to form a complementary, secondary ligated product. It is important to realize that the ligated

products are functionally equivalent to either the target or its complement. By repeated cycles of hybridization and ligation, amplification of the target sequence is achieved. A method for multiplex LCR has also been described (WO 9320227). Gap LCR (GLCR) is a version of LCR where the probes are not adjacent but are separated by 2 to 3 bases.

For amplification of mRNAs, it is within the scope of the present invention to reverse transcribe mRNA into cDNA followed by polymerase chain reaction (RT-PCR); or, to use a single enzyme for both steps as described in U.S. Patent No. 5,322,770 or, to use Asymmetric Gap LCR (RT-AGLCR) as described by Marshall et al.(1994). AGLCR is a modification of GLCR that allows the amplification of RNA.

The PCR technology is the preferred amplification technique used in the present invention. A variety of PCR techniques are familiar to those skilled in the art. For a review of PCR technology, see White (1997) and the publication entitled "PCR Methods and Applications" (1991, Cold Spring Harbor Laboratory Press). In each of these PCR procedures, PCR primers on either side of the nucleic acid sequences to be amplified are added to a suitably prepared nucleic acid sample along with dNTPs and a thermostable polymerase such as Taq polymerase, Pfu polymerase, or Vent polymerase. The nucleic acid in the sample is denatured and the PCR primers are specifically hybridized to complementary nucleic acid sequences in the sample. The hybridized primers are extended. Thereafter, another cycle of denaturation, hybridization, and extension is initiated. The cycles are repeated multiple times to produce an amplified fragment containing the nucleic acid sequence between the primer sites. PCR has further been described in several patents including US Patents 4,683,195; 4,683,202; and 4,965,188, the disclosures of which are incorporated herein by reference in their entireties.

The PCR technology is the preferred amplification technique used to identify new biallelic markers. A typical example of a PCR reaction suitable for the purposes of the present invention is provided in Example 1(c).

One of the aspects of the present invention is a method for the amplification of the human G713 gene, particularly of a fragment of the genomic sequence of SEQ ID Nos 1 to 3 or of the cDNA sequences of SEQ ID Nos 4 or 6, or a fragment or a variant thereof in a test sample, preferably using the PCR technology. Another aspect is a method for the amplification of a nucleotide sequence of the human chromosome 13q31-q33 locus, particularly of a fragment of the genomic sequence of SEQ ID Nos

32 to 69, or a fragment or a variant thereof in a test sample, preferably using the PCR technology. This method comprises the steps of:

- a) contacting a test sample with amplification reaction reagents comprising a pair of amplification primers as described above and located on either side of the polynucleotide region to be amplified, and
- b) optionally, detecting the amplification products.

The invention also concerns a kit for the amplification of a G713 or chromosome 13q31-q33 sequence, particularly of a portion of the G713 genomic sequence of SEQ ID Nos 1 to 3, of the G713 cDNA sequences of SEQ ID Nos 6 or 11 or of the chromosome 13q31-q33 locus, or a variant thereof in a test sample, wherein said kit comprises:

- a) a pair of oligonucleotide primers located on either side of the G713 or chromosome 13q31-q33 region to be amplified;
- b) optionally, the reagents necessary for performing the amplification reaction.

In one embodiment of the above amplification method and kit, the amplification product is detected by hybridization with a labeled probe having a sequence which is complementary to the amplified region. In another embodiment of the above amplification method and kit, primers comprise a sequence which is selected from the group consisting of the nucleotide sequences of B1 to B49, C1 to C49, D1 to D49, and E1 to E49.

In a first embodiment of the present invention, biallelic markers are identified using genomic sequence information generated by the inventors. Sequenced genomic DNA fragments are used to design primers for the amplification of 500 bp fragments. These 500 bp fragments are amplified from genomic DNA and are scanned for biallelic markers. Primers may be designed using the OSP software (Hillier L. and Green P., 1991). All primers may contain, upstream of the specific target bases, a common oligonucleotide tail that serves as a sequencing primer. Those skilled in the art are familiar with primer extensions, which can be used for these purposes.

Preferred primers, useful for the amplification of genomic sequences encoding the candidate genes, focus on promoters, exons and splice sites of the genes. A biallelic marker presents a higher probability to be an eventual causal mutation if it is located in these functional regions of the gene. Preferred amplification primers of the invention include the nucleotide sequences B1 to B49 and C1 to C49, detailed further in Example 1(c), Table 1 and Example 2(b), Table 6.

Sequencing Of Amplified Genomic DNA And Identification Of Single Nucleotide Polymorphisms

The amplification products generated as described above, are then sequenced using any method known and available to the skilled technician. Methods for sequencing DNA using either the dideoxy-mediated method (Sanger method) or the Maxam-Gilbert method are widely known to those of ordinary skill in the art. Such methods are for example disclosed in Sambrook et al.(1989). Alternative approaches include hybridization to high-density DNA probe arrays as described in Chee et al.(1996).

Preferably, the amplified DNA is subjected to automated dideoxy terminator sequencing reactions using a dye-primer cycle sequencing protocol. The products of the sequencing reactions are run on sequencing gels and the sequences are determined using gel image analysis. The polymorphism search is based on the presence of superimposed peaks in the electrophoresis pattern resulting from different bases occurring at the same position. Because each dideoxy terminator is labeled with a different fluorescent molecule, the two peaks corresponding to a biallelic site present distinct colors corresponding to two different nucleotides at the same position on the sequence. However, the presence of two peaks can be an artifact due to background noise. To exclude such an artifact, the two DNA strands are sequenced and a comparison between the peaks is carried out. In order to be registered as a polymorphic sequence, the polymorphism has to be detected on both strands. The above procedure permits those amplification products, which contain biallelic markers to be identified. The detection limit for the frequency of biallelic polymorphisms detected by sequencing pools of 100 individuals is approximately 0.1 for the minor allele, as verified by sequencing pools of known allelic frequencies. However, more than 90% of the biallelic polymorphisms detected by the pooling method have a frequency for the minor allele higher than 0.25. Therefore, the biallelic markers selected by this method have a frequency of at least 0.1 for the minor allele and less than 0.9 for the major allele. Preferably at least 0.2 for the minor allele and less than 0.8 for the major allele, more preferably at least 0.3 for the minor allele and less than 0.7 for the major allele, thus a heterozygosity rate higher than 0.18, preferably higher than 0.32, more preferably higher than 0.42.

In another embodiment, biallelic markers are detected by sequencing individual DNA samples, the frequency of the minor allele of such a biallelic marker may be less than 0.1.

Validation Of The Biallelic Markers Of The Present Invention

The polymorphisms are evaluated for their usefulness as genetic markers by validating that both alleles are present in a population. Validation of the biallelic markers is accomplished by genotyping a group of individuals by a method of the invention and demonstrating that both alleles are present. Microsequencing is a preferred method of genotyping alleles. The validation by genotyping step may be performed on individual samples derived from each individual in the group or by genotyping a pooled sample derived from more than one individual. The group can be as small as one individual if that individual is heterozygous for the allele in question. Preferably the group contains at least three individuals, more preferably the group contains five or six individuals, so that a single validation test will be more likely to result in the validation of more of the biallelic markers that are being tested. It should be noted, however, that when the validation test is performed on a small group it may result in a false negative result if as a result of sampling error none of the individuals tested carries one of the two alleles. Thus, the validation process is less useful in demonstrating that a particular initial result is an artifact, than it is at demonstrating that there is a *bona fide* biallelic marker at a particular position in a sequence. For an indication of whether a particular biallelic marker has been validated, a * is placed next to the microsequencing primer in Table 4. All of the genotyping, haplotyping, association, and interaction study methods of the invention may optionally be performed solely with validated biallelic markers.

Evaluation Of The Frequency Of The Biallelic Markers Of The Present Invention

The validated biallelic markers are further evaluated for their usefulness as genetic markers by determining the frequency of the least common allele at the biallelic marker site. The higher the frequency of the less common allele the greater the usefulness of the biallelic marker is association and interaction studies. The determination of the least common allele is accomplished by genotyping a group of individuals by a method of the invention and demonstrating that both alleles are present. This determination of frequency by genotyping step may be performed on individual samples derived from each individual in the group or by genotyping a pooled sample derived from more than one individual. The group must be large enough to be representative of the population as a whole. Preferably the group contains at least 20 individuals, more preferably the group contains at least 50 individuals, most preferably the group contains at least 100 individuals. Of course the larger the group the greater the accuracy of the frequency determination because of reduced sampling error. A

biallelic marker wherein the frequency of the less common allele is 30% or more is termed a "high quality biallelic marker." All of the genotyping, haplotyping, association, and interaction study methods of the invention may optionally be performed solely with high quality biallelic markers.

5 **Methods For Genotyping An Individual For Biallelic Markers**

Methods are provided to genotype a biological sample for one or more biallelic markers of the present invention, all of which may be performed *in vitro*. Such methods of genotyping comprise determining the identity of a nucleotide at a G713 or 13q31-q33-related biallelic marker site by any method known in the art. These methods find use in genotyping case-control populations in association studies as well as individuals in the context of detection of alleles of biallelic markers which are known to be associated with a given trait, in which case both copies of the biallelic marker present in individual's genome are determined so that an individual may be classified as homozygous or heterozygous for a particular allele.

15 These genotyping methods can be performed on nucleic acid samples derived from a single individual or pooled DNA samples.

Genotyping can be performed using similar methods as those described above for the identification of the biallelic markers, or using other genotyping methods such as those further described below. In preferred embodiments, the comparison of sequences of amplified genomic fragments from different individuals is used to identify new biallelic markers whereas microsequencing is used for genotyping known biallelic markers in diagnostic and association study applications.

In one embodiment the invention encompasses methods of genotyping comprising determining the identity of a nucleotide at a G713-related biallelic marker or the complement thereof in a biological sample; optionally, wherein said G713-related biallelic marker is selected from the group consisting of A1 to A11, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith. In another embodiment the invention encompasses methods of genotyping comprising determining the identity of a nucleotide at a 13q31-q33 -related biallelic marker or the complement thereof in a biological sample; optionally, wherein said 13q31-q33-related biallelic marker is selected from the group consisting of A12 to A49, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said 13q31-q33-related biallelic marker is selected from the group consisting of A16 to A20, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein

said 13q31-q33-related biallelic marker is selected from the group consisting of A14, A15, A17, A18, A27, A28, A34, A35, A38, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said biological sample is derived from a single subject; optionally, wherein the identity of the nucleotides at said biallelic marker is determined for both copies of said biallelic marker present in said individual's genome; optionally, wherein said biological sample is derived from multiple subjects; Optionally, the genotyping methods of the invention encompass methods with any further limitation described in this disclosure, or those following, specified alone or in any combination; Optionally, said method is performed *in vitro*; optionally, further comprising amplifying a portion of said sequence comprising the biallelic marker prior to said determining step; Optionally, wherein said amplifying is performed by PCR, LCR, or replication of a recombinant vector comprising an origin of replication and said fragment in a host cell; optionally, wherein said determining is performed by a hybridization assay, a sequencing assay, a microsequencing assay, or an enzyme-based mismatch detection assay.

Source of Nucleic Acids for genotyping

Any source of nucleic acids, in purified or non-purified form, can be utilized as the starting nucleic acid, provided it contains or is suspected of containing the specific nucleic acid sequence desired. DNA or RNA may be extracted from cells, tissues, body fluids and the like as described above. While nucleic acids for use in the genotyping methods of the invention can be derived from any mammalian source, the test subjects and individuals from which nucleic acid samples are taken are generally understood to be human.

Amplification Of DNA Fragments Comprising Biallelic Markers

Methods and polynucleotides are provided to amplify a segment of nucleotides comprising one or more biallelic marker of the present invention. It will be appreciated that amplification of DNA fragments comprising biallelic markers may be used in various methods and for various purposes and is not restricted to genotyping. Nevertheless, many genotyping methods, although not all, require the previous amplification of the DNA region carrying the biallelic marker of interest. Such methods specifically increase the concentration or total number of sequences that span the biallelic marker or include that site and sequences located either distal or proximal to it. Diagnostic assays may also rely on amplification of DNA segments carrying a biallelic marker of the present invention. Amplification of DNA may be achieved by any method

known in the art. Amplification techniques are described above in the section entitled, "DNA amplification."

Some of these amplification methods are particularly suited for the detection of single nucleotide polymorphisms and allow the simultaneous amplification of a target sequence and the identification of the polymorphic nucleotide as it is further described below.

The identification of biallelic markers as described above allows the design of appropriate oligonucleotides, which can be used as primers to amplify DNA fragments comprising the biallelic markers of the present invention. Amplification can be performed using the primers initially used to discover new biallelic markers which are described herein or any set of primers allowing the amplification of a DNA fragment comprising a biallelic marker of the present invention.

In some embodiments the present invention provides primers for amplifying a DNA fragment containing one or more biallelic markers of the present invention. Preferred amplification primers are listed in Examples 1(c) and 2(b). It will be appreciated that the primers listed are merely exemplary and that any other set of primers which produce amplification products containing one or more biallelic markers of the present invention are also of use.

The spacing of the primers determines the length of the segment to be amplified. In the context of the present invention, amplified segments carrying biallelic markers can range in size from at least about 25 bp to 35 kbp. Amplification fragments from 25-3000 bp are typical, fragments from 50-1000 bp are preferred and fragments from 100-600 bp are highly preferred. It will be appreciated that amplification primers for the biallelic markers may be any sequence which allow the specific amplification of any DNA fragment carrying the markers. Amplification primers may be labeled or immobilized on a solid support as described in "Oligonucleotide probes and primers".

Methods of Genotyping DNA samples for Biallelic Markers

Any method known in the art can be used to identify the nucleotide present at a biallelic marker site. Since the biallelic marker allele to be detected has been identified and specified in the present invention, detection will prove simple for one of ordinary skill in the art by employing any of a number of techniques. Many genotyping methods require the previous amplification of the DNA region carrying the biallelic marker of interest. While the amplification of target or signal is often preferred at present, ultrasensitive detection methods which do not require amplification are also encompassed by the present genotyping methods. Methods well-known to those

skilled in the art that can be used to detect biallelic polymorphisms include methods such as, conventional dot blot analyzes, single strand conformational polymorphism analysis (SSCP) described by Orita et al.(1989), denaturing gradient gel electrophoresis (DGGE), heteroduplex analysis, mismatch cleavage detection, and other conventional techniques as described in Sheffield et al.(1991), White et al.(1992), Grompe et al.(1989 and 1993). Another method for determining the identity of the nucleotide present at a particular polymorphic site employs a specialized exonuclease-resistant nucleotide derivative as described in US patent 4,656,127.

Preferred methods involve directly determining the identity of the nucleotide present at a biallelic marker site by sequencing assay, enzyme-based mismatch detection assay, or hybridization assay. The following is a description of some preferred methods. A highly preferred method is the microsequencing technique. The term "sequencing" is generally used herein to refer to polymerase extension of duplex primer/template complexes and includes both traditional sequencing and microsequencing.

1) Sequencing Assays

The nucleotide present at a polymorphic site can be determined by sequencing methods. In a preferred embodiment, DNA samples are subjected to PCR amplification before sequencing as described above. DNA sequencing methods are described in "Sequencing Of Amplified Genomic DNA And Identification Of Single Nucleotide Polymorphisms".

Preferably, the amplified DNA is subjected to automated dideoxy terminator sequencing reactions using a dye-primer cycle sequencing protocol. Sequence analysis allows the identification of the base present at the biallelic marker site.

2) Microsequencing Assays

In microsequencing methods, the nucleotide at a polymorphic site in a target DNA is detected by a single nucleotide primer extension reaction. This method involves appropriate microsequencing primers which, hybridize just upstream of the polymorphic base of interest in the target nucleic acid. A polymerase is used to specifically extend the 3' end of the primer with one single ddNTP (chain terminator) complementary to the nucleotide at the polymorphic site. Next the identity of the incorporated nucleotide is determined in any suitable way.

Typically, microsequencing reactions are carried out using fluorescent ddNTPs and the extended microsequencing primers are analyzed by electrophoresis on ABI 377 sequencing machines to determine the identity of the incorporated nucleotide as

described in EP 412 883, the disclosure of which is incorporated herein by reference in its entirety. Alternatively capillary electrophoresis can be used in order to process a higher number of assays simultaneously. An example of a typical microsequencing procedure that can be used in the context of the present invention is provided in Example 1(e).

Different approaches can be used for the labeling and detection of ddNTPs. A homogeneous phase detection method based on fluorescence resonance energy transfer has been described by Chen and Kwok (1997) and Chen et al.(1997). In this method, amplified genomic DNA fragments containing polymorphic sites are incubated with a 5'-fluorescein-labeled primer in the presence of allelic dye-labeled dideoxyribonucleoside triphosphates and a modified Taq polymerase. The dye-labeled primer is extended one base by the dye-terminator specific for the allele present on the template. At the end of the genotyping reaction, the fluorescence intensities of the two dyes in the reaction mixture are analyzed directly without separation or purification. All these steps can be performed in the same tube and the fluorescence changes can be monitored in real time. Alternatively, the extended primer may be analyzed by MALDI-TOF Mass Spectrometry. The base at the polymorphic site is identified by the mass added onto the microsequencing primer (see Haff and Smirnov, 1997).

Microsequencing may be achieved by the established microsequencing method or by developments or derivatives thereof. Alternative methods include several solid-phase microsequencing techniques. The basic microsequencing protocol is the same as described previously, except that the method is conducted as a heterogeneous phase assay, in which the primer or the target molecule is immobilized or captured onto a solid support. To simplify the primer separation and the terminal nucleotide addition analysis, oligonucleotides are attached to solid supports or are modified in such ways that permit affinity separation as well as polymerase extension. The 5' ends and internal nucleotides of synthetic oligonucleotides can be modified in a number of different ways to permit different affinity separation approaches, e.g., biotinylation. If a single affinity group is used on the oligonucleotides, the oligonucleotides can be separated from the incorporated terminator reagent. This eliminates the need of physical or size separation. More than one oligonucleotide can be separated from the terminator reagent and analyzed simultaneously if more than one affinity group is used. This permits the analysis of several nucleic acid species or more nucleic acid sequence information per extension reaction. The affinity group need not be on the priming oligonucleotide but could alternatively be present on the template. For

example, immobilization can be carried out via an interaction between biotinylated DNA and streptavidin-coated microtitration wells or avidin-coated polystyrene particles. In the same manner, oligonucleotides or templates may be attached to a solid support in a high-density format. In such solid phase microsequencing reactions, incorporated ddNTPs can be radiolabeled (Syvänen, 1994) or linked to fluorescein (Livak and Hainer, 1994). The detection of radiolabeled ddNTPs can be achieved through scintillation-based techniques. The detection of fluorescein-linked ddNTPs can be based on the binding of antiluorescein antibody conjugated with alkaline phosphatase, followed by incubation with a chromogenic substrate (such as *p*-nitrophenyl phosphate). Other possible reporter-detection pairs include: ddNTP linked to dinitrophenyl (DNP) and anti-DNP alkaline phosphatase conjugate (Harju et al., 1993) or biotinylated ddNTP and horseradish peroxidase-conjugated streptavidin with *o*-phenylenediamine as a substrate (WO 92/15712, the disclosure of which is incorporated herein by reference in its entirety). As yet another alternative solid-phase microsequencing procedure, Nyren et al.(1993) described a method relying on the detection of DNA polymerase activity by an enzymatic luminometric inorganic pyrophosphate detection assay (ELIDA).

Pastinen et al.(1997) describe a method for multiplex detection of single nucleotide polymorphism in which the solid phase minisequencing principle is applied to an oligonucleotide array format. High-density arrays of DNA probes attached to a solid support (DNA chips) are further described below.

In one aspect the present invention provides polynucleotides and methods to genotype one or more biallelic markers of the present invention by performing a microsequencing assay. Preferred microsequencing primers include the nucleotide sequences D1 to D49 and E1 to E49. It will be appreciated that the microsequencing primers listed in Examples 1(e) and 2(d) are merely exemplary and that, any primer having a 3' end immediately adjacent to the polymorphic nucleotide may be used. Similarly, it will be appreciated that microsequencing analysis may be performed for any biallelic marker or any combination of biallelic markers of the present invention. One aspect of the present invention is a solid support which includes one or more microsequencing primers listed in Examples 1(e) and 2(d), or fragments comprising at least 8, 12, 15, 20, 25, 30, 40, or 50 consecutive nucleotides thereof, to the extent that such lengths are consistent with the primer described, and having a 3' terminus immediately upstream of the corresponding biallelic marker, for determining the identity of a nucleotide at a biallelic marker site.

3) Mismatch detection assays based on polymerases and ligases

In one aspect the present invention provides polynucleotides and methods to determine the allele of one or more biallelic markers of the present invention in a biological sample, by mismatch detection assays based on polymerases and/or ligases. These assays are based on the specificity of polymerases and ligases. Polymerization reactions places particularly stringent requirements on correct base pairing of the 3' end of the amplification primer and the joining of two oligonucleotides hybridized to a target DNA sequence is quite sensitive to mismatches close to the ligation site, especially at the 3' end. Methods, primers and various parameters to amplify DNA fragments comprising biallelic markers of the present invention are further described above in "Amplification Of DNA Fragments Comprising Biallelic Markers".

Allele Specific Amplification Primers

Discrimination between the two alleles of a biallelic marker can also be achieved by allele specific amplification, a selective strategy, whereby one of the alleles is amplified without amplification of the other allele. For allele specific amplification, at least one member of the pair of primers is sufficiently complementary with a region of a G713 or 13q31-q33 nucleotide sequence comprising the polymorphic base of a biallelic marker of the present invention to hybridize therewith and to initiate the amplification. Such primers are able to discriminate between the two alleles of a biallelic marker.

This is accomplished by placing the polymorphic base at the 3' end of one of the amplification primers. Because the extension forms from the 3' end of the primer, a mismatch at or near this position has an inhibitory effect on amplification. Therefore, under appropriate amplification conditions, these primers only direct amplification on their complementary allele. Determining the precise location of the mismatch and the corresponding assay conditions are well within the ordinary skill in the art.

Ligation/Amplification Based Methods

The "Oligonucleotide Ligation Assay" (OLA) uses two oligonucleotides which are designed to be capable of hybridizing to abutting sequences of a single strand of a target molecules. One of the oligonucleotides is biotinylated, and the other is detectably labeled. If the precise complementary sequence is found in a target molecule, the oligonucleotides will hybridize such that their termini abut, and create a ligation substrate that can be captured and detected. OLA is capable of detecting single nucleotide polymorphisms and may be advantageously combined with PCR as

described by Nickerson et al.(1990). In this method, PCR is used to achieve the exponential amplification of target DNA, which is then detected using OLA.

Other amplification methods which are particularly suited for the detection of single nucleotide polymorphism include LCR (ligase chain reaction), Gap LCR (GLCR) which are described above in "DNA Amplification". LCR uses two pairs of probes to exponentially amplify a specific target. The sequences of each pair of oligonucleotides, is selected to permit the pair to hybridize to abutting sequences of the same strand of the target. Such hybridization forms a substrate for a template-dependant ligase. In accordance with the present invention, LCR can be performed with oligonucleotides having the proximal and distal sequences of the same strand of a biallelic marker site. In one embodiment, either oligonucleotide will be designed to include the biallelic marker site. In such an embodiment, the reaction conditions are selected such that the oligonucleotides can be ligated together only if the target molecule either contains or lacks the specific nucleotide that is complementary to the biallelic marker on the oligonucleotide. In an alternative embodiment, the oligonucleotides will not include the biallelic marker, such that when they hybridize to the target molecule, a "gap" is created as described in WO 90/01069, the disclosure of which is incorporated herein by reference in its entirety. This gap is then "filled" with complementary dNTPs (as mediated by DNA polymerase), or by an additional pair of oligonucleotides. Thus at the end of each cycle, each single strand has a complement capable of serving as a target during the next cycle and exponential allele-specific amplification of the desired sequence is obtained.

Ligase/Polymerase-mediated Genetic Bit AnalysisTM is another method for determining the identity of a nucleotide at a preselected site in a nucleic acid molecule (WO 95/21271). This method involves the incorporation of a nucleoside triphosphate that is complementary to the nucleotide present at the preselected site onto the terminus of a primer molecule, and their subsequent ligation to a second oligonucleotide. The reaction is monitored by detecting a specific label attached to the reaction's solid phase or by detection in solution.

4) Hybridization Assay Methods

A preferred method of determining the identity of the nucleotide present at a biallelic marker site involves nucleic acid hybridization. The hybridization probes, which can be conveniently used in such reactions, preferably include the probes defined herein. Any hybridization assay may be used including Southern hybridization,

Northern hybridization, dot blot hybridization and solid-phase hybridization (see Sambrook et al., 1989).

Hybridization refers to the formation of a duplex structure by two single stranded nucleic acids due to complementary base pairing. Hybridization can occur
5 between exactly complementary nucleic acid strands or between nucleic acid strands that contain minor regions of mismatch. Specific probes can be designed that hybridize to one form of a biallelic marker and not to the other and therefore are able to discriminate between different allelic forms. Allele-specific probes are often used in pairs, one member of a pair showing perfect match to a target sequence containing the
10 original allele and the other showing a perfect match to the target sequence containing the alternative allele. Hybridization conditions should be sufficiently stringent that there is a significant difference in hybridization intensity between alleles, and preferably an essentially binary response, whereby a probe hybridizes to only one of the alleles. Stringent, sequence specific hybridization conditions, under which a probe will
15 hybridize only to the exactly complementary target sequence are well known in the art (Sambrook et al., 1989). Stringent conditions are sequence dependent and will be different in different circumstances. Generally, stringent conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. Although such hybridization can be performed in
20 solution, it is preferred to employ a solid-phase hybridization assay. The target DNA comprising a biallelic marker of the present invention may be amplified prior to the hybridization reaction. The presence of a specific allele in the sample is determined by detecting the presence or the absence of stable hybrid duplexes formed between the probe and the target DNA. The detection of hybrid duplexes can be carried out by a
25 number of methods. Various detection assay formats are well known which utilize detectable labels bound to either the target or the probe to enable detection of the hybrid duplexes. Typically, hybridization duplexes are separated from unhybridized nucleic acids and the labels bound to the duplexes are then detected. Those skilled in the art will recognize that wash steps may be employed to wash away excess target
30 DNA or probe as well as unbound conjugate. Further, standard heterogeneous assay formats are suitable for detecting the hybrids using the labels present on the primers and probes.

Two recently developed assays allow hybridization-based allele discrimination with no need for separations or washes (see Landegren U. et al., 1998). The TaqMan
35 assay takes advantage of the 5' nuclease activity of Taq DNA polymerase to digest a

DNA probe annealed specifically to the accumulating amplification product. TaqMan probes are labeled with a donor-acceptor dye pair that interacts via fluorescence energy transfer. Cleavage of the TaqMan probe by the advancing polymerase during amplification dissociates the donor dye from the quenching acceptor dye, greatly increasing the donor fluorescence. All reagents necessary to detect two allelic variants can be assembled at the beginning of the reaction and the results are monitored in real time (see Livak et al., 1995). In an alternative homogeneous hybridization based procedure, molecular beacons are used for allele discriminations. Molecular beacons are hairpin-shaped oligonucleotide probes that report the presence of specific nucleic acids in homogeneous solutions. When they bind to their targets they undergo a conformational reorganization that restores the fluorescence of an internally quenched fluorophore (Tyagi et al., 1998).

The polynucleotides provided herein can be used to produce probes which can be used in hybridization assays for the detection of biallelic marker alleles in biological samples. These probes are characterized in that they preferably comprise between 8 and 50 nucleotides, and in that they are sufficiently complementary to a sequence comprising a biallelic marker of the present invention to hybridize thereto and preferably sufficiently specific to be able to discriminate the targeted sequence for only one nucleotide variation. A particularly preferred probe is 25 nucleotides in length. Preferably the biallelic marker is within 4 nucleotides of the center of the polynucleotide probe. In particularly preferred probes, the biallelic marker is at the center of said polynucleotide. Preferred probes comprise a nucleotide sequence selected from the group consisting of amplicons listed in Tables 1 and 6 and the sequences complementary thereto, or a fragment thereof, said fragment comprising at least about 8 consecutive nucleotides, preferably 10, 15, 20, more preferably 25, 30, 40, 47, or 50 consecutive nucleotides and containing a polymorphic base. Preferred probes comprise a nucleotide sequence selected from the group consisting of P1 to P49 and the sequences complementary thereto. In preferred embodiments the polymorphic base(s) are within 5, 4, 3, 2, 1, nucleotides of the center of the said polynucleotide, more preferably at the center of said polynucleotide.

Preferably the probes of the present invention are labeled or immobilized on a solid support. Labels and solid supports are further described in "Oligonucleotide Probes and Primers". The probes can be non-extendable as described in "Oligonucleotide Probes and Primers".

By assaying the hybridization to an allele specific probe, one can detect the presence or absence of a biallelic marker allele in a given sample. High-Throughput parallel hybridization in array format is specifically encompassed within "hybridization assays" and are described below.

5) *Hybridization To Addressable Arrays Of Oligonucleotides*

Hybridization assays based on oligonucleotide arrays rely on the differences in hybridization stability of short oligonucleotides to perfectly matched and mismatched target sequence variants. Efficient access to polymorphism information is obtained through a basic structure comprising high-density arrays of oligonucleotide probes attached to a solid support (e.g., the chip) at selected positions. Each DNA chip can contain thousands to millions of individual synthetic DNA probes arranged in a grid-like pattern and miniaturized to the size of a dime.

The chip technology has already been applied with success in numerous cases. For example, the screening of mutations has been undertaken in the BRCA1 gene, in *S. cerevisiae* mutant strains, and in the protease gene of HIV-1 virus (Hacia et al., 1996; Shoemaker et al., 1996; Kozal et al., 1996). Chips of various formats for use in detecting biallelic polymorphisms can be produced on a customized basis by Affymetrix (GeneChip™), Hyseq (HyChip and HyGnostics), and Protogene Laboratories.

In general, these methods employ arrays of oligonucleotide probes that are complementary to target nucleic acid sequence segments from an individual which, target sequences include a polymorphic marker. EP 785280, the disclosure of which is incorporated herein by reference in its entirety, describes a tiling strategy for the detection of single nucleotide polymorphisms. Briefly, arrays may generally be "tiled" for a large number of specific polymorphisms. By "tiling" is generally meant the synthesis of a defined set of oligonucleotide probes which is made up of a sequence complementary to the target sequence of interest, as well as preselected variations of that sequence, e.g., substitution of one or more given positions with one or more members of the basis set of nucleotides. Tiling strategies are further described in PCT application No. WO 95/11995. In a particular aspect, arrays are tiled for a number of specific, identified biallelic marker sequences. In particular, the array is tiled to include a number of detection blocks, each detection block being specific for a specific biallelic marker or a set of biallelic markers. For example, a detection block may be tiled to include a number of probes, which span the sequence segment that includes a specific polymorphism. To ensure probes that are complementary to each allele, the probes are synthesized in pairs differing at the biallelic marker. In addition to the probes

5 differing at the polymorphic base, monosubstituted probes are also generally tiled within the detection block. These monosubstituted probes have bases at and up to a certain number of bases in either direction from the polymorphism, substituted with the remaining nucleotides (selected from A, T, G, C and U). Typically the probes in a tiled
10 detection block will include substitutions of the sequence positions up to and including those that are 5 bases away from the biallelic marker. The monosubstituted probes provide internal controls for the tiled array, to distinguish actual hybridization from artefactual cross-hybridization. Upon completion of hybridization with the target sequence and washing of the array, the array is scanned to determine the position on
15 the array to which the target sequence hybridizes. The hybridization data from the scanned array is then analyzed to identify which allele or alleles of the biallelic marker are present in the sample. Hybridization and scanning may be carried out as described in PCT application No. WO 92/10092 and WO 95/11995 and US patent No. 5,424,186.

20 Thus, in some embodiments, the chips may comprise an array of nucleic acid sequences of fragments of about 15 nucleotides in length. In further embodiments, the chip may comprise an array including at least one of the sequences selected from the group consisting of amplicons listed in Tables 1 and 6 and the sequences complementary thereto, or a fragment thereof, said fragment comprising at least about
25 8 consecutive nucleotides, preferably 10, 15, 20, more preferably 25, 30, 40, 47, or 50 consecutive nucleotides and containing a polymorphic base. In preferred embodiments the polymorphic base is within 5, 4, 3, 2, 1, nucleotides of the center of the said polynucleotide, more preferably at the center of said polynucleotide. In some embodiments, the chip may comprise an array of at least 2, 3, 4, 5, 6, 7, 8 or more of
30 these polynucleotides of the invention. Solid supports and polynucleotides of the present invention attached to solid supports are further described in "Oligonucleotide Probes And Primers".

6) Integrated Systems

35 Another technique, which may be used to analyze polymorphisms, includes multicomponent integrated systems, which miniaturize and compartmentalize processes such as PCR and capillary electrophoresis reactions in a single functional device. An example of such technique is disclosed in US patent 5,589,136, the disclosure of which is incorporated herein by reference in its entirety, which describes the integration of PCR amplification and capillary electrophoresis in chips.

Integrated systems can be envisaged mainly when microfluidic systems are used. These systems comprise a pattern of microchannels designed onto a glass, silicon, quartz, or plastic wafer included on a microchip. The movements of the samples are controlled by electric, electroosmotic or hydrostatic forces applied across different areas of the microchip to create functional microscopic valves and pumps with no moving parts.

For genotyping biallelic markers, the microfluidic system may integrate nucleic acid amplification, microsequencing, capillary electrophoresis and a detection method such as laser-induced fluorescence detection.

Methods Of Genetic Analysis Using The Biallelic Markers Of The Present Invention

Different methods are available for the genetic analysis of complex traits (see Lander and Schork, 1994). The search for disease-susceptibility genes is conducted using two main methods: the linkage approach in which evidence is sought for cosegregation between a locus and a putative trait locus using family studies, and the association approach in which evidence is sought for a statistically significant association between an allele and a trait or a trait causing allele (Khoury et al., 1993). In general, the biallelic markers of the present invention find use in any method known in the art to demonstrate a statistically significant correlation between a genotype and a phenotype. The biallelic markers may be used in parametric and non-parametric linkage analysis methods. Preferably, the biallelic markers of the present invention are used to identify genes associated with detectable traits using association studies, an approach which does not require the use of affected families and which permits the identification of genes associated with complex and sporadic traits.

The genetic analysis using the biallelic markers of the present invention may be conducted on any scale. The whole set of biallelic markers of the present invention or any subset of biallelic markers of the present invention corresponding to the candidate gene may be used. Further, any set of genetic markers including a biallelic marker of the present invention may be used. A set of biallelic polymorphisms that could be used as genetic markers in combination with the biallelic markers of the present invention has been described in WO 98/20165. As mentioned above, it should be noted that the biallelic markers of the present invention may be included in any complete or partial genetic map of the human genome. These different uses are specifically contemplated in the present invention and claims.

Linkage Analysis

Linkage analysis is based upon establishing a correlation between the transmission of genetic markers and that of a specific trait throughout generations within a family. Thus, the aim of linkage analysis is to detect marker loci that show cosegregation with a trait of interest in pedigrees.

Parametric Methods

When data are available from successive generations there is the opportunity to study the degree of linkage between pairs of loci. Estimates of the recombination fraction enable loci to be ordered and placed onto a genetic map. With loci that are genetic markers, a genetic map can be established, and then the strength of linkage between markers and traits can be calculated and used to indicate the relative positions of markers and genes affecting those traits (Weir, 1996). The classical method for linkage analysis is the logarithm of odds (lod) score method (see Morton, 1955; Ott, 1991). Calculation of lod scores requires specification of the mode of inheritance for the disease (parametric method). Generally, the length of the candidate region identified using linkage analysis is between 2 and 20Mb. Once a candidate region is identified as described above, analysis of recombinant individuals using additional markers allows further delineation of the candidate region. Linkage analysis studies have generally relied on the use of a maximum of 5,000 microsatellite markers, thus limiting the maximum theoretical attainable resolution of linkage analysis to about 600 kb on average.

Linkage analysis has been successfully applied to map simple genetic traits that show clear Mendelian inheritance patterns and which have a high penetrance (i.e., the ratio between the number of trait positive carriers of allele *a* and the total number of *a* carriers in the population). However, parametric linkage analysis suffers from a variety of drawbacks. First, it is limited by its reliance on the choice of a genetic model suitable for each studied trait. Furthermore, as already mentioned, the resolution attainable using linkage analysis is limited, and complementary studies are required to refine the analysis of the typical 2Mb to 20Mb regions initially identified through linkage analysis. In addition, parametric linkage analysis approaches have proven difficult when applied to complex genetic traits, such as those due to the combined action of multiple genes and/or environmental factors. It is very difficult to model these factors adequately in a lod score analysis. In such cases, too large an effort and cost are needed to recruit the adequate number of affected families required for applying

linkage analysis to these situations, as recently discussed by Risch, N. and Merikangas, K. (1996).

Non-Parametric Methods

The advantage of the so-called non-parametric methods for linkage analysis is that they do not require specification of the mode of inheritance for the disease, they tend to be more useful for the analysis of complex traits. In non-parametric methods, one tries to prove that the inheritance pattern of a chromosomal region is not consistent with random Mendelian segregation by showing that affected relatives inherit identical copies of the region more often than expected by chance. Affected relatives should show excess "allele sharing" even in the presence of incomplete penetrance and polygenic inheritance. In non-parametric linkage analysis the degree of agreement at a marker locus in two individuals can be measured either by the number of alleles identical by state (IBS) or by the number of alleles identical by descent (IBD). Affected sib pair analysis is a well-known special case and is the simplest form of these methods.

The biallelic markers of the present invention may be used in both parametric and non-parametric linkage analysis. Preferably biallelic markers may be used in non-parametric methods which allow the mapping of genes involved in complex traits. The biallelic markers of the present invention may be used in both IBD- and IBS- methods to map genes affecting a complex trait. In such studies, taking advantage of the high density of biallelic markers, several adjacent biallelic marker loci may be pooled to achieve the efficiency attained by multi-allelic markers (Zhao et al., 1998).

Population Association Studies

The present invention comprises methods for identifying if the G713 gene or a 13q31-q33 gene or nucleotide sequence is associated with a detectable trait using the biallelic markers of the present invention. In one embodiment the present invention comprises methods to detect an association between a biallelic marker allele or a biallelic marker haplotype and a trait. Further, the invention comprises methods to identify a trait causing allele in linkage disequilibrium with any biallelic marker allele of the present invention.

As described above, alternative approaches can be employed to perform association studies: genome-wide association studies, candidate region association studies and candidate gene association studies. In a preferred embodiment, the biallelic markers of the present invention are used to perform candidate gene association studies. The candidate gene analysis clearly provides a short-cut

approach to the identification of genes and gene polymorphisms related to a particular trait when some information concerning the biology of the trait is available. Further, the biallelic markers of the present invention may be incorporated in any map of genetic markers of the human genome in order to perform genome-wide association studies. Methods to generate a high-density map of biallelic markers has been described in US Provisional Patent application serial number 60/082,614. The biallelic markers of the present invention may further be incorporated in any map of a specific candidate region of the genome (a specific chromosome or a specific chromosomal segment for example).

As mentioned above, association studies may be conducted within the general population and are not limited to studies performed on related individuals in affected families. Association studies are extremely valuable as they permit the analysis of sporadic or multifactor traits. Moreover, association studies represent a powerful method for fine-scale mapping enabling much finer mapping of trait causing alleles than linkage studies. Studies based on pedigrees often only narrow the location of the trait causing allele. Association studies using the biallelic markers of the present invention can therefore be used to refine the location of a trait causing allele in a candidate region identified by Linkage Analysis methods. Moreover, once a chromosome segment of interest has been identified, the presence of a candidate gene such as a candidate gene of the present invention, in the region of interest can provide a shortcut to the identification of the trait causing allele. Biallelic markers of the present invention can be used to demonstrate that a candidate gene is associated with a trait. Such uses are specifically contemplated in the present invention.

Determining The Frequency Of A Biallelic Marker Allele Or Of A Biallelic Marker Haplotype In A Population

Association studies explore the relationships among frequencies for sets of alleles between loci.

Determining The Frequency Of An Allele In A Population

Allelic frequencies of the biallelic markers in a populations can be determined using one of the methods described above under the heading "Methods for genotyping an individual for biallelic markers", or any genotyping procedure suitable for this intended purpose. Genotyping pooled samples or individual samples can determine the frequency of a biallelic marker allele in a population. One way to reduce the number of genotypings required is to use pooled samples. A major obstacle in using pooled samples is in terms of accuracy and reproducibility for determining accurate

DNA concentrations in setting up the pools. Genotyping individual samples provides higher sensitivity, reproducibility and accuracy and; is the preferred method used in the present invention. Preferably, each individual is genotyped separately and simple gene counting is applied to determine the frequency of an allele of a biallelic marker or of a genotype in a given population.

The invention also relates to methods of estimating the frequency of an allele in a population comprising: a) genotyping individuals from said population for said biallelic marker according to the method of the present invention; b) determining the proportional representation of said biallelic marker in said population. In addition, the methods of estimating the frequency of an allele in a population of the invention encompass methods with any further limitation described in this disclosure, or those following, specified alone or in any combination; optionally, wherein a G713-related biallelic marker is selected from the group consisting of A1 to A11, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein a 13q31-q33-related biallelic marker is selected from the group consisting of A12 to A49, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said 13q31-q33-related biallelic marker is selected from the group consisting of A14, A15, A17, A18, A27, A28, A34, A35, A38 and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said 13q31-q33-related biallelic marker is selected from the group consisting of A16 to A20, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, determining the frequency of a biallelic marker allele in a population may be accomplished by determining the identity of the nucleotides for both copies of said biallelic marker present in the genome of each individual in said population and calculating the proportional representation of said nucleotide at said G713- or 13q31-q33-related biallelic marker for the population; Optionally, determining the proportional representation may be accomplished by performing a genotyping method of the invention on a pooled biological sample derived from a representative number of individuals, or each individual, in said population, and calculating the proportional amount of said nucleotide compared with the total.

Determining The Frequency Of A Haplotype In A Population

The gametic phase of haplotypes is unknown when diploid individuals are heterozygous at more than one locus. Using genealogical information in families gametic phase can sometimes be inferred (Perlin et al., 1994). When no genealogical

information is available different strategies may be used. One possibility is that the multiple-site heterozygous diploids can be eliminated from the analysis, keeping only the homozygotes and the single-site heterozygote individuals, but this approach might lead to a possible bias in the sample composition and the underestimation of low-frequency haplotypes. Another possibility is that single chromosomes can be studied independently, for example, by asymmetric PCR amplification (see Newton et al, 1989; Wu et al., 1989) or by isolation of single chromosome by limit dilution followed by PCR amplification (see Ruano et al., 1990). Further, a sample may be haplotyped for sufficiently close biallelic markers by double PCR amplification of specific alleles (Sarkar, G. and Sommer S. S., 1991). These approaches are not entirely satisfying either because of their technical complexity, the additional cost they entail, their lack of generalization at a large scale, or the possible biases they introduce. To overcome these difficulties, an algorithm to infer the phase of PCR-amplified DNA genotypes introduced by Clark, A.G.(1990) may be used. Briefly, the principle is to start filling a preliminary list of haplotypes present in the sample by examining unambiguous individuals, that is, the complete homozygotes and the single-site heterozygotes. Then other individuals in the same sample are screened for the possible occurrence of previously recognized haplotypes. For each positive identification, the complementary haplotype is added to the list of recognized haplotypes, until the phase information for all individuals is either resolved or identified as unresolved. This method assigns a single haplotype to each multiheterozygous individual, whereas several haplotypes are possible when there are more than one heterozygous site. Alternatively, one can use methods estimating haplotype frequencies in a population without assigning haplotypes to each individual. Preferably, a method based on an expectation-maximization (EM) algorithm (Dempster et al., 1977) leading to maximum-likelihood estimates of haplotype frequencies under the assumption of Hardy-Weinberg proportions (random mating) is used (see Excoffier L. and Slatkin M., 1995). The EM algorithm is a generalized iterative maximum-likelihood approach to estimation that is useful when data are ambiguous and/or incomplete. The EM algorithm is used to resolve heterozygotes into haplotypes. Haplotype estimations are further described below under the heading "Statistical Methods." Any other method known in the art to determine or to estimate the frequency of a haplotype in a population may be used. The invention also encompasses methods of estimating the frequency of a haplotype for a set of biallelic markers in a population, comprising the steps of: a) genotyping at least one G713- or 13q31-q33-related biallelic marker according to a method of the

invention for each individual in said population; b) genotyping a second biallelic marker by determining the identity of the nucleotides at said second biallelic marker for both copies of said second biallelic marker present in the genome of each individual in said population; and c) applying a haplotype determination method to the identities of the nucleotides determined in steps a) and b) to obtain an estimate of said frequency. In addition, the methods of estimating the frequency of a haplotype of the invention encompass methods with any further limitation described in this disclosure, or those following, specified alone or in any combination: optionally, wherein said G713-related biallelic marker is selected from the group consisting of A1 to A11, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said 13q31-q33-related biallelic marker is selected from the group consisting of A12 to A49, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said 13q31-q33-related biallelic marker is selected from the group consisting of A16 to A20, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said 13q31-q33-related biallelic marker is selected from the group consisting of A14, A15, A17, A18, A27, A28, A34, A35, A38, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, said haplotype determination method is performed by asymmetric PCR amplification, double PCR amplification of specific alleles, the Clark algorithm, or an expectation-maximization algorithm.

Linkage Disequilibrium Analysis

Linkage disequilibrium is the non-random association of alleles at two or more loci and represents a powerful tool for mapping genes involved in disease traits (see Ajioka R.S. et al., 1997). Biallelic markers, because they are densely spaced in the human genome and can be genotyped in greater numbers than other types of genetic markers (such as RFLP or VNTR markers), are particularly useful in genetic analysis based on linkage disequilibrium.

When a disease mutation is first introduced into a population (by a new mutation or the immigration of a mutation carrier), it necessarily resides on a single chromosome and thus on a single "background" or "ancestral" haplotype of linked markers. Consequently, there is complete disequilibrium between these markers and the disease mutation: one finds the disease mutation only in the presence of a specific set of marker alleles. Through subsequent generations recombination events occur between the disease mutation and these marker polymorphisms, and the

disequilibrium gradually dissipates. The pace of this dissipation is a function of the recombination frequency, so the markers closest to the disease gene will manifest higher levels of disequilibrium than those that are further away. When not broken up by recombination, "ancestral" haplotypes and linkage disequilibrium between marker alleles at different loci can be tracked not only through pedigrees but also through populations. Linkage disequilibrium is usually seen as an association between one specific allele at one locus and another specific allele at a second locus.

The pattern or curve of disequilibrium between disease and marker loci is expected to exhibit a maximum that occurs at the disease locus. Consequently, the amount of linkage disequilibrium between a disease allele and closely linked genetic markers may yield valuable information regarding the location of the disease gene. For fine-scale mapping of a disease locus, it is useful to have some knowledge of the patterns of linkage disequilibrium that exist between markers in the studied region. As mentioned above the mapping resolution achieved through the analysis of linkage disequilibrium is much higher than that of linkage studies. The high density of biallelic markers combined with linkage disequilibrium analysis provides powerful tools for fine-scale mapping. Different methods to calculate linkage disequilibrium are described below under the heading "Statistical Methods".

Population-Based Case-Control Studies Of Trait-Marker Associations

As mentioned above, the occurrence of pairs of specific alleles at different loci on the same chromosome is not random and the deviation from random is called linkage disequilibrium. Association studies focus on population frequencies and rely on the phenomenon of linkage disequilibrium. If a specific allele in a given gene is directly involved in causing a particular trait, its frequency will be statistically increased in an affected (trait positive) population, when compared to the frequency in a trait negative population or in a random control population. As a consequence of the existence of linkage disequilibrium, the frequency of all other alleles present in the haplotype carrying the trait-causing allele will also be increased in trait positive individuals compared to trait negative individuals or random controls. Therefore, association between the trait and any allele (specifically a biallelic marker allele) in linkage disequilibrium with the trait-causing allele will suffice to suggest the presence of a trait-related gene in that particular region. Case-control populations can be genotyped for biallelic markers to identify associations that narrowly locate a trait causing allele. As any marker in linkage disequilibrium with one given marker associated with a trait will be associated with the trait. Linkage disequilibrium allows the relative frequencies in

case-control populations of a limited number of genetic polymorphisms (specifically biallelic markers) to be analyzed as an alternative to screening all possible functional polymorphisms in order to find trait-causing alleles. Association studies compare the frequency of marker alleles in unrelated case-control populations, and represent powerful tools for the dissection of complex traits.

Case-Control Populations (Inclusion Criteria)

Population-based association studies do not concern familial inheritance but compare the prevalence of a particular genetic marker, or a set of markers, in case-control populations. They are case-control studies based on comparison of unrelated case (affected or trait positive) individuals and unrelated control (unaffected, trait negative or random) individuals. Preferably the control group is composed of unaffected or trait negative individuals. Further, the control group is ethnically matched to the case population. Moreover, the control group is preferably matched to the case-population for the main known confusion factor for the trait under study (for example age-matched for an age-dependent trait). Ideally, individuals in the two samples are paired in such a way that they are expected to differ only in their disease status. The terms "trait positive population", "case population" and "affected population" are used interchangeably herein.

An important step in the dissection of complex traits using association studies is the choice of case-control populations (see Lander and Schork, 1994). A major step in the choice of case-control populations is the clinical definition of a given trait or phenotype. Any genetic trait may be analyzed by the association method proposed here by carefully selecting the individuals to be included in the trait positive and trait negative phenotypic groups. Four criteria are often useful: clinical phenotype, age at onset, family history and severity. The selection procedure for continuous or quantitative traits (such as blood pressure for example) involves selecting individuals at opposite ends of the phenotype distribution of the trait under study, so as to include in these trait positive and trait negative populations individuals with non-overlapping phenotypes. Preferably, case-control populations comprise phenotypically homogeneous populations. Trait positive and trait negative populations comprise phenotypically uniform populations of individuals representing each between 1 and 98%, preferably between 1 and 80%, more preferably between 1 and 50%, and more preferably between 1 and 30%, most preferably between 1 and 20% of the total population under study, and preferably selected among individuals exhibiting non-overlapping phenotypes. The clearer the difference between the two trait phenotypes,

the greater the probability of detecting an association with biallelic markers. The selection of those drastically different but relatively uniform phenotypes enables efficient comparisons in association studies and the possible detection of marked differences at the genetic level, provided that the sample sizes of the populations under study are significant enough.

In preferred embodiments, a first group of between 50 and 300 trait positive individuals, preferably about 100 individuals, are recruited according to their phenotypes. A similar number of control individuals are included in such studies.

Association Analysis

The invention also comprises methods of detecting an association between a genotype and a phenotype, comprising the steps of: a) determining the frequency of at least one G713- or 13q31-q33-related biallelic marker in a trait positive population according to a genotyping method of the invention; b) determining the frequency of said G713- or 13q31-q33-related biallelic marker in a control population according to a genotyping method of the invention; and c) determining whether a statistically significant association exists between said genotype and said phenotype. In addition, the methods of detecting an association between a genotype and a phenotype of the invention encompass methods with any further limitation described in this disclosure, or those following, specified alone or in any combination: optionally, wherein said G713-related biallelic marker is selected from the group consisting of A1 to A11, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said 13q31-q33-related biallelic marker is selected from the group consisting of A12 to A49, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said 13q31-q33-related biallelic marker is selected from the group consisting of A16 to A20, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said 13q31-q33-related biallelic marker is selected from the group consisting of A14, A15, A17, A18, A27, A28, A34, A35, A38, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith. Optionally, said control population may be a trait negative population, or a random population; Optionally, each of said genotyping steps a) and b) may be performed on a pooled biological sample derived from each of said populations; Optionally, each of said genotyping of steps a) and b) is performed separately on biological samples derived from each individual in said population or a subsample thereof.

The general strategy to perform association studies using biallelic markers derived from a region carrying a candidate gene is to scan two groups of individuals (case-control populations) in order to measure and statistically compare the allele frequencies of the biallelic markers of the present invention in both groups.

5 If a statistically significant association with a trait is identified for at least one or more of the analyzed biallelic markers, one can assume that: either the associated allele is directly responsible for causing the trait (i.e. the associated allele is the trait causing allele), or more likely the associated allele is in linkage disequilibrium with the trait causing allele. The specific characteristics of the associated allele with respect to the
10 candidate gene function usually give further insight into the relationship between the associated allele and the trait (causal or in linkage disequilibrium). If the evidence indicates that the associated allele within the candidate gene is most probably not the trait causing allele but is in linkage disequilibrium with the real trait causing allele, then the trait causing allele can be found by sequencing the vicinity of the associated
15 marker, and performing further association studies with the polymorphisms that are revealed in an iterative manner.

Association studies are usually run in two successive steps. In a first phase, the frequencies of a reduced number of biallelic markers from the candidate gene are determined in the trait positive and control populations. In a second phase of the
20 analysis, the position of the genetic loci responsible for the given trait is further refined using a higher density of markers from the relevant region. However, if the candidate gene under study is relatively small in length, as is the case for G713, a single phase may be sufficient to establish significant associations.

Haplotype Analysis

25 As described above, when a chromosome carrying a disease allele first appears in a population as a result of either mutation or migration, the mutant allele necessarily resides on a chromosome having a set of linked markers: the ancestral haplotype. This haplotype can be tracked through populations and its statistical association with a given trait can be analyzed. Complementing single point (allelic)
30 association studies with multi-point association studies also called haplotype studies increases the statistical power of association studies. Thus, a haplotype association study allows one to define the frequency and the type of the ancestral carrier haplotype. A haplotype analysis is important in that it increases the statistical power of an analysis involving individual markers.

In a first stage of a haplotype frequency analysis, the frequency of the possible haplotypes based on various combinations of the identified biallelic markers of the invention is determined. The haplotype frequency is then compared for distinct populations of trait positive and control individuals. The number of trait positive individuals, which should be, subjected to this analysis to obtain statistically significant results usually ranges between 30 and 300, with a preferred number of individuals ranging between 50 and 150. The same considerations apply to the number of unaffected individuals (or random control) used in the study. The results of this first analysis provide haplotype frequencies in case-control populations, for each evaluated haplotype frequency a p-value and an odd ratio are calculated. If a statistically significant association is found the relative risk for an individual carrying the given haplotype of being affected with the trait under study can be approximated.

An additional embodiment of the present invention encompasses methods of detecting an association between a haplotype and a phenotype, comprising the steps of: a) estimating the frequency of at least one haplotype in a trait positive population, according to a method of the invention for estimating the frequency of a haplotype; b) estimating the frequency of said haplotype in a control population, according to a method of the invention for estimating the frequency of a haplotype; and c) determining whether a statistically significant association exists between said haplotype and said phenotype. In addition, the methods of detecting an association between a haplotype and a phenotype of the invention encompass methods with any further limitation described in this disclosure, or those following: optionally, wherein said G713-related biallelic marker is selected from the group consisting of A1 to A11, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said 13q31-q33-related biallelic marker is selected from the group consisting of A12 to A49, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said 13q31-q33-related biallelic marker is selected from the group consisting of A16 to A20, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said 13q31-q33-related biallelic marker is selected from the group consisting of A14, A15, A17, A18, A27, A28, A34, A35, A38, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith. Optionally, said control population is a trait negative population, or a random population. Optionally, said method comprises the additional steps of determining the phenotype in said trait positive and said control populations prior to step c).

Interaction Analysis

The biallelic markers of the present invention may also be used to identify patterns of biallelic markers associated with detectable traits resulting from polygenic interactions. The analysis of genetic interaction between alleles at unlinked loci requires individual genotyping using the techniques described herein. The analysis of allelic interaction among a selected set of biallelic markers with appropriate level of statistical significance can be considered as a haplotype analysis. Interaction analysis comprises stratifying the case-control populations with respect to a given haplotype for the first loci and performing a haplotype analysis with the second loci with each subpopulation.

Statistical methods used in association studies are further described below.

Testing For Linkage In The Presence Of Association

The biallelic markers of the present invention may further be used in TDT (transmission/disequilibrium test). TDT tests for both linkage and association and is not affected by population stratification. TDT requires data for affected individuals and their parents or data from unaffected sibs instead of from parents (see Spielmann S. et al., 1993; Schaid D.J. et al., 1996, Spielmann S. and Ewens W.J., 1998). Such combined tests generally reduce the false – positive errors produced by separate analyses.

Statistical methods

In general, any method known in the art to test whether a trait and a genotype show a statistically significant correlation may be used.

1) Methods In Linkage Analysis

Statistical methods and computer programs useful for linkage analysis are well-known to those skilled in the art (see Terwilliger J.D. and Ott J., 1994; Ott J., 1991).

2) Methods To Estimate Haplotype Frequencies In A Population

As described above, when genotypes are scored, it is often not possible to distinguish heterozygotes so that haplotype frequencies cannot be easily inferred. When the gametic phase is not known, haplotype frequencies can be estimated from the multilocus genotypic data. Any method known to person skilled in the art can be used to estimate haplotype frequencies (see Lange K., 1997; Weir, B.S., 1996) Preferably, maximum-likelihood haplotype frequencies are computed using an Expectation- Maximization (EM) algorithm (see Dempster et al., 1977; Excoffier L. and Slatkin M., 1995). This procedure is an iterative process aiming at obtaining maximum-likelihood estimates of haplotype frequencies from multi-locus genotype data when the

gametic phase is unknown. Haplotype estimations are usually performed by applying the EM algorithm using for example the EM-HAPLO program (Hawley M. E. et al., 1994) or the Arlequin program (Schneider et al., 1997). The EM algorithm is a generalized iterative maximum likelihood approach to estimation and is briefly described below.

Please note that in the present section, "Methods To Estimate Haplotype Frequencies In A Population," of this text, phenotypes will refer to multi-locus genotypes with unknown phase. Genotypes will refer to known-phase multi-locus genotypes.

A sample of N unrelated individuals is typed for K markers. The data observed are the unknown-phase K-locus phenotypes that can be categorized in F different phenotypes. Suppose that we have H underlying possible haplotypes (in case of K biallelic markers, $H=2^K$).

For phenotype j, suppose that c_j genotypes are possible. We thus have the following equation

$$P_j = \sum_{i=1}^{c_j} pr(genotype_i) = \sum_{i=1}^{c_j} pr(h_k, h_l) \quad \text{Equation 1}$$

where P_j is the probability of the phenotype j, h_k and h_l are the two haplotypes constituent the genotype i. Under the Hardy-Weinberg equilibrium, $pr(h_k, h_l)$ becomes:

$$pr(h_k, h_l) = pr(h_k)^2 \text{ if } h_k = h_l, pr(h_k, h_l) = 2 pr(h_k).pr(h_l) \text{ if } h_k \neq h_l. \quad \text{Equation 2}$$

The successive steps of the E-M algorithm can be described as follows:

Starting with initial values of the of haplotypes frequencies, noted $p_1^{(0)}, p_2^{(0)}, \dots, p_H^{(0)}$, these initial values serve to estimate the genotype frequencies (Expectation step) and then estimate another set of haplotype frequencies (Maximization step), noted $p_1^{(1)}, p_2^{(1)}, \dots, p_H^{(1)}$, these two steps are iterated until changes in the sets of haplotypes frequency are very small.

A stop criterion can be that the maximum difference between haplotype frequencies between two iterations is less than 10^{-7} . These values can be adjusted according to the desired precision of estimations.

At a given iteration s, the Expectation step comprises calculating the genotypes frequencies by the following equation:

$$pr(genotype_i)^{(s)} = pr(phenotype_j) \cdot pr(genotype_i | phenotype_j)^{(s)}$$

$$= \frac{n_j}{N} \cdot \frac{pr(h_k, h_l)^{(s)}}{P_j^{(s)}} \quad \text{Equation 3}$$

where genotype i occurs in phenotype j , and where h_k and h_l constitute genotype i . Each probability is derived according to eq. 1, and eq. 2 described above.

Then the Maximization step simply estimates another set of haplotype frequencies given the genotypes frequencies. This approach is also known as the gene-counting method (Smith, 1957).

$$P_t^{(s+1)} = \frac{1}{2} \sum_{j=1}^F \sum_{i=1}^{c_j} \delta_{it} \cdot pr(genotype_i)^{(s)} \quad \text{Equation 4}$$

Where δ_{it} is an indicator variable which count the number of time haplotype t in genotype i . It takes the values of 0, 1 or 2.

To ensure that the estimation finally obtained is the maximum-likelihood estimation several values of departures are required. The estimations obtained are compared and if they are different the estimations leading to the best likelihood are kept.

3) Methods To Calculate Linkage Disequilibrium Between Markers

A number of methods can be used to calculate linkage disequilibrium between any two genetic positions, in practice linkage disequilibrium is measured by applying a statistical association test to haplotype data taken from a population.

Linkage disequilibrium between any pair of biallelic markers comprising at least one of the biallelic markers of the present invention (M_i , M_j) having alleles (a_i/b_i) at marker M_i and alleles (a_j/b_j) at marker M_j can be calculated for every allele combination (a_i, a_j ; a_i, b_j ; b_i, a_j and b_i, b_j), according to the Piazza formula:

$\Delta_{a_i a_j} = \sqrt{\theta 4} - \sqrt{(\theta 4 + \theta 3)(\theta 4 + \theta 2)}$, where:

$\theta 4 = - - =$ frequency of genotypes not having allele a_i at M_i and not having allele a_j at M_j

$\theta 3 = - + =$ frequency of genotypes not having allele a_i at M_i and having allele a_j at M_j

$\theta 2 = + - =$ frequency of genotypes having allele a_i at M_i and not having allele a_j at M_j

Linkage disequilibrium (LD) between pairs of biallelic markers (M_i , M_j) can also be calculated for every allele combination (a_i, a_j ; a_i, b_j ; b_i, a_j and b_i, b_j), according to the maximum-likelihood estimate (MLE) for delta (the composite genotypic disequilibrium

coefficient), as described by Weir (Weir B. S., 1996). The MLE for the composite linkage disequilibrium is:

$$D_{aiaj} = (2n_1 + n_2 + n_3 + n_4/2)/N - 2(\text{pr}(a_i) \cdot \text{pr}(a_j))$$

Where $n_1 = \Sigma$ phenotype ($a_i/a_i, a_j/a_j$), $n_2 = \Sigma$ phenotype ($a_i/a_i, a_j/b_j$), $n_3 = \Sigma$ phenotype ($a_i/b_i, a_j/a_j$), $n_4 = \Sigma$ phenotype ($a_i/b_i, a_j/b_j$) and N is the number of individuals in the sample.

This formula allows linkage disequilibrium between alleles to be estimated when only genotype, and not haplotype, data are available.

Another means of calculating the linkage disequilibrium between markers is as follows. For a couple of biallelic markers, $M_i (a/b_i)$ and $M_j (a/b_j)$, fitting the Hardy-Weinberg equilibrium, one can estimate the four possible haplotype frequencies in a given population according to the approach described above.

The estimation of gametic disequilibrium between a_i and a_j is simply:

$$D_{aiaj} = \text{pr}(\text{haplotype}(a_i, a_j)) - \text{pr}(a_i) \cdot \text{pr}(a_j).$$

Where $\text{pr}(a_i)$ is the probability of allele a_i and $\text{pr}(a_j)$ is the probability of allele a_j and where $\text{pr}(\text{haplotype}(a_i, a_j))$ is estimated as in Equation 3 above.

For a couple of biallelic marker only one measure of disequilibrium is necessary to describe the association between M_i and M_j .

Then a normalized value of the above is calculated as follows:

$$D'_{aiaj} = D_{aiaj} / \max(-\text{pr}(a_i) \cdot \text{pr}(a_j), -\text{pr}(b_i) \cdot \text{pr}(b_j)) \text{ with } D_{aiaj} < 0$$

$$D'_{aiaj} = D_{aiaj} / \max(\text{pr}(b_i) \cdot \text{pr}(a_j), \text{pr}(a_i) \cdot \text{pr}(b_j)) \text{ with } D_{aiaj} > 0$$

The skilled person will readily appreciate that other linkage disequilibrium calculation methods can be used.

Linkage disequilibrium among a set of biallelic markers having an adequate heterozygosity rate can be determined by genotyping between 50 and 1000 unrelated individuals, preferably between 75 and 200, more preferably around 100.

4) Testing For Association

Methods for determining the statistical significance of a correlation between a phenotype and a genotype, in this case an allele at a biallelic marker or a haplotype made up of such alleles, may be determined by any statistical test known in the art and with any accepted threshold of statistical significance being required. The application of particular methods and thresholds of significance are well within the skill of the ordinary practitioner of the art.

Testing for association is performed by determining the frequency of a biallelic marker allele in case and control populations and comparing these frequencies with a

statistical test to determine if there is a statistically significant difference in frequency which would indicate a correlation between the trait and the biallelic marker allele under study. Similarly, a haplotype analysis is performed by estimating the frequencies of all possible haplotypes for a given set of biallelic markers in case and control populations, and comparing these frequencies with a statistical test to determine if there is a statistically significant correlation between the haplotype and the phenotype (trait) under study. Any statistical tool useful to test for a statistically significant association between a genotype and a phenotype may be used. Preferably the statistical test employed is a chi-square test with one degree of freedom. A P-value is calculated (the P-value is the probability that a statistic as large or larger than the observed one would occur by chance).

Statistical Significance

In preferred embodiments, significance for diagnosis purposes, either as a positive basis for further diagnostic tests or as a preliminary starting point for early preventive therapy, the p value related to a biallelic marker association is preferably about 1×10^{-2} or less, more preferably about 1×10^{-4} or less, for a single biallelic marker analysis and about 1×10^{-3} or less, still more preferably 1×10^{-6} or less and most preferably of about 1×10^{-8} or less, for a haplotype analysis involving two or more markers. These values are believed to be applicable to any association studies involving single or multiple marker combinations.

The skilled person can use the range of values set forth above as a starting point in order to carry out association studies with biallelic markers of the present invention. In doing so, significant associations between the biallelic markers of the present invention and a trait can be revealed and used for diagnosis and drug screening purposes.

Phenotypic Permutation

In order to confirm the statistical significance of the first stage haplotype analysis described above, it might be suitable to perform further analyses in which genotyping data from case-control individuals are pooled and randomized with respect to the trait phenotype. Each individual genotyping data is randomly allocated to two groups, which contain the same number of individuals as the case-control populations used to compile the data obtained in the first stage. A second stage haplotype analysis is preferably run on these artificial groups, preferably for the markers included in the haplotype of the first stage analysis showing the highest relative risk coefficient. This experiment is reiterated preferably at least between 100 and 10000 times. The

repeated iterations allow the determination of the probability to obtain the tested haplotype by chance.

Assessment Of Statistical Association

To address the problem of false positives similar analysis may be performed with the same case-control populations in random genomic regions. Results in random regions and the candidate region are compared as described in a co-pending US Provisional Patent Application entitled "Methods, Software And Apparati For Identifying Genomic Regions Harboring A Gene Associated With A Detectable Trait," U.S. Serial Number 60/107,986, filed November 10, 1998, the contents of which are incorporated herein by reference.

5) Evaluation Of Risk Factors

The association between a risk factor (in genetic epidemiology the risk factor is the presence or the absence of a certain allele or haplotype at marker loci) and a disease is measured by the odds ratio (OR) and by the relative risk (RR). If $P(R^+)$ is the probability of developing the disease for individuals with R and $P(R^-)$ is the probability for individuals without the risk factor, then the relative risk is simply the ratio of the two probabilities, that is:

$$RR = P(R^+)/P(R^-)$$

In case-control studies, direct measures of the relative risk cannot be obtained because of the sampling design. However, the odds ratio allows a good approximation of the relative risk for low-incidence diseases and can be calculated:

$$OR = \left[\frac{F^+}{1-F^+} \right] / \left[\frac{F^-}{(1-F^-)} \right]$$

$$OR = (F^+/(1-F^+))/(F^-/(1-F^-))$$

F^+ is the frequency of the exposure to the risk factor in cases and F^- is the frequency of the exposure to the risk factor in controls. F^+ and F^- are calculated using the allelic or haplotype frequencies of the study and further depend on the underlying genetic model (dominant, recessive, additive...).

One can further estimate the attributable risk (AR) which describes the proportion of individuals in a population exhibiting a trait due to a given risk factor. This measure is important in quantifying the role of a specific factor in disease etiology and in terms of the public health impact of a risk factor. The public health relevance of this measure lies in estimating the proportion of cases of disease in the population that could be prevented if the exposure of interest were absent. AR is determined as follows:

$$AR = P_E (RR-1) / (P_E (RR-1)+1)$$

AR is the risk attributable to a biallelic marker allele or a biallelic marker haplotype. P_E is the frequency of exposure to an allele or a haplotype within the population at large; and RR is the relative risk which, is approximated with the odds ratio when the trait under study has a relatively low incidence in the general population.

Association of 13q31-q33 Biallelic Markers of the Invention with "a trait"

In one preferred embodiment of the invention, a correlation was found between the biallelic markers comprised in BAC 5 and BAC 9, the DNA inserts of which are contained in the human chromosome 13q31-q33 region and schizophrenia, results of the association study are further described in details in Example 2(f). BAC B1 to BAC B9 are referred to throughout the present specification simply to illustrate the experimental procedures used by the inventors to identify the biallelic markers described herein, more particularly the biallelic markers in association with schizophrenia. Once the biallelic markers of the invention have been discovered and the association of a number of them with schizophrenia established, the one skilled in the art is enabled to reproduce the teachings of the present specification with the knowledge of the methods described herein as well as with the knowledge of the nucleic acid sequences disclosed in the appended Sequence Listing, without any need to use again any of the BACs B1 to B9 that only represent the starting material of the inventors.

More precisely, the biallelic markers 99-15663-298, 99-15665-398, 99-15672-166 and 99-15664-185 which are located in BAC 5 show a slight association with schizophrenia, and more particularly with familial cases of schizophrenia. Comparably, the biallelic markers 99-5919-215, 99-5862-167, 99-16032-292 and 99-16038-118 which are located in BAC 9 also show a slight association with schizophrenia.

The inventors also considered the LD values between every set of two biallelic markers of the human chromosome 13q31-q33 region for cases and controls. Indeed, a difference of LD between two markers in the cases compared to the controls can reveal an association of these biallelic markers with the studied trait. The inventors noticed that the highest relative difference in LD value between cases and controls was observed for BAC 5 and BAC 9.

Similar association studies can also be carried out with other biallelic markers within the scope of the invention, preferably with biallelic markers in LD with the

markers associated with schizophrenia as described above, including the biallelic markers of SEQ ID Nos 32-69.

Similar association studies can be carried out by the skilled technician using the biallelic markers of the invention defined above, with different trait + and trait - populations. Suitable further examples of association studies using biallelic markers of the human chromosome 13q31-q33 region, including the biallelic markers of SEQ ID Nos 32-69, involve studies on the following populations:

- a trait + population suffering from schizophrenia treated with agents acting against schizophrenia or against schizophrenia symptoms and suffering from side-effects resulting from this treatment and an trait - population suffering from schizophrenia treated with the same agents without any substantial side-effects, or
- a trait + population suffering from schizophrenia treated with agents acting against schizophrenia or schizophrenia symptoms showing a beneficial response and a trait - population suffering from schizophrenia treated with same agents without any beneficial response.

Haplotype frequency analysis

From the data resulting from the association analysis between alleles of the biallelic markers located on BAC 5 of the human chromosome 13q31-q33 region and schizophrenia, several haplotypes were shown to be statistically associated (see Table 15). For example, a preferred haplotype comprises the two biallelic markers 99-15672-166 (allele T) and 99-15664-185 (allele T). This haplotype is significantly associated with schizophrenia with a p-value of $2,5 \times 10^{-5}$. Among 1000 random permutation iterations between cases and controls, only 1 ‰ of the resulting p-values are equal or below to the one experimentally obtained in Table 15 for the haplotype 1. These results clearly validate the statistical significance of the haplotype 1 of the present invention. Furthermore, three markers-haplotypes and the four markers haplotype comprising the two biallelic markers 99-15672-166 (allele T) and 99-15664-185 (allele T) are also considered to be significant of an association with schizophrenia (haplotypes 7, 8 and 11 of Table 15).

The haplotype analysis described above shows that a gene linked to schizophrenia susceptibility lies at proximity of the markers defining haplotype 1 on the human genome.

From the results from Tables 16 and 17 with the biallelic markers located on BAC 9, the inserts of which are comprised in the human chromosome 13q31-q33 region, several haplotypes were shown to be significantly associated with

schizophrenia. For example, a preferred haplotype (haplotype 5 in Table 16 and 17) comprises the two biallelic markers 99-5862-167 (allele C) and 99-16032-292 (allele C). This haplotype is considered to be significant of an association with schizophrenia with a p-value less than 10^{-6} . Among 1000 permutation iterations, none of the resulting p-values are equal or below to the p-value experimentally obtained for the considered haplotype in Table 16 and in Table 17. These results clearly validate the statistical significance of the haplotype of the present invention. Three markers-haplotypes (haplotypes 18, 19 and 17 of Tables 16 and 17) and one four-markers haplotype (haplotype 25 of Tables 16 and 17) comprising the biallelic marker 99-5862-167 (allele C), and more frequently the two biallelic markers 99-5862-167 (allele C) and 99-16032-292 (C), are also considered to be significant of an association with schizophrenia. Indeed they present a p-value inferior to 10^{-6} .

The haplotypes 5, 17, 18, 19 and 25 of Tables 16 and 17 are associated with familial schizophrenia and are thus located in a region harboring a gene involved in the predisposition or in the development of schizophrenia.

The highest significant association with schizophrenia has been obtained for haplotypes combining the biallelic markers 99-15672-166 (allele T) and 99-15664-185 (allele T) located on BAC 5 with the biallelic markers 99-5862-167 (allele T) and 99-16032-292 (allele C) located on BAC 9. Several haplotypes, more particularly three markers-haplotypes 7, 8 and 9 and the four markers-haplotype 11 of Table 18 are highly significant of an association with schizophrenia with a p-value less than 10^{-6} . Moreover, haplotypes 7 and 11 present a p-value less than 10^{-10} . Among 50,000 permutation iterations, less than 2 % of the resulting p-values are equal or below to the experimentally obtained p-values for haplotypes 7, 8, and 11 of Table 18.

Additionally, the data from Example 2(h)(iv) demonstrate that when all the possible combinations (haplotypes) of two or three markers among the markers listed in Table 7 are studied for their association with schizophrenia, the haplotypes that are the most strongly associated with schizophrenia only contain biallelic markers located in BAC B5 and/or BAC B9.

Moreover, a selection (1%) of the two markers- and the three markers-haplotypes giving the more significant p-value has been performed, and then the number of selected haplotypes has been restricted to those for which the estimated haplotype frequency in the cases population was not less than 0.2 (20%). All these selected haplotypes contained biallelic markers located in BAC B5 and/or BAC B9 (data not shown).

Without wishing to be bound by any particular theory, the inventors believe that in order to be sufficiently significant to be reliable for diagnosis purposes, either as a positive basis for further diagnostic tests or as a preliminary starting point for early preventive therapy, the p value related to a biallelic marker association is preferably about 1×10^{-2} or less, more preferably about 1×10^{-4} or less, for a single biallelic marker analysis and about 1×10^{-3} or less, still more preferably 1×10^{-6} or less and most preferably of about 1×10^{-8} or less, for a haplotype analysis involving several markers. These values are believed to be applicable to any association studies involving single or multiple marker combinations.

The skilled person can use the range of values set forth above as a starting point in order to carry out association studies with other biallelic markers of the human chromosome 13q31-q33 region, or with markers from other genomic DNA sequences. In doing so, further significant associations between biallelic markers of the human chromosome 13q31-q33 region and schizophrenia can be revealed and used for diagnosis and drug screening purposes.

Using the method described above and evaluating the associations for single marker alleles or for haplotypes permits an estimation of the risk a corresponding carrier has to develop a given trait, and particularly in the context of the present invention, a disease, preferably schizophrenia. Significance thresholds of relative risks are to be adapted to the reference sample population used.

It is difficult to evaluate accurately quantified boundaries for the so-called "significant risk". Indeed, and as it has been demonstrated previously, several traits observed in a given population are multifactorial in that they are not only the result of a single genetic predisposition but also of other factors such as environmental factors or the presence of further, apparently unrelated, haplotype associations. Thus, the evaluation of a significant risk must take these parameters into consideration in order to, in a certain manner, weigh the potential importance of external parameters in the development of a given trait.

Without wishing to be bound to any invariable model or theory based on the above statistical analyses, the inventors believe that a "significant risk" to develop a given trait is evaluated differently depending on the trait under consideration.

It will of course be understood by practitioners skilled in the treatment of schizophrenia that the present invention does not intend to provide an absolute identification of individuals who could be at risk of developing schizophrenia but rather to indicate a certain degree or likelihood of developing the disease.

However, this information is extremely valuable as it can, in certain circumstances, be used to initiate preventive treatments or to allow an individual carrying a significant haplotype to foresee warning signs such as minor symptoms. In diseases such as schizophrenia, the knowledge of a potential predisposition, even if this predisposition is not absolute, might contribute in a very significant manner to treatment efficacy. Similarly, a diagnosed predisposition to a potential side-effect could immediately direct the physician toward a treatment for which such side-effects have not been observed during clinical trials.

Identification Of Biallelic Markers In Linkage Disequilibrium With The Biallelic Markers of the Invention

Once a first biallelic marker has been identified in a genomic region of interest, the practitioner of ordinary skill in the art, using the teachings of the present invention, can easily identify additional biallelic markers in linkage disequilibrium with this first marker. As mentioned before any marker in linkage disequilibrium with a first marker associated with a trait will be associated with the trait. Therefore, once an association has been demonstrated between a given biallelic marker and a trait, the discovery of additional biallelic markers associated with this trait is of great interest in order to increase the density of biallelic markers in this particular region. The causal gene or mutation will be found in the vicinity of the marker or set of markers showing the highest correlation with the trait.

Identification of additional markers in linkage disequilibrium with a given marker involves: (a) amplifying a genomic fragment comprising a first biallelic marker from a plurality of individuals; (b) identifying of second biallelic markers in the genomic region harboring said first biallelic marker; (c) conducting a linkage disequilibrium analysis between said first biallelic marker and second biallelic markers; and (d) selecting said second biallelic markers as being in linkage disequilibrium with said first marker. Subcombinations comprising steps (b) and (c) are also contemplated.

Methods to identify biallelic markers and to conduct linkage disequilibrium analysis are described herein and can be carried out by the skilled person without undue experimentation. The present invention then also concerns biallelic markers which are in linkage disequilibrium with the biallelic markers A1 to A11 and A12 to A49, and which are expected to present similar characteristics in terms of their respective association with a given trait. Preferably, the invention concerns biallelic markers

which are in linkage disequilibrium with the 13q31-q33-related biallelic markers A16 to A20.

Identification Of Functional Mutations

5 Mutations in a candidate gene such as a 13q31-q33 gene or G713, for example, which are responsible for a detectable phenotype or trait may be identified by comparing the sequences of the candidate gene from trait positive and control individuals. Once a positive association is confirmed with a biallelic marker of the present invention, the identified locus can be scanned for mutations. In a preferred embodiment, functional regions such as exons and splice sites, promoters and other regulatory regions of the candidate gene are scanned for mutations. In a preferred embodiment the sequence of the candidate gene is compared in trait positive and control individuals. Preferably, trait positive individuals carry the haplotype shown to be associated with the trait and trait negative individuals do not carry the haplotype or allele associated with the trait. The detectable trait or phenotype may comprise a variety of manifestations of altered G713 or the 13q31-q33 candidate gene function.

The mutation detection procedure is essentially similar to that used for biallelic marker identification. The method used to detect such mutations generally comprises the following steps:

- amplification of a region of the G713 or 13q31-q33 candidate gene comprising a biallelic marker or a group of biallelic markers associated with the trait from DNA samples of trait positive patients and trait-negative controls;
- sequencing of the amplified region;
- comparison of DNA sequences from trait positive and control individuals;
- determination of mutations specific to trait-positive patients.

25 In one embodiment, said biallelic marker is a G713-related biallelic marker selected from the group consisting of A1 to A11, and the complements thereof. In another embodiment, said biallelic marker is a 13q31-q33-related biallelic marker selected from the group consisting of A12 to A49, and the complements thereof. In preferred embodiment, said 13q31-q33-related biallelic marker is selected from the group consisting of A16 to A20, and the complements thereof. It is preferred that candidate polymorphisms be then verified by screening a larger population of cases and controls by means of any genotyping procedure such as those described herein, preferably using a microsequencing technique in an individual test format. Polymorphisms are considered as candidate mutations when present in cases and controls at frequencies compatible with the expected association results.

Polymorphisms are considered as candidate "trait-causing" mutations when they exhibit a statistically significant correlation with the detectable phenotype.

Biallelic Markers Of The Invention In Methods Of Genetic Diagnostics

The biallelic markers of the present invention can also be used to develop diagnostics tests capable of identifying individuals who express a detectable trait as the result of a specific genotype or individuals whose genotype places them at risk of developing a detectable trait at a subsequent time. The trait analyzed using the present diagnostics may be any detectable trait, including central nervous system diseases such as schizophrenia. Such a diagnosis can be useful in the staging, monitoring, prognosis and/or prophylactic or curative therapy of such diseases.

The diagnostic techniques of the present invention may employ a variety of methodologies to determine whether a test subject has a biallelic marker pattern associated with an increased risk of developing a detectable trait or whether the individual suffers from a detectable trait as a result of a particular mutation, including methods which enable the analysis of individual chromosomes for haplotyping, such as family studies, single sperm DNA analysis or somatic hybrids.

The present invention provides diagnostic methods to determine whether an individual is at risk of developing a disease or suffers from a disease resulting from a mutation or a polymorphism in a G713 or 13q31-q33 gene. The present invention also provides methods to determine whether an individual has a susceptibility to a particular disease such as schizophrenia.

These methods involve obtaining a nucleic acid sample from the individual and, determining, whether the nucleic acid sample contains at least one allele or at least one biallelic marker haplotype, indicative of a risk of developing the trait or indicative that the individual expresses the trait as a result of possessing a particular G713 or 13q31-q33 polymorphism or mutation (trait-causing allele).

Preferably, in such diagnostic methods, a nucleic acid sample is obtained from the individual and this sample is genotyped using methods described above in "Methods Of Genotyping DNA Samples For Biallelic markers. The diagnostics may be based on a single biallelic marker or a on group of biallelic markers. In each of these methods, a nucleic acid sample is obtained from the test subject and the biallelic marker pattern of one or more of the biallelic markers A1 to A49 is determined.

In one embodiment, a PCR amplification is conducted on the nucleic acid sample to amplify regions in which polymorphisms associated with a detectable phenotype have

been identified. The amplification products are sequenced to determine whether the individual possesses one or more G713 or 13q31-q33 polymorphisms associated with a detectable phenotype. The primers used to generate amplification products may comprise the primers listed in Tables 1 and 6. Alternatively, the nucleic acid sample is subjected to microsequencing reactions as described above to determine whether the individual possesses one or more G713 or 13q31-q33 polymorphisms associated with a detectable phenotype resulting from a mutation or a polymorphism in a G713 or 13q31-q33 gene. The primers used in the microsequencing reactions may include the primers listed in Tables 4 and 8, respectively. In another embodiment, the nucleic acid sample is contacted with one or more allele specific oligonucleotide probes which, specifically hybridize to one or more G713 or 13q31-q33 alleles associated with a detectable phenotype. The probes used in the hybridization assay may include the probes listed in Tables 3 and 7, respectively. In another embodiment, the nucleic acid sample is contacted with a second G713 or 13q31-q33 oligonucleotide capable of producing an amplification product when used with the allele specific oligonucleotide in an amplification reaction. The presence of an amplification product in the amplification reaction indicates that the individual possesses one or more G713 or 13q31-q33 alleles associated with a detectable phenotype.

In a preferred embodiment the identity of the nucleotide present at, at least one, 13q31-q33-related biallelic marker selected from the group consisting of A12 to A49 and the complements thereof, preferably at least one biallelic marker selected from the group consisting of A16 to A20, and the complements thereof, is determined and the detectable trait is schizophrenia. Diagnostic kits comprise any of the polynucleotides of the present invention.

These diagnostic methods based on G713 and 13q31-q33 related biallelic markers are extremely valuable as they can, in certain circumstances, be used to initiate preventive treatments or to allow an individual carrying a significant haplotype to foresee warning signs such as minor symptoms. G713 and 13q31-q33 diagnostics, which analyze and predict response to a drug or side effects to a drug, may be used to determine whether an individual should be treated with a particular drug. For example, if the diagnostic indicates a likelihood that an individual will respond positively to treatment with a particular drug, the drug may be administered to the individual. Conversely, if the diagnostic indicates that an individual is likely to respond negatively to treatment with a particular drug, an alternative course of treatment may be

prescribed. A negative response may be defined as either the absence of an efficacious response or the presence of toxic side effects.

Clinical drug trials represent another application for the markers of the present invention. One or more markers indicative of response to an agent acting against schizophrenia or to side effects to an agent acting against schizophrenia may be identified using the methods described above. Thereafter, potential participants in clinical trials of such an agent may be screened to identify those individuals most likely to respond favorably to the drug and exclude those likely to experience side effects. In that way, the effectiveness of drug treatment may be measured in individuals who respond positively to the drug, without lowering the measurement as a result of the inclusion of individuals who are unlikely to respond positively in the study and without risking undesirable safety problems.

PREVENTION AND TREATMENT OF SCHIZOPHRENIA

Notably because the risk of suicide, it is important to detect schizophrenia susceptibility of individuals. Consequently, the invention also concerns a method for the treatment of schizophrenia comprising the following steps:

- selecting an individual whose DNA comprises alleles of a biallelic marker or of a group of biallelic markers of the human chromosome 13q31-q33 region, associated with schizophrenia;
- following up said individual for the appearance (and optionally the development) of the symptoms related to schizophrenia; and
- administering a treatment acting against schizophrenia or against schizophrenia symptoms to said individual at an appropriate stage of the disease.

In one embodiment, the biallelic marker is one of those defined in SEQ ID Nos 32 to 69. In a preferred embodiment, the biallelic marker is selected from the group consisting of A16 to A20.

Another embodiment of the present invention consists of a method for the treatment of schizophrenia comprising the following steps:

- selecting an individual whose DNA comprises alleles of a biallelic marker or of a group of biallelic markers of the human chromosome 13q31-q33 region gene, associated with schizophrenia;
- administering a preventive treatment of schizophrenia to said individual.

In one embodiment, the biallelic marker is one of those defined in SEQ ID Nos 32 to 69. In a preferred embodiment, the biallelic marker is selected from the group consisting of A16 to A20.

In a further embodiment, the present invention concerns a method for the treatment of schizophrenia comprising the following steps:

- selecting an individual whose DNA comprises alleles of a biallelic marker or of a group of biallelic markers of the human chromosome 13q31-q33 region associated with schizophrenia;
- administering a preventive treatment of schizophrenia to said individual;
- following up said individual for the appearance and the development of schizophrenia symptoms; and optionally
- administering a treatment acting against schizophrenia or against schizophrenia symptoms to said individual at the appropriate stage of the disease.

In one embodiment, the biallelic marker is one of those defined in SEQ ID Nos 32 to 69. In a preferred embodiment, the biallelic marker is selected from the group consisting of A16 to A20.

To enlighten the choice of the appropriate beginning of the treatment of schizophrenia, the present invention also concerns a method for the treatment of schizophrenia comprising the following steps:

- selecting an individual suffering from schizophrenia whose DNA comprises alleles of a biallelic marker or of a group of biallelic markers of the human chromosome 13q31-q33 region associated with the gravity of schizophrenia or of the schizophrenia symptoms; and
- administering a treatment acting against schizophrenia or schizophrenia symptoms to said individual.

In one embodiment, the biallelic marker is one of those defined in SEQ ID Nos 32 to 69. In a preferred embodiment, the biallelic marker is selected from the group consisting of A16 to A20.

The invention also concerns a method for the treatment of schizophrenia in a selected population of individuals. The method comprises :

- selecting an individual suffering from schizophrenia and whose DNA comprises alleles of a biallelic marker or of a group of biallelic markers of the human chromosome 13q31-q33 region associated with a positive response to treatment with an effective amount of a medicament acting against schizophrenia or schizophrenia symptoms,

- and/or whose DNA does not comprise alleles of a biallelic marker or of a group of biallelic markers of the human chromosome 13q31-q33 region associated with a negative response to treatment with said medicament; and
- administering at suitable intervals an effective amount of said medicament to said selected individual.

In some embodiments, the biallelic marker is one of those defined in SEQ ID Nos 32 to 69.

In the context of the present invention, a "positive response" to a medicament can be defined as comprising a reduction of the symptoms related to the disease.

In the context of the present invention, a "negative response" to a medicament can be defined as comprising either a lack of positive response to the medicament which does not lead to a symptom reduction or which leads to a side-effect observed following administration of the medicament.

The invention also relates to a method of determining whether a subject is likely to respond positively to treatment with a medicament.

The method comprises identifying a first population of individuals who respond positively to said medicament and a second population of individuals who respond negatively to said medicament. One or more biallelic markers is identified in the first population which is associated with a positive response to said medicament or one or more biallelic markers is identified in the second population which is associated with a negative response to said medicament. The biallelic markers may be identified using the techniques described herein.

A DNA sample is then obtained from the subject to be tested. The DNA sample is analyzed to determine whether it comprises alleles of one or more biallelic markers associated with a positive response to treatment with the medicament and/or alleles of one or more biallelic markers associated with a negative response to treatment with the medicament.

In some embodiments, the medicament may be administered to the subject in a clinical trial if the DNA sample contains alleles of one or more biallelic markers associated with a positive response to treatment with the medicament and/or if the DNA sample lacks alleles of one or more biallelic markers associated with a negative response to treatment with the medicament. In preferred embodiments, the medicament is a drug acting against schizophrenia. In one embodiment, the biallelic marker is one of those defined in SEQ ID Nos 32 to 69.

Using the method of the present invention, the evaluation of drug efficacy may be conducted in a population of individuals likely to respond favorably to the medicament.

Another aspect of the invention is a method of using a medicament comprising obtaining a DNA sample from a subject, determining whether the DNA sample contains alleles of one or more biallelic markers associated with a positive response to the medicament and/or whether the DNA sample contains alleles of one or more biallelic markers associated with a negative response to the medicament, and administering the medicament to the subject if the DNA sample contains alleles of one or more biallelic markers associated with a positive response to the medicament and/or if the DNA sample lacks alleles of one or more biallelic markers associated with a negative response to the medicament.

The invention also concerns a method for the clinical testing of a medicament, preferably a medicament acting against schizophrenia or schizophrenia symptoms.

The method comprises the following steps:

- administering a medicament, preferably a medicament susceptible of acting against schizophrenia or schizophrenia symptoms to a heterogeneous population of individuals,
- identifying a first population of individuals who respond positively to said medicament and a second population of individuals who respond negatively to said medicament,
- identifying biallelic markers in said first population which are associated with a positive response to said medicament,
- selecting individuals whose DNA comprises biallelic markers associated with a positive response to said medicament, and
- administering said medicament to said individuals.

Such methods are deemed to be extremely useful to increase the benefit/risk ratio resulting from the administration of medicaments which may cause undesirable side effects and/or be inefficacious to a portion of the patient population to which it is normally administered.

Once an individual has been diagnosed as suffering from schizophrenia, selection tests are carried out to determine whether the DNA of this individual comprises alleles of a biallelic marker or of a group of biallelic markers associated with a positive response to treatment or with a negative response to treatment which may include either side effects or unresponsiveness.

The selection of the patient to be treated using the method of the present invention can be carried out through the detection methods described above. The individuals which are to be selected are preferably those whose DNA does not comprise alleles of a biallelic marker or of a group of biallelic markers associated with a negative response to treatment. The knowledge of an individual's genetic predisposition to unresponsiveness or side effects to particular medicaments allows the clinician to direct treatment toward appropriate drugs against schizophrenia or schizophrenia symptoms.

Once the patient's genetic predispositions have been determined, the clinician can select appropriate treatment for which negative response, particularly side effects, has not been reported or has been reported only marginally for the patient.

EXPRESSION OF A G713 REGULATORY OR CODING POLYNUCLEOTIDE OF THE INVENTION.

Any of the regulatory polynucleotides or the coding polynucleotides of the invention may be inserted into recombinant vectors for expression in a recombinant host cell or a recombinant host organism.

Thus, the present invention also encompasses a family of recombinant vectors that contains either a regulatory polynucleotide selected from the group consisting of any one of the regulatory polynucleotides derived from the *G713* genomic sequence, a coding polynucleotide or from the *G713* genomic sequence or the *G713* cDNA, or also a coding polynucleotide from the mouse *G713* cDNA.

Consequently, the present invention further deals with a recombinant vector comprising either a regulatory polynucleotide contained in one of the nucleic acids of SEQ ID Nos 1 and 3, or a polynucleotide comprising the *G713* coding sequence, or both.

In a first preferred embodiment, a recombinant vector of the invention is used as an expression vector : (a) the *G713* regulatory sequence comprised therein drives the expression of a coding polynucleotide operably linked thereto; (b) the *G713* coding sequence is operably linked to regulation sequences allowing its expression in a suitable cell host and/or host organism.

In a second preferred embodiment, a recombinant vector of the invention is used to amplify the inserted polynucleotide derived from a *G713* genomic sequence selected from the group consisting of the nucleic acids of SEQ ID Nos 1 to 3 or a *G713* cDNA of SEQ ID Nos 4 or 6 in a suitable cell host , this polynucleotide being amplified with the replication of the recombinant vector.

More particularly, the present invention relates to expression vectors which include nucleic acids encoding a G713 protein, preferably the human or murine G713 protein selected from the group consisting of the amino acid sequences of SEQ ID Nos 5, and 7 described therein, under the control of a regulatory sequence selected among the G713 regulatory polynucleotides, or alternatively under the control of an exogenous regulatory sequence.

A recombinant expression vector comprising a nucleic acid selected from the group consisting of nucleotide positions 1076 to 3075 of SEQ ID No 1, or biologically active fragments or variants thereof, is also part of the present invention.

The invention also encompasses a recombinant expression vector comprising :

- a) a nucleic acid comprising a regulatory polynucleotide of nucleotide positions 1076 to 3075 of SEQ ID No 1, or a biologically active fragment or variant thereof;
- b) a polynucleotide encoding a polypeptide or a polynucleotide of interest operably linked with said nucleic acid.
- c) optionally, a nucleic acid comprising a 3'-regulatory polynucleotide, preferably a 3'-regulatory polynucleotide of the invention, or a biologically active fragment or variant thereof.

The nucleic acid comprising the nucleotide sequence of SEQ ID No 1 or a biologically active fragment or variant thereof may also comprises the 5'-UTR sequence located between the nucleotide at position 1 and the nucleotide at position 658 of SEQ ID No 4, or a biologically active fragment or variant thereof.

The invention also pertains to a recombinant vector useful for the expression of the G713 coding sequence, wherein said vector comprises a nucleic acid of SEQ ID No 4 or a nucleic acid having at least 99.5% nucleotide identity with a polynucleotide of SEQ ID No 4.

The invention also deals with a recombinant vector useful for the expression of the murine G713 coding sequence, wherein said vector comprises a nucleic acid of SEQ ID No 6 or a nucleic acid having at least 95% nucleotide identity with a polynucleotide of SEQ ID No 6.

Some of the elements which can be found in the vectors of the present invention are described in further detail in the following sections.

a) Vectors

A recombinant vector according to the invention comprises, but is not limited to, a YAC (Yeast Artificial Chromosome), a BAC (Bacterial Artificial Chromosome), a phage, a phagemid, a cosmid, a plasmid or even a linear DNA molecule which may

consist of a chromosomal, non-chromosomal and synthetic DNA. Such a recombinant vector can comprise a transcriptional unit comprising an assembly of:

- (1) a genetic element or elements having a regulatory role in gene expression, for example promoters or enhancers. Enhancers are cis-acting elements of DNA, usually from about 10 to 300 bp in length that act on the promoter to increase the transcription.
- (2) a structural or coding sequence which is transcribed into mRNA and eventually translated into a polypeptide, and
- (3) appropriate transcription initiation and termination sequences. Structural units intended for use in yeast or eukaryotic expression systems preferably include a leader sequence enabling extracellular secretion of translated protein by a host cell. Alternatively, where a recombinant protein is expressed without a leader or transport sequence, it may include an N-terminal residue. This residue may or may not be subsequently cleaved from the expressed recombinant protein to provide a final product.

Generally, recombinant expression vectors will include origins of replication, selectable markers permitting transformation of the host cell, and a promoter derived from a highly expressed gene to direct transcription of a downstream structural sequence. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably a leader sequence capable of directing secretion of the translated protein into the periplasmic space or the extracellular medium.

The selectable marker genes for selection of transformed host cells are preferably dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, TRP1 for *S. cerevisiae* or tetracycline, rifampicin or ampicillin resistance in *E. coli*, or levan saccharase for mycobacteria.

As a representative but non-limiting example, useful expression vectors for bacterial use can comprise a selectable marker and a bacterial origin of replication derived from commercially available plasmids comprising genetic elements of pBR322 (ATCC 37017). Such commercial vectors include, for example, pKK223-3 (Pharmacia, Uppsala, Sweden), and GEM1 (Promega Biotec, Madison, WI, USA).

Large numbers of suitable vectors and promoters are known to those of skill in the art, and commercially available, such as bacterial vectors : pQE70, pQE60, pQE-9 (Qiagen), pbs, pD10, phagescript, psiX174, pbluescript SK, pbsks, pNH8A, pNH16A, pNH18A, pNH46A (Stratagene); ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5

(Pharmacia); or eukaryotic vectors : pWLNEO, pSV2CAT, pOG44, pXT1, pSG (Stratagene); pSVK3, pBPV, pMSG, pSVL (Pharmacia); baculovirus transfer vector pVL1392/1393 (Pharmingen); pQE-30 (QIAexpress).

A suitable vector for the expression of a G713 polypeptide of SEQ ID No 5 or 7 is a baculovirus vector that can be propagated in insect cells and in insect cell lines. A specific suitable host vector system is the pVL1392/1393 baculovirus transfer vector (Pharmingen) that is used to transfect the SF9 cell line (ATCC N^oCRL 1711) which is derived from *Spodoptera frugiperda*.

Other suitable vectors for the expression of a G713 polypeptide of SEQ ID Nos 5 or 7 in a baculovirus expression system include those described by Chai et al. (1993), Vlasak et al. (1983) and Lenhard et al. (1996).

Mammalian expression vectors will comprise an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5'-flanking non-transcribed sequences. DNA sequences derived from the SV40 viral genome, for example SV40 origin, early promoter, enhancer, splice and polyadenylation sites may be used to provide the required non-transcribed genetic elements.

b) Promoters

The suitable promoter regions used in the expression vectors according to the present invention are chosen taking into account the cell host in which the heterologous gene has to be expressed.

A suitable promoter may be heterologous with respect to the nucleic acid for which it controls the expression or alternatively can be endogenous to the native polynucleotide containing the coding sequence to be expressed. Additionally, the promoter is generally heterologous with respect to the recombinant vector sequences within which the construct promoter/coding sequence has been inserted.

Preferred bacterial promoters are the LacI, LacZ, the T3 or T7 bacteriophage RNA polymerase promoters, the polyhedrin promoter, or the p10 protein promoter from baculovirus (Kit Novagen) (Smith et al., 1983; O'Reilly et al., 1992), the lambda PR promoter or also the trc promoter.

Promoter regions can be selected from any desired gene using, for example, CAT (chloramphenicol transferase) vectors and more preferably pKK232-8 and pCM7 vectors. Particularly preferred bacterial promoters include lacI, lacZ, T3, T7, gpt, lambda PR, PL and trp. Eukaryotic promoters include CMV immediate early, HSV

thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-L. Selection of a convenient vector and promoter is well within the level of ordinary skill in the art.

The choice of a promoter is well within the ability of a person skilled in the field of genetic engineering. For example, one may refer to the book of Sambrook et al. (1989) or also to the procedures described by Fuller et al. (1996).

The vector containing the appropriate DNA sequence as described above, more preferably G713 gene regulatory polynucleotide, a polynucleotide encoding a G713 polypeptide of SEQ ID Nos 5 or 7 or both of these polynucleotides, can be utilized to transform an appropriate host to allow the expression of the desired polypeptide or polynucleotide.

c) Other types of vectors

The *in vivo* expression of a G713 polypeptide of SEQ ID Nos 5 or 7 may be useful in order to correct a genetic defect related to the expression of the native gene in a host organism or to the production of a biologically inactive G713 protein.

Consequently, the present invention also deals with recombinant expression vectors mainly designed for the *in vivo* production of a G713 polypeptide of SEQ ID Nos 5 or 7 by the introduction of the appropriate genetic material in the organism of the patient to be treated. This genetic material may be introduced *in vitro* in a cell that has been previously extracted from the organism, the modified cell being subsequently reintroduced in the said organism, directly *in vivo* into the appropriate tissue.

By "vector" according to this specific embodiment of the invention is intended either a circular or a linear DNA molecule.

One specific embodiment for a method for delivering a protein or peptide to the interior of a cell of a vertebrate *in vivo* comprises the step of introducing a preparation comprising a physiologically acceptable carrier and a naked polynucleotide operatively coding for the polypeptide of interest into the interstitial space of a tissue comprising the cell, whereby the naked polynucleotide is taken up into the interior of the cell and has a physiological effect.

In a specific embodiment, the invention provides a composition for the *in vivo* production of the G713 protein or polypeptide described herein. It comprises a naked polynucleotide operatively coding for this polypeptide, in solution in a physiologically acceptable carrier, and suitable for introduction into a tissue to cause cells of the tissue to express the said protein or polypeptide.

Compositions comprising a polynucleotide are described in PCT application N° WO 90/11092 (Vical Inc.) and also in PCT application N° WO 95/11307 (Institut Pasteur, INSERM, Université d'Ottawa) as well as in the articles of Tasson et al. (1996) and of Huygen et al. (1996).

5 The amount of vector to be injected to the desired host organism varies according to the site of injection. As an indicative dose, it will be injected between 0,1 and 100 µg of the vector in an animal body, preferably a mammal body, for example a mouse body.

10 In another embodiment of the vector according to the invention, it may be introduced *in vitro* in a host cell, preferably in a host cell previously harvested from the animal to be treated and more preferably a somatic cell such as a muscle cell. In a subsequent step, the cell that has been transformed with the vector coding for the desired G713 polypeptide or the desired fragment thereof is reintroduced into the animal body in order to deliver the recombinant protein within the body either locally or
15 systemically.

In one specific embodiment, the vector is derived from an adenovirus. Preferred adenovirus vectors according to the invention are those described by Feldman and Steg (1996) or Ohno et al. (1994). Another preferred recombinant adenovirus
20 according to this specific embodiment of the present invention is the human adenovirus type 2 or 5 (Ad 2 or Ad 5) or an adenovirus of animal origin (French patent application N° FR-93.05954).

Retrovirus vectors and adeno-associated virus vectors are generally understood to be the recombinant gene delivery systems of choice for the transfer of exogenous polynucleotides *in vivo* , particularly to mammals, including humans. These
25 vectors provide efficient delivery of genes into cells, and the transferred nucleic acids are stably integrated into the chromosomal DNA of the host

Particularly preferred retroviruses for the preparation or construction of retroviral *in vitro* or *in vitro* gene delivery vehicles of the present invention include retroviruses selected from the group consisting of Mink-Cell Focus Inducing Virus, Murine Sarcoma
30 Virus, Reticuloendotheliosis virus and Rous Sarcoma virus. Particularly preferred Murine Leukemia Viruses include the 4070A and the 1504A viruses, Abelson (ATCC No VR-999), Friend (ATCC No VR-245), Gross (ATCC No VR-590), Rauscher (ATCC No VR-998) and Moloney Murine Leukemia Virus (ATCC No VR-190; PCT Application No WO 94/24298). Particularly preferred Rous Sarcoma Viruses include Bryan high
35 titer (ATCC Nos VR-334, VR-657, VR-726, VR-659 and VR-728). Other preferred

retroviral vectors are those described in Roth et al. (Roth J.A. et al., 1996), PCT Application No WO 93/25234, PCT Application No WO 94/ 06920, Roux et al., 1989, Julian et al., 1992 and Neda et al., 1991.

Yet another viral vector system that is contemplated by the invention consists in the adeno-associated virus (AAV). The adeno-associated virus is a naturally occurring defective virus that requires another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle (Muzyczka et al., 1992). It is also one of the few viruses that may integrate its DNA into non-dividing cells, and exhibits a high frequency of stable integration (Flotte et al., 1992; Samulski et al., 1989; McLaughlin et al., 1989). One advantageous feature of AAV derives from its reduced efficacy for transducing primary cells relative to transformed cells.

Other compositions containing a vector of the invention advantageously comprise an oligonucleotide fragment of a nucleic sequence selected from the group consisting of nucleotides 1076 to 3075 of SEQ ID No 1 and nucleotides 16330 to 18329 of SEQ ID No 3 as an antisense tool that inhibits the expression of the corresponding G713 gene. Preferred methods using antisense polynucleotide according to the present invention are the procedures described by Sczakiel et al. (1995) or those described in PCT Application No WO 95/24223.

Preferably, the antisense tools are chosen among the polynucleotides (15-200 bp long) that are complementary to the 5'end of the G713 mRNA. In another embodiment, a combination of different antisense polynucleotides complementary to different parts of the desired targeted gene are used.

Preferred antisense polynucleotides according to the present invention are complementary to a sequence of the mRNAs of G713 that contains the translation initiation codon ATG.

Host cells

Another object of the invention consists in host cell that have been transformed or transfected with one of the polynucleotides described therein, and more precisely a polynucleotide either comprising a G713 regulatory polynucleotide or the coding sequence of a G713 polypeptide, preferably a G713 polypeptide having the amino acid sequence of SEQ ID No 5 or 7. Are included host cells that are transformed (prokaryotic cells) or that are transfected (eukaryotic cells) with a recombinant vector such as one of those described above.

A recombinant host cell of the invention comprises any one of the polynucleotides or the recombinant vectors described therein.

A preferred recombinant host cell according to the invention comprises a polynucleotide selected from the following group of polynucleotides :

a) a purified or isolated nucleic acid encoding a G713 polypeptide, or a polypeptide fragment or variant thereof.

b) a purified or isolated nucleic acid comprising at least 20 consecutive nucleotides of a polynucleotide selected from the group consisting of the nucleotide sequences of SEQ ID Nos 4 and 6.

c) a purified or isolated nucleic acid comprising the nucleotide positions 1076 to 3075 of SEQ ID No 1 or a biologically active fragment or variant of the nucleotide positions 1076 to 3075 of SEQ ID No 1.

d) a purified or isolated nucleic acid comprising a 3'-regulatory sequence of the G713 gene, or a biologically active fragment or variant thereof.

e) a polynucleotide consisting of :

(1) a nucleic acid comprising a regulatory polynucleotide of nucleotide positions 1076 to 3075 of SEQ ID No 1 or a biologically active fragment or variant thereof;

(2) a polynucleotide encoding a desired polypeptide or nucleic acid.

(3) Optionally, a nucleic acid comprising a 3'-regulatory sequence, preferably a 3'-regulatory sequence of the G713 gene, or a biologically active fragment or variant thereof, wherein sequences (1), (2) and (3) are operably linked to one other.

Another preferred recombinant cell host according to the present invention is characterized in that its genome or genetic background (including chromosome, plasmids) is modified by the nucleic acid coding for a G713 polypeptide of SEQ ID No 5 or 7.

Preferred host cells used as recipients for the expression vectors of the invention are the following :

a) Prokaryotic host cells : *Escherichia coli* strains (I.E. DH5- α strain) or *Bacillus subtilis*.

b) Eukaryotic host cells : HeLa cells (ATCC N°CCL2; N°CCL2.1; N°CCL2.2), Cv 1 cells (ATCC N°CCL70), COS cells (ATCC N°CRL1650; N°CRL1651), Sf-9 cells (ATCC N°CRL1711).

The constructs in the host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence.

Following transformation of a suitable host and growth of the host to an appropriate cell density, the selected promoter is induced by appropriate means, such as temperature shift or chemical induction, and cells are cultivated for an additional period.

Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.

Microbial cells employed in the expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents. Such methods are well known by the skill artisan.

Transgenic animals

The terms "transgenic animals" or "host animals" are used herein to designate animals that have their genome genetically and artificially manipulated so as to include one of the nucleic acids according to the invention. Preferred animals are non-human mammals and include those belonging to a genus selected from *Mus* (e.g. mice), *Rattus* (e.g. rats) and *Oryctogalus* (e.g. rabbits) which have their genome artificially and genetically altered by the insertion of a nucleic acid according to the invention.

The transgenic animals of the invention all include within a plurality of their cells a cloned recombinant or synthetic DNA sequence, more specifically one of the purified or isolated nucleic acids comprising a *G713* coding sequence, a *G713* regulatory polynucleotide or a DNA sequence encoding an antisense polynucleotide such as described in the present specification.

First preferred transgenic animals according to the invention contain in their somatic cells and/or in their germ line cells a polynucleotide selected from the following group of polynucleotides :

- a) a purified or isolated nucleic acid encoding a *G713* polypeptide, or a polypeptide fragment or variant thereof.
- b) a purified or isolated nucleic comprising at least 20 consecutive nucleotides of a polynucleotide selected from the group consisting of the nucleotide sequences of SEQ ID Nos 4 and 6.
- c) a purified or isolated nucleic acid comprising the nucleotide positions 1076 to 3075 of SEQ ID No 1 or a biologically active fragment or variant of the nucleotide positions 1076 to 3075 of SEQ ID No 1.
- d) a purified or isolated nucleic acid comprising a 3'-regulatory sequence of the *G713* gene, or a biologically active fragment or variant thereof.
- e) a polynucleotide consisting of :
 - (1) a nucleic acid comprising a regulatory polynucleotide of nucleotide positions 1076 to 3075 of SEQ ID No 1 or a biologically active fragment or variant thereof;
 - (2) a polynucleotide encoding a desired polypeptide or nucleic acid.

(3) Optionally, a nucleic acid comprising a 3'-regulatory sequence, preferably a 3'regulatory sequence of the *G713* gene, or a biologically active fragment or variant thereof, wherein sequences (1), (2) and (3) are operably linked to one other.

The replacement of the native genomic *G713* sequence by a defective copy of said sequence may be preformed by techniques of gene targeting. Such techniques are notably described by Burright et al. (1997), Bates et al. (1997), Mangiarini et al. (1996, 1997), Davies et al. (1997a, 1997b), which are herein incorporated by reference.

Second preferred transgenic animals of the invention have the murine *G713* gene replaced either by a defective copy of the murine *G713* gene or by an interrupted copy of the human *G713* gene. A "defective copy" of a murine or a human *G713* gene, is intended to designate a modified copy of these genes that is not or poorly transcribed in the resulting recombinant host animal or a modified copy of these genes leading to the absence of synthesis of the corresponding translation product or alternatively leading to a modified and/or truncated translation product lacking the biological activity of the wild type *G713* protein. The altered translation product thus contains amino acid modifications, deletions and substitutions. Modifications and deletions may render the naturally occurring gene nonfunctional, thus leading to a "knockout animal". These transgenic animals are critical for the creation of animal models of human diseases, and for eventual treatment of disorders or diseases of the central nervous system, like schizophrenia or bipolar disorder. Examples of such knockout mice are described in the PCT Applications Nos WO 97/34641, WO 96/12792 and WO 98/02354, which are herein incorporated by reference.

The endogenous murine *G713* gene can be interrupted by the insertion, between two contiguous nucleotides of said gene, of a part of all of a marker gene placed under the control of the appropriate promoter, for example the endogenous promoter of the endogenous murine *G713* gene. The marker gene may be the neomycin resistance gene (*neo*) that may e operably linked to the phosphoglycerate kinase-1 (PGK-1) promoter, as described in the PCT Application No WO 98/02534.

Thus, the invention is also directed to a transgenic animal contain in their somatic cells and/or in their germ line cells a polynucleotide selected from the following group of polynucleotides :

- a) a defective copy of the human *G713* gene;
- b) a defective copy of the murine *G713* gene;

c) a defective copy of the endogenous *G713* gene, wherein the expression "endogenous *G713* gene" designates a *G713* gene that is naturally present within the genome of the animal host to be genetically modified.

The invention also concerns a method for obtaining transgenic animals, wherein said methods comprise the steps of :

a) replacing the endogenous copy of the animal *G713* gene by a nucleic acid selected from the group consisting of a defective copy of the human *G713* gene, a defective copy of the murine *G713* gene and a defective copy of the endogenous *G713* gene in animal cells, preferably embryonic stem cells (ES);

b) introducing the recombinant animal cells obtained at step a) in embryos, notably blastocysts of the animal;

c) selecting the resulting transgenic animals, for example by detecting the defective copy of a *G713* gene with one or several primers or probes according to the invention;

Optionally, the transgenic animals may be bred together in order to obtain homozygous transgenic animals for the defective copy of the *G713* gene introduced.

The transgenic animals of the invention thus contain specific sequences of exogenous genetic material such as the nucleotide sequences described above in detail.

In a first preferred embodiment, these transgenic animals may be good experimental models in order to study the diverse pathologies related to central nervous system disorders like schizophrenia or bipolar disorder, in particular concerning the transgenic animals within the genome of which has been inserted one or several copies of a polynucleotide encoding a native *G713* protein, or alternatively a mutant *G713* protein.

In a second preferred embodiment, these transgenic animals may express a desired polypeptide of interest under the control of the regulatory polynucleotides of the *G713* gene, leading to good yields in the synthesis of this protein of interest, and eventually a tissue specific expression of this protein of interest.

Since it is possible to produce transgenic animals of the invention using a variety of different sequences, a general description will be given of the production of transgenic animals by referring generally to exogenous genetic material. This general description can be adapted by those skilled in the art in order to incorporate the DNA sequences into animals. For more details regarding the production of transgenic animals, and specifically transgenic mice, it may be referred to Sandou et al. (1994) and also to US Patents Nos 4,873,191, issued Oct.10, 1989, 5,968,766, issued Dec.

16, 1997 and 5,387,742, issued Feb. 28, 1995, these documents being herein incorporated by reference to disclose methods for producing transgenic mice.

Transgenic animals of the present invention are produced by the application of procedures which result in an animal with a genome that incorporates exogenous genetic material which is integrated into the genome. The procedure involves obtaining the genetic material, or a portion thereof, which encodes either a G713 coding sequence, a G713 regulatory polynucleotide or a DNA sequence encoding an antisense polynucleotide such as described in the present specification.

A recombinant polynucleotide of the invention is inserted into an embryonic or ES stem cell line. The insertion is made using electroporation. The cells subjected to electroporation are screened (e.g. Southern blot analysis) to find positive cells which have integrated the exogenous recombinant polynucleotide into their genome. An illustrative positive-negative selection procedure that may be used according to the invention is described by Mansour et al. (1988). Then, the positive cells are isolated, cloned and injected into 3.5 days old blastocysts from mice. The blastocysts are then inserted into a female host animal and allowed to grow to term. The offsprings of the female host are tested to determine which animals are transgenic e.g. include the inserted exogenous DNA sequence and which are wild-type.

Thus, the present invention also concerns a transgenic animal containing a nucleic acid, a recombinant expression vector or a recombinant host cell according to the invention.

G713 AND MURINE G713 POLYPEPTIDE AND PEPTIDE FRAGMENTS

The present invention also concerns a method for producing one of the polypeptides described herein, and especially a polypeptide selected from the group consisting of the amino acid sequences of SEQ ID Nos 5 and 7 or a fragment or a variant thereof, wherein said method comprises the steps of :

- a) culturing, in an appropriate culture medium, a cell host previously transformed or transfected with the recombinant vector comprising a nucleic acid encoding a G713 polypeptide, or a fragment or a variant thereof;
- b) harvesting the culture medium thus conditioned or lyse the cell host, for example by sonication or by an osmotic shock;
- c) separating or purifying, from the said culture medium, or from the pellet of the resultant host cell lysate the thus produced polypeptide of interest.
- d) Optionally characterizing the produced polypeptide of interest.

In a specific embodiment of the above method, step a) is preceded by a step wherein the nucleic acid coding for a G713 polypeptide, or a fragment or a variant thereof, is inserted in an appropriate vector, optionally after an appropriate cleavage of this amplified nucleic acid with one or several restriction endonucleases. The nucleic acid coding for a G713 polypeptide or a fragment or a variant thereof may be the resulting product of an amplification reaction using a pair of primers according to the invention (by SDA, TAS, 3SR NASBA, TMA etc.).

The polypeptides according to the invention may be characterized by binding an immunoaffinity chromatography column on which polyclonal or monoclonal antibodies directed to a polypeptide selected from the group consisting of the amino acid sequences of seq id nos 5 and 7, or a fragment or a variant thereof, have previously been immobilized. Purification of the recombinant proteins or peptides according to the present invention may be carried out by passage onto a nickel or copper affinity chromatography column. The nickel chromatography column may contain the ni-nta resin (porath et al., 1975). The polypeptides or peptides thus obtained may be purified, for example by high performance liquid chromatography, such as reverse phase and/or cationic exchange hplc, (rougeot et al., 1994). The reason to prefer this kind of peptide or protein purification is the lack of byproducts found in the elution samples which renders the resultant purified protein or peptide more suitable for a therapeutic use.

G713 polypeptide (human)

The term "G713 polypeptides" is used herein to embrace all of the proteins and polypeptides of the present invention. Also forming part of the invention are polypeptides encoded by the polynucleotides of the invention, as well as fusion polypeptides comprising such polypeptides. The invention embodies G713 proteins from humans, including isolated or purified G713 proteins consisting of, consisting essentially of, or comprising the sequence of SEQ ID No 5.

The present invention embodies isolated, purified, and recombinant polypeptides comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID No 5.

The invention also encompasses a purified, isolated, or recombinant polypeptides comprising an amino acid sequence having at least 70, 75, 80, 85, 90, 95, 98 or 99% amino acid identity with the amino acid sequence of SEQ ID No. 5 or a fragment thereof. In a preferred embodiment, a variant polypeptide comprises amino acid changes ranging from 1, 2, 3, 4, 5, 10 to 20 substitutions, additions or deletions of one amino acid, preferably from 1 to 10, more preferably from 1 to 5 and most

preferably from 1 to 3 substitutions, additions or deletions of one amino acid. The preferred amino acid changes are those which have little or no influence on the biological activity or the capacity of the variant G713 polypeptide to be recognized by antibodies raised against a native G713 protein. In a second preferred embodiment, a mutated G713 polypeptide comprises amino acid changes ranging from 1 to about 200 deletions of one amino acid and of at least one amino acid substitution or addition, preferably from 1 to 10, 20 or 30 amino acid substitutions or additions. The amino acid substitutions are generally non conservative in terms of polarity, charge, hydrophilicity properties of the substitute amino acid when compared with the native amino acid. The amino acid changes occurring in such a mutated G713 polypeptide may be determinant for the biological activity or for the capacity of the mutated G713 polypeptide to be recognized by antibodies raised against a native G713.

The G713 polypeptide of the amino acid sequence of SEQ ID No 5 has 458 amino acids in length. This polypeptide has a strong amino acid sequence identity with the mouse G713 polypeptide of SEQ ID No 7, specifically 87.9% nucleic acid identity.

As shown in Figure 1, a particular region of the G713 polypeptide located in its N-terminal portion has interesting features. A large hydrophilic region begins at the amino acid in position 68 (R) and ends at the amino acid in position 101 (P) of the amino acid sequence of G713. A large region having a good probability to be exposed to the outer environment begins at the amino acid in position 62 (A) and ends at the amino acid in position 101 (P) of the amino acid sequence of G713. A large region having good antigenicity properties begins at the amino acid in position 63 (K) and ends at the amino acid in position 102 (S) of the amino acid sequence of G713.

Figures 2 and 3 depict the two-dimensional structure of the G713 protein according, respectively, to the Chou and Fasman method and to the Garnier-Oguthorpe-Robson method. These two models confirm that region spanning between the amino acid around the position 60 and the amino acid around the position 115 of the G713 protein has particular hydrophilicity properties that make this peptide stretch valuable, notably for the production of antibodies specific to this protein.

Thus, a polypeptide comprising a peptide sequence corresponding to the amino acid sequence beginning at the amino acid in position 62 and ending at the amino acid in position 102 of the G713 protein may be used for raising specific antibodies to a G713 protein, and specifically the G713 protein of the amino acid sequence of SEQ ID No 5. Peptide fragments of this polypeptide of interest are also part of the invention. Such peptide fragments have advantageously an amino acid sequence length of at least 8 consecutive amino acids of the polypeptide of interest, and preferably between

10 and 40 amino acids in length, more preferably between 15 and 30 amino acids in length. Another polypeptide of interest according to the present invention consists of a polypeptide comprising a peptide sequence beginning at the amino acid in position 203 and ending at the amino acid in position 458 of the amino acid sequence of SEQ ID No 5 or a peptide fragment thereof.

Both the human and the murine G713 polypeptides are cysteine rich, both having a total of 21 cysteins. Of interest also in view of G713's structure which contains one transmembrane domain, 9 of these cysteins are organized in a domain resembling the frizzled domain (Fz). In particular, said Fz-like domain is located at amino acid positions 304 to 379 of SEQ ID No 5 in the human G713 polypeptide and amino acid positions 313 to 388 of SEQ ID No 7 in the murine polypeptide.

A candidate structure for the G713 polypeptide comprises, consists essentially of or consists of, from the N-terminal to the C-terminal, a protein binding or membrane associated domain, an external domain, a transmembrane domain, and a cytoplasmic domain. The transmembrane domain is located at amino acid positions 417 to 437 in the human G713 polypeptide of SEQ ID No 5, corresponding to amino acid positions 426 to 446 in the murine G713 polypeptide of SEQ ID No 7.

The G713 polypeptide contains, as noted above, a hydrophobic segment located at amino acid positions 40 to 60 in SEQ ID Nos 5 and 7. This domain is indicative of a membrane association and may further comprise a signal peptide domain. Thus, embodiments of the invention include, but are not limited to, peptide fragments of said domain, a G713 polypeptide comprising said domain, fragments of said domain, or specifically lacking said domain. A preferred G713 polypeptide fragment comprises, consists essentially of, or consists of a G713 signal sequence. Signal sequences can have particular use in the targeting of a desired compound for secretion or insertion into the cell membrane. In an exemplary but not limiting example, signal sequences may be fused to a desired polypeptide of interest to direct secretion of said polypeptide, or insertion of said polypeptide into the cell membrane.

The invention further concerns a protein binding domain comprising a hydrophobic domain located at amino acid positions 40 to 60 of SEQ ID Nos 5 and 7. Said protein binding domain is conserved at an exceptionally high rate in the human and murine G713, especially in relation to conservation expected among membrane-associated domains, indicative of a domain essential for binding a target protein. Thus, while not limited to such, embodiments of the invention can include polynucleotides encoding a G713 signal or protein binding sequence, vectors and host cells comprising said polynucleotide, and fusion proteins comprising a G713 signal peptide.

Such polypeptides of interest or its peptide fragments may be obtained either by proteolytic cleavage of the G713 protein or by chemical synthesis.

In a specific embodiment of this polypeptide of interest or its peptide fragments in which they are used to prepare polyclonal or monoclonal antibodies against the G713 protein, this polypeptide or peptide fragments are preferably covalently or non-covalently bound to a carrier molecule, such as human or bovine serum albumin (HSA or BSA).

A further object of the present invention concerns a purified or isolated polypeptide which is encoded by a nucleic acid comprising nucleotide positions 1076 to 3075 of SEQ ID No 1 or fragments or variants thereof.

Such a mutated G713 protein may be the target of diagnostic tools, such as specific monoclonal or polyclonal antibodies, useful for detecting the mutated G713 protein in a sample.

Murine G713 polypeptide

The term "G713 polypeptides" is used herein to embrace all of the proteins and polypeptides of the present invention. Also forming part of the invention are polypeptides encoded by the polynucleotides of the invention, as well as fusion polypeptides comprising such polypeptides. The invention embodies G713 proteins from humans, including isolated or purified G713 proteins consisting of, consisting essentially of, or comprising the sequence of SEQ ID No 7.

The present invention embodies isolated, purified, and recombinant polypeptides comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID No 7. In other preferred embodiments the contiguous stretch of amino acids comprises the site of a mutation or functional mutation, including a deletion, addition, swap or truncation of the amino acids in the G713 protein sequence.

The invention also encompasses a purified, isolated, or recombinant polypeptides comprising an amino acid sequence having at least 70, 75, 80, 85, 90, 95, 98 or 99% amino acid identity with the amino acid sequence of SEQ ID No. 7 or a fragment thereof. The G713 polypeptide of the amino acid sequence of SEQ ID No 7 has 467 amino acids in length. As already mentioned, this polypeptide has a strong amino acid sequence identity with the human G713 polypeptide of SEQ ID No 5, specifically 87.9% nucleic acid identity.

As shown in Figure 1, a particular region of the murine G713 polypeptide located in its N-terminal portion have interesting features. A large hydrophilic region begins at the amino acid in position 66 (R) and ends at the amino acid in position 112

(P) of the amino acid sequence of murine G713. A large region having a good probability to be exposed to the outer environment begins at the amino acid in position 63 (K) and ends at the amino acid in position 112 (P) of the amino acid sequence of murine G713. A large region having good antigenicity properties begins at the amino acid in position 63 (K) and ends at the amino acid in position 113 (S) of the amino acid sequence of murine G713.

Figures 5 and 6 depict the two-dimensional structure of the G713 protein according, respectively, to the Chou and Fasman method and to the Garnier-Oguthorpe-Robson method. These two models confirm that region spanning between the amino acid around the position 65 and the amino acid around the position 120 of the G713 protein has particular hydrophilicity properties that make this peptide stretch valuable, notably for the production of antibodies specific to this protein.

Thus, a polypeptide comprising a peptide sequence corresponding to the amino acid sequence beginning at the amino acid in position 63 and ending at the amino acid in position 113 of the murine G713 protein may be used for raising specific antibodies to a G713 protein, and specifically the murine G713 protein of the amino acid sequence of SEQ ID No 7. Peptide fragments of this polypeptide of interest are also part of the invention. Such peptide fragments have advantageously an amino acid sequence length of at least 8 consecutive amino acids of the polypeptide of interest, and preferably between 10 and 40 amino acids in length, more preferably between 15 and 30 amino acids in length.

Such a polypeptide of interest or its peptide fragments may be obtained either by proteolytic cleavage of the murine G713 protein or by chemical synthesis.

In a specific embodiment of this polypeptide of interest or its peptide fragments in which they are used to prepare polyclonal or monoclonal antibodies against the murine G713 protein, this polypeptide or peptide fragments are preferably covalently or non-covalently bound to a carrier molecule, such as human or bovine serum albumin (HSA or BSA).

A further object of the present invention concerns a purified or isolated polypeptide which is encoded by a nucleic acid comprising a nucleotide sequence of SEQ ID No 6 or fragments or variants thereof.

In the case of an amino acid substitution in the amino acid sequence of a polypeptide according to the invention, one or several -consecutive or non-consecutive- amino acids are replaced by "equivalent" amino acids. The expression "equivalent" amino acid is used herein to designate any amino acid that may be substituted for one of the amino acids belonging to the native protein structure without

decreasing the binding properties of the corresponding peptides to the antibodies raised against the human or murine G713 protein of the amino acid sequence of SEQ ID No 5 or 7. In other words, the "equivalent" amino acids are those which allow the generation or the synthesis of a polypeptide with a modified sequence when compared to the amino acid sequence of the native human or murine G713 protein, said modified polypeptide being able to bind to the antibodies raised against the human or murine G713 protein of the amino acid sequence of SEQ ID No 5 or 7 and/or to induce antibodies recognizing the parent polypeptide consisting in the human or murine G713 polypeptide of the amino acid sequence of SEQ ID No 5 or 7.

These equivalent amino acids may be determined either by their structural homology with the initial amino acids to be replaced, by the similarity of their net charge, and optionally by the results of the cross-immunogenicity between the parent peptides and their modified counterparts. The peptides containing one or several "equivalent" amino acids must retain their specificity and affinity properties to the biological targets of the parent protein, as it can be assessed by a ligand binding assay or an ELISA assay. By an equivalent amino acid is also meant the replacement of a residue in the L-form by a residue in the D form or the replacement of a Glutamic acid (E) residue by a Pyro-glutamic acid compound. The synthesis of peptides containing at least one residue in the D-form is, for example, described by Koch (1977).

A specific embodiment of a modified G713 peptide molecule of interest according to the present invention, includes, but is not limited to, a peptide molecule which is resistant to proteolysis, is a peptide in which the -CONH- peptide bond is modified and replaced by a (CH₂NH) reduced bond, a (NHCO) retro inverso bond, a (CH₂-O) methylene-oxy bond, a (CH₂-S) thiomethylene bond, a (CH₂CH₂) carba bond, a (CO-CH₂) cetomethylene bond, a (CHOH-CH₂) hydroxyethylene bond), a (N-N) bound, a E-alcene bond or also a -CH=CH- bond.

The invention also encompasses a human or murine G713 polypeptide or a fragment or a variant thereof in which at least one peptide bound has been modified as described above.

The polypeptides according to the invention may also be prepared by the conventional methods of chemical synthesis, either in a homogenous solution or in solid phase. As an illustrative embodiment of such chemical polypeptide synthesis techniques, it may be cited the homogenous solution technique described by Houbenweyl (1974). The human or murine G713 polypeptide, or a fragment or a variant thereof may thus be prepared by chemical synthesis in liquid or solid phase by successive couplings of the different amino acid residues to be incorporated (from the

N-terminal end to the C-terminal end in liquid phase, or from the C-terminal end to the N-terminal end in solid phase) wherein the N-terminal ends and the reactive side chains are previously blocked by conventional groups. For solid phase synthesis the technique described by Merrifield (1965) may be used in particular.

5 ANTIBODIES

Any G713 polypeptide or whole protein may be used to generate antibodies capable of specifically binding to an expressed G713 protein or fragments thereof as described. Any of the human or murine G713 polypeptides of SEQ ID Nos 5 or 7 or one of their peptide fragments of interest can be used for the preparation of polyclonal
10 or monoclonal antibodies.

Antibody compositions of the invention may also be capable of specifically binding or specifically bind to a variant of the G713 protein of SEQ ID Nos 5 or 7. For an antibody composition to specifically bind to a first variant of G713, it must demonstrate at least a 5%, 10%, 15%, 20%, 25%, 50%, or 100% greater binding
15 affinity for a full length first variant of the G713 protein than for a full length second variant of the G713 protein in an ELISA, RIA, or other antibody-based binding assay. The invention concerns antibody compositions, either polyclonal or monoclonal, capable of selectively binding, or selectively bind to an epitope-containing a polypeptide comprising a contiguous span of at least 6 amino acids, preferably at least
20 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID No 5 or 7. In a particularly preferred embodiment said contiguous span comprises at least 6, preferably at least 8 to 10, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 contiguous amino acids of SEQ ID No 5 or 7, including:

i) at least one of the amino acid positions 62 to 102 or 203 to 458 of SEQ ID No
25 5; and/or

ii) at least one of the amino acid positions 1 to 467 of SEQ ID No 7.

The invention also concerns a purified or isolated antibody capable of specifically binding to a mutated G713 protein or to a fragment or variant thereof comprising an epitope of the mutated G713 protein. In another preferred embodiment,
30 the present invention concerns an antibody capable of binding to a polypeptide comprising at least 10 consecutive amino acids of a G713 protein and including at least one of the amino acids which can be encoded by the trait causing mutations.

The invention also concerns the use in the manufacture of antibodies of a polypeptide comprising a contiguous span of at least 6 amino acids, preferably at least
35 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID No 5 or 7. In a preferred embodiment, said contiguous span of SEQ

ID No 5 or 7 comprises at of least 6, preferably at least 8 to 10, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 contiguous amino acids of SEQ ID No 5 or 7, including:

ii) at least 1, 2, 3, 5 or 10 of the amino acid positions 62 to 102 or 203 to 458 of SEQ ID No 5; and/or

iii) at least 1, 2, 3, 5 or 10 of the amino acid positions 1 to 467 of SEQ ID No 7.

Non-human animals or mammals, whether wild-type or transgenic, which express a different species of G713 than the one to which antibody binding is desired, and animals which do not express G713 (i.e. a G713 knock out animal as described herein) are particularly useful for preparing antibodies. G713 knock out animals will recognize all or most of the exposed regions of a G713 protein as foreign antigens, and therefore produce antibodies with a wider array of G713 epitopes. Moreover, smaller polypeptides with only 10 to 30 amino acids may be useful in obtaining specific binding to any one of the G713 proteins. In addition, the humoral immune system of animals which produce a species of G713 that resembles the antigenic sequence will preferentially recognize the differences between the animal's native G713 species and the antigen sequence, and produce antibodies to these unique sites in the antigen sequence. Such a technique will be particularly useful in obtaining antibodies that specifically bind to any one of the G713 proteins.

Antibody preparations prepared according to either protocol are useful in quantitative immunoassays which determine concentrations of antigen-bearing substances in biological samples; they are also used semi-quantitatively or qualitatively to identify the presence of antigen in a biological sample. The antibodies may also be used in therapeutic compositions for killing cells expressing the protein or reducing the levels of the protein in the body.

Antibodies of the invention include chimeric single chain Fv antibody fragments (Martineau et al., 1998), antibody fragments obtained through phage display libraries (Ridder et al., 1995; Vaughan et al., 1995) and humanized antibodies (Reinmann et al., 1997; Leger et al., 1997).

The antibodies of the invention may be labeled by any one of the radioactive, fluorescent or enzymatic labels known in the art.

Consequently, the invention is also directed to a method for detecting specifically the presence of a G713 polypeptide according to the invention in a biological sample, said method comprising the following steps :

a) bringing into contact the biological sample with a polyclonal or monoclonal antibody that specifically binds a G713 polypeptide comprising an amino acid sequence of SEQ ID No 5 or 7, or to a peptide fragment or variant thereof; and

b) detecting the antigen-antibody complex formed.

5 The invention also concerns a diagnostic kit for detecting *in vitro* the presence of a G713 polypeptide according to the present invention in a biological sample, wherein said kit comprises:

a) a polyclonal or monoclonal antibody that specifically binds a G713 polypeptide comprising an amino acid sequence of SEQ ID No 5 or 7, or to a peptide
10 fragment or variant thereof, optionally labeled;

b) a reagent allowing the detection of the antigen-antibody complexes formed, said reagent carrying optionally a label, or being able to be recognized itself by a labeled reagent, more particularly in the case when the above-mentioned monoclonal or polyclonal antibody is not labeled by itself.

15 Example of methods of preparing antibodies are provided in Example 1(f).

METHODS FOR SCREENING SUBSTANCES INTERACTING WITH A G713 POLYPEPTIDE

For the purpose of the present invention, a ligand means a molecule, such as a protein, a peptide, an antibody or any synthetic chemical compound capable of binding
20 to the human or murine G713 protein or one of its fragments or variants or to modulate the expression of the polynucleotide coding for G713 or a fragment or variant thereof.

In the ligand screening method according to the present invention, a biological sample or a defined molecule to be tested as a putative ligand of the human or murine G713 protein is brought into contact with the corresponding purified human or murine
25 G713 protein, for example the corresponding purified recombinant human or murine G713 protein produced by a recombinant cell host as described hereinbefore, in order to form a complex between this protein and the putative ligand molecule to be tested.

Another object of the present invention consists of methods and kits for the screening of candidate substances that interact with a human or murine G713
30 polypeptide.

The present invention pertains to methods for screening substances of interest that interact with a human or murine G713 protein or one fragment or variant thereof. By their capacity to bind covalently or non-covalently to a human or murine G713 protein or to a fragment or variant thereof, these substances or molecules may be
35 advantageously used both *in vitro* and *in vivo*.

In vitro, said interacting molecules may be used as detection means in order to identify the presence of a human or murine G713 protein in a sample, preferably a biological sample.

A method for the screening of a candidate substance comprises the following steps :

- a) providing a polypeptide consisting of a human or murine G713 protein or a fragment or a variant thereof;
- b) obtaining a candidate substance;
- c) bringing into contact said polypeptide with said candidate substance;
- d) detecting the complexes formed between said polypeptide and said candidate substance.

In one embodiment of the screening method defined above, the complexes formed between the polypeptide and the candidate substance are further incubated in the presence of a polyclonal or a monoclonal antibody that specifically binds to the human or murine G713 protein or to said fragment or variant thereof.

The invention further concerns a kit for the screening of a candidate substance interacting with the G713 polypeptide, wherein said kit comprises :

- a) a G713 protein having an amino acid sequence selected from the group consisting of the amino acid sequences of SEQ ID Nos 5 and 7 or a peptide fragment or a variant thereof ;
- b) optionally means useful to detect the complex formed between the G713 protein or its peptide fragment or variant and the candidate substance.

In a preferred embodiment of the kit described above, the detection means consist in monoclonal or polyclonal antibodies directed against the G713 protein or a peptide fragment or a variant thereof.

Various candidate substances or molecules can be assayed for interaction with a human or murine G713 polypeptide. These substances or molecules include, without being limited to, natural or synthetic organic compounds or molecules of biological origin such as polypeptides. When the candidate substance or molecule consists of a polypeptide, this polypeptide may be the resulting expression product of a phage clone belonging to a phage-based random peptide library, or alternatively the polypeptide may be the resulting expression product of a cDNA library cloned in a vector suitable for performing a two-hybrid screening assay.

In another embodiment of the present screening method, increasing concentrations of a monoclonal or polyclonal antibody directed against a human or

murine G713 protein or a fragment or a variant thereof is reacted with the considered G713 protein or with a fragment or variant thereof, simultaneously or prior to the addition of the candidate substance or molecule, when performing step c) of said method. By this technique, the detection and optionally the quantification of the complexes formed between the human or murine G713 protein or the fragment or variant thereof and the substance or molecule to be screened allows the one skilled in the art to determine the affinity value of said substance or molecule for said human or murine G713 protein or the fragment or variant thereof.

The invention also pertains to kits useful for performing the hereinbefore described screening method. Preferably, such kits comprise a human or a murine G713 polypeptide or a fragment or a variant thereof, and optionally means useful to detect the complex formed between the human or the murine G713 polypeptide or its fragment or variant and the candidate substance. In a preferred embodiment the detection means consist in monoclonal or polyclonal antibodies directed against the corresponding G713 polypeptide or a fragment or a variant thereof.

A. Candidate ligands obtained from random peptide libraries

In a particular embodiment of the screening method, the putative ligand is the expression product of a DNA insert contained in a phage vector (Parmley and Smith, 1988). Specifically, random peptide phages libraries are used. The random DNA inserts encode for peptides of 8 to 20 amino acids in length (Oldenburg K.R. et al., 1992; Valadon P., et al., 1996; Lucas A.H., 1994; Westerink M.A.J., 1995; Castagnoli L. et al. (Felici F, 1991). According to this particular embodiment, the recombinant phages expressing a protein that binds to the immobilized G713 protein is retained and the complex formed between the G713 protein and the recombinant phage may be subsequently immunoprecipitated by a polyclonal or a monoclonal antibody directed against the G713 protein.

Once the ligand library in recombinant phages has been constructed, the phage population is brought into contact with the immobilized human or murine G713 protein. Then the preparation of complexes is washed in order to remove the non-specifically bound recombinant phages. The phages that bind specifically to the human or murine G713 protein are then eluted by a buffer (acid pH) or immunoprecipitated by the monoclonal antibody produced by the hybridoma anti-G713, and this phage population is subsequently amplified by an over-infection of bacteria (for example *E. coli*). The selection step may be repeated several times, preferably 2-4 times, in order to select

the more specific recombinant phage clones. The last step consists in characterizing the peptide produced by the selected recombinant phage clones either by expression in infected bacteria and isolation, expressing the phage insert in another host-vector system, or sequencing the insert contained in the selected recombinant phages.

B. Candidate ligands obtained through a two-hybrid screening assay.

The yeast two-hybrid system is designed to study protein-protein interactions *in vivo* (Fields and Song, 1989), and relies upon the fusion of a bait protein to the DNA binding domain of the yeast Gal4 protein. This technique is also described in the US Patent N° US 5,667,973 and the US Patent N° 5,283,173 (Fields et al.) the technical teachings of both patents being herein incorporated by reference.

The general procedure of library screening by the two-hybrid assay may be performed as described by Harper et al. (1993) or as described by Cho et al. (1998) or also Fromont-Racine et al. (1997).

The bait protein or polypeptide consists of a human or murine G713 polypeptide or a fragment or variant thereof.

More precisely, the nucleotide sequence encoding the human or murine G713 polypeptide or a fragment or variant thereof is fused to a polynucleotide encoding the DNA binding domain of the GAL4 protein, the fused nucleotide sequence being inserted in a suitable expression vector, for example pAS2 or pM3.

Then, a human cDNA library is constructed in a specially designed vector, such that the human cDNA insert is fused to a nucleotide sequence in the vector that encodes the transcriptional domain of the GAL4 protein. Preferably, the vector used is the pACT vector. The polypeptides encoded by the nucleotide inserts of the human cDNA library are termed "pray" polypeptides.

A third vector contains a detectable marker gene, such as beta galactosidase gene or CAT gene that is placed under the control of a regulation sequence that is responsive to the binding of a complete Gal4 protein containing both the transcriptional activation domain and the DNA binding domain. For example, the vector pG5EC may be used.

Two different yeast strains are also used. As an illustrative but non limiting example the two different yeast strains may be the followings :

- Y190, the phenotype of which is (*MATa*, *Leu2-3*, *112 ura3-12*, *trp1-901*, *his3-D200*, *ade2-101*, *gal4Dgal180D URA3 GAL-LacZ*, *LYS GAL-HIS3*, *cyh*);

- Y187, the phenotype of which is (*MATa gal4 gal80 his3 trp1-901 ade2-101 ura3-52 leu2-3, -112 URA3 GAL-lacZmet*), which is the opposite mating type of Y190.

Briefly, 20 µg of pAS2/G713 and 20 µg of pACT-cDNA library are co-transformed into yeast strain Y190. The transformants are selected for growth on minimal media lacking histidine, leucine and tryptophan, but containing the histidine synthesis inhibitor 3-AT (50 mM). Positive colonies are screened for beta galactosidase by filter lift assay. The double positive colonies (*His⁺, beta-gal⁺*) are then grown on plates lacking histidine, leucine, but containing tryptophan and cycloheximide (10 mg/ml) to select for loss of pAS2/G713 plasmids but retention of pACT-cDNA library plasmids. The resulting Y190 strains are mated with Y187 strains expressing G713 or non-related control proteins; such as cyclophilin B, lamin, or SNF1, as *Gal4* fusions as described by Harper et al. (1993) and by Bram et al. (Bram RJ et al., 1993), and screened for beta galactosidase by filter lift assay. Yeast clones that are *beta gal-* after mating with the control *Gal4* fusions are considered false positives.

In another embodiment of the two-hybrid method according to the invention, interaction between the human or murine G713 or a fragment or variant thereof with cellular proteins may be assessed using the Matchmaker Two Hybrid System 2 (Catalog No. K1604-1, Clontech). As described in the manual accompanying the Matchmaker Two Hybrid System 2 (Catalog No. K1604-1, Clontech), the disclosure of which is incorporated herein by reference, nucleic acids encoding the human or murine G713 protein or a portion thereof, are inserted into an expression vector such that they are in frame with DNA encoding the DNA binding domain of the yeast transcriptional activator GAL4. A desired cDNA, preferably human cDNA, is inserted into a second expression vector such that they are in frame with DNA encoding the activation domain of GAL4. The two expression plasmids are transformed into yeast and the yeast are plated on selection medium which selects for expression of selectable markers on each of the expression vectors as well as GAL4 dependent expression of the HIS3 gene. Transformants capable of growing on medium lacking histidine are screened for GAL4 dependent lacZ expression. Those cells which are positive in both the histidine selection and the lacZ assay contain interaction between G713 and the protein or peptide encoded by the initially selected cDNA insert.

METHOD FOR SCREENING LIGANDS THAT MODULATE THE EXPRESSION OF THE G713 GENE

Another subject of the present invention is a method for screening molecules that modulate the expression of the G713 protein. Such a screening method comprises the steps of :

- a) cultivating a prokaryotic or an eukaryotic cell that has been transfected with a nucleotide sequence encoding the G713 protein, placed under the control of its own promoter;
- b) bringing into contact the cultivated cell with a molecule to be tested;
- c) quantifying the expression of the G713 protein.

Using DNA recombination techniques well known by the one skill in the art, the G713 protein encoding DNA sequence is inserted into an expression vector, downstream from its promoter sequence. As an illustrative example, the promoter sequence of the *G713* gene is contained in the nucleic acid of nucleotide positions 1076 to 3075 of SEQ ID No 1.

The quantification of the expression of the G713 protein may be realized either at the mRNA level or at the protein level. In the latter case, polyclonal or monoclonal antibodies may be used to quantify the amounts of the G713 protein that have been produced, for example in an ELISA or a RIA assay.

In a preferred embodiment, the quantification of the *G713* mRNA is realized by a quantitative PCR amplification of the cDNA obtained by a reverse transcription of the total mRNA of the cultivated *G713*-transfected host cell, using a pair of primers specific for *G713*.

The present invention also concerns a method for screening substances or molecules that are able to increase, or in contrast to decrease, the level of expression of the *G713* gene. Such a method may allow the one skilled in the art to select substances exerting a regulating effect on the expression level of the *G713* gene and which may be useful as active ingredients included in pharmaceutical compositions for treating patients suffering from deficiencies in the regulation of expression of the *G713* gene.

Thus, is also part of the present invention a method for the screening of a candidate substance or molecule that modulates the expression of the *G713* gene, wherein said method comprises the following steps:

- a) providing a recombinant host cell containing a nucleic acid, wherein said nucleic acid comprises a 5'UTR sequence of the *G713* cDNA of SEQ ID No 4, or one of its biologically active fragments or variants, the 5'UTR sequence or its biologically

active fragment or variant being operably linked to a polynucleotide encoding a detectable protein;

b) obtaining a candidate substance, and;

c) determining the ability of the candidate substance to modulate the expression levels of the polynucleotide encoding the detectable protein.

In another specific embodiment of the above screening method, the nucleic acid that comprises a nucleotide sequence selected from the group consisting of the 5'UTR sequence of the *G713* cDNA of SEQ ID No 6 or one of its biologically active fragments or variants, includes a promoter sequence which is exogenous with respect to the *G713* 5'UTR sequences defined therein.

The invention further deals with a kit for the screening of a candidate substance modulating the expression of the *G713* gene, wherein said kit comprises :
a recombinant vector that comprises a nucleic acid including a 5'UTR sequence of the *G713* cDNA of SEQ ID No 6, or one of their biologically active fragments or variants, the 5'UTR sequence or its biologically active fragment or variant being operably linked to a polynucleotide encoding a detectable protein.

The invention also pertains to a method for screening of a candidate substance or molecule that modulates the expression of the *G713* gene, this method comprises the following steps:

- a) providing a recombinant cell host containing a nucleic acid, wherein said nucleic acid comprises a nucleotide sequence of SEQ ID No 4 or a biologically active fragment or variant thereof located upstream a polynucleotide encoding a detectable protein;
- b) obtaining a candidate substance, and
- c) determining the ability of the candidate substance to modulate the expression levels of the polynucleotide encoding the detectable protein.

Among the preferred polynucleotides encoding a detectable protein, there may be cited polynucleotides encoding beta galactosidase, green fluorescent protein (GFP) and chloramphenicol acetyl transferase (CAT).

The invention also pertains to kits useful for performing the hereinbefore described screening method. Preferably, such kits comprise a recombinant vector that allows the expression of a nucleotide sequence of SEQ ID No 4 or a biologically active fragment or variant thereof located upstream a polynucleotide encoding a detectable protein.

For the design of suitable recombinant vectors useful for performing the screening methods described above, it will be referred to the section of the present specification wherein the preferred recombinant vectors of the invention are detailed.

Expression levels and patterns of *G713* may be analyzed by solution hybridization with long probes as described in International Patent Application No. WO 97/05277, the entire contents of which are incorporated herein by reference. Briefly, the *G713* cDNA or the *G713* genomic DNA described above, or fragments thereof, is inserted at a cloning site immediately downstream of a bacteriophage (T3, T7 or SP6) RNA polymerase promoter to produce antisense RNA. Preferably, the *G713* insert comprises at least 100 or more consecutive nucleotides of the genomic DNA sequence or the cDNA sequences, particularly those comprising at least one of SEQ ID Nos 1 T O4 OR 6 or those encoding a mutated *G713*. The plasmid is linearized and transcribed in the presence of ribonucleotides comprising modified ribonucleotides (i.e. biotin-UTP and DIG-UTP). An excess of this doubly labeled RNA is hybridized in solution with mRNA isolated from cells or tissues of interest. The hybridizations are performed under standard stringent conditions (40-50°C for 16 hours in an 80% formamide, 0.4 M NaCl buffer, pH 7-8). The unhybridized probe is removed by digestion with ribonucleases specific for single-stranded RNA (i.e. RNases CL3, T1, Phy M, U2 or A). The presence of the biotin-UTP modification enables capture of the hybrid on a microtitration plate coated with streptavidin. The presence of the DIG modification enables the hybrid to be detected and quantified by ELISA using an anti-DIG antibody coupled to alkaline phosphatase.

METHODS FOR INHIBITING THE EXPRESSION OF A *G713* GENE

Other therapeutic compositions according to the present invention comprise advantageously an oligonucleotide fragment of the nucleic sequence of the human or murine *G713* as an antisense tool that inhibits the expression of the corresponding *G713* gene. Preferred methods using antisense polynucleotide according to the present invention are the procedures described by Sczakiel et al. (1995).

Preferably, the antisense tools are chosen among the polynucleotides (15-200 bp long) that are complementary to the 5' end of the human or murine *G713* mRNA. In another embodiment, a combination of different antisense polynucleotides complementary to different parts of the desired targeted gene are used.

Preferred antisense polynucleotides according to the present invention are complementary to a sequence of the human or murine mRNAs of *G713* that contains the translation initiation codon ATG

The antisense nucleic acids should have a length and melting temperature sufficient to permit formation of an intracellular duplex having sufficient stability to inhibit the expression of the human or murine *G713* mRNA in the duplex. Strategies for designing antisense nucleic acids suitable for use in gene therapy are disclosed in Green et al., (1986) and Izant and Weintraub, (1984), the disclosures of which are incorporated herein by reference.

In some strategies, antisense molecules are obtained by reversing the orientation of the human or murine *G713* coding region with respect to a promoter so as to transcribe the opposite strand from that which is normally transcribed in the cell. The antisense molecules may be transcribed using in vitro transcription systems such as those which employ T7 or SP6 polymerase to generate the transcript. Another approach involves transcription of human or murine *G713* antisense nucleic acids in vivo by operably linking DNA containing the antisense sequence to a promoter in a suitable expression vector.

Alternatively, suitable antisense strategies are those described by Rossi et al. (1991), in the International Applications Nos. WO 94/23026, WO 95/04141, WO 92/18522 and in the European Patent Application No. EP 0 572 287 A2

An alternative to the antisense technology that is used according to the present invention consists in using ribozymes that will bind to a target sequence via their complementary polynucleotide tail and that will cleave the corresponding RNA by hydrolyzing its target site (namely "hammerhead ribozymes"). Briefly, the simplified cycle of a hammerhead ribozyme consists of (1) sequence specific binding to the target RNA via complementary antisense sequences; (2) site-specific hydrolysis of the cleavable motif of the target strand; and (3) release of cleavage products, which gives rise to another catalytic cycle. Indeed, the use of long-chain antisense polynucleotide (at least 30 bases long) or ribozymes with long antisense arms are advantageous. A preferred delivery system for antisense ribozyme is achieved by covalently linking these antisense ribozymes to lipophilic groups or to use liposomes as a convenient vector. Preferred antisense ribozymes according to the present invention are prepared as described by Sczakiel et al. (1995), the specific preparation procedures being referred to in said article being herein incorporated by reference.

COMPUTER RELATED EMBODIMENTS

As used herein the term "nucleic acid codes of the invention" encompass the nucleotide sequences comprising, consisting essentially of, or consisting of any one of the following:

5 a) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID Nos 1, 2 or 3, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions:

10 1 to 1000, 1001 to 2000, 2001 to 3000, 3001 to 4000 and 4001 to 5222 of SEQ ID No. 1;

15 1 to 1000, 1001 to 2000, 2001 to 3000, 3001 to 4000 and 4001 to 5000, 5001 to 6000, 6001 to 7000, 7001 to 8000, 8001 to 9000, 9001 to 10000, 10001 to 11000, 11001 to 12000, 12001 to 13000, 13001 to 14000, 14001 to 15000, 15001 to 16000, 16001 to 17000, 17001 to 18000, 18001 to 19000, 19001 to 20000 and 20001 to 21278 of SEQ ID No 2; and

20 1 to 1000, 1001 to 2000, 2001 to 3000, 3001 to 4000 and 4001 to 5000, 5001 to 6000, 6001 to 7000, 7001 to 8000, 8001 to 9000, 9001 to 10000, 10001 to 11000, 11001 to 12000, 12001 to 13000, 13001 to 14000, 14001 to 15000, 15001 to 16000, 16001 to 17000, 17001 to 18000, 18001 to 19000, 19001 to 20000, 20001 to 21000 and 21001 to 21636 of SEQ ID No 3;

b) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID Nos 1, 2 or 3, or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions:

25 SEQ ID No 1: 1 to 3236, 3547 to 3585 and 4649 to 5222, or a variant thereof or a sequence complementary thereto;

SEQ ID No 2: 1 to 16155 and 16331 to 21278 or a variant thereof or a sequence complementary thereto; and

30 SEQ ID No 3: 1 to 5531, 6844 to 7237, 7798 to 8184, 8667 to 9074, and 9356 to 21636, or a variant thereof or a sequence complementary thereto;

c) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 31 or the complements thereof, wherein said contiguous span comprises nucleotide positions 1 to 480 and 717 to 983 of SEQ ID No 31;

d) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 4, or the complements thereof, wherein said contiguous span of SEQ ID No 4 comprises at least one of the following nucleotide positions of SEQ ID No 4: 1 to 519 and 2563 to 5566;

5 e) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 6, or the complements thereof;

f) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID Nos 32 to 69, or the complements thereof; and,

10 g) a nucleotide sequence complementary to any one of the preceding nucleotide sequences.

The "nucleic acid codes of the invention" further encompass nucleotide sequences homologous to:

15 a) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID Nos 1 to 3, wherein said contiguous span comprises at least one of the following nucleotide positions:

SEQ ID No 1: 1 to 3236, 3547 to 3585 and 4649 to 5222, or a variant thereof or a sequence complementary thereto;

20 SEQ ID No 2: 1 to 16155 and 16331 to 21278 or a variant thereof or a sequence complementary thereto; and

SEQ ID No 3: 1 to 5531, 6844 to 7237, 7798 to 8184, 8667 to 9074, and 9356 to 21636 or a variant thereof or a sequence complementary thereto;

25 b) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 4 or the complements thereof, wherein said contiguous span of SEQ ID No 4 comprises at least one of the following nucleotide positions of SEQ ID No 4: 1 to 519 and 2563 to 5566; and,

30 c) a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 6, or the complements thereof;

d) sequences complementary to all of the preceding sequences.

Homologous sequences refer to a sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, 80%, or 75% homology to these contiguous spans. Homology may be determined using any method described herein, including BLAST2N with the default parameters or with any modified parameters. Homologous sequences also may

include RNA sequences in which uridines replace the thymines in the nucleic acid codes of the invention. It will be appreciated that the nucleic acid codes of the invention can be represented in the traditional single character format (See the inside back cover of Stryer, Lubert. *Biochemistry*, 3rd edition. W. H Freeman & Co., New York.) or in any other format or code which records the identity of the nucleotides in a sequence.

As used herein the term "polypeptide codes of the invention" encompass the polypeptide sequences comprising a contiguous span of at least 6, 8, 10, 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID Nos 5 or 7. It will be appreciated that the polypeptide codes of the invention can be represented in the traditional single character format or three letter format (See the inside back cover of Stryer, Lubert. *Biochemistry*, 3rd edition. W. H Freeman & Co., New York.) or in any other format or code which records the identity of the polypeptides in a sequence.

It will be appreciated by those skilled in the art that the nucleic acid codes of the invention and polypeptide codes of the invention can be stored, recorded, and manipulated on any medium which can be read and accessed by a computer. As used herein, the words "recorded" and "stored" refer to a process for storing information on a computer medium. A skilled artisan can readily adopt any of the presently known methods for recording information on a computer readable medium to generate manufactures comprising one or more of the nucleic acid codes of the invention, or one or more of the polypeptide codes of the invention. Another aspect of the present invention is a computer readable medium having recorded thereon at least 2, 5, 10, 15, 20, 25, 30, or 50 nucleic acid codes of the invention. Another aspect of the present invention is a computer readable medium having recorded thereon at least 2, 5, 10, 15, 20, 25, 30, or 50 polypeptide codes of the invention.

Computer readable media include magnetically readable media, optically readable media, electronically readable media and magnetic/optical media. For example, the computer readable media may be a hard disk, a floppy disk, a magnetic tape, CD-ROM, Digital Versatile Disk (DVD), Random Access Memory (RAM), or Read Only Memory (ROM) as well as other types of other media known to those skilled in the art.

Embodiments of the present invention include systems, particularly computer systems which store and manipulate the sequence information described herein. One example of a computer system 100 is illustrated in block diagram form in Figure 7. As used herein, "a computer system" refers to the hardware components, software components, and data storage components used to analyze the nucleotide sequences of the nucleic acid codes of the invention or the amino acid sequences of the polypeptide

codes of the invention. In one embodiment, the computer system 100 is a Sun Enterprise 1000 server (Sun Microsystems, Palo Alto, CA). The computer system 100 preferably includes a processor for processing, accessing and manipulating the sequence data. The processor 105 can be any well-known type of central processing unit, such as the Pentium III from Intel Corporation, or similar processor from Sun, Motorola, Compaq or International Business Machines.

Preferably, the computer system 100 is a general purpose system that comprises the processor 105 and one or more internal data storage components 110 for storing data, and one or more data retrieving devices for retrieving the data stored on the data storage components. A skilled artisan can readily appreciate that any one of the currently available computer systems are suitable.

In one particular embodiment, the computer system 100 includes a processor 105 connected to a bus which is connected to a main memory 115 (preferably implemented as RAM) and one or more internal data storage devices 110, such as a hard drive and/or other computer readable media having data recorded thereon. In some embodiments, the computer system 100 further includes one or more data retrieving device 118 for reading the data stored on the internal data storage devices 110.

The data retrieving device 118 may represent, for example, a floppy disk drive, a compact disk drive, a magnetic tape drive, etc. In some embodiments, the internal data storage device 110 is a removable computer readable medium such as a floppy disk, a compact disk, a magnetic tape, etc. containing control logic and/or data recorded thereon. The computer system 100 may advantageously include or be programmed by appropriate software for reading the control logic and/or the data from the data storage component once inserted in the data retrieving device.

The computer system 100 includes a display 120 which is used to display output to a computer user. It should also be noted that the computer system 100 can be linked to other computer systems 125a-c in a network or wide area network to provide centralized access to the computer system 100.

Software for accessing and processing the nucleotide sequences of the nucleic acid codes of the invention or the amino acid sequences of the polypeptide codes of the invention (such as search tools, compare tools, and modeling tools etc.) may reside in main memory 115 during execution.

In some embodiments, the computer system 100 may further comprise a sequence comparer for comparing the above-described nucleic acid codes of the invention or the polypeptide codes of the invention stored on a computer readable

medium to reference nucleotide or polypeptide sequences stored on a computer readable medium. A "sequence comparer" refers to one or more programs which are implemented on the computer system 100 to compare a nucleotide or polypeptide sequence with other nucleotide or polypeptide sequences and/or compounds including but not limited to peptides, peptidomimetics, and chemicals stored within the data storage means. For example, the sequence comparer may compare the nucleotide sequences of nucleic acid codes of the invention or the amino acid sequences of the polypeptide codes of the invention stored on a computer readable medium to reference sequences stored on a computer readable medium to identify homologies, motifs implicated in biological function, or structural motifs. The various sequence comparer programs identified elsewhere in this patent specification are particularly contemplated for use in this aspect of the invention.

Figure 8 is a flow diagram illustrating one embodiment of a process 200 for comparing a new nucleotide or protein sequence with a database of sequences in order to determine the homology levels between the new sequence and the sequences in the database. The database of sequences can be a private database stored within the computer system 100, or a public database such as GENBANK, PIR OR SWISSPROT that is available through the Internet.

The process 200 begins at a start state 201 and then moves to a state 202 wherein the new sequence to be compared is stored to a memory in a computer system 100. As discussed above, the memory could be any type of memory, including RAM or an internal storage device.

The process 200 then moves to a state 204 wherein a database of sequences is opened for analysis and comparison. The process 200 then moves to a state 206 wherein the first sequence stored in the database is read into a memory on the computer. A comparison is then performed at a state 210 to determine if the first sequence is the same as the second sequence. It is important to note that this step is not limited to performing an exact comparison between the new sequence and the first sequence in the database. Well-known methods are known to those of skill in the art for comparing two nucleotide or protein sequences, even if they are not identical. For example, gaps can be introduced into one sequence in order to raise the homology level between the two tested sequences. The parameters that control whether gaps or other features are introduced into a sequence during comparison are normally entered by the user of the computer system.

Once a comparison of the two sequences has been performed at the state 210, a determination is made at a decision state 210 whether the two sequences are the same. Of course, the term "same" is not limited to sequences that are absolutely identical. Sequences that are within the homology parameters entered by the user will be marked as "same" in the process 200.

If a determination is made that the two sequences are the same, the process 200 moves to a state 214 wherein the name of the sequence from the database is displayed to the user. This state notifies the user that the sequence with the displayed name fulfills the homology constraints that were entered. Once the name of the stored sequence is displayed to the user, the process 200 moves to a decision state 218 wherein a determination is made whether more sequences exist in the database. If no more sequences exist in the database, then the process 200 terminates at an end state 220. However, if more sequences do exist in the database, then the process 200 moves to a state 224 wherein a pointer is moved to the next sequence in the database so that it can be compared to the new sequence. In this manner, the new sequence is aligned and compared with every sequence in the database.

It should be noted that if a determination had been made at the decision state 212 that the sequences were not homologous, then the process 200 would move immediately to the decision state 218 in order to determine if any other sequences were available in the database for comparison.

Accordingly, one aspect of the present invention is a computer system comprising a processor, a data storage device having stored thereon a nucleic acid code of the invention or a polypeptide code of the invention, a data storage device having retrievably stored thereon reference nucleotide sequences or polypeptide sequences to be compared to the nucleic acid code of the invention or polypeptide code of the invention and a sequence comparer for conducting the comparison. The sequence comparer may indicate a homology level between the sequences compared or identify structural motifs in the nucleic acid code of the invention and polypeptide codes of the invention or it may identify structural motifs in sequences which are compared to these nucleic acid codes and polypeptide codes. In some embodiments, the data storage device may have stored thereon the sequences of at least 2, 5, 10, 15, 20, 25, 30, or 50 of the nucleic acid codes of the invention or polypeptide codes of the invention.

Another aspect of the present invention is a method for determining the level of homology between a nucleic acid code of the invention and a reference nucleotide

sequence, comprising the steps of reading the nucleic acid code and the reference nucleotide sequence through the use of a computer program which determines homology levels and determining homology between the nucleic acid code and the reference nucleotide sequence with the computer program. The computer program may be any of a number of computer programs for determining homology levels, including those specifically enumerated herein, including BLAST2N with the default parameters or with any modified parameters. The method may be implemented using the computer systems described above. The method may also be performed by reading 2, 5, 10, 15, 20, 25, 30, or 50 of the above described nucleic acid codes of the invention through the use of the computer program and determining homology between the nucleic acid codes and reference nucleotide sequences.

Figure 9 is a flow diagram illustrating one embodiment of a process 250 in a computer for determining whether two sequences are homologous. The process 250 begins at a start state 252 and then moves to a state 254 wherein a first sequence to be compared is stored to a memory. The second sequence to be compared is then stored to a memory at a state 256. The process 250 then moves to a state 260 wherein the first character in the first sequence is read and then to a state 262 wherein the first character of the second sequence is read. It should be understood that if the sequence is a nucleotide sequence, then the character would normally be either A, T, C, G or U. If the sequence is a protein sequence, then it should be in the single letter amino acid code so that the first and sequence sequences can be easily compared.

A determination is then made at a decision state 264 whether the two characters are the same. If they are the same, then the process 250 moves to a state 268 wherein the next characters in the first and second sequences are read. A determination is then made whether the next characters are the same. If they are, then the process 250 continues this loop until two characters are not the same. If a determination is made that the next two characters are not the same, the process 250 moves to a decision state 274 to determine whether there are any more characters either sequence to read.

If there aren't any more characters to read, then the process 250 moves to a state 276 wherein the level of homology between the first and second sequences is displayed to the user. The level of homology is determined by calculating the proportion of characters between the sequences that were the same out of the total number of sequences in the first sequence. Thus, if every character in a first 100

nucleotide sequence aligned with a every character in a second sequence, the homology level would be 100%.

Alternatively, the computer program may be a computer program which compares the nucleotide sequences of the nucleic acid codes of the present invention, to reference
5 nucleotide sequences in order to determine whether the nucleic acid code of the invention differs from a reference nucleic acid sequence at one or more positions. Optionally such a program records the length and identity of inserted, deleted or substituted nucleotides with respect to the sequence of either the reference polynucleotide or the nucleic acid code of the invention. In one embodiment, the
10 computer program may be a program which determines whether the nucleotide sequences of the nucleic acid codes of the invention contain one or more single nucleotide polymorphisms (SNP) with respect to a reference nucleotide sequence. These single nucleotide polymorphisms may each comprise a single base substitution, insertion, or deletion.

Another aspect of the present invention is a method for determining the level of
15 homology between a polypeptide code of the invention and a reference polypeptide sequence, comprising the steps of reading the polypeptide code of the invention and the reference polypeptide sequence through use of a computer program which determines homology levels and determining homology between the polypeptide code and the
20 reference polypeptide sequence using the computer program.

Accordingly, another aspect of the present invention is a method for determining whether a nucleic acid code of the invention differs at one or more nucleotides from a reference nucleotide sequence comprising the steps of reading the nucleic acid code and the reference nucleotide sequence through use of a computer
25 program which identifies differences between nucleic acid sequences and identifying differences between the nucleic acid code and the reference nucleotide sequence with the computer program. In some embodiments, the computer program is a program which identifies single nucleotide polymorphisms the method may be implemented by the computer systems described above and the method illustrated in Figure 9. The
30 method may also be performed by reading at least 2, 5, 10, 15, 20, 25, 30, or 50 of the nucleic acid codes of the invention and the reference nucleotide sequences through the use of the computer program and identifying differences between the nucleic acid codes and the reference nucleotide sequences with the computer program.

In other embodiments the computer based system may further comprise an identifier for identifying features within the nucleotide sequences of the nucleic acid codes of the invention or the amino acid sequences of the polypeptide codes of the invention.

An "identifier" refers to one or more programs which identifies certain features within the above-described nucleotide sequences of the nucleic acid codes of the invention or the amino acid sequences of the polypeptide codes of the invention. In one embodiment, the identifier may comprise a program which identifies an open reading frame in the cDNAs codes of the invention.

Figure 10 is a flow diagram illustrating one embodiment of an identifier process 300 for detecting the presence of a feature in a sequence. The process 300 begins at a start state 302 and then moves to a state 304 wherein a first sequence that is to be checked for features is stored to a memory 115 in the computer system 100. The process 300 then moves to a state 306 wherein a database of sequence features is opened. Such a database would include a list of each feature's attributes along with the name of the feature. For example, a feature name could be "Initiation Codon" and the attribute would be "ATG". Another example would be the feature name "TAATAA Box" and the feature attribute would be "TAATAA". An example of such a database is produced by the University of Wisconsin Genetics Computer Group (www.gcg.com).

Once the database of features is opened at the state 306, the process 300 moves to a state 308 wherein the first feature is read from the database. A comparison of the attribute of the first feature with the first sequence is then made at a state 310. A determination is then made at a decision state 316 whether the attribute of the feature was found in the first sequence. If the attribute was found, then the process 300 moves to a state 318 wherein the name of the found feature is displayed to the user.

The process 300 then moves to a decision state 320 wherein a determination is made whether more features exist in the database. If no more features do exist, then the process 300 terminates at an end state 324. However, if more features do exist in the database, then the process 300 reads the next sequence feature at a state 326 and loops back to the state 310 wherein the attribute of the next feature is compared against the first sequence.

It should be noted, that if the feature attribute is not found in the first sequence at the decision state 316, the process 300 moves directly to the decision state 320 in order to determine if any more features exist in the database.

In another embodiment, the identifier may comprise a molecular modeling program which determines the 3-dimensional structure of the polypeptides codes of the

invention. In some embodiments, the molecular modeling program identifies target sequences that are most compatible with profiles representing the structural environments of the residues in known three-dimensional protein structures. (See, e.g., Eisenberg et al., U.S. Patent No. 5,436,850 issued July 25, 1995). In another technique, the known three-dimensional structures of proteins in a given family are superimposed to define the structurally conserved regions in that family. This protein modeling technique also uses the known three-dimensional structure of a homologous protein to approximate the structure of the polypeptide codes of the invention. (See e.g., Srinivasan, et al., U.S. Patent No. 5,557,535 issued September 17, 1996). Conventional homology modeling techniques have been used routinely to build models of proteases and antibodies. (Sowdhamini et al., (1997)). Comparative approaches can also be used to develop three-dimensional protein models when the protein of interest has poor sequence identity to template proteins. In some cases, proteins fold into similar three-dimensional structures despite having very weak sequence identities. For example, the three-dimensional structures of a number of helical cytokines fold in similar three-dimensional topology in spite of weak sequence homology.

The recent development of threading methods now enables the identification of likely folding patterns in a number of situations where the structural relatedness between target and template(s) is not detectable at the sequence level. Hybrid methods, in which fold recognition is performed using Multiple Sequence Threading (MST), structural equivalencies are deduced from the threading output using a distance geometry program DRAGON to construct a low resolution model, and a full-atom representation is constructed using a molecular modeling package such as QUANTA.

According to this 3-step approach, candidate templates are first identified by using the novel fold recognition algorithm MST, which is capable of performing simultaneous threading of multiple aligned sequences onto one or more 3-D structures. In a second step, the structural equivalencies obtained from the MST output are converted into interresidue distance restraints and fed into the distance geometry program DRAGON, together with auxiliary information obtained from secondary structure predictions. The program combines the restraints in an unbiased manner and rapidly generates a large number of low resolution model confirmations. In a third step, these low resolution model confirmations are converted into full-atom models and subjected to energy minimization using the molecular modeling package QUANTA. (See e.g., Aszodi et al., (1997)).

The results of the molecular modeling analysis may then be used in rational drug design techniques to identify agents which modulate the activity of the polypeptide codes of the invention.

Accordingly, another aspect of the present invention is a method of identifying a
5 feature within the nucleic acid codes of the invention or the polypeptide codes of the invention comprising reading the nucleic acid code(s) or the polypeptide code(s) through the use of a computer program which identifies features therein and identifying features within the nucleic acid code(s) or polypeptide code(s) with the computer
10 program. In one embodiment, computer program comprises a computer program which identifies open reading frames. In a further embodiment, the computer program identifies structural motifs in a polypeptide sequence. In another embodiment, the computer program comprises a molecular modeling program. The method may be performed by reading a single sequence or at least 2, 5, 10, 15, 20, 25, 30, or 50 of the
15 nucleic acid codes of the invention or the polypeptide codes of the invention through the use of the computer program and identifying features within the nucleic acid codes or polypeptide codes with the computer program.

The nucleic acid codes of the invention or the polypeptide codes of the invention may be stored and manipulated in a variety of data processor programs in a variety of formats. For example, they may be stored as text in a word processing file,
20 such as MicrosoftWORD or WORDPERFECT or as an ASCII file in a variety of database programs familiar to those of skill in the art, such as DB2, SYBASE, or ORACLE. In addition, many computer programs and databases may be used as sequence comparers, identifiers, or sources of reference nucleotide or polypeptide sequences to be compared to the nucleic acid codes of the invention or the polypeptide codes of the
25 invention. The following list is intended not to limit the invention but to provide guidance to programs and databases which are useful with the nucleic acid codes of the invention or the polypeptide codes of the invention. The programs and databases which may be used include, but are not limited to: MacPattern (EMBL), DiscoveryBase (Molecular Applications Group), GeneMine (Molecular Applications Group), Look (Molecular
30 Applications Group), MacLook (Molecular Applications Group), BLAST and BLAST2 (NCBI), BLASTN and BLASTX (Altschul et al, 1990), FASTA (Pearson and Lipman, 1988), FASTDB (Brutlag et al., 1990), Catalyst (Molecular Simulations Inc.), Catalyst/SHAPE (Molecular Simulations Inc.), Cerius².DBAccess (Molecular Simulations Inc.), HypoGen (Molecular Simulations Inc.), Insight II, (Molecular Simulations Inc.),
35 Discover (Molecular Simulations Inc.), CHARMm (Molecular Simulations Inc.), Felix

(Molecular Simulations Inc.), DelPhi, (Molecular Simulations Inc.), QuanteMM, (Molecular Simulations Inc.), Homology (Molecular Simulations Inc.), Modeler (Molecular Simulations Inc.), ISIS (Molecular Simulations Inc.), Quanta/Protein Design (Molecular Simulations Inc.), WebLab (Molecular Simulations Inc.), WebLab Diversity Explorer (Molecular Simulations Inc.), Gene Explorer (Molecular Simulations Inc.), SeqFold (Molecular Simulations Inc.), the EMBL/Swissprotein database, the MDL Available Chemicals Directory database, the MDL Drug Data Report data base, the Comprehensive Medicinal Chemistry database, Derwent's World Drug Index database, the BioByteMasterFile database, the Genbank database, and the Genseqn database. Many other programs and data bases would be apparent to one of skill in the art given the present disclosure.

Motifs which may be detected using the above programs include sequences encoding leucine zippers, helix-turn-helix motifs, glycosylation sites, ubiquitination sites, alpha helices, and beta sheets, signal sequences encoding signal peptides which direct the secretion of the encoded proteins, sequences implicated in transcription regulation such as homeoboxes, acidic stretches, enzymatic active sites, substrate binding sites, and enzymatic cleavage sites.

EXAMPLE 1: G713

Example 1(a) : Isolation of a mRNA encoding the murine G713 polypeptide.

A homology search in Genbank with the coding sequences from the human G713 transcription product revealed the presence of one mouse EST sequence (Accession number W89905) referenced in the database. This Genbank EST sequence has a 80% homology to the 5'-end of the human G713 transcript and to another mouse EST having the Accession number AA027647, with approximately the same degree of homology to the 3'-end of the human G713 coding sequence.

In order to amplify the murine G713 mRNA, the following pair of primers has been designed :

- Primer 1 (g713CTGLF132) : 5'-GGCTGTGCGTTCCCAAATA-3' (SEQ ID No 14);
and

- Primer 2 : (moCTGR1511) : 5'-TGTCCTCGAGCGTGGGG-3' (SEQ ID No 26).

A Long Range PCR amplification has been performed using the Marathon Ready cDNA library from mouse brain (Clontech, Ref. 7450-1, batch No 8010338) and a fragment of 1405 bp was amplified and sequenced by primer walking.

For excluding the presence of artefactual products, another couple of primers were designed, which are the following :

- Primer 1 (moCTGLR20) : 5'-CGGAGGAGGGGATACGGAAATTAAAC-3' (SEQ ID No 27); and

- Primer 2 (moCTG1440) : 5'-TGGGTCACTGCTGCTCTGTGCCAAG-3' (SEQ ID No 28).

A Long Range PCR amplification was performed using the mouse brain Marathon Ready cDNA library and a fragment of about 1.5 kb has been amplified. End sequencing of this amplification product confirmed its identity as the mouse G713 mRNA, as it is determined below.

A set of nested primers has been designed from the 3'-end of the above 1.5 kb fragment, which is the following :

- Primer 1 (moCTG5RACE1) : 5'-TCACAGTGTCTCGGCCACT-3' (SEQ ID No 29); and

- Primer 2 (moCTG5RACEn) : 5'-TCCTCCACACAGTGCTCACG-3' (SEQ ID No 30).

These nested primers were used with the marathon primers AP1 and AP2 for performing a nested RACE reaction from the same mouse brain cDNA library. One fragment of approximately 700 bp was obtained and sequenced by primer walking. Contiguation of the whole above mouse brain cDNA sequences resulted in a fragment covering the coding part of the mouse G713 cDNA.

Example 1(b): Detection of G713 biallelic markers : DNA extraction.

Donors were unrelated and healthy. They presented a sufficient diversity for being representative of a French heterogeneous population. The DNA from 100 individuals was extracted and tested for the detection of the biallelic markers.

30 ml of peripheral venous blood were taken from each donor in the presence of EDTA. Cells (pellet) were collected after centrifugation for 10 minutes at 2000 rpm. Red cells were lysed by a lysis solution (50 ml final volume : 10 mM Tris pH7.6; 5 mM MgCl₂; 10 mM NaCl). The solution was centrifuged (10 minutes, 2000 rpm) as many times as necessary to eliminate the residual red cells present in the supernatant, after resuspension of the pellet in the lysis solution.

The pellet of white cells was lysed overnight at 42°C with 3.7 ml of lysis solution composed of:

- 3 ml TE 10-2 (Tris-HCl 10 mM, EDTA 2 mM) / NaCl 0.4 M

- 200 µl SDS 10%

- 500 μ l K-proteinase (2 mg K-proteinase in TE 10-2 / NaCl 0.4 M).

For the extraction of proteins, 1 ml saturated NaCl (6M) (1/3.5 v/v) was added. After vigorous agitation, the solution was centrifuged for 20 minutes at 10000 rpm.

For the precipitation of DNA, 2 to 3 volumes of 100% ethanol were added to the previous supernatant, and the solution was centrifuged for 30 minutes at 2000 rpm. The DNA solution was rinsed three times with 70% ethanol to eliminate salts, and centrifuged for 20 minutes at 2000 rpm. The pellet was dried at 37°C, and resuspended in 1 ml TE 10-1 or 1 ml water. The DNA concentration was evaluated by measuring the OD at 260 nm (1 unit OD = 50 μ g/ml DNA).

To determine the presence of proteins in the DNA solution, the OD 260 / OD 280 ratio was determined. Only DNA preparations having a OD 260 / OD 280 ratio between 1.8 and 2 were used in the subsequent examples described below.

The pool was constituted by mixing equivalent quantities of DNA from each individual.

Example 1(c): Detection of the biallelic markers: amplification of genomic DNA by PCR

The amplification of specific genomic sequences of the DNA samples of example 1(b) was carried out on the pool of DNA obtained previously. In addition, 50 individual samples were similarly amplified.

PCR assays were performed using the following protocol:

Final volume	25 μ l
DNA	2 ng/ μ l
MgCl ₂	2 mM
dNTP (each)	200 μ M
primer (each)	2.9 ng/ μ l
Ampli Taq Gold DNA polymerase	0.05 unit/ μ l
PCR buffer (10x = 0.1 M TrisHCl pH8.3 0.5M KCl	1x

Each pair of first primers was designed using the sequence information of the G713 gene disclosed herein and the OSP software (Hillier & Green, 1991). This first pair of primers was about 20 nucleotides in length and had the sequences disclosed in Table 1 in the columns labeled PU and RP.

TABLE 1

Amplicon	SEQ ID No	Primer name	Position range of amplification primer in SEQ ID		Primer name	Complementary position range of amplification primer in SEQ ID	
8-58	1	B1	4572	4587	C1	4990	5005
99-16063	2	B2	3045	3062	C2	3547	3565
99-16073	2	B3	6058	6076	C3	6493	6512
99-16074	2	B4	9661	9678	C4	10119	10136
99-13817	2	B5	14754	14774	C5	15183	15203
99-16066	2	B6	20137	20155	C6	20569	20588
99-13821	3	B7	7946	7965	C7	8454	8472
99-13525	3	B8	15943	15960	C8	16430	16447
99-13526	3	B9	16950	16970	C9	17381	17401
99-15215	3	B10	15475	15495	C10	15954	15974
99-15208	3	B11	19315	19333	C11	19797	19817

Preferably, the primers contained a common oligonucleotide tail upstream of the specific bases targeted for amplification which was useful for sequencing.

Primers PU contain the following additional PU 5' sequence:

5 TGTAACGACGGCCAGT; primers RP contain the following RP 5' sequence: CAGGAAACAGCTATGACC. The primer containing the additional PU 5' sequence is listed in SEQ ID No 70. The primer containing the additional RP 5' sequence is listed in SEQ ID No 71.

10 The synthesis of these primers was performed following the phosphoramidite method, on a GENSET UFPS 24.1 synthesizer.

DNA amplification was performed on a Genius II thermocycler. After heating at 95°C for 10 min, 40 cycles were performed. Each cycle comprised: 30 sec at 95°C, 54°C for 1 min, and 30 sec at 72°C. For final elongation, 10 min at 72°C ended the amplification. The quantities of the amplification products obtained were determined on 15 96-well microtiter plates, using a fluorometer and Picogreen as intercalant agent (Molecular Probes).

Example 1(d): Detection of the biallelic markers: sequencing of amplified genomic DNA and identification of polymorphisms.

20 The sequencing of the amplified DNA obtained in example 1(c) was carried out on ABI 377 sequencers. The sequences of the amplification products were determined

using automated dideoxy terminator sequencing reactions with a dye terminator cycle sequencing protocol. The products of the sequencing reactions were run on sequencing gels and the sequences were determined using gel image analysis (ABI Prism DNA Sequencing Analysis software (2.1.2 version) and the above mentioned proprietary "Trace" basecaller).

The sequence data were further evaluated using the above mentioned polymorphism analysis software designed to detect the presence of biallelic markers among the pooled amplified fragments. The polymorphism search was based on the presence of superimposed peaks in the electrophoresis pattern resulting from different bases occurring at the same position as described previously.

The localization of the biallelic markers are as shown in Table 2.

Table 2

Biallelic Markers

BM	SEQ ID No	Marker Name	Localization in GENE gene	Polymorphism		BM position in SEQ ID
				all1	all2	
A1	1	8-58-301	Intron 1	C	T	4872
A2	2	99-16063-218	Intron 1	A	G	3262
A3	2	99-16073-282	Intron 1	C	T	6231
A4	2	99-16074-266	Intron 1	A	G	9871
A5	2	99-13817-215	Intron 1	C	T	14968
A6	2	99-16066-123	Intron 2	C	T	20259
A7	3	99-13821-332	Exon 3	C	T	8277
A8	3	99-13525-395	3' portion of genomic sequence	A	G	16053
A9	3	99-13526-368	3' portion of genomic sequence	A	G	17032
A10	3	99-15215-60	3' portion of genomic sequence	C	T	15915
A11	3	99-15208-87	3' portion of genomic sequence	A	G	19401

BM refers to "biallelic marker". All1 and all2 refer respectively to allele 1 and allele 2 of the biallelic marker.

Table 3

BM	SEQ ID NO	Marker Name	Position range of probes in SEQ ID No		Probes
A1	1	8-58-301	4849	4895	P1

A2	2	99-16063-218	3239	3285	P2
A3	2	99-16073-282	6208	6254	P3
A4	2	99-16074-266	9848	9894	P4
A5	2	99-13817-215	14945	14991	P5
A6	2	99-16066-123	20236	20282	P6
A7	3	99-13821-332	8254	8300	P7
A8	3	99-13525-395	16030	16076	P8
A9	3	99-13526-368	17009	17055	P9
A10	3	99-15215-60	15892	15938	P10
A11	3	99-15208-87	19378	19424	P11

Example 1(e): Validation of the polymorphisms through microsequencing

5 The biallelic markers identified in Example (d) were further confirmed and their respective frequencies were determined through microsequencing. Microsequencing was carried out for each individual DNA sample described in Example (b).

Amplification from genomic DNA of individuals was performed by PCR as described above for the detection of the biallelic markers with the same set of PCR primers (Table 1).

10 The preferred primers used in microsequencing were about 20 nucleotides in length and hybridized just upstream of the considered polymorphic base. According to the invention, the primers used in microsequencing are detailed in Table 4.

TABLE 4

Marker Name	SEQ ID No.	Biallelic Marker	Mis. 1	Position range of microsequencing primer mis 1 in SEQ ID No		Mis. 2	Complementary position range of microsequencing primer mis. 2 in SEQ ID No	
8-58-301	1	A1	D1	4853	4871	E1	4873	4891
99-16063-218	2	A2	D2	3243	3261	E2	3263	3281
99-16073-282	2	A3	D3	6212	6230	E3	6232	6250
99-16074-266	2	A4	D4	9852	9870	E4	9872	9890
99-13817-215	2	A5	D5	14949	14967	E5	14969	14987
99-16066-123	2	A6	D6	20240	20258	E6	20260	20278
99-13821-332	3	A7	D7	8258	8276	E7	8278	8296

99-13525-395	3	A8	D8	16034	16052	E8	16054	16072
99-13526-368	3	A9	D9	17013	17031	E9	17033	17051
99-15215-60	3	A10	D10	15896	15914	E10	15916	15634
99-15208-87	3	A11	D11	19382	19400	E11	19402	19420

Mis 1 and Mis 2 respectively refer to microsequencing primers which hybridized with the non-coding strand of the *G713* gene or with the coding strand of the *G713* gene.

5 The microsequencing reaction was performed as follows :

After purification of the amplification products, the microsequencing reaction mixture was prepared by adding, in a 20 µl final volume: 10 pmol microsequencing oligonucleotide, 1 U Thermosequenase (Amersham E79000G), 1.25 µl Thermosequenase buffer (260 mM Tris HCl pH 9.5, 65 mM MgCl₂), and the two
10 appropriate fluorescent ddNTPs (Perkin Elmer, Dye Terminator Set 401095) complementary to the nucleotides at the polymorphic site of each biallelic marker tested, following the manufacturer's recommendations. After 4 minutes at 94°C, 20 PCR cycles of 15 sec at 55°C, 5 sec at 72°C, and 10 sec at 94°C were carried out in a Tetrad PTC-225 thermocycler (MJ Research). The unincorporated dye terminators
15 were then removed by ethanol precipitation. Samples were finally resuspended in formamide-EDTA loading buffer and heated for 2 min at 95°C before being loaded on a polyacrylamide sequencing gel. The data were collected by an ABI PRISM 377 DNA sequencer and processed using the GENESCAN software (Perkin Elmer).

20 Following gel analysis, data were automatically processed with software that allows the determination of the alleles of biallelic markers present in each amplified fragment.

The software evaluates such factors as whether the intensities of the signals resulting from the above microsequencing procedures are weak, normal, or saturated, or whether the signals are ambiguous. In addition, the software identifies significant
25 peaks (according to shape and height criteria). Among the significant peaks, peaks corresponding to the targeted site are identified based on their position. When two significant peaks are detected for the same position, each sample is categorized classification as homozygous or heterozygous type based on the height ratio.

30 **Table 5 : Restriction map of the *G713* 5' regulatory polynucleotide of SEQ ID No 4**

Name	Sequence	Position	Fragment	lengths
1 AATII		0	-1 2001	-1 2001
1 ACCI	GT'ATAC	164	163 1837	163 1837
1 AFLII		0	-1 2001	-1 2001
1 AFLIII		0	-1 2001	-1 2001
1 APAI	GGGCC'C	1469	1468	8
2 APAI	GGGCC'C	1477	8 524	524 1468
1 APALI	G'TGCAC	378	377	377
2 APALI	G'TGCAC	1041	663 960	663 960
1 ASUII		0	-1 2001	-1 2001
1 AVRII		0	-1 2001	-1 2001
1 BALI		0	-1 2001	-1 2001
1 BAMHI	G'GATCC	1127	1126 874	874 1126
1 BCLI	T'GATCA	109	108 1892	108 1892
1 BGLII		0	-1 2001	-1 2001
1 BSMI	CG'CATTC	1138	1137 863	863 1137
1 BSPMI	ACCTGCTGCT'	528	527	500
2 BSPMI	CGGTCGATGCAGGT	1028	500 973	527 973
1 BSPMII	TCCGG'A	1857	1856 144	144 1856
1 BSTEII	G'GTCACC	349	348	280
2 BSTEII	G'GTGACC	629	280 1372	348 1372
1 BSTXI	CCATCCCT'TTGG	317	316 1684	316 1684
1 CLAI		0	-1 2001	-1 2001
1 DRAI	TTT'AAA	52	51	51
2 DRAI	TTT'AAA	239	187 1762	187 1762
1 DRAIII	CACTCG'GTG	487	486 1514	486 1514
1 EAEI	C'GGCCG	1330	1329	19
2 EAEI	C'GGCCA	1349	19	652

1090337 90540850

			652	1329
1 ECOB		0	-1 2001	-1 2001
1 ECOK		0	-1 2001	-1 2001
1 ECORI		0	-1 2001	-1 2001
1 ECORV		0	-1 2001	-1 2001
1 ESPI		0	-1 2001	-1 2001
1 FSPI	TGC'GCA	491	490 1510	490 1510
1 HINCII		0	-1 2001	-1 2001
1 HINDIII		0	-1 2001	-1 2001
1 HPAI		0	-1 2001	-1 2001
1 KPNI		0	-1 2001	-1 2001
1 MLUI		0	-1 2001	-1 2001
1 MSTII		0	-1 2001	-1 2001
1 NAEI	GCC'GGC	1534	1533 467	467 1533
1 NCOI		0	-1 2001	-1 2001
1 NDEI		0	-1 2001	-1 2001
1 NHEI		0	-1 2001	-1 2001
1 NOTI	GC'GGCCGC	1330	1329 671	671 1329
1 NRUI		0	-1 2001	-1 2001
1 NSII	ATGCA'T	333	332 1668	332 1668
1 PFIMI		0	-1 2001	-1 2001
1 PPUMI	GG'GTCCT	400	399	361
2 PPUMI	AG'GTCCT	761	361 1240	399 1240
1 PSTI		0	-1 2001	-1 2001
1 PVUI		0	-1 2001	-1 2001
1 PVUII		0	-1	-1

0907507-08001

			2001	2001
1 RSRII	CG'GTCCG	1121	1120 880	880 1120
1 SACI	GAGCT'C	1563	1562	143
2 SACI	GAGCT'C	1706	143 295	295 1562
1 SALI		0	-1 2001	-1 2001
1 SCAI	AGT'ACT	19	18 1982	18 1982
1 SNABI		0	-1 2001	-1 2001
1 SPEI		0	-1 2001	-1 2001
1 SPHI		0	-1 2001	-1 2001
1 SSPI		0	-1 2001	-1 2001
1 STUI		0	-1 2001	-1 2001
1 STYI	C'CTTGG	403	402 1598	402 1598
1 TTHIII		0	-1 2001	-1 2001
1 XBAI		0	-1 2001	-1 2001
1 XHOI		0	-1 2001	-1 2001
1 XMAIII	C'GGCCG	1330	1329 671	671 1329
1 XMNI		0	-1 2001	-1 2001

Example 1(f): Preparation of Antibody Compositions to the G713 protein

Substantially pure protein or polypeptide is isolated from transfected or transformed cells containing an expression vector encoding the G713 protein or a portion thereof. The concentration of protein in the final preparation is adjusted, for example, by concentration on an Amicon filter device, to the level of a few micrograms/ml. Monoclonal or polyclonal antibody to the protein can then be prepared as follows:

A. Monoclonal Antibody Production by Hybridoma Fusion

Monoclonal antibody to epitopes in the G713 protein or a portion thereof can be prepared from murine hybridomas according to the classical method of Kohler, G. and Milstein, C., (1975) or derivative methods thereof. Also see Harlow, E., and D. Lane. 1988..

Briefly, a mouse is repetitively inoculated with a few micrograms of the G713 protein or a portion thereof over a period of a few weeks. The mouse is then sacrificed, and the antibody producing cells of the spleen isolated. The spleen cells are fused by means of polyethylene glycol with mouse myeloma cells, and the excess unfused cells destroyed by growth of the system on selective media comprising aminopterin (HAT media). The successfully fused cells are diluted and aliquots of the dilution placed in wells of a microtiter plate where growth of the culture is continued. Antibody-producing clones are identified by detection of antibody in the supernatant fluid of the wells by immunoassay procedures, such as ELISA, as originally described by Engvall, (1980), and derivative methods thereof. Selected positive clones can be expanded and their monoclonal antibody product harvested for use. Detailed procedures for monoclonal antibody production are described in Davis, L. et al. Basic Methods in Molecular Biology Elsevier, New York. Section 21-2.

B. Polyclonal Antibody Production by Immunization

Polyclonal antiserum containing antibodies to heterogeneous epitopes in the G713 protein or a portion thereof can be prepared by immunizing suitable non-human animal with the G713 protein or a portion thereof, which can be unmodified or modified to enhance immunogenicity. A suitable non-human animal is preferably a non-human mammal is selected, usually a mouse, rat, rabbit, goat, or horse. Alternatively, a crude preparation which has been enriched for G713 concentration can be used to generate antibodies. Such proteins, fragments or preparations are introduced into the non-human mammal in the presence of an appropriate adjuvant (e.g. aluminum hydroxide, RIBI, etc.) which is known in the art. In addition the protein, fragment or preparation can be pretreated with an agent which will increase antigenicity, such agents are known in the art and include, for example, methylated bovine serum albumin (mBSA), bovine serum albumin (BSA), Hepatitis B surface antigen, and keyhole limpet hemocyanin (KLH). Serum from the immunized animal is collected, treated and tested according to known procedures. If the serum contains polyclonal antibodies to undesired epitopes, the polyclonal antibodies can be purified by immunoaffinity chromatography.

Effective polyclonal antibody production is affected by many factors related both to the antigen and the host species. Also, host animals vary in response to site of inoculations and dose, with both inadequate or excessive doses of antigen resulting in low titer antisera. Small doses (ng level) of antigen administered at multiple intradermal sites appears to be most reliable. Techniques for producing and

processing polyclonal antisera are known in the art, see for example, Mayer and Walker (1987). An effective immunization protocol for rabbits can be found in Vaitukaitis, J. et al. (1971).

Booster injections can be given at regular intervals, and antiserum harvested when antibody titer thereof, as determined semi-quantitatively, for example, by double immunodiffusion in agar against known concentrations of the antigen, begins to fall. See, for example, Ouchterlony, O. et al., (1973). Plateau concentration of antibody is usually in the range of 0.1 to 0.2 mg/ml of serum (about 12 μ M). Affinity of the antisera for the antigen is determined by preparing competitive binding curves, as described, for example, by Fisher, D., (1980).

Antibody preparations prepared according to either the monoclonal or the polyclonal protocol are useful in quantitative immunoassays which determine concentrations of antigen-bearing substances in biological samples; they are also used semi-quantitatively or qualitatively to identify the presence of antigen in a biological sample. The antibodies may also be used in therapeutic compositions for killing cells expressing the protein or reducing the levels of the protein in the body.

EXAMPLE 2: Schizophrenia-related biallelic markers

EXAMPLE 2(a) : Detection of SG2 biallelic markers: DNA extraction

Donors were unrelated and healthy. They presented a sufficient diversity for being representative of a French heterogeneous population. The DNA from 100 individuals was extracted and tested for the detection of the biallelic markers.

Briefly, 30 ml of peripheral venous blood were taken from each donor in the presence of EDTA. Cells (pellet) were collected after centrifugation for 10 minutes at 2000 rpm. Red cells were lysed by a lysis solution (50 ml final volume : 10 mM Tris pH7.6; 5 mM $MgCl_2$; 10 mM NaCl). The solution was centrifuged (10 minutes, 2000 rpm) as many times as necessary to eliminate the residual red cells present in the supernatant, after resuspension of the pellet in the lysis solution.

The pellet of white cells was lysed overnight at 42°C with 3.7 ml of lysis solution composed of:

- 3 ml TE 10-2 (Tris-HCl 10 mM, EDTA 2 mM) / NaCl 0.4 M
- 200 μ l SDS 10%
- 500 μ l K-proteinase (2 mg K-proteinase in TE 10-2 / NaCl 0.4 M).

For the extraction of proteins, 1 ml saturated NaCl (6M) (1/3.5 v/v) was added. After vigorous agitation, the solution was centrifuged for 20 minutes at 10000 rpm.

For the precipitation of DNA, 2 to 3 volumes of 100% ethanol were added to the previous supernatant, and the solution was centrifuged for 30 minutes at 2000 rpm. The DNA solution was rinsed three times with 70% ethanol to eliminate salts, and centrifuged for 20 minutes at 2000 rpm. The pellet was dried at 37°C, and resuspended in 1 ml TE 10-1 or 1 ml water. The DNA concentration was evaluated by measuring the OD at 260 nm (1 unit OD = 50 µg/ml DNA).

To determine the presence of proteins in the DNA solution, the OD 260 / OD 280 ratio was determined. Only DNA preparations having a OD 260 / OD 280 ratio between 1.8 and 2 were used in the subsequent examples described below.

The pool was constituted by mixing equivalent quantities of DNA from each individual.

EXAMPLE 2(b): Detection of biallelic markers: amplification of genomic DNA by PCR

The amplification of specific genomic sequences of the DNA samples of example 2(a) was carried out on the pool of DNA obtained previously. In addition, 50 individual samples were similarly amplified.

PCR assays were performed using the following protocol:

Final volume	25 µl
DNA	2 ng/µl
MgCl ₂	2 mM
dNTP (each)	200 µM
primer (each)	2.9 ng/µl
Ampli Taq Gold DNA polymerase	0.05 unit/µl
PCR buffer (10x = 0.1 M TrisHCl pH8.3 0.5M KCl	1x

Each pair of first primers was designed using the sequence information of the human chromosome 13q31-q33 region of interest disclosed herein and the OSP software (Hillier & Green, 1991). This first pair of primers was about 20 nucleotides in length and had the sequences disclosed in Table 6.

Table 6

Amplicon	SEQ ID No	Primer name	Position range of amplification primer in SEQ ID		Primer name	Complementary position range of amplification primer in SEQ ID	
99-15663	32	B12	1	18	C12	430	450
99-15665	33	B13	1	20	C13	458	476
99-15672	34	B14	1	18	C14	533	551

99-15664	35	B15	1	19	C15	483	502
99-5919	36	B16	1	19	C16	435	455
99-5862	37	B17	1	20	C17	430	450
99-16032	38	B18	1	19	C18	384	403
99-16038	39	B19	1	19	C19	456	476
99-5897	40	B20	1	18	C20	475	492
99-13601	41	B21	1	19	C21	500	517
99-13925	42	B22	1	20	C22	513	533
99-13929	43	B23	1	19	C23	460	480
99-14021	44	B24	1	18	C24	460	477
99-14359	45	B25	1	18	C25	457	475
99-14364	46	B26	1	19	C26	453	473
99-15056	47	B27	1	18	C27	482	502
99-15229	48	B28	1	20	C28	476	494
99-15232	49	B29	1	18	C29	467	485
99-15241	50	B30	1	19	C30	444	464
99-15244	51	B31	1	20	C31	532	550
99-15252	52	B32	1	18	C32	433	452
99-15253	53	B33	1	19	C33	459	477
99-15256	54	B34	1	18	C34	439	456
99-15261	55	B35	1	19	C35	481	501
99-15280	56	B36	1	18	C36	521	541
99-15353	57	B37	1	18	C37	495	514
99-15355	58	B38	1	18	C38	471	489
99-15685	59	B39	1	18	C39	449	468
99-15695	60	B40	1	18	C40	481	500
99-15703	61	B41	1	18	C41	452	472
99-15870	62	B42	1	21	C42	452	470
99-16321	63	B43	1	20	C43	451	469
99-16333	64	B44	1	19	C44	524	544
99-5873	65	B45	1	18	C45	457	475
99-5912	66	B46	11	31	C46	494	511
99-6012	67	B47	1	19	C47	467	485
99-6080	68	B48	1	18	C48	509	529
99-7308	69	B49	1	18	C49	469	489

Preferably, the primers contained a common oligonucleotide tail upstream of the specific bases targeted for amplification which was useful for sequencing.

Primers PU contain the following additional PU 5' sequence:

TGTAACGACGGCCAGT; primers RP contain the following RP 5' sequence: CAGGAACAGCTATGACC. The primer containing the additional PU 5' sequence is listed in SEQ ID No 70. The primer containing the additional RP 5' sequence is listed in SEQ ID No 71.

The synthesis of these primers was performed following the phosphoramidite method, on a GENSET UFPS 24.1 synthesizer.

DNA amplification was performed on a Genius II thermocycler. After heating at 95°C for 10 min, 40 cycles were performed. Each cycle comprised: 30 sec at 95°C, 54°C for 1 min, and 30 sec at 72°C. For final elongation, 10 min at 72°C ended the amplification. The quantities of the amplification products obtained were determined on 96-well microtiter plates, using a fluorometer and Picogreen as intercalant agent (Molecular Probes).

EXAMPLE 2(c): Detection of biallelic markers: sequencing of amplified genomic DNA and identification of polymorphisms

The sequencing of the amplified DNA obtained in example 2(b) was carried out on ABI 377 sequencers. The sequences of the amplification products were determined using automated dideoxy terminator sequencing reactions with a dye terminator cycle sequencing protocol. The products of the sequencing reactions were run on sequencing gels and the sequences were determined using gel image analysis ABI Prism DNA Sequencing Analysis software (2.1.2 version) and the above mentioned proprietary "Trace" basecaller.

The sequence data were further evaluated using the above mentioned polymorphism analysis software designed to detect the presence of biallelic markers among the pooled amplified fragments. The polymorphism search was based on the presence of superimposed peaks in the electrophoresis pattern resulting from different bases occurring at the same position as described previously.

34 fragments of amplification were analyzed. In these segments, 34 biallelic markers were detected. The localization of these biallelic markers is as shown in Table 7.

TABLE 7

Amplicon	BM	Marker Name	Polymorphism		SEQ ID No.	BM position in SEQ ID No	Position of probes in SEQ ID No.		Probes
			all1	all2					
99-15663	A12	99-15663-298	C	T	32	298	275	321	P12
99-15665	A13	99-15665-398	A	G	33	398	375	421	P13
99-15672	A14	99-15672-166	C	T	34	166	143	189	P14
99-15664	A15	99-15664-185	G	T	35	185	162	208	P15
99-5919	A16	99-5919-215	A	G	36	205	182	228	P16
99-5862	A17	99-5862-167	C	T	37	157	134	180	P17
99-16032	A18	99-16032-292	A	C	38	292	269	315	P18
99-16038	A19	99-16038-118	A	G	39	118	95	141	P19
99-5897	A20	99-5897-143	A	C	40	133	110	156	P20
99-13601	A21	99-13601-360	A	G	41	360	337	383	P21
99-13925	A22	99-13925-97	A	G	42	97	74	120	P22
99-13929	A23	99-13929-201	A	C	43	201	178	224	P23
99-14021	A24	99-14021-108	A	G	44	108	85	131	P24

99-14359	A25	99-14359-314	G	C	45	314	291	337	P25
99-14364	A26	99-14364-415	C	T	46	316	293	339	P26
99-15056	A27	99-15056-99	C	T	47	99	76	122	P27
99-15229	A28	99-15229-412	A	G	48	412	389	435	P28
99-15232	A29	99-15232-291	G	T	49	291	268	314	P29
99-15241	A30	99-15241-347	A	G	50	347	324	370	P30
99-15244	A31	99-15244-196	A	G	51	196	173	219	P31
99-15252	A32	99-15252-404	C	T	52	404	381	427	P32
99-15253	A33	99-15253-382	C	T	53	382	359	405	P33
99-15256	A34	99-15256-392	C	T	54	392	369	415	P34
99-15261	A35	99-15261-202	A	G	55	200	177	223	P35
99-15280	A36	99-15280-432	C	T	56	432	409	455	P36
99-15353	A37	99-15353-428	C	T	57	428	405	451	P37
99-15355	A38	99-15355-150	C	T	58	150	127	173	P38
99-15685	A39	99-15685-227	A	G	59	227	204	250	P39
99-15695	A40	99-15695-428	C	T	60	428	405	451	P40
99-15703	A41	99-15703-310	C	T	61	310	287	333	P41
99-15870	A42	99-15870-400	A	G	62	400	377	423	P42
99-16321	A43	99-16321-287	A	C	63	287	264	310	P43
99-16333	A44	99-16333-194	A	G	64	194	171	217	P44
99-5873	A45	99-5873-159	C	T	65	149	126	172	P45
99-5912	A46	99-5912-49	A	G	66	49	26	72	P46
99-6012	A47	99-6012-220	G	T	67	210	187	233	P47
99-6080	A48	99-6080-99	C	T	68	89	66	112	P48
99-7308	A49	99-7308-157	C	T	69	156	133	179	P49

BM refers to "biallelic marker". All1 and all2 refer respectively to allele 1 and allele 2 of the biallelic marker.

EXAMPLE 2(d): Validation of the polymorphisms through microsequencing

The biallelic markers identified in example 2(c) were further confirmed and their respective frequencies were determined through microsequencing. Microsequencing was carried out for each individual DNA sample described in Example 2(a).

Amplification from genomic DNA of individuals was performed by PCR as described above for the detection of the biallelic markers with the same set of PCR primers (Table 6).

The preferred primers used in microsequencing were about 19 nucleotides in length and hybridized just upstream of the considered polymorphic base.

According to the invention, the primers used in microsequencing are detailed in Table 8.

Table 8

Marker Name	Biallelic Marker	SEQ ID No.	Mis. 1	Position range of microsequencing primer mis. 1 in SEQ ID No.		Mis. 2	Complementary position range of microsequencing primer mis. 2 in SEQ ID No.	
99-15663-298	A12	32	D12	279	297	E12	299	317
99-15665-398	A13	33	D13	379	397	E13	399	417
99-15672-166	A14	34	D14	147	165	E14	167	185
99-15664-185	A15	35	D15	166	184	E15	186	204
99-5919-215	A16	36	D16	186	204	E16	206	224
99-5862-167	A17	37	D17	138	156	E17	158	176
99-16032-292	A18	38	D18	273	291	E18	293	311
99-16038-118	A19	39	D19	99	117	E19	119	137
99-5897-143	A20	40	D20	114	132	E20	134	152
99-13601-360	A21	41	D21	341	359	E21	361	379
99-13925-97	A22	42	D22	78	96	E22	98	116
99-13929-201	A23	43	D23	182	200	E23	202	220
99-14021-108	A24	44	D24	89	107	E24	109	127
99-14359-314	A25	45	D25	295	313	E25	315	333
99-14364-415	A26	46	D26	297	315	E26	317	335
99-15056-99	A27	47	D27	80	98	E27	100	118
99-15229-412	A28	48	D28	393	411	E28	413	431
99-15232-291	A29	49	D29	272	290	E29	292	310
99-15241-347	A30	50	D30	328	346	E30	348	366
99-15244-196	A31	51	D31	177	195	E31	197	215
99-15252-404	A32	52	D32	385	403	E32	405	423
99-15253-382	A33	53	D33	363	381	E33	383	401
99-15256-392	A34	54	D34	373	391	E34	393	411
99-15261-202	A35	55	D35	181	199	E35	201	219
99-15280-432	A36	56	D36	413	431	E36	433	451
99-15353-428	A37	57	D37	409	427	E37	429	447
99-15355-150	A38	58	D38	131	149	E38	151	169
99-15685-227	A39	59	D39	208	226	E39	228	246
99-15695-428	A40	60	D40	409	427	E40	429	447
99-15703-310	A41	61	D41	291	309	E41	311	329
99-15870-400	A42	62	D42	381	399	E42	401	419
99-16321-287	A43	63	D43	268	286	E43	288	306
99-16333-194	A44	64	D44	175	193	E44	195	213
99-5873-159	A45	65	D45	130	148	E45	150	168
99-5912-49	A46	66	D46	30	48	E46	50	68
99-6012-220	A47	67	D47	191	209	E47	211	229
99-6080-99	A48	68	D48	70	88	E48	90	108
99-7308-157	A49	69	D49	137	155	E49	157	175

The microsequencing reaction was performed as follows :

After purification of the amplification products, the microsequencing reaction mixture was prepared by adding, in a 20µl final volume: 10 pmol microsequencing

oligonucleotide, 1 U Thermosequenase (Amersham E79000G), 1.25 µl Thermosequenase buffer (260 mM Tris HCl pH 9.5, 65 mM MgCl₂), and the two appropriate fluorescent ddNTPs (Perkin Elmer, Dye Terminator Set 401095) complementary to the nucleotides at the polymorphic site of each biallelic marker tested, following the manufacturer's recommendations. After 4 minutes at 94°C, 20 PCR cycles of 15 sec at 55°C, 5 sec at 72°C, and 10 sec at 94°C were carried out in a Tetrad PTC-225 thermocycler (MJ Research). The unincorporated dye terminators were then removed by ethanol precipitation. Samples were finally resuspended in formamide-EDTA loading buffer and heated for 2 min at 95°C before being loaded on a polyacrylamide sequencing gel. The data were collected by an ABI PRISM 377 DNA sequencer and processed using the GENESCAN software (Perkin Elmer).

Following gel analysis, data were automatically processed with software that allows the determination of the alleles of biallelic markers present in each amplified fragment.

The software evaluates such factors as whether the intensities of the signals resulting from the above microsequencing procedures are weak, normal, or saturated, or whether the signals are ambiguous. In addition, the software identifies significant peaks (according to shape and height criteria). Among the significant peaks, peaks corresponding to the targeted site are identified based on their position. When two significant peaks are detected for the same position, each sample is categorized classification as homozygous or heterozygous type based on the height ratio.

EXAMPLE 2(e): Association study between schizophrenia and the biallelic markers of the invention: collection of DNA samples from affected and non-affected individuals

a) Affected population

All the samples were collected from a large epidemiological study of schizophrenia undertaken in hospital centers of Quebec from October 1995 to April 1997. The population was composed of French Caucasian individuals. The study design consisted in the ascertainment of cases and two of their first degree relatives (parents or siblings).

As a whole, 956 schizophrenic cases were ascertained according to the following inclusion criteria :

- the diagnosis had been done by a psychiatrist;

- the diagnosis had been done at least 3 years before recruitment time, in order to exclude individuals suffering from transient manic-depressive psychosis or depressive disorders;
- the patient ancestors had been living in Quebec for at least 6 generations;
- it was possible to get a blood sample from 2 close relatives.

Among the 956 schizophrenic ascertained cases, 834 individuals were included in the study for the following reasons :

- for the included individual cases, the diagnosis of schizophrenia was established according to the DSM-IV (Diagnostic and Statistical Manual, Fourth edition, Revised 1994, American Psychiatric Press);
- samples from individuals suffering from schizoaffective disorder were discarded;
- individuals suffering from catatonic schizophrenia were also excluded from the population of schizophrenic cases;
- were also excluded the individuals having a first degree relative or 2 or more second degree relatives suffering from depression or mood disorder;
- individuals having had severe head trauma, severe obstretical complications, encephalitis, or meningitis before onset of symptoms were also excluded;
- has also been excluded from the population of schizophrenic cases a patient suffering from epilepsy and treated with anticonvulsants.

The age at onset was not added as an inclusion criteria.

b) Unaffected population

Control cases were respectively ascertained based on the following cumulative criteria:

- the individual must not be affected by schizophrenia or any other psychiatric disorder;
- the individual must have 35 years old or more;
- the individual must belong to the French-Canadian population;
- the individual must have one or two first degree relative available for blood sampling.

Controls were matched with cases sex when possible. The unaffected population retained for the study was composed of 214 individuals, and more particularly of 141 individuals randomly selected among them.

The different populations included in the association study of this patent are characterized in more detail in Table 9.

Table 9

	Probands	
	Cases	Controls
Sample size	216	214
Gender		
Male	152	115
Female	64	98
Familial history of psychosis¹		
positive	83	-
none	133	214

¹close relatives (first or second degree)

	Relatives of	
	Cases	Controls
Sample size	417	424
Nber of mothers	169	120
Nber of fathers	94	78
Nber of sibs	154	226
Nber of trios father-mother-proband	73	60

As seen in Table 9 above, 216 Proband cases were finally selected among the initial 834 available individuals (upper part of the Table), wherein 417 relatives of these Proband cases were also included in this study.

c) Cases and Control Populations Selected for the Association Study

For the control populations, the Proband cases under study were 214, wherein 424 relatives of these Proband cases were also taken into account for this study.

The association data that are presented in the Examples 2(f) to 2(h) were obtained on a population size detailed in Table 10 below, wherein the individuals have been randomly selected from the populations detailed before in Table 9.

Table 10

	Probands	
	Cases	Controls
Sample size	141	141
Gender		
Male	96	96
Female	45	45
Familial history of psychosis		
Positive	78	-
None	63	141

Both case and control populations form two groups, each group consisting of unrelated individuals that do not share a known common ancestor. Additionally, the individuals of the control population were selected among those having no family history of schizophrenia or schizophrenic disorder.

EXAMPLE 2(f): Association study between schizophrenia and the biallelic markers of the invention : genotyping of affected and control individuals

a) BACs covering the genomic region of interest (13q31-q33)

Nine BACs were selected that cover the region of interest and several biallelic markers were generated in each of these BACs, as described in Examples 2(a) to 2(c), for performing the association study detailed hereafter. The nine BACs used as well as the biallelic markers contained therein are depicted in Table 11. The BACs used can eventually be ordered on the basis of the mapping information of ESTs or STSs sequences respectively contained in these BACs and referenced in nucleic acid sequences databases.

Table 11

BAC	Size (kb)	# amplicons	# polymorphic amplicons	# of SNPs genotyped (mean distance (kb))	SNPs genotyped
B1	125	29	5	3 (1/41)	99-14359/314
					99-16321/287
					99-16333/194
	100	16	0	0	0

B2	120	2	4	3 (1/40)	99-7308/157
					99-14364/415
					99-14021/108
B3	125	12	10	4 (1/31)	99-15232/291
					99-6080/99
					99-6012/220
					99-15229/412
B4	100	11	2	2 (1/50)	99-15241/347
					99-15244/196
B5	115	22	5	4 (1/28)	99-15663/298
					99-15665/398
					99-15672/166
					99-15664/185
B6	300	53	13	9 (1/33)	99-15056/99
					99-5873/159
					99-15252/404
					99-15256/392
					99-15261/202
					99-15280/432
					99-15355/150
					99-15253/382
					99-15353/428
B7	85	22	10	3 (1/28)	99-15685/227
					99-15695/428
					99-15703/310
B8	130	52	15	4 (1/32.5)	99-15870/400
					99-5897/143
					99-5862/167
					99-5919/215
B9	225	31	11	5 ⁽¹⁾ (1/45)	99-16032/292
					99-16038/118
		249	67	34	

(1) : 99-5897/143, 99-5862/167 and 99-5919/215 are also in bac B9

b) Results from the genotyping

The general strategy to perform the association studies was to individually scan the DNA samples from all individuals in each of the populations described above in order to establish the allele frequencies of biallelic markers, and among them the biallelic markers of the invention, in the diploid genome of the tested individuals belonging to each of these populations.

Allelic frequencies of every biallelic marker in each population (cases and controls) were determined by performing microsequencing reactions on amplified fragments obtained by genomic PCR performed on the DNA samples from each individual. Genomic PCR and microsequencing were performed as detailed above in examples 2(a) to 2(c) using the described PCR and microsequencing primers.

Then, for each allele of the biallelic markers included in this study, the difference between the allelic frequency in the unaffected population and in the population affected by schizophrenia was calculated and the absolute value of the difference was determined. The more the difference in allelic frequency for a particular biallelic marker or a particular set of biallelic markers, the more probable an association between the genomic region harboring this particular biallelic marker or set of biallelic markers and schizophrenia.

The absolute value of the difference of allelic frequency between the affected and the unaffected population is observed for each of the biallelic markers used for this study, every biallelic marker being assigned to its respective BAC from BAC B1 to BAC B9. Biallelic markers located respectively on BAC B5 and on BAC B9 show a slight association with schizophrenia. These results are a first indication according which the presence of a genetic determinant involved in the predisposition or the development of schizophrenia, most probably a gene or at least one gene, may be located in the genomic inserts carried by these two BACs or in the surrounding genomic sequences of these BACs on chromosome 13q31-q33 region.

EXAMPLE 2(g): Association study between schizophrenia and the biallelic markers of the invention: Comparison of Linkage Disequilibrium between cases and controls.

The values of Linkage Disequilibrium between every set of two markers located in the same BAC was determined, respectively for cases and controls. For BAC B1, wherein three biallelic markers were tested, three LD values were determined (99-16321 v. 99-14359; 99-16321 v. 99-16333; 99-14359 v. 99-16333), which LD values

were respectively 1.00, 1.00 and 1.00 (complete Linkage Disequilibrium). From these LD values, a Mean Normalized LD value was calculated, which is equal to 1.00 in the case of the biallelic markers of BAC B1. The results are presented in Table 12 appended at the end of the specification.

For each BAC B1 to B9, the Mean normalized LD has been determined, respectively for the population of cases (the whole cases and the cases with an available familial history of schizophrenia) and for the population of controls. The right column discloses the values of the difference of LD between populations. The highest relative difference in LD value was observed for BACs B5, B8 and B9 respectively, indicating a non-random distribution of the alleles of the biallelic markers under consideration in these BACs between the cases and the controls.

More precisely, it appears that the relative difference in Mean normalized LD for BAC B5 is significantly higher when the comparison was made between familial cases and controls than when the comparison was made between the whole cases and the controls.

On another hand, a high relative difference in Mean normalized LD for BAC B9 is observed both for the comparison between familial cases and controls and for the comparison between the whole cases and the controls.

EXAMPLE 2(h): Association study between schizophrenia and the biallelic markers of the invention: haplotype frequency analysis.

a) Haplotype frequency analysis on BAC B5.

One way of increasing the statistical power of individual markers is by performing haplotype association analysis.

Haplotype association analysis was performed for all possible combination of markers 99-15663/298, 99-15665/398, 99-15672/166 and 99-15664/185 in each population described in example 2(e).

For a given set of markers, peculiar attention is paid to the haplotype (Max-hap) giving the maximum difference of frequency between cases and controls. If a gene involved in the aetiology of the disease lies close to the markers then a specific haplotype is likely to harbor a morbid mutation.

The strength of association of the Max-hap between cases and controls is compared between set of markers using two approaches :

- a test comparing frequency in cases and controls is constructed and, the p-value is derived assuming it follows a chi2 distribution with 1 degree of freedom,

- another p-value is assessed using the permutation routine described above.

The stronger the difference in the frequency of this haplotype between cases and controls, the lower the p-value and the most likely a morbid mutation is harbored by the haplotype considered.

5 ***Haplotype association analysis in whole cases population and in all controls.***

The results of the statistical analysis of the whole cases versus the control population are presented in Table 13 appended at the end of this specification.

10 The analysis of all possible sets of two, three and four markers (99-15663/298, 99-15665/398, 99-15672/166 and 99-15664/185) available in the BAC B5 was performed.

The column frequency depicts the respective frequencies of the Max-hap in cases and in controls. The haplotype statistics column summarizes the p-value obtained with this haplotype as described above. The last two columns presents the LR test as described before.

15 From the data presented here all p-values are high and superior to 0.01; Moreover, the p-values obtained after random permutations were close to the p-values experimentally obtained; thus none of the set of markers considered give statistical significant differences of frequency between schizophrenic cases and healthy controls.

20 ***Haplotype association analysis in cases with no familial history of psychosis and controls.***

The results of the statistical analysis of the cases with no familial history of psychosis versus the control population are presented in Table 14 appended at the end of this specification.

25 From the data presented in Table 14, it can be observed a high p-value (>0.1) of the chi2 test in each sets of markers considered, thus none of them give statistical significant differences of frequency between schizophrenic cases and healthy controls.

Haplotype association analysis in cases with familial history of psychosis and controls.

30 The results of the analysis of familial cases versus all controls are presented in the Table 15.

From the Table 15, it can be observed that the p-values are significant for several sets of markers (haplotype 1, 7, 8 and 11). Hence a noticeably high haplotype chi2 (17.79) is observed for haplotype 1 (allele T from marker 99-15672/166 and allele T from marker 99-15664/185).

The analysis of this BAC shows an indication that a gene involved in the predisposition or the development of schizophrenia may lie near BAC B5. The difference of results between cases with and without family history of psychosis is not contradictory with this conclusions but may suggest heterogeneity in the aetiology of the disease.

b) Haplotype frequency analysis on BAC B9.

For every two, three, four and five marker sets involving markers 99-5897-143, 99-5862-167, 99-16032-292, 99-16038-118, and 99-5919-215 available in this BAC, haplotype association analysis was performed in this BAC with the strategy described above for every population described in Example 2(e).

Haplotype association analysis in all schizophrenic cases versus controls

The results of the statistical analysis of the whole cases versus the control population are presented in Table 16 appended at the end of this specification.

All the sets of markers exhibiting a low p-value are presented in Table 16. For different sets of markers, several Max-hap lead to chi2-associated p-value inferior to 10^{-5} , particularly for one two markers-haplotype (haplotype 5), three three-markers haplotype (haplotype 18, 19 and 17) and one four markers- haplotype (haplotype 25), which is highly significant. This strength of association is corroborated by the permutation-associated p-value which is inferior to 10^{-3} . From these results it can be concluded that a gene involved in the susceptibility to schizophrenia is likely to lie near this BAC.

Haplotype association analysis in familial schizophrenic cases versus controls

The results of the statistical analysis of the familial schizophrenic cases versus the control population are presented in Table 17 appended at the end of the specification.

The same pattern of association is observed in the analysis of the sub-sample of familial cases versus healthy controls. Again several Max-hap leads to chi2-associated p-value inferior to 10^{-5} . It can be observed a high Chi2 value and a significant low p-value (less than 10^{-6}) for the majority of the haplotypes tested, and particularly for one two markers-haplotype (haplotype 5), for four three markers-haplotypes (haplotypes 19, 18, 17 and 11) and for three four markers-haplotypes (haplotypes 25, 21, 23 and 22) and for one five markers-haplotype (haplotype 26). For haplotypes 5, 11, 17, 18, 19 and 25, the p-value is less than 10^{-6} , which is highly significant. Moreover, for each of these haplotypes, the corresponding p-value after permutation is much lower than the p-value calculated assuming that the test has a

chi2 distribution which clearly indicates that the low chi2 p-value observed is not a random value.

From the results detailed above, it can be concluded that the haplotypes described in Table 17, and particularly haplotypes 5, 17, 18, 19 and 25, are in association with familial schizophrenia and are thus located in a region harboring a genetic determinant involved in the predisposition or in the development of schizophrenia.

It can be noticed, notably for haplotype 5, that the haplotype giving the highest difference of frequency is less represented in the cases than in the controls. Assuming that a sensitivity gene to schizophrenia maps near BAC B9, it can be expected that the Max-hap for a given set of associated markers leads to a positive difference. In the relation with the results obtained on BAC B5, the results can be explained by the fact that, in this particular case, there are two haplotype alleles (and not a single one) among the four possible haplotype alleles, that are associated with schizophrenia, as a result of a genetic event having occurred between the two markers 99-15672/166 and 99-15664/185 of BAC B5 and the two markers 99-5862/167 and 99-16032/292 of BAC B9, for example a crossing-over event.

c) Haplotype association analysis combining markers of BAC B5 and BAC B9.

To confirm this hypothesis, two markers from BAC B5 (99-15672/166 and 99-15664/185) and two markers from BAC B9 (99-5862/167 and 99-16032/192) were combined and the haplotype association analysis on familial cases against controls was performed.

The results of every sets of two, three and four markers combinations of these markers are presented in Table 18. Haplotype giving the maximum positive (MaxP) and negative (MaxN) difference of frequency between cases and controls are presented.

Every combination of markers involving 99-15672/166 and 99-15664/185 gives a highly significant p-value in the chi2 test. Notably the combination of the four markers gives a p-value inferior to 10^{-11} which is the best value obtained. Hence, for haplotype 7, 8, 9 and 11, the Max-hap with combined markers of B9 and B5 always leads to a positive difference of frequency between cases and controls. These results solves the apparent contradiction of the results obtained on BAC B9, i.e the maximum difference of frequency observed is negative, and reinforces the conclusion of the existence of a gene involved in the predisposition or in the development of schizophrenia in this region.

d) Association analysis with haplotypes containing two or three markers contained in either Bacs B1 to B9.

Starting from the results presented above, the inventors have studied extensively the statistical significance of association of all the possible two markers- and three markers- haplotypes (combinations of the markers listed in Table 7) with schizophrenia. The data are presented below.

Association analysis with the two markers-haplotypes

The statistical analysis of the association between haplotypes including all the combinations of two markers among the 34 biallelic markers of the invention listed in Table 7 was performed. The analysis was carried out by comparing the haplotype frequencies between controls (141 individuals) and schizophrenia familial cases (78 individuals). Then, the Chi2 value of the difference in haplotype frequency between the selected controls and cases was determined, and the corresponding p value with one degree of freedom was calculated. The results are presented in Figure 11, wherein each bar of the histogram denotes the number of haplotypes (ordinate) having a p-value falling in a specified range (abscissa).

Among the 561 possible haplotypes studied, only two haplotypes (0.4 %) were strongly associated with schizophrenia, with a p-value in the range between 5×10^{-5} and 1×10^{-5} , which are the following :

- Haplotype A : markers 99-15672/166 (allele T) and 99-15664/185 (allele T) (p-value = 2.5×10^{-5}), these markers being located on BAC B5 (see Table 11); Haplotype A is the same as haplotype 1 depicted in Table 15;
- Haplotype B : markers 99-15664/185 (allele T) and 99-5862/167 (allele T) (p-value = 3.9×10^{-5}), these markers being located respectively on BAC B5 and BAC B9 (see Table 11); Haplotype B is the same as haplotype 2 depicted in Table 18;

These results confirm that genomic sequences within BAC B5 and BAC B9 may lie at the proximity of at least one gene involved in the susceptibility, the occurrence or the development of schizophrenia in human.

Association analysis with three markers-haplotypes

The statistical analysis of the association between haplotypes including all the combinations of three markers among the 34 biallelic markers of the invention listed in Table 7 was performed using the Chi2 test and calculating the resulting p value. The analysis was carried out by comparing the haplotype frequencies between controls (141 individuals) and schizophrenia familial cases (78 individuals). Then, the Chi2 value of the difference in haplotype frequency between the selected controls and cases

was determined, and the corresponding p value with one degree of freedom was calculated. The results are presented in Figure 12, wherein each bar of the histogram denotes the number of haplotypes (ordinate) having a p-value falling in a specified range (abscissa).

5 Among the 5984 haplotypes studied, only three haplotypes (0.05%) were strongly associated with schizophrenia, with a p-value in the range between 5×10^{-5} and 1×10^{-5} , which are the following :

10 - Haplotype A : markers 99-15672/166 (allele T) and 99-15664/185 (allele T) and 99-5862/167 (allele T) (p-value of 1.5×10^{-12}), these markers being located respectively on BAC B5, BAC B5 and BAC B9 (see Table 11); Haplotype A is the same than haplotype 7 depicted in Table 18;

15 - Haplotype B : markers 99-15672/166 (allele T), 99-5862/167 (allele T) and 99-16032/292 (allele C) (p-value = 1.5×10^{-10}), these markers being located respectively on BAC B5, BAC B9 and BAC B9 (see Table 11); Haplotype B is the same as haplotype 8 depicted in Table 18;

- Haplotype C : markers 99-15672/166 (allele T), 99-15664/185 (allele T) and 99-5897/143 (allele A) (p-value in the range 10^{-9} - 10^{-10}), these markers being located respectively on BAC B5, BAC B5 and BAC B9 (see Table 11)

20 These results further confirm the data analysis of the two markers-haplotypes described above, following which the genomic sequences within BAC B5 and BAC B9 may lie at the proximity of at least one gene involved in the susceptibility, the occurrence or the development of schizophrenia in human.

All documents and GenBank accession numbers cited herein are incorporated herein by reference in their entirety.

25 While the preferred embodiment of the invention has been illustrated and described, it will be appreciated that various changes can be made therein by the one skilled in the art without departing from the spirit and scope of the invention.

TABLE 12

Comparison of Linkage disequilibrium between cases and controls

BAC	Mean normalized LD ⁽¹⁾		Relative difference (%) ⁽²⁾	
	all cases (N=141)	familial cases (N=78)	controls (N=141)	
B1	1,00	1,00	1,00	allcases/all controls
B2	0,48	0,38	0,48	Familial cases/controls
B3	0,72	0,78	0,75	0,00
B4	1,00	1,00	1,00	-21,53
B5	0,60	0,68	0,57	4,68
B6	0,57	0,57	0,58	0,00
B7	0,23	0,23	0,21	19,76
B8	0,22	0,27	0,21	-1,52
B9	0,44	0,52	0,28	9,37
				25,70
				85,92

1: Mean of all normalized LD between markers belonging to the same bac.

2: 100* (LD(cases)-LD(controls)/LD(controls))

TABLE 13
ANALYSIS ON BAC B5 : ALL CASES / ALL CONTROLS

DESCRIPTION		HAPLOTYPE	STATISTICS			
			Frequency ⁽¹⁾		Statistics on a haplotype ⁽²⁾	
haplotype #	# mks	sample size (Cases/Controls)	Cases	Controls	X ²	p-value (X ²) ⁽⁴⁾ p-value (permut) ⁽⁵⁾
haplotype1	2	103/135	0,207	0,122	6,31	1,10E-02
haplotype2		130/137	0,192	0,116	5,92	1,40E-02
haplotype3		128/133	0,196	0,128	4,45	3,40E-02
haplotype4		138/133	0,301	0,229	3,54	5,80E-02
haplotype5		112/136	0,014	0,004	1,59	2,10E-01
haplotype6		110/131	0,015	0,004	1,54	2,10E-01
haplotype7	3	102/135	0,045	0,01	6,12	1,30E-02
haplotype8		100/130	0,047	0,01	5,83	1,50E-02
haplotype9		128/132	0,196	0,119	5,8	1,60E-02
haplotype10		110/131	0,015	0,004	1,54	2,10E-01
haplotype11	4	100/130	0,047	0,01	5,83	1,50E-02
						8,00E-02

1: Frequency of the haplotype leading to the maximum chi square test

2: Test on the frequency of this haplotype in cases vs in controls

4: p- value assuming a chi-square distribution with 1 degree of freedom

5: p- value obtained by permutating affected status in the sample

100 permutations for haplotypes 3, 5, 6, 7, 8, 10 and 11

500 permutations for haplotypes 1, 2, 4 and 9

TABLE 14

ANALYSIS ON BAC B5 : CASES with no family history / ALL CONTROLS

DESCRIPTION		HAPLOTYPE		STATISTICS		
				Frequency ⁽¹⁾	Statistics on a haplotype ⁽²⁾	
haplotype #	# mks sample size (Cases/Controls)			Cases	Controls	X ² p-value (X ²) ⁽⁴⁾ p-value (permut) ⁽⁵⁾
haplotype 1	45/135	99-15663/298	99-15665/398	0,11	0,12	0,11
haplotype 2	62/137	T	-	0,146	0,116	0,7
haplotype 3	60/133	-	G	0,153	0,128	0,43
haplotype 4	61/133	T	G	0,27	0,229	0,77
haplotype 5	46/136	T	-	0,21	0,22	0,09
haplotype 6	44/131	-	G	0,22	0,22	0,04
haplotype 9	45/135	C	-	0,042	0,039	0,002
haplotype 10	43/130	-	A	0,015	0,01	0,12
haplotype 7	60/132	T	G	0,153	0,119	0,82
haplotype 8	44/131	T	G	0,22	0,22	0,04
haplotype 11	43/130	C	A	0,015	0,01	0,12

1: Frequency of the haplotype leading to the maximum chi square test with familial cases

2: Test on the frequency of this haplotype in cases vs in controls

3: Likelihood ratio test

4: p-value assuming a chi-square distribution with 1 degree of freedom

5: p-value obtained by permutating affected status in the sample (*100 permutations)

#

TABLE 15
ANALYSIS ON BAC B5 : CASES WITH FAMILY HISTORY / ALL CONTROLS

DESCRIPTION		HAPLOTYPE		STATISTICS		
				Frequency ⁽¹⁾	Statistics on a haplotype ⁽²⁾	
haplotype #	# mks sample size (Cases/Controls)			Cases	Controls	χ^2 p-value (χ^2_1) ⁽⁴⁾ p-value (permut) ⁽⁵⁾
haplotype 1	58/135	99-15663/298	99-15665/398	0,3	0,122	17,79 2,50E-05 1,00E-03
haplotype 2	68/137	T	T	0,236	0,116	9,97 1,60E-03 2,00E-03
haplotype 3	68/133		T	0,236	0,128	7,64 5,50E-03 6,00E-03
haplotype 4	77/133	T	G	0,325	0,229	4,56 3,20E-02 1,60E-02
haplotype 5	66/136	T	G	0,287	0,220	2,13 1,40E-01 2,80E-01
haplotype 6	66/131	T	G	0,287	0,225	1,8 1,70E-01 4,00E-01
haplotype 7	57/135	C	T	0,081	0,010	13,65 2,10E-04 2,00E-03
haplotype 8	57/130		A	0,081	0,010	12,69 3,70E-04 1,40E-02
haplotype 9	68/132	T	G	0,236	0,119	9,18 2,40E-03 8,00E-03
haplotype 10	66/131	T	G	0,287	0,225	1,8 1,70E-01 3,90E-01
haplotype 11	4 57/130	C	A	0,081	0,010	12,69 3,70E-04 1,20E-02

1: Frequency of the haplotype leading to the maximum chi square test

2: Test on the frequency of this haplotype in cases vs in controls

4: p-value assuming a chi-square distribution with 1 degree of freedom

5: p-value obtained by permutating affected status in the sample

100 permutations for haplotypes 5, 6 and 10

500 permutations for haplotypes 2, 3, 4, 7, 8, 9 and 11

1000 permutations for haplotype 1

#

TABLE 16

ANALYSIS ON BAC B9 : ALL CASES / ALL CONTROLS

DESCRIPTION		HAPLOTYPE		STATISTICS		
				Frequency ⁽¹⁾	Statistics on a haplotype ⁽²⁾	
haplotype #	# mks	sample size (Cases/Controls)		Cases	Controls	X ² p-value (X ²) ⁽⁴⁾ p-value (permut) ⁽⁵⁾
haplotype 5	2	131/134	99-5897/143	0,068	0,222	25,32 4,70E-07 <1,00E-03
haplotype 10		135/139		0,034	0,156	23,72 1,10E-06 <1,00E-03
haplotype 9		132/138		0,042	0,163	21,08 4,40E-06 <1,00E-03
haplotype 6		133/135		0,079	0,219	20,67 5,40E-06 <1,00E-03
haplotype 18	3	131/134		0,029	0,166	27,74 1,30E-07 <1,00E-03
haplotype 19		133/135		0,034	0,162	24,79 6,40E-07 <1,00E-03
haplotype 17		130/134		0,067	0,218	24,55 7,10E-07 <1,00E-03
haplotype 11		125/133		0,066	0,216	23,62 1,10E-06 <1,00E-03
haplotype 20		131/138		0,035	0,157	22,58 2,00E-06 <1,00E-03
haplotype 15		126/137		0,036	0,156	21,53 3,40E-06 <1,00E-03
haplotype 16		129/138		0,037	0,155	21,07 4,40E-06 <1,00E-03
haplotype 12		127/134		0,078	0,217	19,93 7,70E-06 <1,00E-03
haplotype 25	4	130/134		0,03	0,162	26,28 2,90E-07 <1,00E-03
haplotype 21		124/133		0,066	0,218	23,77 1,10E-06 <1,00E-03
haplotype 22		125/133		0,033	0,158	22,74 1,80E-06 <1,00E-03
haplotype 23		127/134		0,035	0,159	22,33 2,20E-06 <1,00E-03
haplotype 24		125/137		0,038	0,156	20,19 7,00E-06 <1,00E-03
haplotype 26	5	124/133		0,035	0,16	22,46 2,10E-06 <1,00E-03

1: Frequency of the haplotype leading to the maximum chi square test

2: Test on the frequency of this haplotype in cases vs in controls

3: Test on the distribution of frequency possible with the set of markers in cases vs in controls (Likelihood ratio test)

4: p-value assuming that the test has a chi-square distribution with 1 degree of freedom

5: p-value obtained by permutating affected status in the sample (1000 permutations for all haplotypes)

T09080-90540860

TABLE 17

ANALYSIS ON BAC B9 : CASES WITH FAMILY HISTORY / ALL CONTROLS

DESCRIPTION		HAPLOTYPE		STATISTICS		
				Frequency ⁽¹⁾	Statistics on a haplotype ⁽²⁾	
haplotype #	# mks	sample size (Cases/Controls)		Cases	Controls	X^2 p-value (X^2) ⁽⁴⁾ p-value (permut) ⁽⁵⁾
haplotype 5	2	74/133	99-5897/143	0,031	0,224	26,96 <1,00E-03
haplotype 10		77/138		0,012	0,157	22,03 <1,00E-03
haplotype 9		75/137		0,026	0,164	17,94 <1,00E-02
haplotype 1		70/136	A	0,148	0,29	10,15 <1,00E-02
haplotype 7		76/137	C	0,257	0,385	7,12 <1,00E-02
haplotype 19	3	76/134	C	0	0,163	27,72 <1,00E-03
haplotype 18		74/133	C	0	0,167	27,71 <1,00E-03
haplotype 17		74/133	C	0,031	0,22	26,35 <1,00E-02
haplotype 11		68/132	A	0,024	0,218	26,3 <1,00E-02
haplotype 12		70/133	A	0,035	0,219	23,68 <1,00E-03
haplotype 20		75/137	A	0,013	0,158	21,27 <1,00E-02
haplotype 16		71/137	A	0,015	0,156	19,37 <1,00E-02
haplotype 15		69/136	A	0,015	0,157	18,95 <1,00E-02
haplotype 25	4	74/133	C	0	0,164	27,07 <1,00E-03
haplotype 21		68/132	C	0,024	0,219	26,58 <1,00E-02
haplotype 23		70/133	C	0	0,16	25 <1,00E-02
haplotype 22		68/132	C	0	0,159	24,2 <1,00E-02
haplotype 24		69/136	C	0,015	0,157	18,78 <1,00E-03
haplotype 26	5	68/132	A	0	0,161	24,53 <1,00E-03

1: Frequency of the haplotype leading to the maximum chi square test.

2: Test on the frequency of this haplotype in cases vs in controls

4: p- value assuming a chi-square distribution with 1 degree of freedom

5: p-value obtained by permutating affected status in the sample (*100 permutations; **1000 permutations)

100 permutations for haplotypes 9, 1, 7, 17, 11, 20, 16, 15, 21, 22 and 23

1000 permutations for haplotypes 5, 10, 17, 18, 12, 25, 24 and 26

TABLE 18
HAPLOTYPE ANALYSIS ON BAC B5 (2 markers) and B9 (2 markers)

CASES WITH FAMILY HISTORY / ALL CONTROLS (maxM*)

DESCRIPTION		HAPLOTYPE		STATISTICS		
haplotype # mks	sample size (Cases/Controls)			Frequency ⁽¹⁾	Statistics on a haplotype ⁽³⁾	
				Cases	Controls	pvalue (X ²) ⁽⁴⁾ pvalue (permut) ⁽⁵⁾
haplotype 1	58/135	T	16672/166	0.3	0.122	17.79 2.50E-05 1.00E-04
haplotype 2	66/134	T	16664/185	0.286	0.12	16.86 3.90E-05 1.70E-03
haplotype 3	67/136	T	99- 6862/167	0.272	0.141	10.27 1.30E-03 4.30E-03
haplotype 4	67/134	T	99- 6862/167	0.342	0.206	8.79 3.00E-03 9.80E-03
haplotype 5	74/133	T	99- 6862/167	0.347	0.216	8.47 3.60E-03 1.10E-02
haplotype 6	65/134	T	99- 6862/167	0.218	0.135	4.5 3.40E-02 1.00E-01
haplotype 7	57/131	T	99- 6862/167	0.296	0.042	49.02 1.50E-12 2.60E-04
haplotype 8	65/132	T	99- 6862/167	0.289	0.036	40.72 1.50E-10 4.00E-05
haplotype 9	56/133	T	99- 6862/167	0.17	0.023	27.34 1.70E-07 1.90E-02
haplotype 10	64/130	T	99- 6862/167	0.192	0.083	9.79 1.70E-03 5.40E-02
haplotype 11	55/129	T	99- 6862/167	0.199	0.013	41.63 9.10E-11 2.00E-04
10000 permutations for haplotypes 1-6, 9 and 10; 50000 permutations for haplotypes 7, 8 and 11*						

*maxM: Table of haplotypes giving the Maximum positive difference between cases/controls.

CASES WITH FAMILY HISTORY / ALL CONTROLS (maxS**)

DESCRIPTION		HAPLOTYPE		STATISTICS		
haplotype # mks	sample size (Cases/Controls)			Frequency ⁽¹⁾	Statistics on a haplotype ⁽³⁾	
				Cases	Controls	pvalue (X ²) ⁽⁴⁾ pvalue (permut) ⁽⁵⁾
haplotype 1	74/133	C	16672/166	0.031	0.224	26.96 2.00E-07 1.00E-04
haplotype 2	67/136	C	16664/185	0.094	0.311	23.33 1.30E-06 1.00E-04
haplotype 3	66/134	C	99- 6862/167	0.078	0.152	4.4 3.60E-02 1.20E-01
haplotype 4	65/134	G	99- 6862/167	0.218	0.317	4.24 3.80E-02 5.80E-02
haplotype 5	67/134	C	99- 6862/167	0.185	0.277	4.03 4.30E-02 4.80E-02
haplotype 6	58/135	C	99- 6862/167	0.079	0.145	3.17 7.40E-02 9.00E-02
haplotype 7	65/132	C	99- 6862/167	0.01	0.146	17.88 2.60E-05 3.00E-04
haplotype 8	64/130	G	99- 6862/167	0.035	0.177	15.32 8.70E-05 2.50E-03
haplotype 9	56/133	C	99- 6862/167	0	0.098	11.83 5.60E-04 5.20E-03
haplotype 10	57/131	T	99- 6862/167	0	0.079	9.48 2.10E-03 1.20E-01
haplotype 11	55/129	C	99- 6862/167	0.013	0.152	15.15 9.70E-05 1.60E-02
10000 permutations for haplotypes 1-6, 8 and 9; 50000 permutations for haplotypes 7, 10 and 11.						

**maxS: Table of haplotypes giving the Maximum negative difference between cases/controls.

1: Frequency of the haplotype leading to the maximum chi square test

2: Test on the frequency of this haplotype in cases vs in controls

4: p-value assuming a chi-square distribution with 1 degree of freedom

5: p-value obtained by permutating affected us in the sample (*10 000 permutations)

REFERENCES:

- Abbondanzo SJ et al., 1993, *Methods in Enzymology*, Academic Press, New York, pp 803-823 / Ajioka R.S. et al., *Am. J. Hum. Genet.*, 60:1439-1447, 1997 / Altschul et al., 1990, *J. Mol. Biol.* 215(3):403-410 / Altschul et al., 1993, *Nature Genetics* 3:266-272 / Altschul et al., 1997, *Nuc. Acids Res.* 25:3389-3402 / Anton M. et al., 1995, *J. Virol.*, **69** : 4600-4606 / Araki K et al. (1995) *Proc. Natl. Acad. Sci. U S A.* 92(1):160-4. / Aszódi et al., *Proteins:Structure, Function, and Genetics*, Supplement 1:38-42 (1997) / Ausubel et al. (1989) *Current Protocols in Molecular Biology*, Green Publishing Associates and Wiley Interscience, N.Y. / Barany F., 1991, *Proc. Natl. Acad. Sci. USA*, **88** : 189-193 / Basset AS et al., 1994, *Am. J. Hum. Genet.*, **54** : 864-870 / Bates GP et al., 1997a, *Hum. Mol. Genet.*, **6**(10) : 1633-1637 / Bates GP et al., 1997b, *Molecular Medicine today*, November 1997, 508 : 515 / Baubonis W. (1993) *Nucleic Acids Res.* 21(9):2025-9. / Beaucage et al., *Tetrahedron Lett* 1981, **22**: 1859-1862 / Blouin JL et al., 1998, *Nature Genetics*, **20** : 70-73 / / Bradley A., 1987, *Production and analysis of chimaeric mice.* In: E.J. Robertson (Ed.), *Teratocarcinomas and embryonic stem cells: A practical approach.* IRL Press, Oxford, pp.113. / Bram RJ et al., 1993, *Mol. Cell Biol.*, **13** : 4760-4769 / Brinkman RR et al., *Am. J. Hum. Genet.*, **60** : 1202-1210 / / Brown EL, Belagaje R, Ryan MJ, Khorana HG, *Methods Enzymol* 1979;**68**:109-151 / / Bruisten s. et al., 1993, *AIDS Res. Hum. Retroviruses*, **9** : 259-265 / Brutlag et al. *Comp. App. Biosci.* 6:237-245, 1990 / Burg JL et al., 1996, *Mol. and Cell. Probes*, **10** : 257-271 / Burright et al., 1997, *Brain Pathology*, **7** : 965-977 / Bush et al., 1997, *J. Chromatogr.*, **777** : 311-328 / Castagnoli L. et al. (Felici F.), 1991, *J. Mol. Biol.*, **222**:301-310 / Chai H. et al. (1993) *Biotechnol. Appl. Biochem.* 18:259-273. / Chee et al. (1996) *Science.* 274:610-614. / Chen and Kwok *Nucleic Acids Research* 25:347-353 1997 / Chen et al. (1987) *Mol. Cell. Biol.* 7:2745-2752. / Chen et al. *Proc. Natl. Acad. Sci. USA* 94/20 10756-10761, 1997 / Cho RJ et al., 1998, *Proc. Natl. Acad. Sci. USA*, **95**(7) : 3752-3757 / Chou J.Y., 1989, *Mol. Endocrinol.*, **3**: 1511-1514. / Clark A.G. (1990) *Mol. Biol. Evol.* 7:111-122. / Coles R, Caswell R, Rubinsztein DC, *Hum Mol Genet* 1998;**7**:791-800 / Compton J. (1991) *Nature.* 350(6313):91-92. / Davies SW et al., *Cell*, **90** : 537-548 / Davis L.G., M.D. Dibner, and J.F. Battey, *Basic Methods in Molecular Biology*, ed., Elsevier Press, NY, 1986 / Dempster et al., (1977) *J. R. Stat. Soc.*, 39B:1-38. / Dent DS & Latchman DS (1993) *The DNA mobility shift assay.* In: *Transcription Factors: A Practical Approach* (Latchman DS, ed.) pp1-26. Oxford: IRL

Press / Duck P. et al., 1990, *Biotechniques*, **9** : 142-147 / Eckner R. et al. (1991) *EMBO J.* 10:3513-3522. / Edwards et Leatherbarrow, *Analytical Biochemistry*, **246**, 1-6 (1997) / Engvall, E., *Meth. Enzymol.* 70:419 (1980) / Excoffier L. and Slatkin M. (1995) *Mol. Biol. Evol.*, 12(5): 921-927. / Feldman and Steg, 1996,

5 Medecine/Sciences, synthese, 12:47-55 / Felici F., 1991, *J. Mol. Biol.*, Vol. 222:301-310 / Fields and Song, 1989, *Nature*, **340** : 245-246 / Fisher, D., Chap. 42 in: *Manual of Clinical Immunology*, 2d Ed. (Rose and Friedman, Eds.) Amer. Soc. For Microbiol., Washington, D.C. (1980) / Flotte et al. (1992) *Am. J. Respir. Cell Mol. Biol.* 7:349-356. / Fodor et al. (1991) *Science* 251:767-777. / Fraley et al. (1979) *Proc. Natl.*

10 *Acad. Sci. USA.* 76:3348-3352. / Fried M, Crothers DM, *Nucleic Acids Res* 1981;**9**:6505-6525 / Fromont-Racine M. et al., 1997, *Nature Genetics*, **16**(3) : 277-282 / Fuller S. A. et al. (1996) *Immunology in Current Protocols in Molecular Biology*, Ausubel et al. Eds, John Wiley & Sons, Inc., USA. / Furth P.A. et al. (1994) *Proc. Natl. Acad. Sci USA.* 91:9302-9306. / Garner MM, Revzin A, *Nucleic Acids Res* 1981;**9**:3047-3060 / Geysen H. Mario et al. 1984. *Proc. Natl. Acad. Sci. U.S.A.* 81:3998-4002 / Ghosh and Bacchawat, 1991, Targeting of liposomes to hepatocytes, IN: *Liver Diseases, Targeted diagnosis and therapy using specific receptors and ligands*. Wu et al. Eds., Marcel Dekker, New York, pp. 87-104. / Gonnet et al., 1992, *Science* 256:1443-1445 / Gopal (1985) *Mol. Cell. Biol.*, 5:1188-1190. / Gossen M. et al. (1992) *Proc. Natl. Acad. Sci. USA.* 89:5547-5551. / Gossen M. et al. (1995) *Science.* 268:1766-1769. / Graham et al. (1973) *Virology* 52:456-457. / Green et al., *Ann. Rev. Biochem.* **55**:569-597 (1986) / Griffin et al. *Science* **245**:967-971 (1989) / Grompe, M. (1993) *Nature Genetics.* 5:111-117. / Grompe, M. et al. (1989) *Proc. Natl. Acad. Sci. U.S.A.* 86:5855-5892. / Gu H. et al. (1993) *Cell* 73:1155-1164. /

20 Gu H. et al. (1994) *Science* 265:103-106. / Guatelli J C et al. *Proc. Natl. Acad. Sci. USA.* 35:273-286. / Hacia JG, Brody LC, Chee MS, Fodor SP, Collins FS, *Nat Genet* 1996;**14**(4):441-447 / Haff L. A. and Smirnov I. P. (1997) *Genome Research*, 7:378-388. / Hames B.D. and Higgins S.J. (1985) *Nucleic Acid Hybridization: A Practical Approach*. Hames and Higgins Ed., IRL Press, Oxford. / Harju L, Weber T, Alexandrova L, Lukin M, Ranki M, Jalanko A, *Clin Chem* 1993;**39**(11Pt 1):2282-2287 / Harland et al. (1985) *J. Cell. Biol.* 101:1094-1095. / Harlow, E., and D. Lane. 1988. *Antibodies A Laboratory Manual*. Cold Spring Harbor Laboratory. pp. 53-242 / Harper JW et al., 1993, *Cell*, **75** : 805-816 / Hawley M.E. et al. (1994) *Am. J. Phys. Anthropol.* 18:104. / Henikoff and Henikoff, 1993, *Proteins* 17:49-61 / Higgins et al.,

35 1996, *Methods Enzymol.* 266:383-402 / Hillier L. and Green P. *Methods Appl.*,

- 1991, 1: 124-8. / Hoess et al. (1986) *Nucleic Acids Res.* 14:2287-2300. /
 Houbenweyl, 1974, in *Meuthode der Organischen Chemie*, E. Wunsch Ed., Volume 15-
 I et 15-II, Thieme, Stuttgart / Huang L. et al. (1996) *Cancer Res* 56(5):1137-1141. /
 Huygen et al. (1996) *Nature Medicine*. 2(8):893-898. / Izant JG, Weintraub H, *Cell*
 1984 Apr;36(4):1007-15 / Julian et al. (1992) *J. Gen. Virol.* 73:3251-3255. /
 Kanegae Y. et al., *Nucl. Acids Res.* 23:3816-3821 (1995). / Karlin and Altschul,
 1990, *Proc. Natl. Acad. Sci. USA* 87:2267-2268 / Khoury J. et al., *Fundamentals of*
Genetic Epidemiology, Oxford University Press, NY, 1993 / Kievitis T. et al., 1991, *J.*
Virol. Methods, 35 : 91-92 / Kim U-J. et al. (1996) *Genomics* 34:213-218. / Klein et
 al. (1987) *Nature*. 327:70-73. / Koch Y., 1977, *Biochem. Biophys. Res. Commun.*,
 74:488-491 / Kohler, G. and Milstein, C., *Nature* 256:495 (1975) / Koller et al. (1992)
Annu. Rev. Immunol. 10:705-730. / Kozal MJ, Shah N, Shen N, Yang R, Fucini R,
 Merigan TC, Richman DD, Morris D, Hubbell E, Chee M, / Kwoh D Y et al., 1989,
Proc. Natl. Acad. Sci. USA, 86 : 1173-1177 / Gingeras TR, *Nat Med* 1996;2(7):753-
 759 / Lander and Schork, *Science*, 265, 2037-2048, 1994 / Landegren U. et al.
 (1998) *Genome Research*, 8:769-776. / Lange K. (1997) *Mathematical and Statistical*
Methods for Genetic Analysis. Springer, New York. / Leger OJ, et al., 1997, *Hum*
Antibodies, 8(1): 3-16 / Lenhard T. et al. (1996) *Gene*. 169:187-190. / Li SH et al.,
 1993, *Genomics*, 16 : 572-579 / Lin MW et al., 1997, *Hum. Genet.*, 99(3) : 417-420 /
 Lin Z, Floros J, 1998, *Biotechniques*, 24(6):937-940 / Linton M.F. et al. (1993) *J.*
Clin. Invest. 92:3029-3037. / Liu Z. et al. (1994) *Proc. Natl. Acad. Sci. USA*. 91:
 4528-4262. / Livak et al., *Nature Genetics*, 9:341-342, 1995 / Livak KJ, Hainer JW,
Hum Mutat 1994;3(4):379-385 / Lizardi PM et al., 1988, *Bio/Technology*, 6 : 1197-
 1202 / Lockhart et al. *Nature Biotechnology* 14: 1675-1680, 1996 / Lucas A.H., 1994,
 In : *Development and Clinical Uses of Haemophilus b Conjugate*; / Mackey K,
 Steinkamp A, Chomczynski P, 1998, *Mol Biotechnol*, 9(1):1-5 / Mangiarini L. et al.,
 1996, *Cell*, 87 : 493-506 / Mangiarini L. et al., 1997, *Nature Genetics*, 15 : 197-200 /
 Martineau P, Jones P, Winter G, 1998, *J Mol Biol*, 280(1):117-127 / Mansour S.L. et
 al. (1988) *Nature*. 336:348-352. / Marshall R. L. et al. (1994) *PCR Methods and*
Applications. 4:80-84. / McCormick et al. (1994) *Genet. Anal. Tech. Appl.* 11:158-
 164. / McInnis et al., 1993, *Am. J. Hum. Genet.*, 53 : 385-390 / McLaughlin B.A. et
 al. (1996) *Am. J. Hum. Genet.* 59:561-569. / Merrifield RB, 1965, *Nature*,
 207(996): 522-523 / Merrifield RB., 1965, *Science*, 150(693): 178-185 / Miele EA et
 al., 1983, *J. Mol. Biol.*, 171 : 281-295 / / Morton N.E., *Am.J. Hum.Genet.*, 7:277-318,
 1955 / Muzyczka et al. (1992) *Curr. Topics in Micro. and Immunol.* 158:97-129. /

Nada S. et al. (1993) *Cell* 73:1125-1135. / Nagy A. et al., 1993, *Proc. Natl. Acad. Sci. USA*, **90**: 8424-8428. / Narang SA, Hsiung HM, Brousseau R, *Methods Enzymol* 1979;**68**:90-98 / Neda et al. (1991) *J. Biol. Chem.* 266:14143-14146. / Newton et al. (1989) *Nucleic Acids Res.* 17:2503-2516. / Nickerson D.A. et al. (1990) *Proc. Natl. Acad. Sci. U.S.A.* 87:8923-8927. / Nicolau C. et al., 1987, *Methods Enzymol.*, **149**:157-76. / Nicolau et al. (1982) *Biochim. Biophys. Acta.* 721:185-190. / Nyren P, Pettersson B, Uhlen M, *Anal Biochem* 1993;**208**(1):171-175 / O'Reilly et al. (1992) *Baculovirus Expression Vectors: A Laboratory Manual.* W. H. Freeman and Co., New York. / Ohno et al. (1994) *Science.* 265:781-784. / Oldenburg K.R. et al., 1992, *Proc. Natl. Acad. Sci.*, **89**:5393-5397 / Orita et al. (1989) *Proc. Natl. Acad. Sci. U.S.A.* 86: 2776-2770. / Ott J., *Analysis of Human Genetic Linkage*, John Hopkins University Press, Baltimore, 1991 / Ouchterlony, O. et al., Chap. 19 in: *Handbook of Experimental Immunology* D. Wier (ed) Blackwell (1973) / Oryn C. et al., 1996, *Mol. Cell. Probes*, **10** : 319-324 / Parmley and Smith, *Gene*, 1988, **73**:305-318 / Pastinen et al., *Genome Research* 1997; **7**:606-614 / Pearson and Lipman, 1988, *Proc. Natl. Acad. Sci. USA* 85(8):2444-2448 / Pease S. and William R.S., 1990, *Exp. Cell. Res.*, **190**: 209-211. / Perlin et al. (1994) *Am. J. Hum. Genet.* 55:777-787. / Peterson et al., 1993, *Proc. Natl. Acad. Sci. USA*, **90** : 7593-7597 / Pietu et al. *Genome Research* 6:492-503, 1996 / Potter et al. (1984) *Proc. Natl. Acad. Sci. U.S.A.* 81(22):7161-7165 / Porath J et al., 1975, *Nature*, **258**(5536) : 598-599. / Ramunsen et al., 1997, *Electrophoresis*, **18** : 588-598 / Reid L.H. et al. (1990) *Proc. Natl. Acad. Sci. U.S.A.* 87:4299-4303. / Reimann KA, et al., 1997, *AIDS Res Hum Retroviruses.* **13**(11): 933-943 / Ridder R, Schmitz R, Legay F, Gram H, 1995, *Biotechnology (N Y)*, **13**(3):255-260 / Risch, N. and Merikangas, K. (*Science*, **273**:1516-1517, 1996 / Robertson E., 1987, *Embryo-derived stem cell lines.* In: E.J. Robertson Ed. *Teratocarcinomas and embryonic stem cells: a practical approach.* IRL Press, Oxford, pp. 71. / Ross CA et al., 1993, *TINS*, **16**, 254-260 / Rossi et al., *Pharmacol. Ther.* **50**:245-254, (1991) / Roth J.A. et al. (1996) *Nature Medicine.* **2**(9):985-991. / Rougeot, C. et al., *Eur. J. Biochem.* **219** (3): 765-773, 1994 / Roux et al. (1989) *Proc. Natl. Acad. Sci. U.S.A.* 86:9079-9083. / Ruano et al. (1990) *Proc. Natl. Acad. Sci. U.S.A.* 87:6296-6300. / Saiki R K et al., 1985, *Science*, **230** : 1350-1354 / Sambrook, J., Fritsch, E.F., and T. Maniatis. (1989) *Molecular Cloning: A Laboratory Manual.* 2ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York / Samson M, et al. (1996) *Nature*, 382(6593):722-725. / Samulski et al. (1989) *J. Virol.* 63:3822-3828. / Sanchez-Pescador R. (1988) *J. Clin. Microbiol.*

26(10):1934-1938. / Sandou et al., 1994, Science, **265** : 1875-1878 / Sarkar, G. and Sommer S.S. (1991) Biotechniques. / Sauer B. et al. (1988) Proc. Natl. Acad. Sci. U.S.A. 85:5166-5170. / Schaid D.J. et al., Genet. Epidemiol.,13:423-450, 1996 / Schedl A. et al., 1993a, Nature, **362**: 258-261. / Schedl et al., 1993b, Nucleic Acids Res., **21**: 4783-4787. / Schena et al. Science **270**:467-470, 1995 / Schena et al., 1996, Proc Natl Acad Sci U S A, **93**(20):10614-10619 / Schneider et al.(1997) Arlequin: A Software For Population Genetics Data Analysis. University of Geneva. / Schwartz and Dayhoff, eds., 1978, Matrices for Detecting Distance Relationships: Atlas of Protein Sequence and Structure, Washington: National Biomedical Research Foundation / Sczakiel G. et al. (1995) Trends Microbiol. 3(6):213-217. / Segev D. et al., 1992, Amplification of nucleic acid sequences by the "Repair Chain Reaction". In : Non-radioactive labeling and detection of biomolecules. Kessler C. Springer-Verlag, Berlin, New York, pp. 142-147 / Shay J.W. et al., 1991, Biochem. Biophys. Acta, **1072**: 1-7. / Sheffield, V.C. et al. (1991) Proc. Natl. Acad. Sci. U.S.A. 49:699-706. / Shizuya et al. (1992) Proc. Natl. Acad. Sci. U.S.A. 89:8794-8797. / Shoemaker DD, et al., Nat Genet 1996;**14**(4):450-456 / Smith (1957) Ann. Hum. Genet. 21:254-276. / Smith et al. (1983) Mol. Cell. Biol. 3:2156-2165. / Sosnowski RG, et al., Proc Natl Acad Sci U S A 1997;**94**:1119-1123 / Sowdhamini et al., Protein Engineering 10:207, 215 (1997) / Spargo C A et al., 1996, Mol. Cell. Probes, **10** : 247-256 / Spielmann S. and Ewens W.J., Am. J. Hum. Genet., 62:450-458, 1998 / Spielmann S. et al., Am. J. Hum. Genet., 52:506-516, 1993 / Sternberg N.L. (1992) Trends Genet. 8:1-16. / Sternberg N.L. (1994) Mamm. Genome. 5:397-404. / Stone BB et al., 1996, Mol. Cell. Probes, **10** : 359-370 / Stryer, L., Biochemistry, 4th edition, 1995 / Syvanen AC, Clin Chim Acta 1994;**226**(2):225-236 / Szabo A. et al. Curr Opin Struct Biol **5**, 699-705 (1995) / Tacson et al. (1996) Nature Medicine. 2(8):888-892. / Te Riele et al. (1990) Nature. 348:649-651. / Terwilliger J.D. and Ott J., Handbook of Human Genetic Linkage, John Hopkins University Press, London, 1994 / Thomas K.R. et al. (1986) Cell. 44:419-428. / Thomas K.R. et al. (1987) Cell. 51:503-512. / Thompson et al., 1994, Nucleic Acids Res. 22(2):4673-4680 / Tur-Kaspa et al. (1986) Mol. Cell. Biol. 6:716-718. / Tyagi et al. (1998) Nature Biotechnology. 16:49-53. / Urdea M.S. (1988) Nucleic Acids Research. 11:4937-4957. / Urdea M.S. et al.(1991) Nucleic Acids Symp. Ser. 24:197-200. / Vaitukaitis, J. et al. J. Clin. Endocrinol. Metab. 33:988-991 (1971) / Valadon P., et al., 1996, J. Mol. Biol., **261**:11-22 / Van der Lugt et al. (1991) Gene. 105:263-267. / Vlasak R. et al. (1983) Eur. J. Biochem. 135:123-126. / Wabiko et al. (1986) DNA.5(4):305-314.

/ Walker et al. (1996) Clin. Chem. 42:9-13. / Wang et al., 1997, Chromatographia,
44 : 205-208 / Weir, B.S. (1996) Genetic data Analysis II: Methods for Discrete
population genetic Data, Sinauer Assoc., Inc., Sunderland, MA, U.S.A. / Westerink
M.A.J., 1995, Proc. Natl. Acad. Sci., 92:4021-4025 / White, M.B. et al. (1992)
5 Genomics. 12:301-306. / White, M.B. et al. (1997) Genomics. 12:301-306. / Wong
et al. (1980) Gene. 10:87-94. / Wood S.A. et al., 1993, Proc. Natl. Acad. Sci. USA,
90: 4582-4585. / Wu and Wu (1987) J. Biol. Chem. 262:4429-4432. / Wu and Wu
(1988) Biochemistry. 27:887-892. / Wu et al. (1989) Proc. Natl. Acad. Sci. U.S.A.
86:2757. / Yagi T. et al. (1990) Proc. Natl. Acad. Sci. U.S.A. 87:9918-9922. /
10 Zhao et al., Am. J. Hum. Genet., 63:225-240, 1998 / Zou Y. R. et al. (1994) Curr.
Biol. 4:1099-1103.

T09080 90540860

Sequence listing free text

The following free text appears in the accompanying Sequence Listing:

homo sapiens

mus musculus

5 amplification

oligonucleotide

sequencing

potential

microsequencing

10 oligo

primer

upstream

downstream

fragment

15 polymorphic

variant

version

complement

in

20 for

SEQ

sequence

base

homology

25 EST

ref

EMBL

with

Genbank

30 regulation

region

What is claimed:

1. An isolated, purified, or recombinant polynucleotide comprising a contiguous span of at least 12 nucleotides of SEQ ID Nos 1 to 4, 6 and 31, or the complements thereof, wherein said contiguous span comprises:

- at least one of the following nucleotide positions of SEQ ID No 1: 1 to 3585 and 4644 to 5222; and/or
- at least one of the following nucleotide positions of SEQ ID No 2: 1 to 16155 and 16331 to 21278; and/or
- at least one of the following nucleotide positions of SEQ ID No 3: 1 to 5531 and 6355 to 21636; and/or
- at least one of the following nucleotide positions of SEQ ID No 4: 1 to 519 and 2563 to 5566; and/or
- at least one of the following nucleotide positions of SEQ ID No 6: 1 to 1791.

2. An isolated, purified, or recombinant polynucleotide comprising a contiguous span of at least 12 nucleotides of SEQ ID No 31, or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions of SEQ ID No 31: 1 to 480 and 717 to 983.

3. An isolated, purified, or recombinant polynucleotide consisting essentially of a contiguous span of 8 to 50 nucleotides of anyone of SEQ ID Nos 1 to 3 and 32 to 69 or the complement thereof, wherein said span includes a *G713* or *13q31-q33*-related biallelic marker in said sequence.

4. A polynucleotide according to claim 3, wherein said *G713* or *13q31-q33*-related biallelic marker is selected from the group consisting of A1 to A49, and the complements thereof.

5. A polynucleotide according to claim 3, wherein said *13q31-q33*-related biallelic marker is selected from the group consisting of A16 to A20 and the complements thereof.

6. A polynucleotide according to claim 3, wherein said contiguous span is 18 to 35 nucleotides in length and said biallelic marker is within 4 nucleotides of the center of said polynucleotide.

7. A polynucleotide according to claim 6, wherein said polynucleotide consists of said contiguous span and said contiguous span is 25 nucleotides in length and said biallelic marker is at the center of said polynucleotide.

8. A polynucleotide according to claim 6, wherein said polynucleotide consists essentially of a sequence selected from the following sequences: P1 to P49, and the complementary sequences thereto.

9. A polynucleotide according to any one of claims 1, 2 or 3, wherein the 3' end of said contiguous span is present at the 3' end of said polynucleotide.

10. A polynucleotide according to claim 3, wherein the 3' end of said contiguous span is located at the 3' end of said polynucleotide and said biallelic marker is present at the 3' end of said polynucleotide.

11. An isolated, purified, or recombinant polynucleotide consisting essentially of a contiguous span of 8 to 50 nucleotides of anyone of SEQ ID Nos 1 to 3 and 32 to 69 or the complement thereof, wherein the 3' end of said contiguous span is located at the 3' end of said polynucleotide, and wherein the 3' end of said polynucleotide is located within 20 nucleotides upstream of a *G713* or *13q31-q33*-related biallelic marker in said sequence.

12. A polynucleotide according to claim 11, wherein the 3' end of said polynucleotide is located 1 nucleotide upstream of said *G713* or *13q31-q33*-related biallelic marker in said sequence.

13. A polynucleotide according to claim 12, wherein said polynucleotide consists essentially of a sequence selected from the following sequences: D1 to D49, and E1 to E49.

14. An isolated, purified, or recombinant polynucleotide consisting essentially of a sequence selected from the following sequences: B1 to B49 and C1 to C49.

15. An isolated, purified, or recombinant polynucleotide which encodes a polypeptide comprising a contiguous span of at least 6 amino acids of SEQ ID Nos 5 or 7.

16. A polynucleotide for use in a genotyping assay for determining the identity of the nucleotide at a *G713- or 13q31-q33*-related biallelic marker, or the complement thereof.

17. A polynucleotide according to claim 16, wherein the polynucleotide is used in an assay selected from the group consisting of a hybridization assay, a sequencing assay, a microsequencing assay and a mismatch detection assay.

18. A polynucleotide according to claim 16, wherein the polynucleotide is used in amplifying a segment of nucleotides comprising said biallelic marker.

19. A polynucleotide according to any one of claims 1, 2, 3, 11 and 14 to 16 attached to a solid support.

20. An array of polynucleotides comprising at least one polynucleotide according to claim 19.

21. An array according to claim 20, wherein said array is addressable.

22. A polynucleotide according to any one of claims 1, 2, 3, 11 and 14 to 16 further comprising a label.

23. A recombinant vector comprising a polynucleotide according to any one of claims 1, 2, or 15.

24. A host cell comprising a recombinant vector according to claim 23.

25. A non-human host animal or mammal comprising a recombinant vector according to claim 23.

26. A mammalian host cell comprising a *G713* gene disrupted by homologous recombination with a knock out vector, comprising a polynucleotide according to any one of claims 1, 2, or 15.

5 27. A non-human host mammal comprising a *G713* gene disrupted by homologous recombination with a knock out vector, comprising a polynucleotide according to any one of claims 1, 2, or 15.

10 28. A method of genotyping comprising determining the identity of a nucleotide at a *G713- or 13q31-q33*-related biallelic marker or the complement thereof in a biological sample.

15 29. A method according to claim 28, wherein said biological sample is derived from a single subject.

30. A method according to claim 29, wherein the identity of the nucleotides at said biallelic marker is determined for both copies of said biallelic marker present in said individual's genome.

20 31. A method according to claim 28, wherein said biological sample is derived from multiple subjects.

25 32. A method according to claim 28, further comprising amplifying a portion of said sequence comprising the biallelic marker prior to said determining step.

33. A method according to claim 32, wherein said amplifying is performed by PCR.

30 34. A method according to claim 28, wherein said determining is performed by an assay selected from the group consisting of a hybridization assay, a sequencing assay, a microsequencing assay and an enzyme-based mismatch assay.

35 35. A method of estimating the frequency of an allele of a *G713- or 13q31-q33*-related biallelic marker in a population comprising:

a) genotyping individuals from said population for said biallelic marker according to the method of claim 28; and

b) determining the proportional representation of said biallelic marker in said population.

36. A method of detecting an association between a genotype and a trait, comprising the steps of:

- a) determining the frequency of at least one *G713- or 13q31-q33*-related biallelic marker in trait positive population according to the method of claim 35;
- b) determining the frequency of at least one *G713- or 13q31-q33*-related biallelic marker in a control population according to the method of claim 35; and
- c) determining whether a statistically significant association exists between said genotype and said trait.

37. A method of estimating the frequency of a haplotype for a set of biallelic markers in a population, comprising:

- a) genotyping at least one *G713- or 13q31-q33*-related biallelic marker according to claim 29 for each individual in said population;
- b) genotyping a second biallelic marker by determining the identity of the nucleotides at said second biallelic marker for both copies of said second biallelic marker present in the genome of each individual in said population; and
- c) applying a haplotype determination method to the identities of the nucleotides determined in steps a) and b) to obtain an estimate of said frequency.

38. A method according to claim 37, wherein said haplotype determination method is selected from the group consisting of asymmetric PCR amplification, double PCR amplification of specific alleles, the Clark algorithm, or an expectation-maximization algorithm.

39. A method of detecting an association between a haplotype and a trait, comprising the steps of:

- a) estimating the frequency of at least one haplotype in a trait positive population according to the method of claim 37;
- b) estimating the frequency of said haplotype in a control population according to the method of claim 37; and
- c) determining whether a statistically significant association exists between said haplotype and said trait.

40. A method according to claim 36, wherein said genotyping steps a) and b) are performed on a single pooled biological sample derived from each of said populations.

41. A method according to claim 36, wherein said genotyping steps a) and b) performed separately on biological samples derived from each individual in said populations.

42. A method according to either claim 36 or 39, wherein said trait is schizophrenia.

43. A method according to either claim 36 or 39, wherein said control population is a trait negative population.

44. A method according to either claim 36 or 39, wherein said case control population is a random population.

45. An isolated, purified, or recombinant polypeptide comprising a contiguous span of at least 6 amino acids of SEQ ID Nos 5 or 7.

46. An isolated or purified antibody composition are capable of selectively binding to an epitope-containing fragment of a polypeptide according to claim 45, wherein said epitope comprises:

- at least one of the amino acid positions 62 to 102 or 203 to 458 of SEQ ID No 5, and/or;
- amino acid positions 1 to 467 of SEQ ID No 7.

47. A method of determining whether an individual is at risk of developing schizophrenia, comprising:

- a) genotyping at least one 13q31-q33-related biallelic marker according to the method of claim 30; and
- b) correlating the result of step a) with a risk of developing schizophrenia.

48. A method according to any one of claims 28, 35, 36, 37, 39 and 47 wherein said 13q31-q33-related biallelic marker is selected from the group consisting of A12 to A49 and the complements thereof.

49. A method according to claim 47, wherein said 13q31-q33-related biallelic marker is selected from the following list of biallelic markers: A16 to A20, and the complements thereof.

50. A diagnostic kit comprising a polynucleotide according to any one of claims 3, 8, 12, 13 and 14.

51. A computer readable medium having stored thereon a sequence selected from the group consisting of a nucleic acid code comprising one of the following:

- a) a contiguous span of at least 12 nucleotides of SEQ ID Nos 1, 2 or 3, or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions:
- 1 to 3236, 3547 to 3585 and 4649 to 5222 of SEQ ID No 1, or a variant thereof or a sequence complementary thereto;
 - 1 to 16155 and 16331 to 21278 of SEQ ID No 2 or a variant thereof or a sequence complementary thereto; and
 - 1 to 5531, 6844 to 7237, 7798 to 8184, 8667 to 9074, and 9356 to 21636 of SEQ ID No 3, or a variant thereof or a sequence complementary thereto;
- b) a contiguous span of at least 12 nucleotides of SEQ ID No 31 or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions: 1 to 480 and 717 to 983 of SEQ ID No 31;
- c) a contiguous span of at least 12 nucleotides of SEQ ID No 4 or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions: 1 to 519 and 2563 to 5566 of SEQ ID No 4;
- d) a contiguous span of at least 12 nucleotides of SEQ ID No 6 or the complements thereof;
- e) a contiguous span of at least 12 nucleotides of at least one of SEQ ID Nos 32 to 69, or the complements thereof; and
- f) a nucleotide sequence complementary to any one of the preceding nucleotide sequences.

52. A computer readable medium having stored thereon a sequence consisting of a polypeptide code comprising a contiguous span of at least 6 amino acids of SEQ ID Nos 5 or 7.

53. A computer system comprising a processor and a data storage device wherein said data storage device a computer readable medium according to with claim 51 or 52.

5

54. A computer system according to claim 53, further comprising a sequence comparer and a data storage device having reference sequences stored thereon.

10

55. A computer system of Claim 54 wherein said sequence comparer comprises a computer program which indicates polymorphisms.

56. A computer system of Claim 53 further comprising an identifier which identifies features in said sequence.

15

57. A method for comparing a first sequence to a reference sequence, comprising the steps of:

reading said first sequence and said reference sequence through use of a computer program which compares sequences; and

20

determining differences between said first sequence and said reference sequence with said computer program,

wherein said first sequence is selected from the group consisting of a nucleic acid code comprising one of the following:

25

a) a contiguous span of at least 12 nucleotides of SEQ ID Nos 1, 2 or 3, or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions:

1 to 3236, 3547 to 3585 and 4649 to 5222 of SEQ ID No 1, or a variant thereof or a sequence complementary thereto;

1 to 16155 and 16331 to 21278 of SEQ ID No 2 or a variant thereof or a sequence complementary thereto; and

30

1 to 5531, 6844 to 7237, 7798 to 8184, 8667 to 9074, and 9356 to 21636 of SEQ ID No 3, or a variant thereof or a sequence complementary thereto;

b) a contiguous span of at least 12 nucleotides of SEQ ID No 31 or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions: 1 to 480 and 717 to 983 of SEQ ID No 31;

- c) a contiguous span of at least 12 nucleotides of SEQ ID No 4 or the complements thereof, wherein said contiguous span comprises at least one of the following nucleotide positions: 1 to 519 and 2563 to 5566 of SEQ ID No 4;
- d) a contiguous span of at least 12 nucleotides of SEQ ID No 6 or the complements thereof;
- e) a contiguous span of at least 12 nucleotides of at least one of SEQ ID Nos 32 to 69, or the complements thereof;
- f) a nucleotide sequence complementary to any one of the preceding nucleotide sequences; and
- a polypeptide code comprising a contiguous span of at least 6 amino acids of SEQ ID Nos 5 or 7.

T09080" 90540860

1/12

PEPTIDESTRUCTURE of: human_prot.pep ck: 2321, 1 to 458




FIGURE 1

2/12




FIGURE 2

3/12

KD Hydrophilicity >=1.3
 KD Hydrophobicity >=1.3

PLOTSTRUCTURE of: human_prot.pep ck: 2321.
 Garnier-Osguthorpe-Robson Prediction




FIGURE 3

4/12

PEPTIDESTRUCTURE of: g713estmouse.0.12_tr13.pep ck: 1880, 1 to 467




FIGURE 4




FIGURE 5

6/12

○ KD Hydrophilicity >=1.3
◇ KD Hydrophobicity >=1.3

PLOTSTRUCTURE of: g713estmouse.0.12_tr13.pep ck: 1880
Garnier-Osguthorpe-Robson Prediction




FIGURE 6




FIGURE 7




FIGURE 8




FIGURE 9




FIGURE 10

FIGURE 11





FIGURE 12



<110> Genset SA

<120> Genes, proteins and biallelic markers related to central nervous system disease

<130> D18483

<150> 60/103,955

<151> 1998-10-12

<150> 60/106,457

<151> 1998-10-30

<160> 71

<170> Patent.pm

<210> 1

<211> 5222

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> 1076̄.3075

<223> 5' regulatory region

<220>

<221> exon

<222> 3076..4643

<223> exon 1

<220>

<221> allele

<222> 4872

<223> 8-58-301 : polymorphic base C or T

<220>

<221> allele

<222> 3606

<223> insertion of AGAG in SEQID4

 $\langle 220 \rangle$

<221> primer_bind

<222> 4572..4587

<223> 8-58.pu

<220>

<221> primer bind

<222> 4990..5005

<223> 8-58.rp complement

<220>

<221> misc binding

<222> 4849̄.4895

<223> 8-58-301.probe

<220>

<221> primer_bind
<222> 4853..4871
<223> 8-58-301.mis

<220>

<221> primer_bind
<222> 4873..4891
<223> 8-58-301.mis complement

<220>

<221> misc_feature
<222> 148,686,902,1258,1322,2440,2794,2852,3018..3023,3052..3053,3064
3067,3428..3429,3489,3545,5131,5182
<223> n=a, g, c or t

<400> 1

caatatacag	gtcacacaca	acacagccca	cttatctgtc	agtagtccta	ccagtgcctt	60
gggctccttc	aagggtccaa	gtccttgaaa	tttgctgtcc	ttctgaattg	tccttttctc	120
ctccctagaa	gacttccttc	tgctcccntt	aaatgtcccc	aattcctatc	tatccctagt	180
ccctcttaaa	atccaactgg	agtttactgc	tctactctga	agtctcaaaa	catgctaata	240
ttcacagatt	accttgattt	gtaattgttg	gcctagttag	tattatctgc	cccttgacta	300
agcttcaaga	ggccagactt	ggtcttttat	ctgtcttcca	acagttcatt	ctagaaccac	360
cacacaacaa	acaaaagtca	aattgggttct	caacagttta	ctttcagtgg	gcttgctgtc	420
ttaaaattgt	cttttataaa	aatatcctaa	ttcatgagaa	acattagagg	aaggcaaggc	480
ccagcttact	taaaaataat	taactatagt	ctgttacata	aagtaaaaaa	agattaaaca	540
ctattatatt	aatgcagtat	ataagacttt	tactaagtat	caactgaacta	ccttctgaga	600
catgattttt	actagatctg	aatagtaata	agataagtca	cagagtcttc	ttttgcttcg	660
gttccttggt	tgataattat	gaaccnttta	aatttatatt	gtttatttta	tttcccctag	720
ttttcgttct	ctttctgatt	taatcacaca	tgacagagta	gacattggat	gctaataaat	780
tcagccacca	ttaaaatggt	tgtgtctgat	taaaattaat	gcattattga	agggaaatat	840
attattatct	aataagtgtg	gatgtgtatt	ctatcatact	tcaatccttc	gaaaatgctg	900
gnactagtga	atatcacaaa	acaggaaatt	agtaatacaa	aataaaaaatg	ttaggaagat	960
gctgtaaaat	gaaaatactg	attatatctg	ggtgttgata	tcacccatgac	tttttaaaat	1020
gctcttctga	tttttacacc	ttttttacaa	tgacacaaact	gtacttgat	aataatagtt	1080
atgtcagcga	gaatgtatgc	actcgtatct	agttaagaaa	tattgtggca	tgtacagtac	1140
agtcctgatt	aataaacaat	ctgggttaata	aataataatt	ttgtctgtat	tatgaggaaa	1200
aactgacatt	actcagaaat	tcaacacact	gaaatcgaaa	gtactagaat	gatctacntt	1260
acacaaatcg	tcttttataaa	cactacatga	cacttgagta	aaccagccat	caaacaggac	1320
gncggctttt	ggatgatcat	tacctatagt	tggaagaac	tgaaaatttt	taggggtaaa	1380
atttagtgta	tacagtacct	tattatgcag	cagaagaggc	tagtaggtcg	aatcctgccc	1440
aagaggtttt	gcaattttct	cttttaaaaa	cacctacttc	tcccgcaccc	ccaacaccca	1500
cagcgctcct	taaaggaaaa	tggatacggg	tgcccatccc	ctttggtttc	tcaatgcatt	1560
ttacttagaa	agaggtcacc	tagtaagacc	catgtggtga	atgtgcaccc	gggaggggca	1620
tgagggtcct	tggaaagcac	cgcagagagg	gcgacaccgc	aaaccgctgt	cccacgcgac	1680
ccccggggcg	agccggggca	gcgctgcact	cgggtgcgcac	cggcagcgct	tggcaccac	1740
gccacctgct	gtccccgcgg	gtctggcagg	ggcaaggggc	ggagtgggca	ggatcttcag	1800
atcaaaggag	accgatgctt	gcccacggca	tccagcgtag	gagccggaat	cgaggtgacc	1860
ccagattttc	ccagagtgtc	tgtctccttt	cccttctcag	aactccgaga	gccaacgcta	1920
aggggcacca	gaggctcaga	ctgcggcggc	gactcgcagg	caccagctc	gcccgcggct	1980
gcggaggtcc	tcggaggagc	ccaccgggga	gggggtctgg	acgcaggcag	cgggggcaga	2040
gggagggtcg	aagccgctcc	agagggtcca	gggtccgagg	ggagccctcg	gagacgcgga	2100
cgggtgcgcg	ggagggcagg	gctaggcagt	gaccccggtt	ggcacagggc	ttactgtttc	2160
ttcctaagac	tctatgaggc	cacttctaata	cgtttacttt	agaataggaa	agaaaacata	2220
gacaaatggg	tggctgtcac	ccaggcagct	acacgggtcg	tgcaggtgca	caggcgtgag	2280
cgccattctc	ccgtgtcaca	cagcaggacg	gaataactgc	acgcactggg	agcgatggat	2340
ctcgcggtcc	gggatccgag	acgcattcag	agaccaaata	tcacctcatc	cctcctctag	2400
ccaattcgag	cttctctcgc	ggacccccac	cttccatccn	gaagtggctc	ggtccttagt	2460
tgagaggact	ctgccagac	cctcgcacca	gtagagacct	ctgcccgggc	gcctgcaact	2520
cggacgcttc	ccggagccag	agcgtgcggg	cggcagggcc	gcgaggagcc	tcaccggcca	2580
tgcggtccgc	agcttgactt	ttatttttct	cttcagtgat	taaaacaaaa	tatcgtggac	2640
agggggacag	aaaggaaaga	gcaggcgctt	gagcccgggg	agccgggcgg	gggcccccg	2700

gccccgcggc cccgcgcgcg cccgcccccg cgcgccttct ccctcctccc gggccgagcc 2760
 ggccgactg cgccaggatg gagcgaagtc ggcngcggga ggagatgacg caaaagccag 2820
 cgctcccccc aaaaaagtgt ttctccagga cngaagatgg cggcaactta gcccgcggac 2880
 tgaagatgac tgtggctctc gggaggccca gccaggcga ttccggcccg agctccgcgg 2940
 gaggcggcgt cagcagtcgg agccccggcg gcggcgcccc cgggcggccc tgcggcagcg 3000
 gcggcggcgg cggcggcnnn nnnagcactt agagcgcggg gtgggggggtg gnnngggagg 3060
 agcngcnccg ccggaggcag cccaggctcc ggactctggg agagccagcg cggagcagga 3120
 gcgggaggcg gaggagaaga agaaggagaa ggaaaggaa gaggaggaa agggaggaa 3180
 gaagaggagg agggaggagg ggaggggagg cgctccgggc gccgtcagtg ggcagcggag 3240
 gcgcggcatg cccctggcag gggagagcgg gctgggctcc gcggggccat ggggacccgc 3300
 gcgctgacaa tgctgggtg accggagccg cgcagccac cctgtcacct ccaccatcgc 3360
 cccctgcacc cagcctcgcc gccggccacc agcaccagcc tcctccgtct ctctctctct 3420
 ctctctcnnn attattgttt cccactctac agaggatgg gtccggctgat gattaggaag 3480
 caagtacagn cttccttcaa agcctggtaa tatttatgta ggcaaaagag acagagagag 3540
 ataanaagaga gggagaggga gagagagaga gaggagagag ggagagggga agagagagaa 3600
 agagaggaga gagaagaaac gggaggaggg gataaggaaa ttaaaccctt taagtcaatg 3660
 catattgttg tgacaccggc acaggcgccc tcacgggtga gtccggccagg gctgtgcgtt 3720
 cccaaaatat gaccaggggt gcttggtatg gtcggcagta tgacgacggc ttaaaaatct 3780
 gggtggcagc accccgagag aacgagaaac cgttcatcga ttccgagagg gctcagaaat 3840
 ggcgactgtc tctggcatct ctcttgtttt tcacagtcct gctctctgat cacttgtggt 3900
 tctgcgcga ggccaagctg acccgggccc gggacaagga gcaccagcag cagcagcggc 3960
 agcagcagca gcagcagcag cagcagcggc agcggcagca gcagcagcag cagcggcggc 4020
 agcaggagcc ctcttgccc gcgctcctgg cgagcatggg ggagtcctcg cccgcgcgcc 4080
 aggcacacag actcctctcc gccctcctcg ccccccacct gccccctcc ccgggagacg 4140
 gcggcggcgg cggcggcaag ggcaaccgag gcaaagacga ccggggcaag gctctttttc 4200
 taggaaactc tgccaagccc gtgtggcgcc tggagacttg ttacccccag ggcgcgtcct 4260
 cgggccagtg cttcacggtg gagaatgcgg acgcgggttg cgcaggaac tggagtcggg 4320
 gggcggccgg gggggacggg caggaggtga ggagcaagca tccactccg ctctggaact 4380
 tgtcggattt ttacctttcg ttttgtaatt cctacacact ttgggagttg ttctcggggt 4440
 tgtccagtc caacactttg aactgcagtc tggatgtggt gctcaaggaa ggcggcgaga 4500
 tgaccacttg caggcagtc gtcgaggctt accaggacta tgaccaccat gctcaggaga 4560
 aatacgaaga gtttgaaagc gtgctccaca aatattttaca gtcggaggag tactcggtag 4620
 aatctctgtc tgaagactgt aaggtaggaa ccctcggggg tttccccctt tcctgcactt 4680
 tcctatctct gcttggttg ggtgtcttct caagtttatt attattattt tttggctatg 4740
 gttttgttac tttgtgttt ctgcggttat taagagcttg gcttgctgtt tgagatgaga 4800
 atacctggtg gattgctggt ggactgactg atgccttctt ctgggagtc ttggaagatc 4860
 agggaaagtcc cyggttatct gagataatca agctggcact ttaactgttt cttacattca 4920
 tgcagttggc tcaaaactct ttacatcttt taagaaaagg aagttgaaaa agtcttgtca 4980
 ggaaaatagc aatgagactg cacactgatg ctcacaggta aagtcagaag agttcgagac 5040
 aggcattgtg ggtttgcaat atagatctgc acacaggaa gctctcatag tgacatcatt 5100
 aagttggtg agcaagagaa gtggtttag nttgtttcgg tagttaaaaa gaattacctg 5160
 tttttacagg gtaattctg gntgttcaga aaagtctggg ggcctacctg aggatattta 5220
 ct 5222

<210> 2

<211> 21278

<212> DNA

<213> Homo sapiens

<220>

<221> exon

<222> 16158..16329

<223> exon 2

<220>

<221> allele

<222> 3262

<223> 99-16063-218 : polymorphic base A or G

<220>

<221> allele

<222> 6231
<223> 99-16073-282 : polymorphic base A or G

<220>
<221> allele
<222> 9871
<223> 99-16074-266 : polymorphic base C or T

<220>
<221> allele
<222> 14968
<223> 99-13817-215 : polymorphic base C or T

<220>
<221> allele
<222> 20259
<223> 99-16066-123 : polymorphic base C or T

<220>
<221> primer_bind
<222> 3045..3062
<223> 99-16063.pu

<220>
<221> primer_bind
<222> 3547..3565
<223> 99-16063.rp complement

<220>
<221> primer_bind
<222> 6058..6076
<223> 99-16073.rp

<220>
<221> primer_bind
<222> 6493..6512
<223> 99-16073.pu complement

<220>
<221> primer_bind
<222> 9661..9678
<223> 99-16074.rp

<220>
<221> primer_bind
<222> 10119..10136
<223> 99-16074.pu complement

<220>
<221> primer_bind
<222> 14754..14774
<223> 99-13817.pu

<220>
<221> primer_bind
<222> 15183..15203
<223> 99-13817.rp complement

<220>
<221> primer_bind
<222> 20137..20155

109080 90540860

<223> 99-16066.pu

<220>

<221> primer_bind

<222> 20569..20588

<223> 99-16066.rp complement

<220>

<221> misc_binding

<222> 3239..3285

<223> 99-16063-218.probe

<220>

<221> misc_binding

<222> 6208..6254

<223> 99-16073-282.probe

<220>

<221> misc_binding

<222> 9848..9894

<223> 99-16074-266.probe

<220>

<221> misc_binding

<222> 14945..14991

<223> 99-13817-215.probe

<220>

<221> misc_binding

<222> 20236..20282

<223> 99-16066-123.probe

<220>

<221> primer_bind

<222> 3243..3261

<223> 99-16063-218.mis

<220>

<221> primer_bind

<222> 3263..3281

<223> 99-16063-218.mis complement

<220>

<221> primer_bind

<222> 6212..6230

<223> 99-16073-282.mis

<220>

<221> primer_bind

<222> 6232..6250

<223> 99-16073-282.mis complement

<220>

<221> primer_bind

<222> 9852..9870

<223> 99-16074-266.mis

<220>

<221> primer_bind

<222> 9872..9890

<223> 99-16074-266.mis complement

```
<220>
<221> primer_bind
<222> 14949..14967
<223> 99-13817-215.mis
```

```
<220>
<221> primer_bind
<222> 14969..14987
<223> 99-13817-215.mis complement
```

```
<220>
<221> primer_bind
<222> 20240..20258
<223> 99-16066-123.mis
```

```
<220>
<221> primer_bind
<222> 20260..20278
<223> 99-16066-123.mis complement
```

```
<220>
<221> misc_feature
<222> 285,982,2264,2273,2823,11227,11232,13663,13681,13842..13843
16849..16851,17022,17091,18127,20930,20962,20994,21207
<223> n=a, g, c or t
```

<400> 2						
ggg'gcgcacatca	gttcttggggag	atgaactcttg	gcttcacttcc	agtcaggggac	ttaaacttttc	60
tgggcctcgt	attttcaaac	ccatggaata	gaggaaaaat	attactgtct	acctcagagg	120
tttgtgtgaag	aattaaatga	gttactacat	gtaagacctt	tatctagtgtg	ctggcatgca	180
gtgagtgcta	tgccagcatc	agtagttatc	ttctgctttt	gtaaatatgt	tgcattgggtg	240
agattttgaaa	tcaccggtttc	aaattcacta	tgatcattta	tattngctgt	gcgttgatag	300
tggtttataaa	aagtcagaaa	cccgatgcta	agtatgtttt	acattatagt	ctatgaaatt	360
cgagcaacag	gagttttatgt	tttgtcatgt	actcattttg	ttccacagtg	aataagaatc	420
tgttttcaaat	gaactttttac	atttatacca	tgtgaaagaa	acagattatt	ggataatttt	480
tcattgtaaa	agaaacaatt	tccatctaag	catttacaca	ttctaataaa	tgtatagtta	540
acgttatttt	gtgcttacgc	tgaaaaatgt	aaaagatatt	ttctggcctg	acctgatttt	600
aaataatagt	gagtatctta	aattctaagg	aataaaaata	aaccgtattt	ttgccgggggt	660
tttctgaccg	cctctttcca	taacatacaa	ttggcttccc	tttctgtctg	ccttgtccaa	720
ggtcttcatc	caatgcagcc	tgctctctgg	aggctctgct	gtttaggtag	tgggtgtgtg	780
ttaaacccca	ggaacatacc	aaggctcaata	gttttctctc	cagctcactg	actcttaaga	840
aaacgacctt	tatgcagggg	actaaattct	gtaaagacta	ttgaagccat	agttctaaaa	900
aaaagttaga	aacgtccacg	tgtgtggcaa	gtagaaagtt	tttgtttgtt	ttaatgtgta	960
aggaatatgt	cagggtccagt	tnccaatgta	agggaaacaa	gcagaagggtg	tttcattcct	1020
tgataagcta	acgacatctg	acctaatgta	tggaaagtgc	gtctgtgctg	atgcgtgtgt	1080
gtgtgctgtg	gtgtgtgtgc	atatggcgag	agtatggcaa	tcagaattca	ggggatgtga	1140
tgctcctttg	gtttgtgtgt	tcagtatctc	tatggaaaga	gcaggttgat	tgctaagttt	1200
actttgttat	ttgagctttc	agagtgagca	tttaaagatc	tattccatag	acactgttga	1260
ttgtctgggt	cccaccccat	ccccatcccc	atccccacc	atttcgttgc	ttgaaattta	1320
agttttaaatg	tcacctgagg	ccaggtttctg	tggttcacgc	ctgtaattgcc	agtaatttgg	1380
gaagctgatg	caggaggatt	acctgaggcc	aggaattcaa	gaccacctg	ggcaacacag	1440
tgagatccta	tctctattaa	aaatttaaaa	attagctagg	catgggtggca	tgcacctgtt	1500
gtcccagtta	ctcaggaggc	tgaggcgagaa	agatcttgag	ccagggaggc	tgaggctaca	1560
gtgagaataa	aaacaataac	aaaaacaaaa	aataaaaaat	aaggccaggc	acagtaagta	1620
gctcacgcct	gtaatcctag	tactttggga	ggccgaggcg	gggtggatcac	ctgaggtcag	1680
gagtccaaga	ccagcctggc	caacatgggtg	aaaccccgtc	tctgcttaaa	atacaaaaat	1740
tagccagggtg	tggttggtgcg	tgctgtgaat	cccagctact	tggggaggctg	aggcaggaga	1800
atcacttgag	ccactggaggc	ggagggttgc	gtgagccgag	atttgtccac	tgactccag	1860
cctgggtgac	aagtagtgaga	ctccatctca	aaaaacaaaa	caaaataaaa	taaaataaaa	1920
taaaaataaaa	tgttacctga	atattccac	ttaggtatga	aattgatgtg	cttgctttgt	1980

tttattttcca tttgttcttt ctgttggtat tgttggtttt cagtgaggaa tcattaaaaa 2040
 tatcaaatta ttagctgtgg agactctcat ttacctaaga ataactaat aactaatttc 2100
 ttttctaatt tttaaaccaa agttcagtg gagatttggt tattaaaaag tgcaatttgt 2160
 atcacaatca gtactaagcc ataaatcttt atcattgtta ttgatttaaa attatctttg 2220
 agccttgata tatttgcaat tgaatgaaaa taatttggtta agngccttat ttnaggatcc 2280
 atggcagtca gcacggcaaa acacatgcta ggaaagttaa tggtagttt taaattttaa 2340
 gacattgcta cggacataaa atttattagc ttttttaacc agttaacca ttttttacct 2400
 tttttacca tggccaattt ggggctgaaa atataaatat atgtaatttg tattatattt 2460
 atattatata taatttgat tatatttata ttatatacat aattcaaaaa tggagggtatc 2520
 atttgatat acaatgacat atcttattga tgaatgtaaa catgcattct caagacagaa 2580
 aattattaaa attaaatgac cagattttat tacatgtttt gcatcatgat atatgtgctt 2640
 tattaatttg atttttgc atttcagtat tattctacat tttttgccag gctttactct 2700
 gagcataaaa ctgggtgctg ccatttaatt ccaaatatat aatgatcaac tgtctgctcc 2760
 aaagctgcac cttccaatgt taccaccaat tttattatta aggattgtta attccattga 2820
 ttnatagttt tcaataataa tgaataatat tattcattaa tcaataatca actgataatc 2880
 aataattaat taattaatca attaaacaat aatgttatga ttattcataa tccattattg 2940
 tatactaaaa acatatttct gatggatgt ttagctcagg ataaagaaga catgggctaa 3000
 gataggccct ctgtttctgc caaagtagca gagaaaagtc ttctttccta gagttttgtg 3060
 ccctaagcac atttgcagg atgggttcaa agacttgca agtgtgtact tatattctta 3120
 actctataag taggaggatg ctcatTTTTt tctaagatac acacaacaca cttagagaac 3180
 agaaaatgca ctgtattata ctaacttcac aggggttaga ccgcagcaag tcaatggaac 3240
 acaggagca cccaacgaga arctgtcctt gaaaatgttt tagggaggaa ttctaaagt 3300
 ttgcctttca acttaactgt gtatcttcat ttgaatttg gaaccattgt tcatgagtga 3360
 aactatttt tatgttctga atcttcccat ttaagacat atgttttct agcttttaga 3420
 caataacatg atctaaaatg tcaaaataat acattctgct gaatctcagt attactgag 3480
 gaaatacaga aacatggcaa aagttaggaa gaaaatgtt tctttttct gctgtccaca 3540
 aaagttggtg gaacatttat gactgcaaaa aaaaatgagt tattaacact gttttgattg 3600
 aattcaacag atgctctgac tttcttatat atatgtgtgt gtatgtatac atatatattt 3660
 aacaactata aatattttata tgaacaaca ctttcacaag atgccaataa atttagtatg 3720
 agcatttaca tatctaaatc tttctttggc tctagaaact gatgctatgc caaccagaac 3780
 aaagaaatag tagctttcac tactgtcact gctaataaaa ttcagcatca ttacagctta 3840
 tacaaaattg tacttattag cccaatttct atgtctgcc ttaaaaaaat gtatcggaga 3900
 aaatggatgc cattagttaa gttttagat taaactgata ataataatgg caaaacctg 3960
 atcaagtaaa taaatccac taaatagaac aggaatgtgt tgctaagacc aaggccattt 4020
 ggattcaccc tgagcttggtg ttttagaggca ttctttcatt cattcattca ttcattcagg 4080
 cactaatggc tgagtcatgc cagaggctag gccctcctg cggagagttc actgctgcct 4140
 aaagacagac caggttcttg cccttatgtt aatattcggg tcttgccctag tcagttatat 4200
 aaagttcatt aaaatttgct tacataattc aagcaagtgc tcagttttaa atgtctgtgc 4260
 cacacaattt gacaatttac ataatttatt tcagtgctaa agaagttgac aatcgctgtt 4320
 taacttcagt cgggtctct ctaagcgggg cgaacacaca caggacatgc acaagataat 4380
 ctgttaaagt atgacaagaa aataataaat tctacttgca gttataattt tatcctaacc 4440
 tttgcaatca cttgtgctct gtgtgtgttg tataatgtac acattatata acagttcatg 4500
 tgtatataaa tgaatattta tgtaaggga atatgctaaa aatcttaaat ggggtggaata 4560
 actactaaaa atgttttagca agtacaatta aaacatatac aagttagtgt cacttctgta 4620
 taatttaata gttaaatagt tgtttctatg gggaaatagta agccacagag agaaagaagg 4680
 tcttaagacc gggaccagaa aaataagctt cttaattgga ggcggcgggtt acttctagt 4740
 ataggcgatt gttttttcca gatataattc tggctccttc ctaattaaga ttagtggtac 4800
 tcatgtcacc aatttgccag gtttcaagct tgtgttaata agatcacaaa cattgtgagc 4860
 ctttgccatc tttaaaatct ttcactctaa agcaaaacgc acataacagt tgccgaagt 4920
 cttcttttga gcttctttga aaacagccgc attttctttg agctatggag agcagcatag 4980
 aacatgtttg aatcccaaaa gcttaacccc agaaaagata tttcttgcaa gccacaaaca 5040
 attctacact tacagtatca tgagttaata tttacctctg cataactgggt atagaataaa 5100
 acacagtttg atgtgggtg gcggggtgta gggtaaaatg acctaaaagc ccacctgtc 5160
 tctgttacat tttgctgtgg gactttgtcc atattgttta cattctctga gtctcggtt 5220
 tcatattcat aaattagaat aatatcact acatcacaga taccgtgcat tgaaaacacc 5280
 tggcaaaata actgatagta aatagttctt ttttattttt ttacttttta ttttttgaga 5340
 cagagtctca ctctgtcacc caggctggag tgcaatgggt cagtcttggc tccctgcagt 5400
 ttctgactcc tgagttcaag tgattctctt gcctcagct cccaagtagc tggaattaca 5460
 ggcagtcacc gccacgccc gctaattttt gtaatttttt agtagagaca gatttttgcc 5520
 aggttggcca ggctggtctt gaactctga gctcagggtg tccaccacc tggcctccc 5580
 aaagtactag gcttacaggc atgagccacc atgcctggcc ttgaattttt taaatttcaa 5640

tagcttttagt ggtgcaagtg gtttttgggtc acatggatga gttgtataat ggtgaagtct 5700
 gtgatttttag tgcaccgggt acctgagtag tgtacattgt accctacagg tagtttttcta 5760
 tctctcacc ccttcacaaa cccccccatt ctgagctctcc actgtctgtt gtatcaccct 5820
 ggtgaccttt gcatacccca taggttagct cccacttata aatgagaata tgcagtattt 5880
 ggtttttcat tctgagtta cttcaatgca aacttgctgc aaaagaaatt ttgttctttt 5940
 ttttatggct gactagtatt ctatgggtgtt tatattatat acatttcatt atctccttcc 6000
 ttcccttgct gtcttctctc catgctctgc ccttctctcc tctctttctc atatcagaag 6060
 cacactaacc tccacccac tctctctctc gacatgccc tctcactccc tcacatgccg 6120
 tctcttctc ttctccagaa accctcagcc cccattgact tctgctccct ccacacggag 6180
 gtgcactgac gggagcattc acagtgggat tcatcttacc ctggctctc raattttaca 6240
 gcactatttc tgatgccagg gaaaatgtct tatgatgaaa tttttaacct gccctacacc 6300
 tctgctcccc aaggcaccta tctactgtca gactccaaag ttggctctca gtgaaaaatg 6360
 tgggattaac agacagattg gatggtagct aggcacagg tctctgttt catggtaaca 6420
 ggctacaagt ctgtatttca attagaatac tgaagtggtc actctgactt tttaaatatg 6480
 taaattctaa tagaatcact ggcattttttc tgacagtaat gcagaccagg tttaaatagg 6540
 caacatgttt aaagaaccac gtgacacaat tctactccat tcccagggtg ccggttggct 6600
 cttaattttac aaaaggggtt tgcattcata cctttcccag cttctcacta gcaggacaca 6660
 ttaagataat gcagaaaaca acaaagatag tgtggtgtta gctgctgttt cttgaggagc 6720
 aaatgcaatg acaaaatcag aaatgctggc atctgtggga aaaacaaaga atgcaaagag 6780
 cctgctccac tgaggaacag cagattttct ttgagcaaaa gcagattatt cttgtttcaa 6840
 ttataatttt tgtgactgtg acattggtaa agtaggggtg caatcatgca ctcttggtag 6900
 acaagtgacc tgacaatatg gccagaagt aaaactttta gatacatacc aaaagcatta 6960
 tatattctag ttctataatg tgcacagcta tgtaaaagta tcagattctt agataactaa 7020
 ctatagtcta ttatgtcaca ttttccatcc tttactttgg attatatgac aaagtatatgc 7080
 attaaactttc ttcagactct tttttttgcc catttctact aagtgaggct gttacagtaa 7140
 gttcctttct ctttgggttt atgaagaaac gaatacatct gcattttata gtgaattttac 7200
 tgattactta ttatagctct actcagtgcg ttggtattat tggatttttc taaatagatt 7260
 gtagattatg gaagataaca ttcattttatt aatcatcaag tgctccatga aatcttatat 7320
 gagttctgga aaagaaggaa agcctaacac attctctctt ctctatctct tgggtgaatat 7380
 attatccctt tatatcctta gattagtttc agatttctta ttttaagactc aattccattt 7440
 ccctttcttt agaagactga tttcccactt ttttaacctt tttcaacatt ctcaactcac 7500
 tcaagatgtg gagcccaaaa ttgaatttat attgaagtgt tcaattgctg cctttttaga 7560
 gatataaatt ttaataggat cactggcact tttgtgacag tccatacagg ccagggttaa 7620
 taagtggat gtttagagga catgtaatac tctgcacttc taaggcattg cttgttggct 7680
 gagagtccac aaaaggtgct ttcattttact acggggccat tccgactcta gataaggcta 7740
 ttgagttata tccatccacg gccaacactc agaagtagtc ttatggagtg actttcttct 7800
 tttttgatgc ccacagcaga gctcccacca tottctgcac taacatgata atccggtgaa 7860
 ggcagcttgt taaaagagat cttccttcac accaaaggaa acgcttctct atttactgtg 7920
 aagttaattc actggttatt atcatcgtaa atattcattt ctggatataat aatagaactg 7980
 ttctggaaag gtatgaatta gtataacctc tctgtcacc actttttgcc acaatcccag 8040
 ccaaagtagt gtgtccgtt aaataacagc tataaataat actttgccct ctgaagctct 8100
 gtggccttcc atgagctcag aacaataaac cacaccattc cccatctttg tgtgacaatc 8160
 tttctcagct tgcaacccaa tcccatattg tgcttttagga cctgaaccat ggggtctttt 8220
 tggaaggaga gggtcacttc atgaagtgga cttttaaaaa tttatttctt tagttttgt 8280
 ttgtttgttt gttttgtttg tttttgttt cggccttcaa taacggccac tgggttggct 8340
 atatgaaaag ggattcttag gatttaatat gttgggggct catcagggtt cctggtttga 8400
 gtctctgctc tgggcaggat ctccaggcca ggtggactgg ctctcacgct aaccaatcgc 8460
 ggggcatcat tatgcaagcc caaaggccat gttactagtt tccagtgggc attccactga 8520
 cggtaaatct ctgccagata catccagggc actggggata caagaaggca caaagcttgg 8580
 ccttcattcc aagagcatag ggtctgggaa ggagcgagac gagaagacag catcacatgt 8640
 actgaactgc cgaagaagag ctcattgcag ggtctagagg gaatgcagga aaggcttcca 8700
 agtgaggcca cacaggatgg acaggaatta ataggctgag ggattcgtga gggaggtgga 8760
 aggaagagcc tgggtgcagag ccaccgaggg cacgctgcac atcgagtgc ctgcttgc 8820
 ctctgtggc cagagagcag agtgccgggt gggagtgggc agagatgagt ctgactgct 8880
 cagcagggca aggtcgcaga gctgtgaatc ggtaggagc tttgaacatt ctctgggtg 8940
 ttgctgtggg atgggggtgg gtgctgaatt attaaaaatg aagtagtgga ataactctga 9000
 ataatacaat taattttcta tagattgtct taactgcagc atgaagcagg agttcacaac 9060
 tgaaggcaca agggtaggct ccacggggta tatccaaggc agaaatccaa gtgagagatg 9120
 ctgatggcgc gagcagcact ggtgtcagta gaaatcaaga gatttgggca gacatagagc 9180
 tattgaggaa gcaggctcac agggcggtgg gattgaagag ctgtggagcg tggagaggc 9240
 acccgatga cccccagggt tctcacctgc ttcctccga aaagaaggag ccgaattcca 9300

ctttagagtt tgtagtgcct gaggtattga aacagagtga gagagggaga gaaagagaga 9360
 gacagagaaa gagagagaga gatcagcatt ggtaatgaag atttaggctt cactattttta 9420
 aagactacaa ttgaatcacg aggatggacg gttgcccgaga aagaatgtgt agaaacaagc 9480
 ttggaacaga agccggaggg atactaacat tttggggaat ggcagggaaa acaaaacaaac 9540
 aacagcaaca gcaaaacaaat gaagatggag aaggaggggc agaggactaa gagggacacc 9600
 aggataaaac aagtcccagt ggcatttccg gaagctgttc aatcaaccat gatcagggtct 9660
 ggcaagaggt caaataagac aacaactgat tttccagctg gatttgtcag cagagggggcc 9720
 aaggagcttg gaaagaacaa tctcagtggg gtgggttcgag ctgaggccaa atcatagtga 9780
 gatgaagtga aagataaaac aaggaagata ttgactgtta catgagacgt ttattaatga 9840
 ggaagagaga aaaagagaaa actaagtgtc ytctgtgtca tagttaggac acgttttctt 9900
 ttgcataacg ctggagacat attgacaaat gcttcttagg tttccctttt ttcctaagcc 9960
 ctgtgcagat tatctctgga tgggcacatt ctctatttgc gaaagcacag ccgagttgat 10020
 ctgcttttca ccttctgtac aatcatatgt ctgggcagct ccgtgggtgc ataccctgat 10080
 tggccaactg ggcttgcgtt ggccctgtga tgttcgagct gattccctct cctgtataaa 10140
 tggagtctg gatgctggcg tggatgggca ctgcaggagc ctcattttgg tgttgagaat 10200
 gggttgggtg gactgggaaa tgtgggacag agccaacaag ctgaggaggc cctgaaatgc 10260
 aagggaatag accaagtgtg atgacaggat tcaaaaagtg ggtcaccacc agaaaacagg 10320
 aagacatttg cgttttactt caggaaatgg agccaagaca aagccctaga aggcaagggg 10380
 tgctgatgtc ataagacccc ccacaaggga tcaagaagct cagagcgctg cttaccgccc 10440
 atccttaagc ttacttcaca gactcagctc agcctcaagc agtggggcct tcttgtttc 10500
 cctttgagaa tatatcacga tttccaattt ctagggtgcaa tgtgctttca ccagacactg 10560
 acacagacat agcagaaaagc agacattcag acataggaac gtgaaaattt attttgagtt 10620
 tcacctcac ttaaaactgt agcaacatgc gttatgcgtc aaagtgcatt agcctgaggc 10680
 ggttgcgtgc gcagactaat gcttacataa ccaattattt caccacaca taccacaaac 10740
 tcaggccgct agcgggggta gagctggcag aaacggatct aataaaatgt atcaacaaat 10800
 gctacaaaatg tgaaaggaaa gttagtcctt actaataagt ggggggaaaag ggagagcagc 10860
 tgcttagcct cttgatttga agctgacaac catttttaat atctgacatt tttctttgtg 10920
 ataaaatata tagccaacat gatatttttt cagcaggcta acatatattt acattagcaa 10980
 tcttctacct tgctctaaaa tagagagatg gattttggag atgggggtaa tatatattta 11040
 aaaagtaatg agaagctgac ctgctggaaa aatattaatc atagggcatt ttttgaaagg 11100
 ttctgcacag attagctatc ttcaaagtga atgccagaa ccaagagagg acatgaggac 11160
 accacacaag cacacctgcc agccgtctat atggcaccat tgtaaacctt ggtgatcctg 11220
 gtcccgngta gnattttctat tcccaaatgc atgggctact tcaggattgt ccagatttgc 11280
 atgtaacgca tttctttcta gatttctggt cttcacatca ctccccgtaa tcaggaagca 11340
 aagtactccc cctcggtctg tctccggagg ctgtgccgtt ataaccaaag ctttaaaaaa 11400
 aaaaaatctt cattaagagt gtgaaaatga gtttgctaga tgagctctct tgggttctcc 11460
 ttggtctctt cagcctttgc tctccctgat cacctcttca aacaggcctt tgtgaccaag 11520
 ggattctcag ctgagaatcc aaacacaggg tagatgtgga cgtaggctctg gaggtagagg 11580
 gtgggggctc atacagccca ctctgcagaa ctgcaagtga gtttcaaaat gaagtgactt 11640
 gcaaaaaaga aaaaaagaaa aaggatatgt tcggaatgaa taataactca gtgatacctt 11700
 ccgaataaca tggagtgtaa tttcaacagc cgcccagggg ccctaccttg ctgagctgtc 11760
 atctgcatct ttctagacct cacttccgac gttaacagag gctcagctag gtggtctcta 11820
 aggtctttcca ccctggaatg tctcacctta gtgactccag agaccccgac gtatccaatg 11880
 ctcccttcac tttctgtcct ctcaagaagag ttctgtttac aagagttccc actgaaaaaa 11940
 actatggact gggctgtgga gagagttgaa ttccacttat ttgatgccta atttccctgt 12000
 atacgtttcc ttatttgtaa aacatttccc aaacaagtct caagggtctt atgaggaaaag 12060
 atagcaagag agaaaatgct tcaggggaaa aagagaaaaa tcgattcaag tattaagtaa 12120
 aaatgatgct gtcatttggg ccatttttct agtgtagtct gctcctcttg cagacagcac 12180
 cttgagaaca ctgtatgggt ggcagctgtc cagcaaagat tgtgacagtc aataagtcac 12240
 ttccagagga cacagtggag gagcgtgggg gcgggtggggc atttgaaata ccctttcaga 12300
 gcataatttc ctgacaaatc aagctgcttc ttgggtagat ggaggcactg gccatcaagg 12360
 ggaagagtgg gtggatgtcg gcgagccatt actctgtcac cagagacctc gcacacattt 12420
 ttattccttc ccacagttat tctttcgttt catataatta tttatactct gcagtgcac 12480
 atagaaaagc aattttaccta atatttctct ctataggaga aggccaaagc attataaaaa 12540
 agatttctag acttctttgt actccatagt tcttatgaaa taagacaaat atactcattt 12600
 ttcatgatgt gcttttgttt gaagttcttt attactttta agatttagtc aatttgttct 12660
 tctagcccg tgccaccaca aaacatcctt ttcaaccctt tcttgcaaaa acttctagaa 12720
 agacgttggg aagtgtcttg gagccatggc cttctctcac cttcctaaca taggaatctt 12780
 cctcatcggt ttttgacaag aggtattgaa agtctatttg aatttttcta gctctagaga 12840
 actcggcaca tttgaagata gctcattgta tttctatgca tctcttctgg caggaaagct 12900
 cgtctttata tcacgctggg agctacctgt ttgttttttc tcttgtcttt gttttgtgat 12960

tccacaatttt attgttttaa tccatcgtca ttggcacctg gccgttttctc agacacgaga 13020
 taactgtaag aacctcacc ctcgttttgct cttagccgca gtatattctc aggtattctc 13080
 cgttcttcac ataacacagt tttcagggtg ttactaacgt gctatttcac ttttcaagta 13140
 atcatttttca agattctaga agaatttttg tttacttccc atgcgaactt ttaccagttt 13200
 attctgaaat atttttagca aatgtgctgt atgctttgcc tcttttattg taaacacatc 13260
 tacacagaga agataaagcc ttttagttatg taacatctgc ttctcatcct taatctctta 13320
 agtagcaata aaatatctct cctccgtcct tcggatttcg attcagctca catgggttcc 13380
 cccacttggt ttctgatgta tcttaccctt agagctaaaa ttttagaaaa tatttaatac 13440
 tcaaattgagg aatattcatt gcacactcaa agcccaggag gtactcata acggatgcca 13500
 ccgtggagcc tggccggaga ggtcgtcata gctcagtgtg taaggctcgg gattctgccc 13560
 gcagctttgc aaatgatgct cgatcacttt tcttcataac taactactac ctgatactta 13620
 aaaaaaaatg ctgtgatctc ttactagttt ctttttcttt tcnttttttt tttttttttg 13680
 nagttaaaaa aaaatctgca aaggaaatat agcggaaata gaatttaagg agccagaata 13740
 aaaatggata tgttcccatc gggcaatgct gaggaaagtg gttgcaaaga ggatggctag 13800
 atctgaagag actccagtac tggacgcccc accgtctcgg annagagga gacgttggtt 13860
 cttaagactt tatggctgca ggatgcgatt cctattcag aaccattttt aactggaata 13920
 acggtggaaa ggcaacgtgt gagggagcgg tgggaatggg gacccaattt tggccaatga 13980
 aaacatgagc cactttctgg cattacatag ggcactcctt aaagaaaaac aggcaactct 14040
 agactttaga atcccagaaa tgtgcggaaa gcaagctgtc ctcataatgg aatgttattt 14100
 tttgaactgc aggtataagc ctatcctgct tctctagta cctgagaaa gttattaagc 14160
 ccaggaatca gaggatacat ggtcatttcc tactactacg cttagtttac ataataaag 14220
 tcatgtcata ttacgtatca gtcatatta cacaacgct aatgtctatg gcattttgac 14280
 aaacgttttc aacttcccc aaggtttggt aagaaatcat ttcacttttt cttctgaagc 14340
 tgggtgcttc agcctcttgc tggcggcacc acctccacct tcacctgtcc ccctgaggca 14400
 gcctcttgct gtcctcctgg ggcacacagc cacagccac ctcggtttcc cagttggcat 14460
 aagaattctt agaggtttct tcggctattg taacgttttc ttctagtga gtttttcagt 14520
 gtacactggt acgagaagac tcattcaaaa gacctataag aattctaatt atttgtaggt 14580
 tttactaaca agttacatgg tgattgtgag ccattgatga ctggcaaaga aaaattactt 14640
 ttggccattt aaaagtgtat ctcaatttga tatttatctc attttacctc taccaagtca 14700
 ccttgatcac agaataaagc gtcattttga tcaacctaat gttatgaata aaaaaatata 14760
 atcctccttc taccaaatag atattgacct ggggcattga aggccatgct gatttttaggt 14820
 tcatctgcaa actcccttgt gatctcataa gtgctttaa agtagtttct agattaaata 14880
 taggataact attaggaaca cagtctttgg agccctacag aacatgggtt tgaagtctgg 14940
 attttccatt tccattacct aatagtayta ttacttaata ttattcctgt tcaaaatgtg 15000
 agtaatagtt atggtcaaaa gtgcatgctg agaatcacat ggaaaaaaa gtttacagct 15060
 tacttagaaa agagtataaa gttgataaat accagctatt attcttggtt ttattaggta 15120
 tttataatct cttaggctac ctttaactgc tgcgcctcca tttttctagg taaaaatata 15180
 ccggcaaaat gttacttgga taatatatac ctaaaaaata gataagtaaa agccattagt 15240
 gccaggacc tggagaataa ctgaatttca gtaacctgta ctgcaaatg gtacatctgc 15300
 cattgttgta ttgaaattta agatcagctt attcctcgt gtcagaaaaa ggcaattttt 15360
 tcaatgtttg ttttcccaaa tagccacca aacaaagaga tgaatgaagt cccagtctt 15420
 tcacatttga tgaaattaca taaatacgt gcaaacattg atgtggcttg cacatcatcc 15480
 agaaggttga agctgtggct ctgatgaggc ttccctccta ctccaacca caccacagca 15540
 tatgatgtct gctctatgtc ggggtgttct gggctttcag acagtgaat ttttaatgca 15600
 tttgggtgta gtcatgaatg taaatgtcca tatctgcctg ttctgtgcct ctcaaagtcc 15660
 aagatctaaa cagcagtttc ccaaccctg ctggggccatc tttataaagt gcttcgcgcc 15720
 atctagcgtc ctatggaggc atagacgtgg gactccgtgt ggagggaact ggctcatcag 15780
 ccacgttgca agtaactaca gcacagaaga gcaatagagt caattattta ttttacttta 15840
 gatatcgtg aattttgaaa aattaacttc ctgcttaaat ccactgattt tcaaaataagc 15900
 cacataaaat taaagggtcaa aatacctttt acattctatt agggatgcaa tcaaatactg 15960
 ttttgctttt attgaggaga ctttcgttgc tgtgttttta tcaactgcag ctgtcgttgt 16020
 gtaaatagc tttctcacia tgagggtctt cttaggatcc acttgaaacc acagcacgct 16080
 tgcacgttc tcacagtgc tctatcactg taactgttgt cacgcctcta ttttttcat 16140
 tcttctcttt ttttcagatt gtctacaaag cctggctctg tcccagtat tttgaagtca 16200
 cacagtttaa ctgcagaaa gacaattcctt gcaagcaata ctggttgagg gttcagacga 16260
 ggtgtccatt tatattgcc gacaatgatg aagtcattta cggaggcctc tccagtttca 16320
 tctgtacagg tacagtgcg ggtgggagtc tgtacaccag tctccggtgg ttttgctttc 16380
 ttgtgtgatt ttgttttgc ttgtgtttc ctttactga tataacctg aagatgcggc 16440
 tggtagtttt ccgcacttt actaatagaa gcaccgaaag cccccctca caggtctgga 16500
 aatgattcag cttctgtacc acatggtcta tctgtaactg agaccacagt tattcactgt 16560
 gtgaaagaag aaatctgat gcaaaatatt agcaatcatt agatatactt acatgtgacc 16620

tagtatagggt tagattcagc ctgcattgcc tttgaattcc ataagaacag gagatgtgct 16680
 aaggccagtg aaataatgct tttcaaatta gtcagaagtt tatgttctct tgcctatttt 16740
 cttttatttt attttctgag aatttttatg ttactttatc tgtaaaaagt attaaagaca 16800
 ttaaaaaatat ctgcctaaat tgtacgtgtg tgtgtgtgtg tgtgtgtcnn ntattagagc 16860
 cacacaacaa gtctatccat taaacgatgt ttacttcttt cagcaaatga gtcagactgg 16920
 gcaaaacacc aatatcagca ctccctttct ggatatttat aagcattaca taatttaagc 16980
 agaataagat ataaagagca agagcctttt tttaaaaaat anaaatgata attaaatggg 17040
 gagaacaaga tgctttgcca ggggtgggtg ataatccgag tgggtggctct ngcattctct 17100
 tctataacaa taatgctata aggcgtccct ggaattacgt ggctcaagct gtagcacgtt 17160
 ttgttttcaa gtgttttgat aaaacacccat catatgtgta gagacacatg aaaatgctct 17220
 tctgacatta gaattgccaa actcctctaa aacagagtag catattaaga tgctcaacat 17280
 gagaatttat caaattattt cagcatcgct tatttacata cgtattcatt agccacagtg 17340
 ttctaagtga taagctatca agagatagtc tgccaaagct cgccctaaga actggatgag 17400
 tatttctttc tttttttttt tttgagatgg agtctcgctc tgtgtcaccc aggctgggtg 17460
 gatctcggct cactttaagc tccgcctccg gggttcaagt gattctcatg cctcagcctc 17520
 ccgagtagct gagattacag gcgtgcacca ccacacctgg ctaatttttg tatttttagt 17580
 agagacgggt tttcacctg ttggccaggc tgggtctcaa ctctgacct caagtgatcc 17640
 accctccttg gctcccaaa agtggtggaa ttacaggcgt gagccactgt gccagcctg 17700
 gattagttat tcttatgctg cccaagcttg tggaaagaac acgtgactga aggtcaggag 17760
 cattggcctt catcctgttt ctattgtaca ttctctcaga ggcaccaccc cttcactagt 17820
 aaattagaaa gtgcaatggc caaacctcc cccatgtgga tatgctgcaa ggattacaga 17880
 taagagagaa gggcaagtta tgtcattgac cagccatagc cggtgcacac gagaaagtga 17940
 aatgcagaat gatttcacag gcctgtgtgt tattctactg acttgatgct caagtcattt 18000
 tttatgtagc tctctctgc tggaggggga ggaggggaag gaaggaggga agagggaag 18060
 aaggaataag ggaaggaggg aaggaggata tcaatatctt cttgctttga gtttgagaca 18120
 aaattcncca gacacaggct attaatcat attgaatttt gcatacaaca tccacaaat 18180
 aacctgaag ataaggcctt catttttttt ttctgtggg acaatgaggt gtctgtgaca 18240
 tgaggacttc agagaagcta ttcgattttt atgtacaggt tgtgtttatg catttacact 18300
 cacattggct tttgtcctag agaagaacaa tagtttttga accaagttct caaagtagac 18360
 aaaaaacca aatgaagggc gaggtgtttg cgtttatctt ctttttctta catgtatctg 18420
 tatttgtgaa tctgaaatat atgtttgaat gttcacccac ttctccata cacattcaga 18480
 atgccagggt agaattaaat ctctcacttc accacttggg cagagaatcc agtctgcagt 18540
 tttaatgttt ttcgagtttg gtaaaaacag cttcttcata gacatagcta cgtcatttag 18600
 gaaaagtggc aggaaaagag agatttatca gatccagaga aaagtgccat ctccgtgaga 18660
 ggccccctag gataatctca tcaactgaaca tttggaaacc taagaacagt agttcttatg 18720
 tcaactttcag ttgggttaat gttcatttta tgtttaaatt gctcgaaaat atatggaata 18780
 aattctgagg ttatttcacc ctgaagttct gtaaaacaat ctgacagaaa aagataataa 18840
 ttttcatatt gatcttcttt tctaagggtg gacctatgcc tctttgaaga attctcatc 18900
 atgttgataa ctacgagcca tcatctccca tcatcggtta caggtgtccc ttaagagtgc 18960
 actgctgagg ccagatgcag tggctcatgc ctgtaatcca cacaattttg gtaggctgag 19020
 ataggagaat tgcttgaagc caggggtttg aggcagctc ggacaacgta gcaagacct 19080
 gcctctacaa aaaattaaaa ataaagaac tagccagaca cagttatgtg cacctgtagt 19140
 cgcagctatt tggaggcag agacaggatt gcttgagctc aggtgctgga gattgcagtg 19200
 agctgtgac ctgccactgc actcctgctt gggcagcata gcgagaccct gtctcaaatg 19260
 aaaaagaaaa tgaagagtg cactgctgga cctgagcaag gagatttcta ctctgtcca 19320
 tcacagctgc ctgcccgttg cttataagag tcccagacat gggcccaga atgggtttca 19380
 tcttgatga tgtagaata gaggacagct cccagaggac cactggctaa actgtggagt 19440
 ggcttgatc gcgtctaagg aaactagtaa gacatatgtg catataattt gttcccagat 19500
 ttttaagttg acatttttg atgtccgtct cctacaaatg tacacggatt tttaaatagt 19560
 ttacattata aataagtttg caagtaaatg tgagccattt acattctgtt tttttctct 19620
 gaaaacagaa taataaaaag accagtgtag ttatagcatc atttaatctc atacaaaata 19680
 ttttaataaa tatatcaaag ttttaaggga aaaagaaatg ggaagggaga tggtagccc 19740
 agaataaaat aaaaaaatga gagtaggtta tgaaccaag taaaatgcag taacttcac 19800
 aaaaagaatt caccaagtaa ggtgaccttc ctcttgctc cagcaatttt tcttttgaa 19860
 aaaaatcatc aagcatttga tttccactct agatgttaaa atgcaatcat ttctactaa 19920
 gaattaaagg aataggtgga gtttccttca acttcaacag atttaattat aatgggtttc 19980
 ctactatttg aactgcaccc aattcacagc ttccagaagg acggagaatt cctctagga 20040
 tatcgaggat tcttcactta cttttcttat tgacctcaaa aaaaagtatt ctgtaagcac 20100
 gtaactgcat atggcctgat gacagatact gtccatgtga gcatcagttt tcttcaaggt 20160
 gcttctcctt agtgacaaac cagtggcatg gtgattcctt ttcttagcgt tctctgtacc 20220
 cagaatctta gagatctcaa gttcttcctg tcattgtcyt attggctata tactgatacc 20280

```

taggattcct attattcaca aaaaagggaa tatcaccctt tggaatcaat gaacaatttc 20340
tgtaaattgat caggagttat ttaccatttt ggtcacactt actaaattca gtatctcgtg 20400
catcatttct ttatgggtgct cacatcacca tgtaccaaatt ttgaaagttt taaatgtata 20460
tattttttgat catctgctac ctatgatcct ttagtaagcc aggaacttac tttaaaaaat 20520
gaaatatctg agaatgcatg tccattacta tagaatgctt ttgattgagg atgttacaga 20580
aggctcatgac caaatgttct aaccacggat cttgatgaca agcgcattccc cgtgcatatg 20640
tttaattcca attctgtctt aggagataaa aggaaagaca ctttgctga gatttctctt 20700
gaattttttt ctattaaaga ataaaactga cacgtgacta aagaaatggt ttaaaaatta 20760
attggaaaga aattctgagg tgctgtcagg gtgaaacatg tcatttaatg ttaggcatta 20820
ttgagctaaa atttgtcaag gtgggttctg ttgggtttgc aagctcagtt cgcataatgc 20880
agtgtctattt tagaaactca gttgtcttcat ctttaaagtg agggggtggn aagtcgtttt 20940
tggattctac gatgtcaacc cngtcatcgt ggtaattacg tgggcttccc tctnccacac 21000
tcctcgcct cattccagag tcccttgag aaatccttga ttgcttacct ttaacagtga 21060
accaagctga agaaaacaga ggcagcagag gagcacaggc tgtgggtgct atggtaacaa 21120
acattaagaa aattatcatt tgattgatag ataaaataga ccagccatga tttactgctc 21180
tcttacagag ggacaattat tgaaggnaat aaaagtaaaa gttggtctgc tgggggttac 21240
tgacaatgga gataaaacat attttaagaa ttctatgt 21278

```

<210> 3

<211> 21636

<212> DNA

<213> Homo sapiens

<220>

<221> exon

<222> 5537..9359

<223> exon 3

<220>

<221> misc_feature

<222> 16330..18329

<223> 3' regulatory region

<220>

<221> allele

<222> 8277

<223> 99-13821-332 : polymorphic base C or T

<220>

<221> allele

<222> 15915

<223> 99-15215-60 : polymorphic base A or G

<220>

<221> allele

<222> 16053

<223> 99-13525-395 : polymorphic base A or G

<220>

<221> allele

<222> 17032

<223> 99-13526-368 : polymorphic base A or G

<220>

<221> allele

<222> 19401

<223> 99-15208-87 : polymorphic base A or G

<220>

<221> primer_bind

<222> 7946..7965

T090505-000001

<223> 99-13821.pu

<220>

<221> primer_bind

<222> 8454..8472

<223> 99-13821.rp complement

<220>

<221> primer_bind

<222> 15475..15495

<223> 99-15215.rp

<220>

<221> primer_bind

<222> 15943..15960

<223> 99-13525.rp

<220>

<221> primer_bind

<222> 15954..15974

<223> 99-15215.pu complement

<220>

<221> primer_bind

<222> 16430..16447

<223> 99-13525.pu complement

<220>

<221> primer_bind

<222> 16950..16970

<223> 99-13526.rp

<220>

<221> primer_bind

<222> 17381..17401

<223> 99-13526.pu complement

<220>

<221> primer_bind

<222> 19315..19333

<223> 99-15208.pu

<220>

<221> primer_bind

<222> 19797..19817

<223> 99-15208.rp complement

<220>

<221> misc_binding

<222> 8254..8300

<223> 99-13821-332.probe

<220>

<221> misc_binding

<222> 15892..15938

<223> 99-15215-60.probe

<220>

<221> misc_binding

<222> 16030..16076

<223> 99-13525-395.probe

<220>
<221> misc_binding
<222> 17009..17055
<223> 99-13526-368.probe

<220>
<221> misc_binding
<222> 19378..19424
<223> 99-15208-87.probe

<220>
<221> primer_bind
<222> 8258..8276
<223> 99-13821-332.mis

<220>
<221> primer_bind
<222> 8278..8296
<223> 99-13821-332.mis complement

<220>
<221> primer_bind
<222> 15896..15914
<223> 99-15215-60.mis

<220>
<221> primer_bind
<222> 15916..15934
<223> 99-15215-60.mis complement

<220>
<221> primer_bind
<222> 16034..16052
<223> 99-13525-395.mis

<220>
<221> primer_bind
<222> 16054..16072
<223> 99-13525-395.mis complement

<220>
<221> primer_bind
<222> 17013..17031
<223> 99-13526-368.mis

<220>
<221> primer_bind
<222> 17033..17051
<223> 99-13526-368.mis complement

<220>
<221> primer_bind
<222> 19382..19400
<223> 99-15208-87.mis

<220>
<221> primer_bind
<222> 19402..19420
<223> 99-15208-87.mis complement

T 090300 " 505 / 0850

<220>

<221> misc_feature

<222> 110,4287,4291,4453..4454,4506,4520..4521,4558,4580,5958,17188
 17327..17328,17415,17917,17944,17962,17976,18224,19785,20084
 20138,21414,21428,21433,21463,21480

<223> n=a, g, c or t

<400> 3

aaaaaaaaact	ctgtgaggtt	ggtactgtaa	tgtcaaacag	caggtaatga	ttcactagag	60
atttcaaata	gaacagctta	taagcaaaat	atatcagaac	aacatttcan	taccgggaaa	120
atttgctttt	gttttttcct	aatgctaatt	agtgcatttg	tacttgtttg	tgcaaggagg	180
ttcttgtttg	agaaattatt	tttgtttgga	aatatgtttt	tataatttct	tcaatgctga	240
ggaaaaggtc	atttctgtag	gtaggctttc	ctaggaaatt	tgtcccagca	ggttgtgtgc	300
aggtgggttt	tgcgggagaa	ctctcaggca	tgctacctat	gagggggtga	agaaggagaa	360
atttggtaga	gggaaaaaaa	tctgaagctg	ggatggccct	tgagagatgc	cttgacttga	420
gtcaagtgga	cccagccttg	ggacctgtac	atcgttagga	ggctgcctag	ggcctgagaa	480
ataggtcaag	actgctaact	tcaaccaagg	gcagtgtccg	ggaggaatgc	aggggtgaaac	540
catctgtagg	tagcactgcc	aactggagga	gtctgtgccc	ccagggtcca	aggggtgtcat	600
tgatctgctt	atgtgacctt	ctgactctat	ataaggcaaa	gaaataatgg	ccttagaagg	660
ctgcatgtcc	ttgcttattc	agaaatgcat	ttgacagaga	aaaaggcatc	tgtcagaatt	720
caagtccagag	aagaattgat	tagaaaaaag	agctggaaaa	ttttctaggc	agtcccaacc	780
aaaaagacat	tgttttatgg	cataaatcca	aaagaatcaa	agaataggta	aggagacaat	840
aatcaaaacc	tcttagaaat	tagaaagttg	atgcatgcta	acagatttgc	tgaaacttag	900
aaaaagtaat	atgaagtagc	agagaggaaa	cagagtcagt	tcgatttaca	tccagagtca	960
ggtattgaca	acacgagatg	caatggaaga	aagagcaaaa	taaggaagac	tgggtggaag	1020
tcagttttta	gaggcagtc	ggtcccaaaa	tcccattccc	tactcccatc	ccagagactg	1080
ggggcatatt	tcttccctgga	gggaactttt	tctttttgag	atgataaaga	aaaggttggg	1140
ccgggcgcga	tggtctcacgc	ctgtaatccc	agcacttttg	gaggccgagg	cgggcagatc	1200
acgaggtcag	gagatcgaga	ccatcctggc	taacacgggtg	aaaccccgctc	tctactaaaa	1260
atataaaaaa	ttagccgggc	gtggcgccgg	gcgcctgtag	tcccagctac	tccggagggt	1320
gaggcaggag	aatggcgtga	acccgggagg	cgagctctgc	agtgcgcga	gatcgcgcgc	1380
ctgcactcca	gcctgggcga	cagagcgaga	ctccgtctca	aaaaaaaaaag	aaaaagaaaa	1440
agaaaagatt	gttgatctga	gcaacagtag	gaggagtcca	gggcggggga	ccactctgac	1500
caccaggatt	ccatgcacaa	ctccaccctg	aagctgagac	tccccagacc	acatcctgct	1560
tctccctcct	gtcccttgcc	cttctgcttc	ctggatggat	attggataga	cttttctggg	1620
aagtctgatc	aacctaaaga	cagaatttca	aaagtccctc	catcctggcc	gggcacgggtg	1680
gctcaagcct	gtattcccag	cactctggga	ggccgaggcg	ggtggatcac	gagggtcaaga	1740
gatcaagacc	atcctggcca	acatggtgaa	accctgtctc	tactaaaaat	acaaaaaatt	1800
agccagggtg	gttggcgagg	gcctgtagtt	ccagctactg	gggaggctga	ggcagggtgaa	1860
tcacttgaac	ccgggaggca	gagcttgag	tgagctgaga	ttgcaccacc	gagctccagc	1920
ctggcgacag	agcgagactc	tgtctcaaaa	ataaataaat	aaataaaaaat	aaaaataaaa	1980
gtttctccat	tctaacagtt	caggcatgtc	atctcacgtg	cagctcacag	gccgcagccc	2040
tccttaggtg	cccagacttc	ctgtgcttgt	tattttgtgc	agacaactag	gaatgcatgg	2100
tgtttccatg	agaagaacaa	gggacaaaca	aacacaaaag	ggtggcaaca	cagagaaaaat	2160
ggaggggaatt	tattcaggga	gggaatgaaa	cacaacaaat	aagcgtaccc	caaatatctc	2220
agagtgcgaa	aaacataaac	atggttaacca	taaaataaga	acagttgctt	cgaaaagcaa	2280
cattcggaata	acacaaagga	gctcttgga	cttgatccta	gggaaaaaag	caaaattcag	2340
tgaaattatg	tcacgtgaaa	actcaccaaa	ttccctgaaa	gcagagttaa	gggatgaagt	2400
aatatgaaat	attaacagca	gaggttaaga	aattaaagga	caagttctga	aggtccaaca	2460
gccaaacata	ggaccagtgc	ttgaataaat	ctgaagaacg	atcatttcta	aattagaatt	2520
ccatacccag	ccaaacaatc	aattaaatat	gaggtagaat	aaacacactt	taaggcatat	2580
ggcatcttg	aaattcgccc	tcagtgcctt	ttcctactga	agacactaga	ggttgtaaac	2640
cctcaaaagg	agaaagaagg	ggatgaggca	caggatacag	ggaacagggg	atccagcact	2700
gcagtgcacg	gagcagtgga	gactcatcag	gcagtgcggc	aaccagtcca	gatggtggga	2760
ggctgcagga	gatatttctt	cagaaaaaga	ctgatagaac	acttcatgca	gctgaaagaa	2820
ctggcaatgc	atttggtgtg	aatgagttag	aagagggaaa	ataacaagac	aagtattatc	2880
tgtagaaaaa	aaaacgaagt	ggtataggga	tagaaaaattg	gactttacta	catgggttag	2940
ctaagaatta	catttatgtc	atccttatac	tgtaaatgga	acagcaggta	tcaaagttac	3000
tatttatgga	ggaatgggtg	aggggttggg	gggaagcatg	tttgctggag	ggaggaggag	3060
aataaatgtt	ttatctccac	acttctctag	gggaatctac	agataatgct	aaaaatgaaa	3120
aatcaagaag	agcataaaac	atgttattct	cagaaatgca	gctaaataca	aagcagctga	3180

T090506 000000

tttgttctgt	tgcagtaata	taggagcaca	ttttggccat	tgtaattaca	gggaacaaag	6900
ggattgcgga	cacatatctg	gacttctttt	cctcccttat	tgttgtggaa	gagacactag	6960
aaatgctcaa	acacctgcaa	tatacagaat	atacacaatt	ttattccagt	atttccctaa	7020
catatgggtt	aaaattattc	caggatataca	gtgtatgcaa	ttctgcatta	tcacagagga	7080
acaacttctt	ttttaaaaaa	taaataggtc	agccattttt	attaacgtgc	aaaaacttta	7140
tcactctaac	atgctctagg	tagttgagga	aaagaggtct	gatcactgtt	tgtattttat	7200
tttctttgtg	ggaacatttc	acctgctgag	tgtacatgaa	tttgctttct	ataaaaggct	7260
tttatgagtt	tacagtagaa	tcagtggaa	gaagagttaa	taagggtctg	ttttaaaaaa	7320
acaaacaaac	aaacaaaaca	aataattaaa	aaaaaatttt	acattccttc	ctattctcta	7380
actacacttg	ggaagtgcac	ttcagataag	tttgcagtgt	gactgagaga	tgaaggaaat	7440
ccatagaaaa	ggtcctctta	gtgaacaaaa	tttagttatt	aactttatag	ctatgaaatt	7500
tccccgggca	tttgtttttg	ttcaaacaga	ctttaacctc	tgcatcatal	ttaacctgc	7560
gacatgcgta	cagtatgcat	attttgtttt	gaaaaaaaat	gtttcgttcc	agtctgttaa	7620
gaatattcaa	aaataataaa	ggtattgctt	aataaaaattg	ctagaattgt	ttagcagtac	7680
atgcacaata	ttttactaga	ttctttgttt	taatagtgtt	ttgttgagac	tgaaaatctt	7740
aaaatggtct	gcgcaaatat	aaaaaaaaag	aaaacaccaa	aaatgcaaaa	ttctcccgtt	7800
tttgttccct	tttaaaaaat	tttttttctg	caaagtcaaa	tacattcaca	tgtggacaga	7860
tacatacaca	taggcatcat	attttagtgt	atggaaacat	ggtgcttttc	tggggacaca	7920
agctgaggaa	gtgaatggct	cgggggagac	acattaattg	catggaattg	ttgactgtga	7980
aacacttgta	gaaatgagca	ctttggtatc	ccaaccaatg	gtggaatata	gatttcaatg	8040
gcgctggggg	gacgagaagc	agaggaattg	agggtgcaag	tgattcctga	ggaagagctc	8100
acagggtgat	tttattcaga	tgacctctaa	gggaattggc	aggaaggagt	ctgttctgac	8160
ctttatctac	ctctgctgtg	gtaaggccac	tccatgtgcc	atctcaccat	ctcttcagcg	8220
ttctcatgc	tgcttctccc	cgtgccatag	gcgtttccat	tcttgagga	aaatgayaat	8280
gcaagtgcaa	attccactca	cttttatgtg	tatgacaata	aattattctt	tctaaacact	8340
tagcaaaatg	acgaaaagca	gtattcctta	aaatataggt	tttcattttc	tcaatatatt	8400
ttgaactgac	taaagttctt	tacaaagaca	agaggatcag	aaggttccac	ttaccctgtg	8460
tttagcggtt	gtttgaagat	aatgccaaac	aaaagggtgga	aaactaaaac	caccattgct	8520
ttacataaga	ggtacacact	gccccccacc	cccaaaaaaa	aacacagctt	tgaaagtgtg	8580
gagaaacact	gcagtcttca	ttgtaaatat	aaagtataaa	tttaggtgag	gaaggaaacg	8640
taaggaggga	aggggaatga	gtcctttctc	cccataaggt	cagccagcat	tggaatagtc	8700
tctaattctg	gcggaatatt	ttctttgtca	tggtcatcta	ttcttattac	aggagaatga	8760
tttcagtgcc	tagtatttat	tagtgtaaat	gtgtaaccac	tttcccgcaa	tatttccact	8820
ggacatgttg	aagcaaagca	gcttcttctg	gggtcaggca	gaggatccaa	ataggcaacg	8880
actcctttcc	caagctcaga	aacaatcact	gatgatgcag	atttcactac	atccgttgat	8940
tctttgtagt	agttttcctg	gcacacactt	gagcatgctt	aaggttgtgc	atatgttcat	9000
tttgaacaaa	taagttcagc	ccctgctcct	ttgtaatcat	catcttggtt	agtttttcc	9060
gtagaggatg	tctaccgtat	actggctaatt	gaactacaat	attaaaataa	ttattttctgc	9120
aagcaagttg	aaaaccaaga	aaacaatatt	tgtttcataa	atgtatggca	tagattttccc	9180
tgttttattat	tcttttttat	tgcaatagag	aaatttcagt	ttctggaata	tgttggtact	9240
gctaagctaa	atggcaataa	acatagagtt	caatgtcatt	ctttatttgc	ttacattttg	9300
gtgatcagtt	atatgaact	tttcttgcat	taaaaagata	gtatttttcc	cctctctcac	9360
aaggcagtaa	gtgaaagtgt	ttcttttaaa	tggcatcatt	acaaaaagta	atttgggttc	9420
ttaccaataa	atttggtacct	taggtactag	aacctgtagt	cattaaaaca	aaagaaaata	9480
ggcagatagc	agaaacaaaa	gaatgacagg	aaagaaggaa	ggaaagaggg	gagtgaaggga	9540
gggaggggag	aaggggaggga	tagagtcagg	gaatgagggg	gaaaggagggt	ttcatatgaa	9600
tgaataagta	catacttttt	tccgggggaa	aaaaacataa	atgaaataag	caattggatg	9660
ccagacccat	gtgccaaata	cctgaattgg	catatggtat	ttgatattctg	aacaacatca	9720
aaaacgttaa	ccagtctgaa	gcatgattta	cattctttct	cagtaacaaa	gacattttaca	9780
attttctctg	tactcaaagc	attaaatcaa	cacagaactg	aaagctgcat	tttgttttat	9840
ttattttagaa	ctgcagtcag	gtattttaatt	ctctttctgt	gtgtttgttt	gttttttgag	9900
atggcatctt	gctctgttgc	tcaagctgga	atgcagcggc	aagatctctg	ctcactgcaa	9960
cctccacttc	ctgggttcaa	gcgattctcc	tgctcaagc	ctctcgagta	gctgggacta	10020
caggcttggt	ccaccacgcc	tggctaattt	gtgtattttt	agtagagacg	tgggtgtcgcc	10080
atgtttggcca	ggctagtctt	gaactcctga	ccttgggaga	tccgccgatt	aggcctccca	10140
aagtgttggg	attacaggcg	tgagatacca	caccagacca	ggtattttaat	ttcataagtg	10200
tgcatatgca	tatatgaggc	gttagggtta	tatactatgg	catatcttta	gagagatata	10260
aagatatata	tacatacaca	cacacacaca	cacacacaca	cacacacaca	tcgcttgcaa	10320
ataaaacttc	aaccaaaca	ttatgtagtc	cataacagca	catgtatacc	ataatagta	10380
atgatcctac	ttgtttgtca	aagtttagagc	agcatggtca	tttaaaaacc	atatctactt	10440
tgacaaggga	aacagactct	caaaatatct	ccattaatga	ataaatcaca	attttgaaac	10500

aggcagaatc tccatcttcc aagctttaac aatgtttata aaaaacctaa tatagcaggt 10560
 aggtattggg tgacaatgaa taataaagact ttcagtgggg ggggaaggaaa ataactaagt 10620
 atagttttca agcaatgtct tcatgacatt tataagaact atcaaacagc tacaaattct 10680
 agaaattctc caaataatga gaaaatgtat agataatctt cttagccttg gaataaaact 10740
 taaggcatga aacaaaatat gaactatggg ttttattctt gagatactgt acttcagggc 10800
 tatgtttacc acagacaaga cattcagatt aaactcagaa gaaaatcacc tggttatttt 10860
 gtcctgggtc acacaggtag gtaatgcaaa tgatggaaact caagcatctt ctgattacaa 10920
 attacacaag ctggctccga ggacacagtgg gatccctagg tctcagacac acttgaagag 10980
 ttgaatggat tttcttcata ctccaagata tttgtagaat cactcaatct taaatgaaaa 11040
 aatcaaaatg atcaggaaga tctagcgaat gtctcagagt tcgtttgtca tgttacattt 11100
 tgttccatga ctttgctgtg ttattcaata ttttgagggt aaaggagaag agggctctatg 11160
 ggaatatttt aataaaatat agatttttaa ttttattttt taatgtggag aaaaggcaca 11220
 ggatcttagg gcaaagccat ggtttaggga tgagctttgg tcccagggtga cacagggagg 11280
 tcaatgatgt atttgtacgt gacacctcat gcaagaagaa tacttcgtgg caacattgga 11340
 ggcttaaaag agataagtaa tataaatgtg cctggacaaa acagggtgctc agtagtagtt 11400
 agttatcatg actattcatt cacaaagtga aactggattg gcttgctcat agggactgct 11460
 cctggaagtt gtccagagtt tctgaatttc tttggcttat ctcttaatta catttttttt 11520
 ttaacaacac ctccatctct taagctagca gactgaccat caatagattt tcaatacagt 11580
 ttgaaagtct taacatatat tacagaacta aagtgaagctc tgatgacttt taatataaac 11640
 agcattgggt attttcgatt tccactccca aaaggctact actgacaagc aaaagttaaa 11700
 ggcacttaca caaattgaag tggttctaca agcaagtgtg aattgatcaa cagtggtagt 11760
 agaaataatg atgcaacttc aaagtgggtg ttttaaggcag tcatagatca aaaaatatat 11820
 ataaatattt gatgcctctg aatttccttaa aaaaactata gtaattttta acatgaaaat 11880
 gtttaaatg gaacatttat tatgaaaatt aattaaactg aattaatata tattttaatt 11940
 aacactataa ttattataga atgaaataac agtgaanaag ttagaaaacc tggtcagttt 12000
 ttgataaagt atatggaaat agattaagca gggctcttga gtaaattatt tcattgattt 12060
 gtatctattt aggtaggtga gagttgcata gaatcagtg cgagaaggat cagtgaataa 12120
 aatttacaac ttcagtgaag accaggtaat gagcattgat ctatgaatac agactttctt 12180
 cagtgactat ttcccctaaa actcccagct caccgcagca ctgctgcttc aagattccag 12240
 ttattggcgt gctagccaag tagaagggtca tttttaccga aacgcaaatt tcaacttatg 12300
 gccattttct actgaccatt tcatgcaaaa atggataaaa caataggaaa tataaactac 12360
 agcaaaagtt aaagctctat atggagctta aaagaaaacc tcttgctttc tttttcttcc 12420
 tttttctctt gttttctttt tctacctttt tctgcataag gcatttattt tcatatcatg 12480
 ataagcattc tcatgtttgc acttaatttt ccttattttt atttttctta gatttggtga 12540
 tggtgtgtgg catattaaaa gtaggaagga ctgtataaac tcatgtatta tttttaaat 12600
 gtttttctga atgtactcaa gtactttttt atgtgaatat gaacacggaa taaaagtact 12660
 aaaaccagtt aattatgaga gactaagaat gtggaaagga acattccgga gtatattagt 12720
 agctaaagaa atgccttgga tcttaaatat caactttctaa aattattaaa atacaaatat 12780
 taaaaagata tagaggccac tgctaaagtt tgtttacgoc ttattttctt ggttgcttag 12840
 attattcggt ttaggtgaat ttgctttttt tgtccacgtg gttatgttaa cccaattat 12900
 tcatccaaaa cggaaattggc taaactcctt tatgcacata tttatattag ggctgattat 12960
 tttgctcatt gagtttcaaa aaattatcta gaggactgag aagttttcat tgctttactt 13020
 aattttcttt tcgcttgtgt gattttttatt tcttactctt gactatatct ctatacgggt 13080
 tgaagtaaca gggcagaaag ttaagctaatt aatttctgct gacttgataa ttcacagtt 13140
 tgacaaaaag accagtgggc caccattagg aactgaaggc aactgaaatg acatggctta 13200
 ctcttgctgg aatcttagct tgaaagttga acatctactc cacaatgcca cgggatccgt 13260
 tcatgatatc atttgctgaa gcacttgcca agaatttcat tatttagaaa aagcagaatt 13320
 aacattttcta tctattattt ttcttttctt tctttaagct gaaaggcatt cagaggctgt 13380
 cagtaaaata aatctatcag gaacaaaatc attttcaaaa tttttaaaca tgatttattc 13440
 ttgatgcaaa tcttattggt cttacaattc tatgcaagtc aagttgagct aaagcatttt 13500
 tatttaattc aattttcttt cttctgaaat gtgatacagt aaaatcaggt tttgaatatg 13560
 tacaacaca tcaggatgat tattataact acataagtaa aatatatgta aaatattatc 13620
 atatcttcac catatttaga gtctaataat tgttagattt tttgtgtgtg catttttctt 13680
 tccccctca gaaaacgtag ttttttattt aattcatgtg gtttttctat agctttctgg 13740
 gtctcatcaa atttcacatg aaactatgca gagtcatatt tatgttaagg aagacatgca 13800
 attaaaacc taccattttg ttttgttagt cccaacacgt atcaaacaaa aaacttatgt 13860
 tgttagatgt agatttgatt atctcccttt atttatattg gtctctctct ctctctctct 13920
 cccgcctca cctctgtct cactctcact ctctctctct cactttctct ctgactctct 13980
 ttcttttcaa ctccagttgc aggaatggat ctcatattgaa atgagctgca ctgggtctcag 14040
 catggttggt taaccatgta aactatctca tgatgcttag aattgaagag aagcttaaac 14100
 gcttggtgca gaaaaatat ttacaatata caaaacacat taaatatatt attagaaaaa 14160

gtttagttgt gcaacaaaga cctttaattt caactaaaa ctgatgcagt aatgtattac 14220
 aatgacccaa aaagaaatat tcttttcaaa atgacttcgg gaagctatca gagtttgtgg 14280
 gaaaaatgct aaggtaatac tttcctaaga acaaatgtaa agctgcaaac aatgactttg 14340
 aattttttcaa gattagcagt ttggattttac atgtattttta acaaaatata aaaaattttac 14400
 tttcaaactc tggcttttaa aaaaaatcgt gtggctcatg cctgtaatcc cagcactttg 14460
 ggaggctgag gagggcggat cccaaggtca ggagactgag accatcctgg ctaacaaagg 14520
 gaaaccccg ttttactaaa aatacaaaaa attagctggg cgtgggtggcg ggcgcctgta 14580
 gtcccagcta ctccggaggc tgaggcagga gaatggcgtg agcctgggag gcagagcttg 14640
 cagtgagccg agatcgcgcc actgcactcc agcctgggca acagagcgag actacgtctc 14700
 aaaaaaaaa aaaaaaaatc atgtttcaac tgaaatggat atttattatc tgcaaaagtc 14760
 cattttgttg catatattgt ttaaaataat tcttaagaaa ttgttacctt tctattttcta 14820
 tggagaacta acaccttaac acaagcttag ccccttttcc caagacacaa cgtccccccac 14880
 aatgccactg agttttgtgtt tacctgaata ctttcaaacg acagctgata cttgaataac 14940
 atgggtttga actgcatgag ttctcttcta tgaagatttt ctttacctct gccatccctg 15000
 agacagcaaa accaaccctt cctcatcttc ctcttcaaaa gcctactcaa catttgaaga 15060
 tgatgaagac gaaggccttc atgatgactt catatgactt tcccttaata aatagtaaata 15120
 atacttttcc ttctttagt ttttttatac cattttctct tctctagctt actttattgt 15180
 gagaacacaa tttataagca tataaaaggc agtatagcaa gatcccatct ctaaaaaacaa 15240
 atattaaaaa aaaaattagc ttggcagagg ggcaggcact tgtggtccca gctaacagag 15300
 aggctgaggt gggaagattc cttgagccca gaagtctgag attgcagtga tggcaccact 15360
 gcactccagc ctaggtgacc gtatgtcttc attgattatt tctgttatca gtaaggcatc 15420
 tagtcaacag caggctatta gtggttaagt tttgggggag tcaaaattat acatgaattt 15480
 tcaactgttc agaggctaga gcccctaact ccagattttt tcaaggacta tctgtatata 15540
 caattgtagc actgctgcta taaatgtgca gatatgtttt aaatgatcta aggctaacaa 15600
 aaacatatc agcagttttt ttaattttta gaataatcta ttcagaatgt gtatccctgt 15660
 gcaattaatt acaaatagct aaaatcttgc aaaatattta atgtatcaaa tcagcatgtg 15720
 atttcattta tagaaataaa agactagttt tctcccttct tttacccatg aacttggcta 15780
 attaattttc tatttttccc tcaaactttt ctcaaagggtg ggtatgaagg gaaaacttgt 15840
 ttttgtgaca ctagagagaa attgatgaag cctgggcaca acgtcatttg tctccctgtc 15900
 acaaagttgc aggttagctg gccattcatc acctggtaca cagcacacct catcttgacc 15960
 aaagagcacc tttcttcac agagaagctg tgctattgag agcactggga accaggtctg 16020
 aattggaaca agaggcagaa aagcagaatg atrtttcttt ctaaaatcat ataataaaca 16080
 ccaataaaat ttctgaatag tagtaacgtg tcttttgta ttcaaagtag tattatatag 16140
 cttttctctc tcattttatt gaaagtttca ggaaggggga atgtactaaa gcttaaaatt 16200
 aatatctaata gcttttcac ttgagaacag tatgtacatc ttgcacaact atattttagt 16260
 ttgtataaaa tagacatata aattacctgc attcatggct ttcattcatt tatctgaata 16320
 aacttactga gcagcctcta tgttccctggg actgggcaag gcattggaga aatagataca 16380
 aaagacctat ttttggactt ccaggggttc ttagaccact gtggaaaaag ggcatacgat 16440
 tacaatgcac gttatgtaaa aaatatggca aagttagagt acactggaag catttaactc 16500
 ctattgcagc aggttagttg cacaaataga gtggcatttt aaatttaata atcagatcta 16560
 aattcagcca gcaaaagaca cagaaatttt gtcattgtgca aagatgggaa atatcaaaat 16620
 agaaagttgg gggaagagtc actttataaa acaaatgatt accttttagat tgaaagaaag 16680
 tcatgacccc tattgaaaac agacagacaa atgtcgggat aggatctgtt gaggaacaga 16740
 gggagtaaca gtggggaatg cctcaatgct attttgcctt tcagcagaga tgggcagaag 16800
 agatttgaaa aagggttcat ttttatagat gtatgtagggt atttgtatac gtgtgtatgt 16860
 gagttcacc acacatgtat gtatgtgtat taataaccca ctgacctcaa agtaagagag 16920
 aaataggatt taccagtat ttacccaaga atccccatca tctttatccc aggattctgc 16980
 agtcagcaaa ccaggctttt taacactctc caatcatgag gtattttaaag arctccatga 17040
 tttgttttgt atttaacgct gcaataacca ttctcagata aacatgtttg agggcttctt 17100
 gagatacatt tttctaagga aagtttatgg gttaatagag ctttaattgt tttgggtata 17160
 tattttccaa tttccctacc aacatttntg caaaaggcac agagcaatcc agctgtacac 17220
 atgcatgctt gctgcatttt catagaaagt tcttccctacc atgaaaacat accttttact 17280
 cagttctctg aactgtggat ttcacgtcag gagagtaaaa atgtggnggt agttatgttc 17340
 ttgggtttct ttgggagtgg gttcttgagg aaagagatga caaacaagaa taggcaactt 17400
 caggctctca aaccncagaa ttggcaaata tagctaaacc ggaaggggac agtcattttc 17460
 aagtgtgtgt ttttttttaa atatcaggta atttttataa tctacgttta atataacttt 17520
 atcagcaatc aaaaaaaaaa ctggtcaact tgaatgatct tagtctgtctt ttctatgagg 17580
 atctctctct gatgtaaaat atccaaaggc cctgttcaca ccttaggaca ccagttagca 17640
 ttctgttctg ttgtatcaaga aatatatata cagatgctct ttgacttaca atgaggcgcc 17700
 atcctgataa acccataata agttgaaaat attccaagta aaacgtgcat ttggtacaag 17760
 tacacctaac ctactgaaca tcatagttag tctgtcctac ctgaaacgtg cttggaacac 17820

ttacattagc ctacagttga gcaaaatcat ctcacacaaa accaattttt ttttttgaga 17880
 ttagtattca ctcttgttgc ccaggctaga gtgcagnggc acaatctcag ctccctgcaa 17940
 cctntgcctc ctgagttcaa gngattctcc tgccctnaacc tcccaaatac ctgggattac 18000
 aggcattgtc caccacaccc agctaattct gtatttttag tagagatggg gtttcaccgt 18060
 gtttgtcaga caaaacctat tttatagtga agtgtcgaat atctcattta atttattgat 18120
 gtttactga gtgtatatca cttttaaacc atcgaaaagt ttaaaatcat taagtcnaac 18180
 ataactgtc aaaccattat agtcgaggac catctctaata ctgnaatatg aaacattaca 18240
 ttacatattt atgtatcata taatacttca attatataaa atgaattttac atatgaatcg 18300
 aaatagtatc cacacatatt taacaatata tgtacatata tttcattttca catagtgtag 18360
 acccctagaa attaggtcat tgtctgccta ctccaaatat catctaaata ccatccaaag 18420
 gttgaaaatt agttcctcaa ttatgttaac atttcagtggt aaacattaaa atggtagtaa 18480
 ccataagctt gccattaatc cagtaattgac atcagatttt tgaagattta tgttcaattt 18540
 cagacttcat attttaaaag atatgagcta tgagaacatg acaatgatta aaactttaca 18600
 aaataaaata tctggggaga aaggaataat attgggatat attactgaga aggaaaagaa 18660
 ggtgaaagag agacaactta tttttcaggc atctgtcaga gccagaact ttggataaat 18720
 tatttctggc tctcacacaa aacttgcata aaagggtttt taatcctaaa tttttggagg 18780
 agatacaaat ctctgagaga gtatgaaaat gagtcagagt ccataaaatc gggaacatct 18840
 gttcttggtc tcaaacccca tgccaggacc atgttctttc gataacaaca cacttaatac 18900
 agtctgtctc tctaatcag gaaagacaca aggggtctatg aaatcactta aaattcaaga 18960
 tttagcctta attagtaaaa agaaattgca aatttaattg tcagaaatgt ggaagaaatg 19020
 caataacatt gtttaggttt atattcctca aacctttggc ctcaataaa agggttagggt 19080
 tccgtattgg ttaaggatga tcatatcaca tttatataaa atcgctaaca aaatcagtc 19140
 atattaactg aaaaatgggtg ttcaggacaa tgggtcaagat gaataataga cactaactcc 19200
 tattttgaca agtttataaa ttagttaagg atacaggcac atggcttaaa gacaattggc 19260
 agcacacttt tcatcccatg ttctcattct gttgttggca aataacaaat tatctttgtg 19320
 tccagtgaat tagtgatggg aaatcattct cttaaacttg ataaagaaaa ttactgttct 19380
 ccagaaaaaa atatttcaag rgagagaata tcagtgaatg aatgagaact tataaatgta 19440
 aggaatgcct cattataaac atagtattat atccagctca gtgtcaacaa tggtaatttg 19500
 tggaggaggt tagcgattct ccatgaactc gacccaatgt cataaacact catttctcaa 19560
 gaaaacattt aatttaagga accctcagtc tgctttttag caagatatgt agtttcaata 19620
 ataattattc ggtttgaact gttttaaaact taggcacact gggtagttgg cctctccatg 19680
 accaactggc ttttaggcatt gtgtctcactt tctgtgagat ggtagtaagg gataaaactg 19740
 catctgccca gcatacagag gattctggat atcatgggct atccntggct tttagcctgc 19800
 tttctggaaa taagccaaaa ataagtatct ttataaggcc tgctagggtt tatgtgcaga 19860
 aattctaaat aattttcatt atgaaatata gtaaggagag gccgggcatg gtggctcacg 19920
 actgtaatcc cagcattttg ggaggccaag gtgggtggat catgtgaggt caggagttcg 19980
 agaccagcct ggccaacatg gcaaaacccc atcgctgctg aaaaaaaaaa aaaaaaatta 20040
 gctgaacaca gtggcagggtg cctgtagttc cagctgttcg gganactgag gctggaaaat 20100
 tgcttgaac tgggaggtgg aggttgcagt gagctganat ggcatcggtg tactccagcc 20160
 taggtgacag agtgagactc tatctcaaaa atgaaaagag agagagagaa agaaaagagaa 20220
 ggaaagaaag aaagaaagaa ggaagggaag aaggaaggaa ggaagggaag aaggaacaaa 20280
 gaagaaagaa agtgttgaat aaacttgtat ttagattgtc taggattatc tatataaggt 20340
 caaactcaat ttccagatta atattaatct attcccactt aataaaatgt ctctatttct 20400
 atatacactt aagagaccag ggattttgct gatggtaatt taaatttata tagtgaggtt 20460
 tacattttga aattaataac aattttttat tagcattaga gacttaattg tttaaagcaa 20520
 tcttacctac ctactatata agtagctaac tgctgcctac cacagcagtc acacaacagc 20580
 atgagcacia aatgtttaca gttaccatgt cctgcccag agggatatca aaaattacat 20640
 tggcactaca gctaaataaa cccatgtaaa acatatacta taaaagagt tagacatata 20700
 tcacattttt atggaaagta aaacattgcc taattttaga taacaaaagg aaaattgtta 20760
 tctacacaat aaatgaatta aaattctcat ttgtcataaa acagaaagga gagaaaatca 20820
 ggtcacttgt ttactagtca aaattatcag aattcaccca aatatgtagt gtgatacttc 20880
 taaatacaat aatatagaga gaaatatgag ccaattacaa tcatttttat ttagagtact 20940
 agttatttta atgaaattta tttattgata atggaaaact tttattttt tattttatgt 21000
 tacttcaaaa taattattaa cttacggaat agcttcaaga acagtataat agactttttc 21060
 ctgttttccc aaaccatatt ataataaatt gtcaacctga agcctgatca ttcagaatat 21120
 cttaaagtata catttcataa aataaaaagca ttctccttta tatcgatgat acagtattaa 21180
 aaaacagaaa gttatactga tattactacc atctagtcct cagatcctat ccaactttca 21240
 cttactatcc caaaaaataa ctttgagagc aaaagaaccc aatttataat tacatgttgc 21300
 attgagttgc cttgtctctt ctgtctcctt cagtctgaaa cagttcctca gtgtgtattt 21360
 tactttaata gccttgaaac tttggatggg tacaggccag ttacatttta gaangcctcc 21420
 tgatctgnct tgnctgatat ttccatatta ttagcttgag gtnacacatc tttgctaaan 21480

tatcagaaat gtttacccta tcatgtaaaa cattatttta cctgtttcca gtaatgatga 21540
ccttcacttt aattgcatga atgaagtggg agcctcatgc ctgggggatac cacacacaca 21600
cacacacaca cacacacaca cacacacaca cacaca 21636

<210> 4
<211> 5566
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> 659..2032

<220>
<221> allele
<222> 4484
<223> 99-13821-332 : polymorphic base C or T

<220>
<221> polyA_signal
<222> 2531..2536
<223> potential

<220>
<221> polyA_signal
<222> 2538..2543
<223> potential

<220>
<221> polyA_signal
<222> 2873..2878
<223> potential

<220>
<221> polyA_signal
<222> 3307..3312
<223> potential

<220>
<221> polyA_signal
<222> 3843..3848
<223> potential

<220>
<221> polyA_signal
<222> 3859..3864
<223> potential

<220>
<221> polyA_signal
<222> 4524..4529
<223> potential

<220>
<221> polyA_signal
<222> 5536..5541
<223> ATTAAA

<220>
<221> misc_feature
<222> 10,39,2574,2580,2978,4692,4696,5466

<223> n=a, g, c or t

<400> 4

```

ggcagcccan gctccggact ctgggagagc cagcgcggna gcaggagcgg gaggcggagg      60
agaagaagaa ggagaaggaa aggaaggagg aggaagagga ggagaagaag aggaggagga      120
ggaggaggag gggaggcgct ccgggcgccg tcagtgggca gcggaggcgc ggcattgcc      180
tggcagggga gagcgggctg ggctccgcgg ggccatgggg acccgcgcgc tgacaatgcc      240
tgggtggccg gagccgcgcc agccaccctg tcacctccac catcgccccc tgcaccaggc      300
ctcgccgcgg gccaccagca ccagcctcct ccgtctctct ctctctctct ctctccatta      360
ttgtttccca ctctacagag gatggggctg gctgatgatt aggaagcaag tcagaccttc      420
cttcaaagcc tggtaatat tatgtaggca aaagagacag agagagataa aagagaggga      480
gagggagaga gagagagagg agagagggag aggggaagag agagaaagag agagaggaga      540
gagaaaaaac gggaggaggg gataaggaaa ttaaaccctt taagtcaatg catattgtgg      600
tgacaccggc acaggcgccc tcacgggtgga gtcggccagg gctgtgcgtt cccaaaat      658
atg acc agg ggt gct tgg atg tgt cgg cag tat gac gac ggc tta aaa      706
Met Thr Arg Gly Ala Trp Met Cys Arg Gln Tyr Asp Asp Gly Leu Lys
1      5      10      15
atc tgg ttg gca gca ccc cga gag aac gag aaa ccg ttc atc gat tcc      754
Ile Trp Leu Ala Ala Pro Arg Glu Asn Glu Lys Pro Phe Ile Asp Ser
20      25      30
gag agg gct cag aaa tgg cga ctg tct ctg gca tct ctc ttg ttt ttc      802
Glu Arg Ala Gln Lys Trp Arg Leu Ser Leu Ala Ser Leu Leu Phe Phe
35      40      45
aca gtc ctg ctc tct gat cac ttg tgg ttc tgc gcc gag gcc aag ctg      850
Thr Val Leu Leu Ser Asp His Leu Trp Phe Cys Ala Glu Ala Lys Leu
50      55      60
acc cgg gcc cgg gac aag gag cac cag cag cag cag cgg cag cag cag      898
Thr Arg Ala Arg Asp Lys Glu His Gln Gln Gln Gln Arg Gln Gln Gln
65      70      75      80
cag cag cag cag cag cag agg cag cgg cag cag cag cag cag cag cgg      946
Gln Gln Gln Gln Gln Gln Arg Gln Arg Gln Gln Gln Gln Gln Gln Arg
85      90      95
cgg cag cag gag ccc tcc tgg ccc gcg ctc ctg gcg agc atg ggg gag      994
Arg Gln Gln Glu Pro Ser Trp Pro Ala Leu Leu Ala Ser Met Gly Glu
100      105      110
tcc tcg ccc gcc gcc cag gca cac aga ctc ctc tcc gcc tcc tcg tcc      1042
Ser Ser Pro Ala Ala Gln Ala His Arg Leu Leu Ser Ala Ser Ser Ser
115      120      125
ccc acc ctg ccc ccc tcc ccg gga gac ggc ggc ggc ggc ggc ggc aag      1090
Pro Thr Leu Pro Pro Ser Pro Gly Asp Gly Gly Gly Gly Gly Gly Lys
130      135      140
ggc aac cga ggc aaa gac gac cgg ggc aag gct ctt ttt cta gga aac      1138
Gly Asn Arg Gly Lys Asp Asp Arg Gly Lys Ala Leu Phe Leu Gly Asn
145      150      155      160
tct gcc aag ccc gtg tgg cgc ctg gag act tgt tac ccc cag ggc gcg      1186
Ser Ala Lys Pro Val Trp Arg Leu Glu Thr Cys Tyr Pro Gln Gly Ala
165      170      175
tcc tcg ggc cag tgc ttc acg gtg gag aat gcg gac gcg gtg tgc gcc      1234
Ser Ser Gly Gln Cys Phe Thr Val Glu Asn Ala Asp Ala Val Cys Ala
180      185      190
agg aac tgg agt cgg ggg gcg gcc ggg ggg gac ggg cag gag gtg agg      1282
Arg Asn Trp Ser Arg Gly Ala Ala Gly Gly Asp Gly Gln Glu Val Arg
195      200      205
agc aag cat ccc act ccg ctc tgg aac ttg tcg gat ttt tac ctt tcg      1330
Ser Lys His Pro Thr Pro Leu Trp Asn Leu Ser Asp Phe Tyr Leu Ser
210      215      220
ttt tgt aat tcc tac aca ctt tgg gag ttg ttc tcg ggg ttg tcc agt      1378
Phe Cys Asn Ser Tyr Thr Leu Trp Glu Leu Phe Ser Gly Leu Ser Ser
225      230      235      240
ccc aac act ttg aac tgc agt ctg gat gtg gtg ctc aag gaa ggc ggc      1426
Pro Asn Thr Leu Asn Cys Ser Leu Asp Val Val Leu Lys Glu Gly Gly

```

245 250 255
 gag atg acc act tgc agg cag tgc gtc gag gct tac cag gac tat gac 1474
 Glu Met Thr Thr Cys Arg Gln Cys Val Glu Ala Tyr Gln Asp Tyr Asp
 260 265 270
 cac cat gct cag gag aaa tac gaa gag ttt gaa agc gtg ctc cac aaa 1522
 His His Ala Gln Glu Lys Tyr Glu Glu Phe Glu Ser Val Leu His Lys
 275 280 285
 tat tta cag tcg gag gag tac tcg gtg aaa tcc tgt cct gaa gac tgt 1570
 Tyr Leu Gln Ser Glu Glu Tyr Ser Val Lys Ser Cys Pro Glu Asp Cys
 290 295 300
 aag att gtc tac aaa gcc tgg ctc tgt tcc cag tat ttt gaa gtc aca 1618
 Lys Ile Val Tyr Lys Ala Trp Leu Cys Ser Gln Tyr Phe Glu Val Thr
 305 310 315 320
 cag ttt aac tgc aga aag aca att cct tgc aag caa tac tgt ttg gag 1666
 Gln Phe Asn Cys Arg Lys Thr Ile Pro Cys Lys Gln Tyr Cys Leu Glu
 325 330 335
 gtt cag acg agg tgt cca ttt ata ttg ccc gac aat gat gaa gtc atc 1714
 Val Gln Thr Arg Cys Pro Phe Ile Leu Pro Asp Asn Asp Glu Val Ile
 340 345 350
 tac gga ggc ctc tcc agt ttc atc tgt aca ggg ctt tat gaa acc ttt 1762
 Tyr Gly Gly Leu Ser Ser Phe Ile Cys Thr Gly Leu Tyr Glu Thr Phe
 355 360 365
 cta acc aat gat gaa cca gaa tgc tgt gac gtc agg aga gaa gaa aaa 1810
 Leu Thr Asn Asp Glu Pro Glu Cys Cys Asp Val Arg Arg Glu Glu Lys
 370 375 380
 tca aat aac cca tcc aaa ggg acc gta gag aaa agt ggc tcc tgt cac 1858
 Ser Asn Asn Pro Ser Lys Gly Thr Val Glu Lys Ser Gly Ser Cys His
 385 390 395 400
 agg aca tcg ctc aca gtg tca tca gca aca aga ctg tgc aac agc aga 1906
 Arg Thr Ser Leu Thr Val Ser Ser Ala Thr Arg Leu Cys Asn Ser Arg
 405 410 415
 ctc aag ctg tgt gtt ctt gta ctg att ctc tta cac aca gtg ctc aca 1954
 Leu Lys Leu Cys Val Leu Val Leu Ile Leu Leu His Thr Val Leu Thr
 420 425 430
 gcc tcg gca gca cag aac aca gcc gga ctg agc ttt gga ggc atc aac 2002
 Ala Ser Ala Ala Gln Asn Thr Ala Gly Leu Ser Phe Gly Gly Ile Asn
 435 440 445
 acg ctg gaa gaa aac tca acc aat gag gag taa cggaaggacg agtgtcacca 2055
 Thr Leu Glu Glu Asn Ser Thr Asn Glu Glu *
 450 455
 cagcagcagc tggcccgccg tgaaaaatgg caactgctgt ctcattgtaac agaaactggg 2115
 tgcttttacc ctcgaattac ttattgcaag gccttttaggg taaaatttaa acagatgggc 2175
 ctgaatccaa acaaggacac aaccacagct ttttattgac taaaaggctg gaaagtgact 2235
 ttaaattttct cacaccattt tatacactgt gttttaatgt ttggagggtt tatttgcttt 2295
 cgtttttggt tgggtttatt tgtttgttta ttttttgac ttgttaatac aggatttatt 2355
 ttgggggatg gtttctcaga ggtaaaactaa gtctttttcac tgtctctatc tctctatata 2415
 tttctagtca ttgtgtgtgt tcatcagata gttctgtctt tatgtctgt cagcttctat 2475
 tagaggaatg attgctatga cctcatggta tagcaaaaaa caacaacaaa aaaagaataa 2535
 aaaataaaaa agacaaaaaa aagaaaaacaa caaaaaatna aaatnaaaaa aatccctaag 2595
 tctcccttct acccacagaa ccaacaacac ccttcccagc ctttcccttc cctcgccctc 2655
 ttctcgcccc ctaagcaaac aacatccgct tgcttctgtc tgtgtaacca cagtgaatgg 2715
 gtgtgcacgc ttggtgggcc tctgagcccc tggtgcacaa accagaaaca gagcagagcc 2775
 aagggggcct gacaagagtt cctttttagc tgaacaaaca agtgctctcc ataataagggtg 2835
 gaatcagaca gttaacacat ttttatgttg aaaacaaaat aaaaggaaaa aattaaaaaa 2895
 aactatcatg aactgtattg ctccagttcc catccccaaag tggcccagcc ctttcttgct 2955
 ggtccagctg gacaggagca gcnatctaga atcaggatgc ggggagtgag gaagtttttc 3015
 ctttgacaat gaagtggggc tttcattgtg atttttggtc tgttgtagta atataggagc 3075
 acattttggc cattgttaatt acagggaaca aagggattgc ggacacatat ctggacttct 3135
 tttcctccct tattgtttgt gaagagacac tagaaatgct caaacacctg caatatacag 3195
 aatatacaca attttattcc agtattttcc taacatatgg tttaaaatta ttccaggtat 3255
 acagtgtatg caattctgca ttatcacaga ggaacaactt ctttttttaa aaataaatag 3315

0500506 030601

gtcagccatt tttattaaag tgcaaaaact ttatcactct aacatgctct aggtagttga 3375
 ggaaaagagg tctgatcact gtttgtattt ttttttcttt gtgggaacat ttcacctgct 3435
 gagtgtacat gaatttgctt tctataaaag gcttttatga gtttacagta gaatcagtgg 3495
 aaggaagagt taataagggc tgttttttaa aaaacaaaca aacaaacaaa acaaataatt 3555
 aaaaaaaaaat ttacattcc ttcctattct ctaactacac ttgggaagtg cacttcagat 3615
 aagtttgcag tgtgactgag agatgaagga aatccataga aaaggctctc ttagtgaca 3675
 aaatttagtt attaaacttta tagctatgaa atttccccgg gcatttgttt ttgttcaaac 3735
 agactttaac ctctgcatca tacttaaccc tgcgacatgc gtacagtatg catattttgt 3795
 tttgaaaaaa aatgtttcgt tccagtctgt taagaatatt caaaaataat aaagggtattg 3855
 ctttaataaa ttgctagaat tgtttagcag tacatgcaca atattttact agatttttg 3915
 ttttaatagt gttttgttga gactgaaaat cttaaaatgg tctgcgcaaa tacaaaaaaa 3975
 agaaaacacc aaaaatgcaa aattctcccg tttttgttcc tttttaaaaa ttttttttcc 4035
 tgcaaatgca aatacattca catgtggaca gatacataca cataggcatc atattttagt 4095
 gtatggaaac atggtgcttt tctggggaca caagctgagg aagtgaatgg ctggggggag 4155
 acacattaat tgcattggaat tgttgactgt gaaacacttg tagaaatgag cactttggta 4215
 tcccaaccaa tgggtggaata cagatttcaa tggcgctggg gggacgagaa gcagaggaat 4275
 tgaggctgca agtgattcct gaggaagagc tcacagggtg attttattca gatgacctct 4335
 aagggaatgg ctaggaagga gtctgttctg acctttatct acctctgctg tggtaaggcc 4395
 actccatgtg ccattctcacc atctcttcag cgttctctcat gctgcttctc cccgtgccat 4455
 aggcgtttcc attcttgcaag gaaaatgaya atgcaagtgc aaattccact cacttttatt 4515
 ggtagacaa taaattattc tttctaaaca cttagcaaaa tgacgaaaag cagtattcct 4575
 taaaatatag gttttcattt tctcaatata ttttgaactg actaaagttc tttacaaaga 4635
 caagaggatc agaaggttcc acttaccctg gtttttagcgt ttgtttgaag ataatgncaa 4695
 ncaaaagggtg gaaaactaaa accaccattg ctttacataa gaggtacaca ctgcccccca 4755
 cccccaaaaa aaaacacagc tttgaaagtt gggagaaaca ctgcagtctt cattgtaaat 4815
 ataaagtgat aatttaggtg aggaaggaac ggtaaggagg gaagggggaat gagtcccttc 4875
 tccccatcaa gtcagccagc attggaatag tctctaattc tggcggaata ttttctttgt 4935
 catgttcate tattcttatt acaggagaat gatttcagtg cctagtattt attagtgtaa 4995
 gtgtgtaacc actttcccg c aatatttcca ctggacatgt tgaagcaaag cagcttcttc 5055
 tggggtcagg cagaggatcc aaataggcaa cgactccttt cccaagctca gaaacaatca 5115
 ctgatgatgc agatttcact acatccgttg attctttgta gtagttttcc tggcacacac 5175
 ttgagcatgc ttaaggttgt gcatatgttc attttgaaca aataagttca gcccctgctc 5235
 ctttgtaate atcatcttgt ttagtttttc ctgtagagga tgtctaccgt atactggcta 5295
 atgaactaca atattaaaat aattatttct gcaagcaagt tgaaaaccaa gaaaacaata 5355
 tttgtttcat aaatgtatgg catagatttc cctgtttatt attcttttta tctgcaatag 5415
 agaaatttca gtttctggaa tatgttggtta ctgctaagct aaatggcaaa naacatagag 5475
 ttcaatgtca ttctttattg catttacatt tgggtgatacg ttatattgaa cttttcttgc 5535
 attaaaaaga tagtattttt cccctctctc a 5566

<210> 5

<211> 458

<212> PRT

<213> Homo sapiens

<400> 5

Met Thr Arg Gly Ala Trp Met Cys Arg Gln Tyr Asp Asp Gly Leu Lys
 1 5 10 15
 Ile Trp Leu Ala Ala Pro Arg Glu Asn Glu Lys Pro Phe Ile Asp Ser
 20 25 30
 Glu Arg Ala Gln Lys Trp Arg Leu Ser Leu Ala Ser Leu Leu Phe Phe
 35 40 45
 Thr Val Leu Leu Ser Asp His Leu Trp Phe Cys Ala Glu Ala Lys Leu
 50 55 60
 Thr Arg Ala Arg Asp Lys Glu His Gln Gln Gln Gln Arg Gln Gln Gln
 65 70 75 80
 Gln Gln Gln Gln Gln Arg Gln Arg Gln Gln Gln Gln Gln Arg
 85 90 95
 Arg Gln Gln Glu Pro Ser Trp Pro Ala Leu Leu Ala Ser Met Gly Glu
 100 105 110
 Ser Ser Pro Ala Ala Gln Ala His Arg Leu Leu Ser Ala Ser Ser Ser
 115 120 125

Pro Thr Leu Pro Pro Ser Pro Gly Asp Gly Gly Gly Gly Gly Lys
 130 135 140
 Gly Asn Arg Gly Lys Asp Asp Arg Gly Lys Ala Leu Phe Leu Gly Asn
 145 150 155 160
 Ser Ala Lys Pro Val Trp Arg Leu Glu Thr Cys Tyr Pro Gln Gly Ala
 165 170 175
 Ser Ser Gly Gln Cys Phe Thr Val Glu Asn Ala Asp Ala Val Cys Ala
 180 185 190
 Arg Asn Trp Ser Arg Gly Ala Ala Gly Gly Asp Gly Gln Glu Val Arg
 195 200 205
 Ser Lys His Pro Thr Pro Leu Trp Asn Leu Ser Asp Phe Tyr Leu Ser
 210 215 220
 Phe Cys Asn Ser Tyr Thr Leu Trp Glu Leu Phe Ser Gly Leu Ser Ser
 225 230 235 240
 Pro Asn Thr Leu Asn Cys Ser Leu Asp Val Val Leu Lys Glu Gly Gly
 245 250 255
 Glu Met Thr Thr Cys Arg Gln Cys Val Glu Ala Tyr Gln Asp Tyr Asp
 260 265 270
 His His Ala Gln Glu Lys Tyr Glu Glu Phe Glu Ser Val Leu His Lys
 275 280 285
 Tyr Leu Gln Ser Glu Glu Tyr Ser Val Lys Ser Cys Pro Glu Asp Cys
 290 295 300
 Lys Ile Val Tyr Lys Ala Trp Leu Cys Ser Gln Tyr Phe Glu Val Thr
 305 310 315 320
 Gln Phe Asn Cys Arg Lys Thr Ile Pro Cys Lys Gln Tyr Cys Leu Glu
 325 330 335
 Val Gln Thr Arg Cys Pro Phe Ile Leu Pro Asp Asn Asp Glu Val Ile
 340 345 350
 Tyr Gly Gly Leu Ser Ser Phe Ile Cys Thr Gly Leu Tyr Glu Thr Phe
 355 360 365
 Leu Thr Asn Asp Glu Pro Glu Cys Cys Asp Val Arg Arg Glu Glu Lys
 370 375 380
 Ser Asn Asn Pro Ser Lys Gly Thr Val Glu Lys Ser Gly Ser Cys His
 385 390 395 400
 Arg Thr Ser Leu Thr Val Ser Ser Ala Thr Arg Leu Cys Asn Ser Arg
 405 410 415
 Leu Lys Leu Cys Val Leu Val Leu Ile Leu Leu His Thr Val Leu Thr
 420 425 430
 Ala Ser Ala Ala Gln Asn Thr Ala Gly Leu Ser Phe Gly Gly Ile Asn
 435 440 445
 Thr Leu Glu Glu Asn Ser Thr Asn Glu Glu
 450 455

<210> 6

<211> 1791

<212> DNA

<213> mus musculus

<400> 6

agccctcacg ggtggagtgg agtcggccag ggctgtgcgt tcccaaat atg acc agg 58
 Met Thr Arg
 1
 ggt gct tgg atg tgt cgg cag tat gac gac ggc tta aaa atc tgg ttg 106
 Gly Ala Trp Met Cys Arg Gln Tyr Asp Asp Gly Leu Lys Ile Trp Leu
 5 10 15
 gca gca ccc cgg gag aac gag aaa ccg ttc atc gat tca gag cgg gct 154
 Ala Ala Pro Arg Glu Asn Glu Lys Pro Phe Ile Asp Ser Glu Arg Ala
 20 25 30 35
 cag aaa tgg cga ctg tct ctg gct tct ctc ttg ttt ttc aca gtc ctg 202
 Gln Lys Trp Arg Leu Ser Leu Ala Ser Leu Leu Phe Phe Thr Val Leu
 40 45 50

[illegible]

Gly Leu Tyr Glu Thr Phe Leu Thr Asn Asp Glu Pro Glu Cys Cys Asp
 375 380 385
 atc agg agc gag gag caa acc gca ccc aga ccc aaa gga acc gtg gac 1258
 Ile Arg Ser Glu Glu Gln Thr Ala Pro Arg Pro Lys Gly Thr Val Asp
 390 395 400
 aga aga gac tcc tgt ccc agg aca tcg ctc aca gtg tcc tcg gcc acc 1306
 Arg Arg Asp Ser Cys Pro Arg Thr Ser Leu Thr Val Ser Ser Ala Thr
 405 410 415
 aga ctg tgc ccc ggc cgg ctg aag ctg tgt gta ctc gtc ctc att ctc 1354
 Arg Leu Cys Pro Gly Arg Leu Lys Leu Cys Val Leu Val Leu Ile Leu
 420 425 430 435
 ctc cac aca gtg ctc acg gcc tcc gca gcg cag aac tcc acg gga ctg 1402
 Leu His Thr Val Leu Thr Ala Ser Ala Ala Gln Asn Ser Thr Gly Leu
 440 445 450
 ggc ctg ggt ggc ctc ccc acg ctc gag gac aac tcc acc cgg gag gac 1450
 Gly Leu Gly Gly Leu Pro Thr Leu Glu Asp Asn Ser Thr Arg Glu Asp
 455 460 465
 tga gcgcagccag gcgcgtgcgc agagcgcagg gctgggcagg gacacgcgct 1503
 *
 tggcacagag cagcagtgc ccaccgggga tgctcacctg ctgcagcccg ggaactgaac 1563
 ccaccggggt gctctaccct tggacttctc gcaaggcctg tgggtaacat tcaacaagat 1623
 gggcccgatc cccaacatgg acacagccgc agctttttgc cgactaaaag gctgcaagtg 1683
 actcagtttc tcacaccatt ttatacactg tggttttaacg tttggaggtt ttctttgctt 1743
 tcagttcggg ttgggtttat ttcccgtttt taaacttttt tttttttg 1791

<210> 7

<211> 467

<212> PRT

<213> mus musculus

<400> 7

Met Thr Arg Gly Ala Trp Met Cys Arg Gln Tyr Asp Asp Gly Leu Lys
 1 5 10 15
 Ile Trp Leu Ala Ala Pro Arg Glu Asn Glu Lys Pro Phe Ile Asp Ser
 20 25 30
 Glu Arg Ala Gln Lys Trp Arg Leu Ser Leu Ala Ser Leu Leu Phe Phe
 35 40 45
 Thr Val Leu Leu Ser Asp His Leu Trp Phe Cys Ala Glu Ala Lys Leu
 50 55 60
 Thr Arg Thr Arg Asp Lys Glu His His Gln Gln Gln Gln Gln Gln
 65 70 75 80
 Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Arg
 85 90 95
 Gln Gln Gln Arg Gln Arg Gln Gln Gln Arg Gln Arg Gln Gln Glu Pro
 100 105 110
 Ser Trp Pro Ala Leu Leu Ala Ser Met Gly Glu Ser Ser Pro Ala Ala
 115 120 125
 Gln Ala His Arg Leu Leu Ser Ala Ser Ser Ser Pro Thr Leu Pro Pro
 130 135 140
 Ser Pro Gly Gly Gly Gly Gly Ser Lys Gly Asn Arg Gly Lys Asn Asn
 145 150 155 160
 Arg Ser Arg Ala Leu Phe Leu Gly Asn Ser Ala Lys Pro Val Trp Arg
 165 170 175
 Leu Glu Thr Cys Tyr Pro Gln Gly Ala Ser Ser Gly Gln Cys Phe Thr
 180 185 190
 Val Glu Ser Ala Asp Ala Val Cys Ala Arg Asn Trp Ser Arg Gly Ala
 195 200 205
 Ala Ala Gly Glu Glu Gln Ser Ser Arg Gly Ser Arg Pro Thr Pro Leu
 210 215 220
 Trp Asn Leu Ser Asp Phe Tyr Leu Ser Phe Cys Asn Ser Tyr Thr Leu
 225 230 235 240

```
<220>
<223> oligonucleotide 713.LF1.5.1
```

Variable	Mean	SD	Min	Max
Age	38.5	10.2	22	65
Gender	0.5	0.5	0	1
Marital Status	0.7	0.5	0	1
Education	12.5	1.5	9	16
Income	3500	1500	1000	8000
Health Status	0.8	0.4	0	1
Exercise Frequency	2.5	1.5	0	5
Stress Level	4.5	1.5	1	7
Sleep Quality	3.5	1.5	1	6
Dietary Habits	2.5	1.5	0	5
Work-Life Balance	3.5	1.5	1	6
Family Support	4.5	1.5	1	7
Community Involvement	2.5	1.5	0	5
Life Satisfaction	5.5	1.5	3	7
Overall Well-being	4.5	1.5	2	7

<400> 10
actgtctgat tccacctatt atggag 26

<210> 11
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide g713.LF1.5.1n

<400> 11
tgattccacc tattatggag agcac 25

<210> 12
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide g713RACE5R1

<400> 12
gggtagaagg gagacttagg 20

<210> 13
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide g713RACE5R-49

<400> 13
gggcatagca atcattc 17

<210> 14
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide g713CTGLF132

<400> 14
ggctgtgcgt tcccaaaata 20

<210> 15
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide g713RACE3N

<400> 15
aaaaatgttt cgttccagtc tgtaaga 28

<210> 16
<211> 29
<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide g713RACE3Nn

<400> 16

attgctagaa ttgttttagca gtacatgca

29

<210> 17

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide SG1polyA

<400> 17

tttttttttt tttgacagag

20

<210> 18

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide SG1LR100

<400> 18

tttgccattt agcttagcag tacca

25

<210> 19

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide g713.PU

<400> 19

aatattctta acagactgga ac

22

<210> 20

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide g713.RP

<400> 20

ctttatagct atgaaatttc cc

22

<210> 21

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide g34301.PU

<400> 21

ctgatcactt gtggttctgc gccg

24

<210> 22

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide g34301.RP

<400> 22

aggactcccc catgctcgcc ag

22

<210> 23

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide SG1LR1102

<400> 23

aaaatactgg gaacagagcc agg

23

<210> 24

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide SG1LF790

<400> 24

gcacttagag cgcggggt

18

<210> 25

<211> 15

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide SG1LF834

<400> 25

gccggaggca gccca

15

<210> 26

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide moCTGR1511

<400> 26

tgtcctcgag cgtgggg

17

<210> 27

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide moCTGLR20

<400> 27

cggaggaggg gatacggaaa ttaaacc

27

<210> 28

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide moCTG1440

<400> 28

tgggtcactg ctgctctgtg ccaag

25

<210> 29

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide moCTG5RACE1

<400> 29

tcacagtgtc ctggccact

20

<210> 30

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide moCTG5RACEn

<400> 30

tcctccacac agtgctcacg

20

<210> 31

<211> 983

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> 14

<223> n=a, g, c or t

<400> 31

aaaaaaaaaa aaanaacaaa aacaaaacat gaaacaggaa gacaggaaag atccatttga	60
cagagtactt gacacaggag agagaagaaa tactcatgta tctgaaagta ttcaaagggg	120
gagtgttagg agatgaatta atttaaaaaa tgagtaagag taaaatagtt taaagttaga	180
ccctgaggaa ctccaggga gacaaagtaa cacaaggaac aagcaatgtt agccactgcc	240
taactttcct cagggctcatg tgtgcctcgc cataattatg taaacactta cattgttaaa	300
acgaaattcg gagaactagt ttgagtaaag gggaaaagaa agtatgttat tcatgtcggg	360
gttggaataa tgtgatagggt tgaaattctc aatttcctaa ttggaaatca ttaagtcata	420
ctgaaacctg aaaattcaag aactgacaac acaattgatg ttgagatatg gaatttggtg	480
cctgatgaaa gattagaaaa ttattaaaag caatttcttc tgggtggtgc tacaagatgg	540
aagaagaaag gacagaaagc tcttcataat caggtagacg ctttgacttt ttaagtggta	600

T05000" 9054006

```

tgcctatatg ccttttaaaaa acaactcaat ttaaaagaaa attaagagat gctaacagcc 660
gattttaaga aaatttagta aaatattcaa ttgtataaag atacacaaaa tattggttat 720
ctacatgata gcaaagatga attaagggat ggggataaaa ctcttctcaa taacacccaaa 780
attaaaaataa aacataattc atatatctag aaatatcatt acagaaatat gttgaacttg 840
tattaacagc ctctcctcaa aggtagcatg gagaatcatg caaacttaat ttggagatac 900
aaaaaaaatt gagaatgtgt agtggtgttc ttttaattcta actgtaatgg ctgaataata 960
ttttgatcat gattgtgata cta 983

```

<210> 32

<211> 450

<212> DNA

<213> Homo sapiens

<220>

<221> allele

<222> 298

<223> 99-15663-298 : polymorphic base C or T

<220>

<221> misc_binding

<222> 275..321

<223> 99-15663-298.probe

<220>

<221> primer_bind

<222> 279..297

<223> 99-15663-298.mis

<220>

<221> primer_bind

<222> 299..317

<223> 99-15663-298.mis complement

<220>

<221> primer_bind

<222> 1..18

<223> 99-15663.pu

<220>

<221> primer_bind

<222> 430..450

<223> 99-15663.rp complement

<400> 32

```

tcccaccttc ttctaaacgt gttgcttcaa tacgttgata ggtgaggaca cttaaaaatt 60
agactttata gaaatagggt tttttttgtt tacatatata gttcttttgg tatcatatat 120
ttagcctctt tctaaaattt attttttgat actgaaggga gaaataggga gttattaatc 180
aacaggcatt aatttttagtc aagcaaaata aataagctgt agcgatctgc tctgtaacat 240
tgtacctaca gccacaatt atatgttgtc cacttaaaaa tgtgtagat ctcatagyaa 300
ctcttcttac cacaataaag taaaaattct gaaacaataa gtgaatacct aaataatata 360
aacaataata atattgtagt tttgggcact taataaatga cagcctcatt tctcaattag 420
agatcatcac aagttagaca gatgacgatg 450

```

<210> 33

<211> 476

<212> DNA

<213> Homo sapiens

<220>

<221> allele

<222> 398

<223> 99-15665-398 : polymorphic base A or G

<220>

<221> misc_binding

<222> 375..421

<223> 99-15665-398.probe

<220>

<221> primer_bind

<222> 379..397

<223> 99-15665-398.mis

<220>

<221> primer_bind

<222> 399..417

<223> 99-15665-398.mis complement

<220>

<221> primer_bind

<222> 1..20

<223> 99-15665.pu

<220>

<221> primer_bind

<222> 458..476

<223> 99-15665.rp complement

<400> 33

cgtaaagtgtg	aaaagcatag	cctcttcttg	gaatgttaag	tataaatatc	tgaaatactg	60
ggcttgatat	gtcaacagga	gattgatgga	taaaaataga	atztatata	aaaaacaact	120
ggacatatta	gattgttaac	ttggaagaaa	gaccatattc	aaagaagaaa	acatagtgac	180
taattttcaaa	cattttaagt	cttcctcttg	gaaacaaagg	aatatctttg	ttctaact	240
tcaaagaaca	gggttaaaaa	atagactcac	cacagagtaa	atgcacaatt	gacaatcgtg	300
aatgaattaa	aaaccaaaca	aaatatTTTT	tcagctttct	atctatgaaa	ctaagaaaca	360
ggcttcctac	taaggtaatg	aatgtaattc	acagagarca	ttcacgtata	agtttcattc	420
atgtttcaaa	tttcattgat	ttgatcaatg	ggttattcta	ataccctccc	ttattt	476

<210> 34

<211> 547

<212> DNA

<213> Homo sapiens

<220>

<221> allele

<222> 166

<223> 99-15672-166 : polymorphic base C or T

<220>

<221> misc_binding

<222> 143..189

<223> 99-15672-166.probe

<220>

<221> primer_bind

<222> 147..165

<223> 99-15672-166.mis

<220>

<221> primer_bind

<222> 167..185

<223> 99-15672-166.mis complement

<220>
<221> primer_bind
<222> 1..18
<223> 99-15672.pu

<220>
<221> primer_bind
<222> 533..551
<223> 99-15672.rp complement

<400> 34
ccaataccat aactcctcta taggacatgg aagagtatta tatatgacaa atgattgcta 60
tgattattat tatcagtgtt attattatcc taatcctaag taatccaata aaagaaaaat 120
acatctgtgc ctgtgcgtat gtgcacgtgt gtgcagtcaa atacaygttg agtaaaggta 180
aagtctagct gtatttaatc aacctacctg aatcctcagg aaaaaattct aaacctagtt 240
taaaacatgt aaactctaag ctctctcctt atagtcagtt agtagcagca catcttaaaa 300
tctgggtgtga atattctctt agttctacat gagtctaact aaacagagga ttattcttag 360
gtgtttgaaa gagacatatg tgacactgct gttttgagaa caatttaagt gttgtcttgt 420
catgtacaga agttctcata ttactttaca taaatggttg cataattggt ttatagtaaa 480
taatagactg tcaatatttc taggataact ccaaaacaaa atttcctaga mmacattttg 540
aaaaggg 547

<210> 35
<211> 502
<212> DNA
<213> Homo sapiens

<220>
<221> allele
<222> 185
<223> 99-15664-185 : polymorphic base G or T

<220>
<221> misc_binding
<222> 162..208
<223> 99-15664-185.probe

<220>
<221> primer_bind
<222> 166..184
<223> 99-15664-185.mis

<220>
<221> primer_bind
<222> 186..204
<223> 99-15664-185.mis complement

<220>
<221> primer_bind
<222> 1..19
<223> 99-15664.pu

<220>
<221> primer_bind
<222> 483..502
<223> 99-15664.rp complement

<220>
<221> misc_feature
<222> 54

<223> n=a, g, c or t

<400> 35

```
gtttaccatt agcactgtca tatttggtgtg acttgtcatt ctctacagcg gagnacgggc      60
tggcacgggg cctgatgctg acttgcacaa ggggaagcctc ctgtctctga cttccccagg      120
ataattcctg gggaaagtgt gctccctagt gttaagagcg gtttaatggc tggagggtat      180
cagckggctg accaggcaga gaaggagggt gaatcacctc tcagcactct ccacttagac      240
tttgtgtggt cgtcgggtgg tcaaaccctc taactagttg tattgcagat ttggcattcc      300
agtgcaaaca aaagacagaa acacaatgtt cacatgcttt ccagagatca cctggatatc      360
agatcatttg attttcaagt aagtcgaaac cttggtggaa atcattaact atcctgttta      420
tgacaaaaaa ataaaatccc aaatttcttc tcttcatttc ttacctgctt taaaattgta      480
tccaaagcgt graagtaaaa ga                                          502
```

<210> 36

<211> 455

<212> DNA

<213> Homo sapiens

<220>

<221> allele

<222> 205

<223> 99-5919-215 : polymorphic base A or G

<220>

<221> misc_binding

<222> 182..228

<223> 99-5919-215.probe

<220>

<221> primer_bind

<222> 186..204

<223> 99-5919-215.mis

<220>

<221> primer_bind

<222> 206..224

<223> 99-5919-215.mis complement

<220>

<221> primer_bind

<222> 1..19

<223> 99-5919.pu

<220>

<221> primer_bind

<222> 435..455

<223> 99-5919.rp complement

<400> 36

```
ctacagcaat gcagatttca attctgccat tgaattccca gacatattcg tcatcccat      60
tttcatcccc caccaccctg ccattttctt cgtgttaact tgttttctg actcacagaa      120
atcacctttt cctgtataca tttttaggat gtcagacttt attctaata tttctcctag      180
ttgcccccca aaattgtatt ctacrgtgtg attttaaagc tgaattttca agatgatatt      240
tcatatctat attttcacaa gcttttcttc tatgaatgtt attgtcagct gtcagggtgt      300
gagatggtac ttgatactac attctttcca agctgttgcc tgaatcggtt taagacaaag      360
tcattactag gctgtaaact gttgctctgc aaaattgagc agcacgtatt taaccactca      420
tacttcttag ctctccaaca ctttgagtca ataga                                          455
```

<210> 37

<211> 450

<212> DNA

<223> 99-16032-292.mis

<220>
 <221> primer_bind
 <222> 293..311
 <223> 99-16032-292.mis complement

<220>
 <221> primer_bind
 <222> 1..19
 <223> 99-16032.pu

<220>
 <221> primer_bind
 <222> 384..403
 <223> 99-16032.rp complement

<400> 38
 gttgtttaccc cacttcttcc cccagctcc cccttctca cacagttcat gccacatgcc 60
 actctcctgg actactggaa atgcgtcagt ccactctggg ctcatcccat catcccccat 120
 gctgcaacct gagagagagt tgcaagttgc aaatctgatc ttgtcaccac cactctccac 180
 actaaatccc tctaattgct cccctttct ttttgataa attccttctg cttgcatagc 240
 cacgtggttg gcttctatag catcaattca cactgtggtc acctgccttc tmctcactca 300
 ggaacttctc tccattgaag aagttcttct tccccatctc cagggcttcc ccactgacag 360
 ttgtatctcc ccataccaa gccaggtgg tcattctcat cca 403

<210> 39
 <211> 476
 <212> DNA
 <213> Homo sapiens

<220>
 <221> allele
 <222> 118
 <223> 99-16038-118 : polymorphic base A or G

<220>
 <221> misc_binding
 <222> 95..141
 <223> 99-16038-118.probe

<220>
 <221> primer_bind
 <222> 99..117
 <223> 99-16038-118.mis

<220>
 <221> primer_bind
 <222> 119..137
 <223> 99-16038-118.mis complement

<220>
 <221> primer_bind
 <222> 1..19
 <223> 99-16038.pu

<220>
 <221> primer_bind
 <222> 456..476
 <223> 99-16038.rp complement

<400> 39

T 0930506 00000000

gttgcttatt	ctttctctct	tctgcagggt	ataaaggaat	ctgaacacga	ctgatatttt	60
ctttaatttt	tagatccaga	tatacattgg	gtaaaatcta	cttcataagg	tttcaaarga	120
gcattcttct	gagcaaatct	gaaaactctc	taaactctat	tggatatgta	ctctttatct	180
ttatatgaat	ttaaattctt	ctagaagtta	gataaaaactg	tggtaaagct	acataatact	240
tttgacatat	tttcaagcgt	agacaaaactt	caattaattt	gtaagatata	ggaagaaaat	300
ttttccagtt	aaaatgtacc	tcttggtttc	tggagtgtta	gcaaccattc	acacttacag	360
ttcaaacagt	gcaacottgt	aaaacatata	taacttatga	agagatcgat	atctcttttt	420
ataaagcaaa	caagtaaatt	tttcctcaa	tccatgattt	atttttgtga	agtggg	476

<210> 40

<211> 498

<212> DNA

<213> Homo sapiens

<220>

<221> allele

<222> 133

<223> 99-5897-143 : polymorphic base A or C

<220>

<221> misc_binding

<222> 110..156

<223> 99-5897-143.probe

<220>

<221> primer_bind

<222> 114..132

<223> 99-5897-143.mis

<220>

<221> primer_bind

<222> 134..152

<223> 99-5897-143.mis complement

<220>

<221> primer_bind

<222> 1..18

<223> 99-5897.pu

<220>

<221> primer_bind

<222> 475..492

<223> 99-5897.rp complement

<400> 40

aaaagtgttt	gccagtcctg	tttcttacag	agcacagaac	tcagatgctc	ttataaagat	60
acaggataaa	tcacatcatt	tctgtctcca	tcacagaat	attattatat	gatttagatc	120
acttttttaa	aamagaacat	ggacttagta	cagaacaaca	gcaaaagcct	ggggaaggag	180
aggagtgcac	catgaggagt	caatggggag	cagaagccag	tccatttgac	tgatttggtt	240
cgtgtgcaaa	ataattgcta	aataattgca	tatatgtgag	actccgggta	ttttcaaaac	300
cagctggcaa	aattgtgtta	ttctctaccc	tctgtggct	ttcacggggt	ctctgttctc	360
tctccttttc	ctccattctc	ctcttaccct	aattcctgac	cactgtaatc	caataatcta	420
aggtttttag	atttgatga	ctaaggttac	ccatggaatt	gtttggaaat	gtagacctgt	480
aatggagagg	ggagaaaa					498

<210> 41

<211> 517

<212> DNA

<213> Homo sapiens

<220>

<221> allele
<222> 360
<223> 99-13601-360 : polymorphic base A or G

<220>
<221> misc_binding
<222> 337..383
<223> 99-13601-360.probe

<220>
<221> primer_bind
<222> 341..359
<223> 99-13601-360.mis

<220>
<221> primer_bind
<222> 361..379
<223> 99-13601-360.mis complement

<220>
<221> primer_bind
<222> 1..19
<223> 99-13601.pu

<220>
<221> primer_bind
<222> 500..517
<223> 99-13601.rp complement

<400> 41
gttttacttg acagttacca agaattgttt cgcatttaag aaaattatat ctttgatggt 60
tccctcatta atgggtgcctg gatacccaat gcaacacacc tacatcaaac tgcatttgta 120
actgttggtg tcataatgat tctacctaag atgcaagcat acggcatcat tgtgccttgt 180
tgtatggata tgcttgagaa gtcacatgct gaaatacata tattttaaat ttgacagtat 240
ctcctacaat attttcttta tattatagta aggtattaca ttacagttta aaacttatga 300
ctataagcag gtgatattat ctatgaattt catgtgaaat tagcaaaggg acagtctcar 360
atgtttgctg tataaaagtgt atttgaagcc tgatagggtt gagaaacact cagctacagt 420
aagtaaaaac agctctctta gtggttgcc tgttgagaag atcttgaaaa caagggtgaa 480
aatacaaaaag aaactgtgtg gagtctacaa agatatt 517

<210> 42
<211> 533
<212> DNA
<213> Homo sapiens

<220>
<221> allele
<222> 97
<223> 99-13925-97 : polymorphic base A or G

<220>
<221> misc_binding
<222> 74..120
<223> 99-13925-97.probe

<220>
<221> primer_bind
<222> 78..96
<223> 99-13925-97.mis

<220>

<400> 43

[illegible]

```

gggagaatac taataatgga agcattactt ttatttttttc tataaattcc tctggaaata    60
tgtatttctt atgtcctaag gttattaaca aaaagagaaa ataatttctg atttataatt    120
cactttcctt caaaaaataa taactcagtg tctagtaagg taaagcaaaa aaagttaaaa    180
gaaccataaa gtttatttta maatacctac tcagaagcaa aactgacttt ctattaaaaa    240
ttaaaaaaaaa aagttttctt attattgttt tgtttccttg tttttagggtg atgggattgt    300
atttgcaact ctctgggcag taagtataaa aatgccattt ctatgcaccc acctggccag    360
tgtgactggg agaattcttc tttttattaa atgtgcttca agttttaaca actgactttt    420
gttagtgata tgatttatct acccgtgact gtcaaacac acagatgatt tgcatatctc    480

```

<210> 44

<211> 477

<212> DNA

<213> Homo sapiens

<220>

<221> allele

<222> 108

<223> 99-14021-108 : polymorphic base A or G

<220>

<221> misc_binding

<222> 85..131

<223> 99-14021-108.probe

<220>

<221> primer_bind

<222> 89..107

<223> 99-14021-108.mis

<220>

<221> primer_bind

<222> 109..127

<223> 99-14021-108.mis complement

<220>

<221> primer_bind

<222> 1..18

<223> 99-14021.pu

<220>

<221> primer_bind

<222> 460..477

<223> 99-14021.rp complement

<400> 44

```

tttgttggtta atcgcccctt ttctgcaaca cttgtggggtt agggaaaata attctaaagc    60
aagagcaaaag acagagttgg gagatcacca gtgagggttca attttccttc acattcactc    120
tgctccacac ctacagataat catgtgctta actgcgaaac ttgcttgaca attacagaac    180
actttctcac ccattactac cttgatoctc acaattctgt ggggtagtag gagcagatgc    240
tgaaattgcc atacgcaaat cagtgaactg aagcttagag acctccagca ggggcagagg    300
gtcagcggaa actatcccag ggttcagcca acaagaaagt atattggaat cagagtatta    360
aaataagaat aataaaacca actaaaattt accgtgcttt ttatttcac tcagtgcacaa    420
caattcttaa cagtgtcagt gatggatccc tgtgccccag gggacagact tcttact    477

```

<210> 45

<211> 475

<212> DNA

<213> Homo sapiens

<220>

<221> allele

T09020" 90540860

<222> 314
 <223> 99-14359-314 : polymorphic base G or C

<220>
 <221> misc_binding
 <222> 291..337
 <223> 99-14359-314.probe

<220>
 <221> primer_bind
 <222> 295..313
 <223> 99-14359-314.mis

<220>
 <221> primer_bind
 <222> 315..333
 <223> 99-14359-314.mis complement

<220>
 <221> primer_bind
 <222> 1..18
 <223> 99-14359.pu

<220>
 <221> primer_bind
 <222> 457..475
 <223> 99-14359.rp complement

<400> 45
 ataaggggaat ggtgtgaggt gggaccagag gaggtgcac tgagaaagtg agaggggcaa 60
 gacctcaggg gaagaaggga gggctgcacg gatgtctcag gcagagcagg cagcaccgga 120
 aaaggtgggg gacactcctt ttggaccagc atataatttg gttaaagcct ctctgtttc 180
 acctaataata taagcacatt tcaagataaa actactactt tattgtcatc aaatataaaa 240
 gtaattttttt attcagggtt ttctaatact catctataaa ggcatttctt tcccacatgg 300
 catgtgttac aggstgttta acttaaagca attgtaaaag aaaagcctga agaaataagt 360
 ctacaacgat ttacatcgtg tttatttttg tgtcaaaaata tatgttaaaa tatacattag 420
 ctatactaag ggaatcaaga gaagatcata attgtctcta tgacttgga tttag 475

<210> 46
 <211> 473
 <212> DNA
 <213> Homo sapiens

<220>
 <221> allele
 <222> 316
 <223> 99-14364-415 : polymorphic base C or T

<220>
 <221> misc_binding
 <222> 293..339
 <223> 99-14364-415.probe

<220>
 <221> primer_bind
 <222> 297..315
 <223> 99-14364-415.mis

<220>
 <221> primer_bind
 <222> 317..335

<223> 99-14364-415.mis complement

<220>

<221> primer_bind

<222> 1..19

<223> 99-14364.pu

<220>

<221> primer_bind

<222> 453..473

<223> 99-14364.rp complement

<400> 46

gtgttttaat tcaaccagc tataagatac gaaatgatag aattgctcta gattctctat	60
tggttaaata aggagatatt tgtgctattg ccaataatac atgctgtacc tggataaacc	120
cctttgggca agttgtgatg caaataactca agaaaatagg ccacatagtt acaacaggac	180
ttacctaat ccccatggtc atttggctga ttcagtcagt tgctttcaag cctaggttct	240
tggtcacaata ttattacata aactagaatt ttcctattac tattaatttt actttgtatt	300
tttctttata aacttygtac ttattgcttg tcaaatttca gcagaagtac aactcctgag	360
agaataatgc tggctcagag ttttgagatg ataacccttg tctatgaaac tgatgaagtt	420
ggacttaaca acgaacactc cccacagaac tcctgatgct caaatgtggc taa	473

<210> 47

<211> 502

<212> DNA

<213> Homo sapiens

<220>

<221> allele

<222> 99

<223> 99-15056-99 : polymorphic base C or T

<220>

<221> misc_binding

<222> 76..122

<223> 99-15056-99.probe

<220>

<221> primer_bind

<222> 80..98

<223> 99-15056-99.mis

<220>

<221> primer_bind

<222> 100..118

<223> 99-15056-99.mis complement

<220>

<221> primer_bind

<222> 1..18

<223> 99-15056.pu

<220>

<221> primer_bind

<222> 482..502

<223> 99-15056.rp complement

<400> 47

caggaaactc acaagaagsc agatttcctt cgagcacctc ctgaataaag aggcaaaggc	60
cttcttaact cttacaattt acaagtggct atgagtgcyt ttatagttcc cataataatt	120
tctccacgta gacttcctaa ataataattt ctctgtttt atattctctg tgcttatgtt	180

0090506 0090601

tatatcaaac	aagttaccac	ttaatcaaat	gccgatttgc	attgctcact	atgtaacttt	240
aattttcttt	gcctcttatt	tttgatctt	aattctaaaa	ctagatgac	ataaattcat	300
tttagaataa	gcttgatgac	tagccttctt	ttgaaccctt	ttgtgctcct	cacaatattt	360
gtttcgatga	aacagtgcgc	aacatttgat	ctatgattgt	taatagaaaa	acaccaatgt	420
ctcaagttat	tgtaaacata	ggcataattg	acctttgggt	ctataaatat	gtttgggtgt	480
ccccaaaata	cgtctccctt	tt				502

<210> 48

<211> 494

<212> DNA

<213> Homo sapiens

<220>

<221> allele

<222> 412

<223> 99-15229-412 : polymorphic base A or G

<220>

<221> misc_binding

<222> 389..435

<223> 99-15229-412.probe

<220>

<221> primer_bind

<222> 393..411

<223> 99-15229-412.mis

<220>

<221> primer_bind

<222> 413..431

<223> 99-15229-412.mis complement

<220>

<221> primer_bind

<222> 1..20

<223> 99-15229.pu

<220>

<221> primer_bind

<222> 476..494

<223> 99-15229.rp complement

<400> 48

ctgtcattga	gaaatgctac	caataatact	tagagaat	gatacaactc	agtctgaaaa	60
agctaagatt	agcagaacag	agctgtctcc	aaatatttga	agaactat	tatttaaggg	120
attggaccca	tttttgtatg	tagttccaga	ggagcagatg	gtgaccactg	tccaggcaga	180
tgtgtctc	aa tgtaaggaca	acatctgtaa	tattaataat	tagaatgtat	cctgtaattt	240
tctctctacc	cttggaacc	agtcgagatc	cagagtcttt	cactgggagg	cttaaagcct	300
agagcagcct	tggtgctaga	ggcggacagg	gataatgaac	taatcttgaa	ccaattcatc	360
catagcaatc	tcaatgcttt	cgttagctct	tataggtatt	taatacggcc	avaggaatga	420
aggtagtctt	gctggtttag	aagccctgcc	taccacaacc	cctacaccac	cccatcccct	480
gcatagtctg	atgt					494

<210> 49

<211> 485

<212> DNA

<213> Homo sapiens

<220>

<221> allele

<222> 291

<223> 99-15232-291 : polymorphic base G or T

<220>

<221> misc_binding

<222> 268..314

<223> 99-15232-291.probe

<220>

<221> primer_bind

<222> 272..290

<223> 99-15232-291.mis

<220>

<221> primer_bind

<222> 292..310

<223> 99-15232-291.mis complement

<220>

<221> primer_bind

<222> 1..18

<223> 99-15232.pu

<220>

<221> primer_bind

<222> 467..485

<223> 99-15232.rp complement

<400> 49

caatagaaca	ggctgctcct	ttataattat	taatcatagt	gtatattaat	tcatcatcac	60
atacgtggct	agaaaaaaat	ttagaacaaa	aagatatgtg	atatgtaaag	gcctacgata	120
attcagactt	ctttgaggag	agcttttatt	ttattgttat	tcttatttta	tctcttgta	180
atataaattg	agagaataaa	cagacaaaca	ttacaaatta	gtgattaatt	gcatttaaag	240
cctagttaag	actattttaag	actattatgc	ataatacagg	aaaactacct	ktattattta	300
tagtgggtgc	cttctgaagg	atctgaagga	gaatcagttc	tatgcctctc	tcctcattcc	360
caggaggtgc	ctggcattcc	ttggcttgta	gacgcacac	cctaattctc	acctctgcct	420
tcacatggtg	tcccctgtgt	gtgtgttttt	gccccatgtg	tctcctcttt	ttatatggat	480
gccag						485

<210> 50

<211> 464

<212> DNA

<213> Homo sapiens

<220>

<221> allele

<222> 347

<223> 99-15241-347 : polymorphic base A or G

<220>

<221> misc_binding

<222> 324..370

<223> 99-15241-347.probe

<220>

<221> primer_bind

<222> 328..346

<223> 99-15241-347.mis

<220>

<221> primer_bind

<222> 348..366

0900506 030601

ctgcttctcg	ttatgttttc	ctaattgcc	aatggtaaa	aatgagaata	atcattgaaa	60
gagaaagcat	aaagtagcaa	aaatcctttc	cagattaaaa	aacgaagcaa	agcatgtttc	120
ccaagtaata	atactctcat	cttcctccct	aatcctttac	cccactacca	gaagaagagt	180

```

aaaatgtccg gatatrtttg aaggtaaaga tttctccttt taataaaaatt agtcaccttg 240
tacacatcag tagatcttga gaatgaaaag cttttctagt acattcattt caacctataa 300
atgtttgact tttctctgtc attcatttac gacctgtgat cttttcattc cttttcagtt 360
agaatatatt tcaaatattt attgatattt tctatttaac ccataggtta tttggaaata 420
cattgtttta tttctaatat atttgctttt ttttctactt atttcttttt ttcttaattc 480
cacactggtc caaatatatt ctgcatatga tttaatattt taagttctgt agagactaac 540
cttgtgccct                                     550

```

<210> 52

<211> 452

<212> DNA

<213> Homo sapiens

<220>

<221> allele

<222> 404

<223> 99-15252-404 : polymorphic base C or T

<220>

<221> misc_binding

<222> 381..427

<223> 99-15252-404.probe

<220>

<221> primer_bind

<222> 385..403

<223> 99-15252-404.mis

<220>

<221> primer_bind

<222> 405..423

<223> 99-15252-404.mis complement

<220>

<221> primer_bind

<222> 1..18

<223> 99-15252.pu

<220>

<221> primer_bind

<222> 433..452

<223> 99-15252.rp complement

<400> 52

```

atgggggcat atagcaaccc tttagaaaca aaactacaaa aggtaagctt gtcttcttgc 60
atttcctttc tcttactaca tttaacatgg gaggttttct atgtctcaca ttcaaatatt 120
ctcactcggg ctgcctaatt tttccctgat tttccatcac tctttatgaa ggcttgctac 180
tttagaatac acattttctt aacagaagat aataatcaga agatgtctcc caaatataag 240
tccaaatctt tcctatcatg ctgtgttctt tggctctttt gactttattt gaagtcagcc 300
ttgaagggga tagagatagg ctgtatgaag tccacgctga gaagttttgc cctgccctac 360
ttgtcctgta atatttcatg gatagcccag tgggtgattaa accygtgtgt acaggaataa 420
ccatgagaat ttgttaaaaa tataggctct gg                                     452

```

<210> 53

<211> 477

<212> DNA

<213> Homo sapiens

<220>

<221> allele

<222> 382

<223> 99-15253-382 : polymorphic base C or T

<220>

<221> misc_binding

<222> 359..405

<223> 99-15253-382.probe

<220>

<221> primer_bind

<222> 363..381

<223> 99-15253-382.mis

<220>

<221> primer_bind

<222> 383..401

<223> 99-15253-382.mis complement

<220>

<221> primer_bind

<222> 1..19

<223> 99-15253.pu

<220>

<221> primer_bind

<222> 459..477

<223> 99-15253.rp complement

<400> 53

aaaatcaatt	cccacacact	cattttgtac	gctaattttg	taagatcctg	aaaagtttca	60
ctattttatg	gtttcatgtg	ttacagatga	aaaaaaaaact	agaattcaaa	ttttctgagt	120
ttttttttac	aatattttat	gattacaaag	ttagaagact	aagaataaaa	tggcctaatt	180
tccataatgt	gagtggtaaa	tgacagagcac	tggcctaag	aaaatatttc	aaaaaattag	240
tcattctttc	cttaattttt	ttccaacctt	tgatctgttg	aatgagcatt	ttgcatatat	300
aaataaataa	attactttgt	aaataatctt	gactgggttc	tgttgaccac	agtaaccac	360
tgacacagcac	agcctgtaat	tyctatgaac	ctaggggaaat	gtatttaagt	ttattttttg	420
attacacagg	tcctcattgt	gtaactaaac	attgcataga	atatgccagt	gatgatg	477

<210> 54

<211> 456

<212> DNA

<213> Homo sapiens

<220>

<221> allele

<222> 392

<223> 99-15256-392 : polymorphic base C or T

<220>

<221> misc_binding

<222> 369..415

<223> 99-15256-392.probe

<220>

<221> primer_bind

<222> 373..391

<223> 99-15256-392.mis

<220>

<221> primer_bind

<222> 393..411

<223> 99-15256-392.mis complement

<220>
 <221> primer_bind
 <222> 1..18
 <223> 99-15256.pu

<220>
 <221> primer_bind
 <222> 439..456
 <223> 99-15256.rp complement

<400> 54
 cctctctatg atgcttccta ttaagcaatt ggggaaatgt aataaacaag gggtgggtgag 60
 catcttcctt agtgagatgt ttttgggaaga attggataat tgagtgaata atagtgagaa 120
 actcctgtgt ctgatgttgc tccatgttgg aatgctttta tgttctcaga gaatgagtca 180
 ctgagagcca attgtgatga tacacaatgg ttttaccag gttggatatg gtccctctgta 240
 ctggtaccct ttaagtcagt ggcactaatc agtcagtcac tgtcatgctt tgtgttggtc 300
 catcatatgg tatgccctct tagagaacac cctgattagt ccttagacat cttttcaatt 360
 tgaacactgg ggctcctcat tcgggtaaaa aytatggaca gtcagtgaaa ctggttgaat 420
 ggcccctcat agcagattgg atctcaatgc actttg 456

<210> 55
 <211> 501
 <212> DNA
 <213> Homo sapiens

<220>
 <221> allele
 <222> 200
 <223> 99-15261-202 : polymorphic base A or G

<220>
 <221> misc_binding
 <222> 177..223
 <223> 99-15261-202.probe

<220>
 <221> primer_bind
 <222> 181..199
 <223> 99-15261-202.mis

<220>
 <221> primer_bind
 <222> 201..219
 <223> 99-15261-202.mis complement

<220>
 <221> primer_bind
 <222> 1..19
 <223> 99-15261.pu

<220>
 <221> primer_bind
 <222> 481..501
 <223> 99-15261.rp complement

<400> 55
 cttctaattcc tttgtttcca cttattttat ttcattcctc attttatccc ttttttctaa 60
 attccatttt attatactta aggtgctttt aatatggta tcatactcct gatagtgtta 120
 tttctttctt agtctttcta tataagcgct atacgttcac attccatctc ctttggttat 180
 ctttccattt cttcaccgar cctctttgct ctcttttttt atagctgggt cactcaaaat 240

```
<210> 56
<211> 541
<212> DNA
<213> Homo sapiens
```

```
<220>
<221> allele
<222> 432
<223> 99-15280-432 : polymorphic base C or T
```

```
<220>  
<221> misc_binding  
<222> 409..455  
<223> 99-15280-432.probe
```

```
<220>
<221> primer_bind
<222> 413..431
<223> 99-15280-432.mis
```

```
<220>
<221> primer_bind
<222> 433..451
<223> 99-15280-432.mis complement
```

```
<220>
<221> primer_bind
<222> 1..18
<223> 99-15280.pu
```

```
<220>
<221> primer_bind
<222> 521..541
<223> 99-15280.rp complement
```

[illegible]

```
<210> 57
<211> 514
<212> DNA
<213> Homo sapiens
```

```
<220>  
<221> allele  
<222> 428
```

<222> 151..169

[illegible]

<223> 99-15355-150.mis complement

<220>

<221> primer_bind

<222> 1..18

<223> 99-15355.pu

<220>

<221> primer_bind

<222> 471..489

<223> 99-15355.rp complement

<400> 58

taactttctcc	gtctctcctt	cttagcccat	atgtcaataa	tgactgaaag	tattcatttc	60
catcttttaa	ctgcctattc	cagccacctc	ccacctccat	ctctttcctt	ctaagttttc	120
ttcatcttct	actttgggca	aaaggaaaty	gatgtgtcag	acaggcctag	ttttgaattc	180
tggatctgct	agcacttctc	tgtgtgtcct	tggttatatg	atatagtctt	aaaccttaat	240
gttcttgcc	gtaaaatggg	gataataaaa	acctcttaac	agtgggtggt	tcatgcagct	300
ttcattacaa	acttcctcat	tcaaaatctt	caatgatttc	catttttcac	aaaatgaaat	360
tcaaaatttc	tgtagattat	tgagacaagt	cccctactct	tcacctaaat	ttatctttta	420
tttattctct	catcattatc	aacaactact	aggctttggt	gccttgactc	cagaggcaaa	480
aatcttatac						489

<210> 59

<211> 468

<212> DNA

<213> Homo sapiens

<220>

<221> allele

<222> 227

<223> 99-15685-227 : polymorphic base A or G

<220>

<221> misc_binding

<222> 204..250

<223> 99-15685-227.probe

<220>

<221> primer_bind

<222> 208..226

<223> 99-15685-227.mis

<220>

<221> primer_bind

<222> 228..246

<223> 99-15685-227.mis complement

<220>

<221> primer_bind

<222> 1..18

<223> 99-15685.pu

<220>

<221> primer_bind

<222> 449..468

<223> 99-15685.rp complement

<400> 59

aaacaaaggc	acgcagagga	taaggcatga	gtccaaccag	cagcatctcc	ctcccgaatg	60
agtacagaaa	tgatcaatac	tcgaagagaa	aaagatgctt	tcagtgtgct	ttacctgaaa	120

0050540360

acttccttaa	gcagcttcac	tttattgtca	ggatatcgct	ttgtgtttgt	atcatctaag	180
aaagctcgcg	catatgctag	tgggccagca	ttgacctaga	caaagarcaa	agattttcag	240
ttccactagg	aagaaaatca	ccatgaccat	ctgctcagtt	tcagtttgca	ggcactaaaa	300
agcccgttcg	cgtgagctac	tcacaatccc	tgccctccag	gaacttaagc	ccaaaaagaa	360
accacaaagc	tcactctgtt	gcacaccact	tgattccatg	atctcagcca	tcttcagggc	420
acttgatgat	atgggtttact	ttatgtaaga	agaaaccaat	gcttgga		468

<210> 60

<211> 500

<212> DNA

<213> Homo sapiens

<220>

<221> allele

<222> 428

<223> 99-15695-428 : polymorphic base C or T

<220>

<221> misc_binding

<222> 405..451

<223> 99-15695-428.probe

<220>

<221> primer_bind

<222> 409..427

<223> 99-15695-428.mis

<220>

<221> primer_bind

<222> 429..447

<223> 99-15695-428.mis complement

<220>

<221> primer_bind

<222> 1..18

<223> 99-15695.pu

<220>

<221> primer_bind

<222> 481..500

<223> 99-15695.rp complement

<400> 60

atcagccttt	gtgaggagga	ggccctgcct	gctctcctcc	tgagctgatg	ggtcagtcac	60
accaggacaa	aggtctgccc	ggggctgtgt	gggttcctcc	ttcctgagct	gcacaccagc	120
atctgctgaa	caccttctgg	agctcagctc	agtgtctogt	ccagagacac	tggttccttt	180
ggcttctcag	caactctcgg	atctgggcct	gggtctaacc	tcagcgggtg	tcttgcccat	240
ttctagggcc	tcacaattca	gcctcatgtc	ttcacctgtg	gctcttttgc	aaggctcaga	300
aagctctagg	gtcagttcca	gatgactccc	accagcatgc	cagtaggagc	caccaccccc	360
tctcagccag	cgccaccata	ttccaggcaa	attccaactg	acacagactt	caaggaacga	420
ttgtagcygt	tgttcttget	tcttccaaat	ggaagagtgc	attattgggg	tcccttctag	480
cacgcatttc	attccccacc					500

<210> 61

<211> 472

<212> DNA

<213> Homo sapiens

<220>

<221> allele

<222> 310

<223> 99-15870-400.mis complement

Variable	Mean	SD	Min	Max
Age	34.5	10.2	21	55
Gender	0.45	0.50	0	1
Marital status	0.65	0.48	0	1
Education	12.5	1.5	9	16
Income	1500	500	500	3000
Health status	0.75	0.43	0	1
Employment status	0.85	0.36	0	1
Family size	2.5	1.2	1	5
Home ownership	0.95	0.22	0	1
Vehicle ownership	0.80	0.40	0	1
Life satisfaction	4.5	1.0	1	7
Healthcare utilization	0.60	0.49	0	1
Health insurance coverage	0.90	0.30	0	1
Access to healthcare	0.70	0.46	0	1
Healthcare costs	1000	300	500	2000
Healthcare quality	0.85	0.35	0	1
Healthcare accessibility	0.75	0.43	0	1
Healthcare affordability	0.65	0.48	0	1
Healthcare effectiveness	0.80	0.40	0	1
Healthcare safety	0.90	0.30	0	1
Healthcare equity	0.70	0.46	0	1
Healthcare transparency	0.60	0.49	0	1
Healthcare accountability	0.50	0.50	0	1
Healthcare responsiveness	0.75	0.43	0	1
Healthcare patient satisfaction	0.85	0.36	0	1
Healthcare provider satisfaction	0.70	0.46	0	1
Healthcare system performance	0.65	0.48	0	1
Healthcare system efficiency	0.80	0.40	0	1
Healthcare system effectiveness	0.90	0.30	0	1
Healthcare system safety	0.75	0.43	0	1
Healthcare system equity	0.65	0.48	0	1
Healthcare system transparency	0.55	0.50	0	1
Healthcare system accountability	0.45	0.50	0	1
Healthcare system responsiveness	0.70	0.46	0	1
Healthcare system patient satisfaction	0.80	0.40	0	1
Healthcare system provider satisfaction	0.65	0.48	0	1
Healthcare system performance	0.60	0.49	0	1
Healthcare system efficiency	0.75	0.43	0	1
Healthcare system effectiveness	0.85	0.36	0	1
Healthcare system safety	0.90	0.30	0	1
Healthcare system equity	0.70	0.46	0	1
Healthcare system transparency	0.60	0.49	0	1
Healthcare system accountability	0.50	0.50	0	1
Healthcare system responsiveness	0.75	0.43	0	1
Healthcare system patient satisfaction	0.85	0.36	0	1
Healthcare system provider satisfaction	0.70	0.46	0	1
Healthcare system performance	0.65	0.48	0	1
Healthcare system efficiency	0.80	0.40	0	1
Healthcare system effectiveness	0.90	0.30	0	1
Healthcare system safety	0.75	0.43	0	1
Healthcare system equity	0.65	0.48	0	1
Healthcare system transparency	0.55	0.50	0	1
Healthcare system accountability	0.45	0.50	0	1
Healthcare system responsiveness	0.70	0.46	0	1
Healthcare system patient satisfaction	0.80	0.40	0	1
Healthcare system provider satisfaction	0.65	0.48	0	1
Healthcare system performance	0.60	0.49	0	1
Healthcare system efficiency	0.75	0.43	0	1
Healthcare system effectiveness	0.85	0.36	0	1
Healthcare system safety	0.90	0.30	0	1
Healthcare system equity	0.70	0.46	0	1
Healthcare system transparency	0.60	0.49	0	1
Healthcare system accountability	0.50	0.50	0	1
Healthcare system responsiveness	0.75	0.43	0	1
Healthcare system patient satisfaction	0.85	0.36	0	1
Healthcare system provider satisfaction	0.70	0.46	0	1
Healthcare system performance	0.65	0.48	0	1
Healthcare system efficiency	0.80	0.40	0	1
Healthcare system effectiveness	0.90	0.30	0	1
Healthcare system safety	0.75	0.43	0	1
Healthcare system equity	0.65	0.48	0	1
Healthcare system transparency	0.55	0.50	0	1
Healthcare system accountability	0.45	0.50	0	1
Healthcare system responsiveness	0.70	0.46	0	1
Healthcare system patient satisfaction	0.80	0.40	0	1
Healthcare system provider satisfaction	0.65	0.48	0	1
Healthcare system performance	0.60	0.49	0	1
Healthcare system efficiency	0.75	0.43	0	1
Healthcare system effectiveness	0.85	0.36	0	1
Healthcare system safety	0.90	0.30</		

<220>
 <221> primer_bind
 <222> 1..21
 <223> 99-15870.pu

<220>
 <221> primer_bind
 <222> 452..470
 <223> 99-15870.rp complement

<400> 62
 gctcaaatgt atcaaacaca gtttctgtgg tcaagttcct ctcccttttct aaatttgctt 60
 agaggatctc ataaaacgta actcctctga caagggaacc atttttagcac caacactgca 120
 aaagctttctg tggttcctaag ggaaagatcc tttcctgaat taaatttaac ctcttttagta 180
 ctcccatttta gccacctgat aaatccactt gagctatctt ttgggaagag agaggatatct 240
 gggaacaata acacttcctt tttgaacagt ttaataaagc tttgtgagat ttcaagatga 300
 aagataatgt gtaatgctga tagtgccctc caaggctctg cattcatgga tccaattacg 360
 ttttttgtca tggtaaaagc cacagtggat atattaaatr agagtgtggg ttaagaatga 420
 aggcccagga gtctggagat ctggtttcta aggctgactt cacttctgct 470

<210> 63
 <211> 469
 <212> DNA
 <213> Homo sapiens

<220>
 <221> allele
 <222> 287
 <223> 99-16321-287 : polymorphic base A or C

<220>
 <221> misc_binding
 <222> 264..310
 <223> 99-16321-287.probe

<220>
 <221> primer_bind
 <222> 268..286
 <223> 99-16321-287.mis

<220>
 <221> primer_bind
 <222> 288..306
 <223> 99-16321-287.mis complement

<220>
 <221> primer_bind
 <222> 1..20
 <223> 99-16321.pu

<220>
 <221> primer_bind
 <222> 451..469
 <223> 99-16321.rp complement

<400> 63
 ctttaggaat atcccttctg atttgaacaa cattttgcta tccaagttct gtctactttt 60
 ttaacaagtt cttgctccgt gtgtctcctt ttgcttggtc tcaagtaagg gagtaacagg 120
 gataaactcc cactccttgg taaatctttc tatcattttt ggaaatctca tccattgtag 180
 taaatgctct taaatcttca tcttcaggcc gtgacttcca tctagcctcc attcacgttt 240

```

ccggggtttat gtctgcaatg agcattccgt ggctctacat agatgcmcca ccatacctag      300
aaccatgta tcccaaactc aattctttct tccccaggac attacttcct gcacttcctt      360
agtctatcaa tggcactgtt attctcttga ccatctagac ttgaaatfff ggggtttgga      420
ctcctcctgc tcccttgctt tatatgtaat cagacatcaa gtctcaatc      469

```

```

<210> 64
<211> 544
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> allele
<222> 194
<223> 99-16333-194 : polymorphic base A or G

```

```

<220>
<221> misc_binding
<222> 171..217
<223> 99-16333-194.probe

```

```

<220>
<221> primer_bind
<222> 175..193
<223> 99-16333-194.mis

```

```

<220>
<221> primer_bind
<222> 195..213
<223> 99-16333-194.mis complement

```

```

<220>
<221> primer_bind
<222> 1..19
<223> 99-16333.pu

```

```

<220>
<221> primer_bind
<222> 524..544
<223> 99-16333.rp complement

```

```

<400> 64
atttaccctg tctgccttgc aatttcagga tcagtataca tcaaatcaag tgaacaaccc      60
agggaattct gccgttacct tttagaaaca gaataaatat taacagagct ttacttcttt      120
ccaccaagga ggactatatg ttaatacagt aatttacact ggaaaaaata taaatgaaag      180
gggtttagaac ctcrtaactt taaaaataac ataattcctc ctagaacatt cctttcactt      240
gtgattctca aagcactttg catttcccag ctattggcag ggctggaatt aggatcaaag      300
tatcactaaa tggtaggtga aataaatgtg aagctgattt tcaggagtac aggaatggag      360
tcacagggcg acttttaaagt taagaatctg ttggagcagc tgccaataaa tcaaggccca      420
aaggagaaag ttctttggaa accttgaaat attgtataca tttagataat tattgttggt      480
gtcaatgtta acgaaaaaag caataaatca gggagatggc actgatgagt gaggagaaat      540
agac      544

```

```

<210> 65
<211> 475
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> allele
<222> 149
<223> 99-5873-159 : polymorphic base C or T

```

<220>
 <221> misc_binding
 <222> 126..172
 <223> 99-5873-159.probe

<220>
 <221> primer_bind
 <222> 130..148
 <223> 99-5873-159.mis

<220>
 <221> primer_bind
 <222> 150..168
 <223> 99-5873-159.mis complement

<220>
 <221> primer_bind
 <222> 1..18
 <223> 99-5873.pu

<220>
 <221> primer_bind
 <222> 457..475
 <223> 99-5873.rp complement

<220>
 <221> misc_feature
 <222> 409
 <223> n=a, g, c or t

<400> 65
 gcgtaacaat aagcagggtt agtcgccaca aaacttgaga taagaggaaa actaaaaaag 60
 tctaataaaa tcagtagtct taaaaagatg acatgatagg aagagaagtg ttaaaaaaga 120
 aaaaaaatag gtatgaaaga gagtaacaya taccggaaaa gggataaaat acatcctttg 180
 aaagaacaaa gagttattca aattgaattc ttaatgaatt acttaaacag cagattagat 240
 attgttaaaa agaggaatag ggaattaaat gatatatgtg atgatattac ctagtgtaac 300
 catcaaagat gtattgcaaa tgataaagaa aaaaatgctg ccatggcaat attaatatca 360
 taaaaatata ctttaagaag taaataaatg caactaggaa tagagaaans dvhatgaata 420
 ataatatatta amaaavvgta taacaagtat acataagatg taatatccta aaccg 475

<210> 66
 <211> 511
 <212> DNA
 <213> Homo sapiens

<220>
 <221> allele
 <222> 49
 <223> 99-5912-49 : polymorphic base A or G

<220>
 <221> misc_binding
 <222> 26..72
 <223> 99-5912-49.probe

<220>
 <221> primer_bind
 <222> 30..48
 <223> 99-5912-49.mis

```
<220>
<221> primer_bind
<222> 467..485
<223> 99-6012.rp complement
```

```

<400> 67
gtcttgactt gttttcctga ggggtccaggt tgatttgcac gctcttgagg aaatatacac    60
gtcttctcag ttttaataat tgactgacag ccctgtggtt tctcaggacc cagtgaagctg    120
ctgctccag gtcagtctgc aaaggatgct gggtcccttg tggctctatc aagggtgagga    180
atttcctgat tttagagatt tctttatcck aattttgaag actttctttc acatttctag    240
gcataaaaaa atgtacagca ctctactgct tgtttaacaa atggatagtg atatatacgc    300
caacaaagac cacatggagt atttcattga ctatcagaga agtttcctcg aaaggcacca    360
tacttagtgt tttattttcca tgagtgaagg aaaattagtt atttgaagta tttggctgtc    420
tttagttggt tctaaagtag tgctgatttt atatgcccac aatattcata tatacaccca    480
ggata                                         485

```

```

<210> 68
<211> 529
<212> DNA
<213> Homo sapiens

```

```

<220>
<221> allele
<222> 89
<223> 99-6080-99 : polymorphic base C or T

```

```

<220>
<221> misc_binding
<222> 66..112
<223> 99-6080-99.probe

```

```

<220>
<221> primer_bind
<222> 70..88
<223> 99-6080-99.mis

```

```

<220>
<221> primer_bind
<222> 90..108
<223> 99-6080-99.mis complement

```

```

<220>
<221> primer_bind
<222> 1..18
<223> 99-6080.pu

```

```

<220>
<221> primer_bind
<222> 509..529
<223> 99-6080.rp complement

```

```

<400> 68
aaatgtgtcc ctgaaaccca tgctatatcc aactgaatat tctaattgtct ttgattacaa    60
agccatctct agcaatttaa tacaattayg aaatggaaaa gttggcaaat gcaaaacaat    120
agctcgtggt caagggtatgt ctttattagg ggaagtttat cgaaacagat gtttatgcta    180
tttcctataa actagattct aaaatatttt attctataaa gatgtattga ctttatatga    240
aaaaattatt gaaaaatcta caagatgggt aaactcttta gaactatatt tctattacaa    300
gtttattttt aattttcaaaa atgtactgca taaatgcagc aaaaccttta ttgtcacata    360
ttaaaacatg tacattattg tgtgcaaatt aaaatttcat taccttaaac caaaaagtga    420
gttggccaga tagtaaataa tttaggctct aaggctgaaa agcgcttgta ttaattactc    480
aactccacca ctattttgcc aaagcagtca cagacaatac gcattcaca                    529

```

```

<210> 69
<211> 489
<212> DNA
<213> Homo sapiens

```

0080505 0080505

<220>
<221> allele
<222> 156
<223> 99-7308-157 : polymorphic base C or T

<220>
<221> misc_binding
<222> 133..179
<223> 99-7308-157.probe

<220>
<221> primer_bind
<222> 137..155
<223> 99-7308-157.mis

<220>
<221> primer_bind
<222> 157..175
<223> 99-7308-157.mis complement

<220>
<221> primer_bind
<222> 1..18
<223> 99-7308.pu

<220>
<221> primer_bind
<222> 469..489
<223> 99-7308.rp complement

<400> 69
tgtggtcttg atatggtgra ctgtccttca cacacagatg tgggaagcca tgatcatcag 60
ttgcattatt cctgaggggc aatgcattcc agttacatag aaccagtttc tacgtttcag 120
ggtatatgta ttcattggtga caaatttatt cacatyttaa gtaattttaa gtaattcaca 180
ttttaagtaa ttttcctgaa tgtgcctcat tggtctctgt gctctctcag aaaagatgaa 240
ctaaacactg gcatatgtgt tcagatttca acattccgtt gttttcattg tggataattt 300
ctgtcccata tttttgtgta aagtttagaca ataaagtgtt aatattctgg cgtcggcaca 360
ttttctttcc tgataaataa caattcacat atctttttaa aatatacagag aatataagtaa 420
ccaatttcca attctttttt caccatgtat ctattggagt tttaaatga ctaataactaa 480
ggcaactat 489

<210> 70
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> sequencing oligonucleotide PrimerPU

<400> 70
tgtaaaacga cggccagt 18

<210> 71
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> sequencing oligonucleotide PrimerRP

<400> 71
caggaaacag ctatgacc

18

T09020" 905/0860

Please type a plus sign (+) inside this box → ☐

PTO/SB/81 (10-00)
Approved for use through 10/31/2002 OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it display a valid OMB control number

POWER OF ATTORNEY OR AUTHORIZATION OF AGENT

Application Number	09/807,506
Filing Date	April 13, 2001
First Named Inventor	Marta BLUMENMFELD, et al.
Group Art Unit	Unknown
Examiner Name	Unassigned
Attorney Docket Number	50.US3.PCT

I hereby appoint:

☐ Practitioners at Customer Number

000027206

Place Customer
Number Bar Code
Label here

OR

☒ Practitioner(s) named below:

Name	Registration Number
John M. Lucas	43,373
Peter Follette	46,213
Lukas R. Voellmy	43,358

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please change the correspondence address for the above-identified application to:

☐ The above-mentioned Customer Number.

OR

☒ Firm or
Individual Name

John Lucas, Ph.D., J.D.

Address Genset Corporation

Address 10665 Sorrento Valley Road

City San Diego

State CA

Zip 92121-1609

Country USA

Telephone (858) 597-2600

Fax (848) 597-2601

I am the:

☒ Applicant/Inventor.

☐ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

SIGNATURE of Applicant or Assignee of Record

Name Marta Blumenfeld

Signature

Date

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

☐ *Total of _____ forms are submitted.

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (10-00)

Approved for use through 10/31/2002 OMB 0651-0032

U S Patent and Trademark Office, U S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

DECLARATION — Utility or Design Patent Application

Direct all correspondence to: ☒ Customer Number or Bar Code Label 000027206 OR ☒ Correspondence address below

Name John Lucas, Ph.D., J.D.

Address Genset Corporation

Address 10665 Sorrento Valley Road

City San Diego

State CA

ZIP 92121-1609

Country USA

Telephone 858/597-2600

Fax 858/597-2601

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

NAME OF SOLE OR FIRST INVENTOR :

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any]) Marta

Family Name or Surname BLUMENFELD

Inventor's Signature

MBL

Date

26/4/01

Residence: City Paris

State

Country France

Citizenship French

Mailing Address 24 rue Royale

Mailing Address

City Paris

State

ZIP 75008

Country France

NAME OF SECOND INVENTOR:

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any]) Lydie

Family Name or Surname BOUGUELERET

Inventor's Signature

Date

Residence: City Petit Lancy

State

Country Switzerland

Citizenship French

Mailing Address 24 rue Royale

Mailing Address

City Paris

State

ZIP 75008

Country France

☐ Additional inventors are being named on the _____ supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto.

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (10-00)

Approved for use through 10/31/2002 OMB 0651-0032

U S Patent and Trademark Office, U S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

DECLARATION — Utility or Design Patent Application

Direct all correspondence to: ☒ Customer Number or Bar Code Label ☐ 000027206 OR ☒ Correspondence address below

Name John Lucas, Ph.D., J.D.

Address Genset Corporation

Address 10665 Sorrento Valley Road

City San Diego

State CA

ZIP 92121-1609

Country USA

Telephone 858/597-2600

Fax 858/597-2601

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

NAME OF SOLE OR FIRST INVENTOR :

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any]) Marta

Family Name or Surname BLUMENFELD

Inventor's Signature

Date

Residence: City Paris

State

Country France

Citizenship French

Mailing Address 24 rue Royale

Mailing Address

City Paris

State

ZIP 75008

Country France

NAME OF SECOND INVENTOR:

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any]) Lydie

Family Name or Surname BOUGUELERET

Inventor's Signature

Date

26.04.01

Residence: City Petitancy

State

Switzerland
Country

Citizenship French

Mailing Address 24 rue Royale

Mailing Address

City Paris

State

ZIP 75008

Country France

☐ Additional inventors are being named on the _____ supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto.

Please type a plus sign (+) inside this box → ☐

PTO/SB/02A (11-00)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION

ADDITIONAL INVENTOR(S)
Supplemental Sheet
Page ____ of ____

Name of Additional Joint Inventor, if any:

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])

Family Name or Surname

Ilya

CHUMAKOV

Inventor's
Signature

Date

24.04.01

Residence: City

Vaux-le-Penil

State

Country

France

Citizenship

French

Mailing Address

24 rue Royale

Mailing Address

City

Paris

State

ZIP 75008

Country

France

Name of Additional Joint Inventor, if any:

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])

Family Name or Surname

Daniel

COHEN

Inventor's
Signature

Date

Residence: City

Neuilly-sur-Seine

State

Country

France

Citizenship

French

Mailing Address

24 rue Royale

Mailing Address

City

Paris

State

ZIP 75008

Country

France

Name of Additional Joint Inventor, if any:

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])

Family Name or Surname

Laurent

ESSIOUX

Inventor's
Signature

Date

Residence: City

Paris

State

Country

France

Citizenship

French

Mailing Address

24 rue Royale

Mailing Address

City

Paris

State

ZIP 75008

Country

France

Burden Hour Statement: This form is estimated to take 21 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/02A (11-00)
Approved for use through 10/31/2002 OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION

ADDITIONAL INVENTOR(S)
Supplemental Sheet
Page ___ of ___

Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle [if any])		Family Name or Surname	
Ilya		CHUMAKOV	
Inventor's Signature		Date	
Residence: City	Vaux-le-Penil	State	Country France
Mailing Address		Citizenship French	
24 rue Royale			
Mailing Address			
City	Paris	ZIP	75008
State		Country France	
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle [if any])		Family Name or Surname	
Daniel		COHEN	
Inventor's Signature		Date 04/27/01	
Residence: City	Neuilly-sur-Seine	State	Country France
Mailing Address		Citizenship French	
24 rue Royale			
Mailing Address			
City	Paris	ZIP	75008
State		Country France	
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle [if any])		Family Name or Surname	
Laurent		ESSIOUX	
Inventor's Signature		Date	
Residence: City	Paris	State	Country France
Mailing Address		Citizenship French	
24 rue Royale			
Mailing Address			
City	Paris	ZIP	75008
State		Country France	

Burden Hour Statement: This form is estimated to take 21 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this box → ☐

PTO/SB/02A (11-00)
Approved for use through 10/31/2002. OMB 0651-0032

U S Patent and Trademark Office; U S DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION

ADDITIONAL INVENTOR(S)
Supplemental Sheet
Page ____ of ____

Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle [if any])		Family Name or Surname	
Ilya		CHUMAKOV	
Inventor's Signature		Date	
Residence: City	Vaux-le-Penil	State	Country France
Mailing Address		Citizenship French	
24 rue Royale			
Mailing Address			
City	Paris	State	ZIP 75008
		Country	France
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle [if any])		Family Name or Surname	
Daniel		COHEN	
Inventor's Signature		Date	
Residence: City	Neuilly-sur-Seine	State	Country France
Mailing Address		Citizenship French	
24 rue Royale			
Mailing Address			
City	Paris	State	ZIP 75008
		Country	France
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle [if any])		Family Name or Surname	
Laurent		ESSIOUX	
Inventor's Signature		Date	
Residence: City	Paris	State	Country France
Mailing Address		Citizenship French	
24 rue Royale			
Mailing Address			
City	Paris	State	ZIP 75008
		Country	France

Burden Hour Statement: This form is estimated to take 21 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U S Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (10-00)
Approved for use through 10/31/2002. OMB 0651-0032

U S Patent and Trademark Office, U S DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63) <input type="checkbox"/> Declaration Submitted with Initial Filing OR <input checked="" type="checkbox"/> Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)	Attorney Docket Number	50.US3.PCT
	First Named Inventor	Marta BLUMENFELD, et al.
	COMPLETE IF KNOWN	
	Application Number	09 / 807,506
	Filing Date	April 13, 2001
	Group Art Unit	unknown
	Examiner Name	unassigned

As a below named inventor, I hereby declare that:

My residence, mailing address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Genes, Proteins and Biallelic Markers Related to Central Nervous System Disease

(Title of the Invention)

the specification of which

☐ is attached hereto

OR

☒ was filed on (MM/DD/YYYY)

April 13, 2001

as United States Application Number or PCT International

Application Number

09/807,506

and was amended on (MM/DD/YYYY)

(if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
PCT/IB99/01730	WIPO	10/12/1999	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 21 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U S Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/02A (11-00)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION

ADDITIONAL INVENTOR(S)
Supplemental Sheet
Page ____ of ____

Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle [if any])		Family Name or Surname	
Ilya		CHUMAKOV	
Inventor's Signature		Date	
Residence: City Vaux-le-Penil	State	Country France	Citizenship French
Mailing Address 24 rue Royale			
Mailing Address			
City Paris	State	ZIP 75008	Country France
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle [if any])		Family Name or Surname	
Daniel		COHEN	
Inventor's Signature		Date	
Residence: City Neuilly-sur-Seine	State	Country France	Citizenship French
Mailing Address 24 rue Royale			
Mailing Address			
City Paris	State	ZIP 75008	Country France
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle [if any])		Family Name or Surname	
Laurent		ESSIOUX	
Inventor's Signature		Date	
Residence: City Paris	State	Country France	Citizenship French
Mailing Address 24 rue Royale			
Mailing Address			
City Paris	State	ZIP 75008	Country France

Burden Hour Statement: This form is estimated to take 21 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (10-00)

Approved for use through 10/31/2002. OMB 0651-0032

U S Patent and Trademark Office, U S DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

**DECLARATION FOR UTILITY OR
DESIGN
PATENT APPLICATION
(37 CFR 1.63)**

☐ Declaration Submitted with Initial Filing
OR
☒ Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)

Attorney Docket Number	50.US3.PCT
First Named Inventor	Marta BLUMENFELD, et al.
COMPLETE IF KNOWN	
Application Number	09 / 807,506
Filing Date	April 13, 2001
Group Art Unit	unknown
Examiner Name	unassigned

As a below named inventor, I hereby declare that:

My residence, mailing address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Genes, Proteins and Biallelic Markers Related to Central Nervous System Disease

(Title of the Invention)

the specification of which

☐ is attached hereto

OR

☒ was filed on (MM/DD/YYYY) April 13, 2001

as United States Application Number or PCT International

Application Number 09/807,506 and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
PCT/IB99/01730	WIPO	10/12/1999	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 21 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/02A (11-00)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION

ADDITIONAL INVENTOR(S)
Supplemental Sheet
Page ____ of ____

Name of Additional Joint Inventor, if any:

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])

Family Name or Surname

Ilya

CHUMAKOV

**Inventor's
Signature**

Date

Residence: City Vaux-le-Penil

State

Country France

Citizenship French

Mailing Address 24 rue Royale

Mailing Address

City Paris

State

ZIP 75008

Country France

Name of Additional Joint Inventor, if any:

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])

Family Name or Surname

Daniel

COHEN

**Inventor's
Signature**

Date

Residence: City Neuilly-sur-Seine

State

Country France

Citizenship French

Mailing Address 24 rue Royale

Mailing Address

City Paris

State

ZIP 75008

Country France

Name of Additional Joint Inventor, if any:

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])

Family Name or Surname

Laurent

ESSIOUX

**Inventor's
Signature**

Date

Residence: City Paris

State

Country France

Citizenship French

Mailing Address 24 rue Royale

Mailing Address

City Paris

State

ZIP 75008

Country France

Burden Hour Statement: This form is estimated to take 21 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (10-00)

Approved for use through 10/31/2002 OMB 0651-0032

U. S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**DECLARATION FOR UTILITY OR
DESIGN
PATENT APPLICATION
(37 CFR 1.63)**

☐ Declaration Submitted with Initial Filing OR ☒ Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)

Attorney Docket Number	50.US3.PCT
First Named Inventor	Marta BLUMENFELD, et al.
COMPLETE IF KNOWN	
Application Number	09 / 807,506
Filing Date	April 13, 2001
Group Art Unit	unknown
Examiner Name	unassigned

As a below named inventor, I hereby declare that:

My residence, mailing address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Genes, Proteins and Biallelic Markers Related to Central Nervous System Disease

(Title of the Invention)

the specification of which

☐ is attached hereto

OR

☒ was filed on (MM/DD/YYYY) April 13, 2001

as United States Application Number or PCT International

Application Number 09/807,506 and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
PCT/IB99/01730	WIPO	10/12/1999	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 21 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/01 (10-00)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION — Utility or Design Patent ApplicationDirect all correspondence to: ☒ Customer Number **000027206** OR ☒ Correspondence address belowName **John Lucas, Ph.D., J.D.**Address **Genset Corporation**Address **10665 Sorrento Valley Road**City **San Diego**State **CA**ZIP **92121-1609**Country **USA**Telephone **858/597-2600**Fax **858/597-2601**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

NAME OF SOLE OR FIRST INVENTOR :☐ A petition has been filed for this unsigned inventorGiven Name **Marta**
(first and middle [if any])Family Name **BLUMENFELD**
or SurnameInventor's
Signature

Date

Residence: City **Paris**

State

Country **France**Citizenship **French**Mailing Address **24 rue Royale**

Mailing Address

City **Paris**

State

ZIP **75008**Country **France****NAME OF SECOND INVENTOR:**☐ A petition has been filed for this unsigned inventorGiven Name **Lydie**
(first and middle [if any])Family Name **BOUGUELERET**
or SurnameInventor's
Signature

Date

Residence: City **Petit Lancy**

State

Country **Switzerland**Citizenship **French**Mailing Address **24 rue Royale**

Mailing Address

City **Paris**

State

ZIP **75008**Country **France**☐ Additional inventors are being named on the ____ supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto.

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (10-00)

Approved for use through 10/31/2002 OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

**DECLARATION FOR UTILITY OR
DESIGN
PATENT APPLICATION
(37 CFR 1.63)**

☐ Declaration Submitted with Initial Filing
OR
☒ Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)

Attorney Docket Number	50.US3.PCT
First Named Inventor	Marta BLUMENFELD, et al.
COMPLETE IF KNOWN	
Application Number	09 / 807,506
Filing Date	April 13, 2001
Group Art Unit	unknown
Examiner Name	unassigned

As a below named inventor, I hereby declare that:

My residence, mailing address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Genes, Proteins and Biallelic Markers Related to Central Nervous System Disease

(Title of the Invention)

the specification of which

☐ is attached hereto

OR

☒ was filed on (MM/DD/YYYY) April 13, 2001

as United States Application Number or PCT International

(if applicable).

Application Number 09/807,506 and was amended on (MM/DD/YYYY)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
PCT/IB99/01730	WIPO	10/12/1999	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 21 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (10-00)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

DECLARATION — Utility or Design Patent Application

Direct all correspondence to: ☒ Customer Number ☐ Bar Code Label OR ☒ Correspondence address below

Name John Lucas, Ph.D., J.D.

Address Genset Corporation

Address 10665 Sorrento Valley Road

City San Diego

State CA

ZIP 92121-1609

Country USA

Telephone 858/597-2600

Fax 858/597-2601

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

NAME OF SOLE OR FIRST INVENTOR :

☐ A petition has been filed for this unsigned inventor

Given Name Marta
(first and middle [if any])

Family Name BLUMENFELD
or Surname

Inventor's
Signature

Date

Residence: City Paris

State

Country France

Citizenship French

Mailing Address 24 rue Royale

Mailing Address

City Paris

State

ZIP 75008

Country France

NAME OF SECOND INVENTOR:

☐ A petition has been filed for this unsigned inventor

Given Name Lydie
(first and middle [if any])

Family Name BOUGUELERET
or Surname

Inventor's
Signature

Date

Residence: City Petit Lancy

State

Switzerland
Country

Citizenship French

Mailing Address 24 rue Royale

Mailing Address

City Paris

State

ZIP 75008

Country France

☐ Additional inventors are being named on the ____ supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto.

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (10-00)

Approved for use through 10/31/2002 OMB 0651-0032

U S. Patent and Trademark Office; U S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

**DECLARATION FOR UTILITY OR
DESIGN
PATENT APPLICATION
(37 CFR 1.63)**

☐ Declaration Submitted with Initial Filing OR ☒ Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)

Attorney Docket Number	50.US3.PCT
First Named Inventor	Marta BLUMENFELD, et al.
COMPLETE IF KNOWN	
Application Number	09 / 807,506
Filing Date	April 13, 2001
Group Art Unit	unknown
Examiner Name	unassigned

As a below named inventor, I hereby declare that:

My residence, mailing address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Genes, Proteins and Biallelic Markers Related to Central Nervous System Disease

(Title of the Invention)

the specification of which

☐ is attached hereto

OR

☒ was filed on (MM/DD/YYYY)

April 13, 2001

as United States Application Number or PCT International

(if applicable).

Application Number

09/807,506

and was amended on (MM/DD/YYYY)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
PCT/IB99/01730	WIPO	10/12/1999	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 21 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this box →



PTO/SB/01 (10-00)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION — Utility or Design Patent Application

Direct all correspondence to:

Customer Number
or Bar Code Label

000027206

OR ☒

Correspondence address below

Name John Lucas, Ph.D., J.D.

Address Genset Corporation

Address 10665 Sorrento Valley Road

City San Diego

CA

State

ZIP 92121-1609

Country USA

Telephone 858/597-2600

Fax 858/597-2601

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

NAME OF SOLE OR FIRST INVENTOR :

☐ A petition has been filed for this unsigned inventorGiven Name Marta
(first and middle [if any])Family Name BLUMENFELD
or SurnameInventor's
Signature

Date

Residence: City Paris

State

Country France

Citizenship French

Mailing Address 24 rue Royale

Mailing Address

City Paris

State

ZIP 75008

Country France

NAME OF SECOND INVENTOR:

☐ A petition has been filed for this unsigned inventorGiven Name Lydie
(first and middle [if any])Family Name BOUGUELERET
or SurnameInventor's
Signature

Date

Residence: City Petit Lancy

State

Switzerland
Country

Citizenship French

Mailing Address 24 rue Royale

Mailing Address

City Paris

State

ZIP 75008

Country France

☐ Additional inventors are being named on the _____ supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto.

09507206-0950604

Please type a plus sign (+) inside this box → ☐

PTO/SB/81 (10-00)

Approved for use through 10/31/2002 OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it display a valid OMB control number

POWER OF ATTORNEY OR AUTHORIZATION OF AGENT

Application Number	09/807,506
Filing Date	April 13, 2001
First Named Inventor	Marta BLUMENFELD, et al.
Group Art Unit	Unknown
Examiner Name	Unassigned
Attorney Docket Number	50.US3.PCT

I hereby appoint:

☐ Practitioners at Customer Number

000027206 →

Place Customer
Number Bar Code
Label here

OR

☒ Practitioner(s) named below:

Name	Registration Number
John M. Lucas	43,373
Peter Follette	46,213
Lukas R. Voellmy	43,358

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please change the correspondence address for the above-identified application to:

☐ The above-mentioned Customer Number.

OR

☒ Firm or
Individual Name

John Lucas, Ph.D., J.D.

Address Genset Corporation

Address 10665 Sorrento Valley Road

City San Diego State CA Zip 92121-1609

Country USA

Telephone (858) 597-2600 Fax (848) 597-2601

I am the:

☒ Applicant/Inventor.

☐ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

SIGNATURE of Applicant or Assignee of Record

Name Lydie Bougueleret

Signature

Date

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

☐ *Total of _____ forms are submitted.

Please type a plus sign (+) inside this box → ☐

PTO/SB/81 (10-00)

Approved for use through 10/31/2002. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

POWER OF ATTORNEY OR AUTHORIZATION OF AGENT

Application Number	09/807,506
Filing Date	April 13, 2001
First Named Inventor	Marta BLUMENFELD, et al.
Group Art Unit	Unknown
Examiner Name	Unassigned
Attorney Docket Number	50.US3.PCT

I hereby appoint:

☐ Practitioners at Customer Number

000027206

Place Customer
Number Bar Code
Label here

OR

☒ Practitioner(s) named below:

Name	Registration Number
John M. Lucas	43,373
Peter Follette	46,213
Lukas R. Voellmy	43,358

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please change the correspondence address for the above-identified application to:

☐ The above-mentioned Customer Number.

OR

☒ Firm or
Individual Name

John Lucas, Ph.D., J.D.

Address Genset Corporation

Address 10665 Sorrento Valley Road

City San Diego State CA Zip 92121-1609

Country USA

Telephone (858) 597-2600 Fax (848) 597-2601

I am the:

☒ Applicant/Inventor.

☐ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

SIGNATURE of Applicant or Assignee of Record

Name Ilya Chumakov

Signature

Date

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

☐ *Total of _____ forms are submitted.

Please type a plus sign (+) inside this box → ☐

PTO/SB/81 (10-00)

Approved for use through 10/31/2002 OMB 0651-0035

U S Patent and Trademark Office; U S DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it display a valid OMB control number

POWER OF ATTORNEY OR AUTHORIZATION OF AGENT

Application Number	09/807,506
Filing Date	April 13, 2001
First Named Inventor	Marta BLUMENFELD, et al.
Group Art Unit	Unknown
Examiner Name	Unassigned
Attorney Docket Number	50.US3.PCT

I hereby appoint:

☐ Practitioners at Customer Number
OR

000027206

Place Customer
Number Bar Code
Label here

☒ Practitioner(s) named below:

Name	Registration Number
John M. Lucas	43,373
Peter Follette	46,213
Lukas R. Voellmy	43,358

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please change the correspondence address for the above-identified application to:

☐ The above-mentioned Customer Number.

OR

☒ Firm or
Individual Name John Lucas, Ph.D., J.D.

Address Genset Corporation

Address 10665 Sorrento Valley Road

City San Diego State CA Zip 92121-1609

Country USA

Telephone (858) 597-2600 Fax (848) 597-2601

I am the:

☒ Applicant/Inventor.

☐ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

SIGNATURE of Applicant or Assignee of Record

Name Daniel Cohen

Signature

Date

04/27/01

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

☐ *Total of _____ forms are submitted.

Please type a plus sign (+) inside this box → ☐

PTO/SB/81 (10-00)
Approved for use through 10/31/2002 OMB 0651-0035
U S Patent and Trademark Office; U S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it display a valid OMB control number

POWER OF ATTORNEY OR AUTHORIZATION OF AGENT

Application Number	09/807,506
Filing Date	April 13, 2001
First Named Inventor	Marta BLUMENFELD, et al.
Group Art Unit	Unknown
Examiner Name	Unassigned
Attorney Docket Number	50.US3.PCT

I hereby appoint:

☐ Practitioners at Customer Number
OR

000027206 →

Place Customer
Number Bar Code
Label here

☒ Practitioner(s) named below:

Name	Registration Number
John M. Lucas	43,373
Peter Follette	46,213
Lukas R. Voellmy	43,358

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please change the correspondence address for the above-identified application to:

☐ The above-mentioned Customer Number.

OR

☒ Firm or
Individual Name John Lucas, Ph.D., J.D.

Address Genset Corporation

Address 10665 Sorrento Valley Road

City San Diego State CA Zip 92121-1609

Country USA

Telephone (858) 597-2600 Fax (848) 597-2601

I am the:

☒ Applicant/Inventor.

☐ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

SIGNATURE of Applicant or Assignee of Record

Name Laurent Essioux

Signature 

Date 06/26

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

☐ *Total of _____ forms are submitted.